This document is an excerpt from the EUR-Lex website
Document 32018R0669
Commission Regulation (EU) 2018/669 of 16 April 2018 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixturesText with EEA relevance.
Rozporządzenie Komisji (UE) 2018/669 z dnia 16 kwietnia 2018 r. zmieniające, w celu dostosowania do postępu naukowo-technicznego, rozporządzenie Parlamentu Europejskiego i Rady (WE) nr 1272/2008 w sprawie klasyfikacji, oznakowania i pakowania substancji i mieszaninTekst mający znaczenie dla EOG.
Rozporządzenie Komisji (UE) 2018/669 z dnia 16 kwietnia 2018 r. zmieniające, w celu dostosowania do postępu naukowo-technicznego, rozporządzenie Parlamentu Europejskiego i Rady (WE) nr 1272/2008 w sprawie klasyfikacji, oznakowania i pakowania substancji i mieszaninTekst mający znaczenie dla EOG.
C/2018/2154
Dz.U. L 115 z 4.5.2018, p. 1–755
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
In force
|
4.5.2018 |
PL |
Dziennik Urzędowy Unii Europejskiej |
L 115/1 |
ROZPORZĄDZENIE KOMISJI (UE) 2018/669
z dnia 16 kwietnia 2018 r.
zmieniające, w celu dostosowania do postępu naukowo-technicznego, rozporządzenie Parlamentu Europejskiego i Rady (WE) nr 1272/2008 w sprawie klasyfikacji, oznakowania i pakowania substancji i mieszanin
(Tekst mający znaczenie dla EOG)
KOMISJA EUROPEJSKA,
uwzględniając Traktat o funkcjonowaniu Unii Europejskiej,
uwzględniając rozporządzenie Parlamentu Europejskiego i Rady (WE) nr 1272/2008 z dnia 16 grudnia 2008 r. w sprawie klasyfikacji, oznakowania i pakowania substancji i mieszanin, zmieniające i uchylające dyrektywy 67/548/EWG i 1999/45/WE oraz zmieniające rozporządzenie (WE) nr 1907/2006 (1), w szczególności jego art. 53 ust. 1,
a także mając na uwadze, co następuje:
|
(1) |
Tabele 3.1 i 3.2 w załączniku VI do rozporządzenia (WE) nr 1272/2008 zawierają wykazy zharmonizowanej klasyfikacji oraz oznakowania substancji stwarzających zagrożenie, które jednak we wszystkich wersjach językowych tego rozporządzenia występują tylko w języku angielskim. |
|
(2) |
W dniu 2 grudnia 2008 r. (2) Komisja zobowiązała się do zapewnienia, by nazwy chemiczne ujęte w tabelach 3.1 i 3.2 załącznika VI do rozporządzenia (WE) nr 1272/2008, odpowiadające międzynarodowej terminologii chemicznej, opublikowane zostały w tych językach, w których opublikowano samo rozporządzenie. |
|
(3) |
Tabela 3.1 w załączniku VI do rozporządzenia (WE) nr 1272/2008 była wielokrotnie zmieniana w celu uwzględnienia postępu naukowo-technicznego poprzez dodanie, usunięcie lub zmianę substancji lub ich klasyfikacji. W celu uwzględnienia tych zmian i zapewnienia, by wszystkie nazwy chemiczne w tabeli 3.1 w załączniku VI do rozporządzenia (WE) nr 1272/2008 były w tym języku, w którym opublikowano samo rozporządzenie, tabelę 3.1 należy częściowo zastąpić. |
|
(4) |
Biorąc pod uwagę odstępstwo (3) mające zastosowanie do tłumaczenia na język irlandzki aktów, które nie są przyjmowane wspólnie przez Parlament Europejski i Radę, nazw chemicznych w tabeli 3.1 załącznika VI nie należy tłumaczyć na ten język. |
|
(5) |
Tabela 3.2 zawiera wykaz zharmonizowanej klasyfikacji oraz oznakowania substancji stwarzających zagrożenie oparty o kryteria ustanowione w załączniku VI do dyrektywy Rady 67/548/EWG (4) uchylonej ze skutkiem od dnia 1 czerwca 2015 r. W związku z tym należy skreślić tabelę 3.2 zgodnie z art. 1 ust. 2 rozporządzenia Komisji (UE) 2016/1179 (5) ze skutkiem od dnia 1 czerwca 2017 r. Tabela ta nie powinna zatem zostać zmieniona. W wyniku tego tabelę 3.1 przemianowano na tabelę 3 zgodnie z art. 2 ust. 2 rozporządzenia Komisji (UE) 2017/776 (6) ze skutkiem od dnia 1 czerwca 2017 r. |
|
(6) |
Dostawcom należy zapewnić wystarczająco dużo czasu na dostosowanie oznakowania i opakowań substancji i mieszanin do nowego tłumaczenia przepisów oraz na sprzedaż istniejących zapasów. |
|
(7) |
Dostawcy powinni mieć możliwość stosowania niniejszego rozporządzenia przed datą rozpoczęcia jego stosowania, co ma na celu zapewnienie wysokiego poziomu ochrony zdrowia ludzi i ochrony środowiska, a dostawcom – wystarczającej elastyczności. |
|
(8) |
Środki przewidziane w niniejszym rozporządzeniu są zgodne z opinią komitetu ustanowionego na mocy art. 133 rozporządzenia (WE) nr 1907/2006 Parlamentu Europejskiego i Rady (7), |
PRZYJMUJE NINIEJSZE ROZPORZĄDZENIE:
Artykuł 1
Wpisy określone w załączniku VI do rozporządzenia (WE) nr 1272/2008 odpowiadające wpisom określonym w załączniku do niniejszego rozporządzenia zastępuje się wpisami określonymi w załączniku do niniejszego rozporządzenia.
Artykuł 2
Niniejsze rozporządzenie wchodzi w życie dwudziestego dnia po jego opublikowaniu w Dzienniku Urzędowym Unii Europejskiej.
Niniejsze rozporządzenie stosuje się od dnia 1 grudnia 2019 r.
Na zasadzie odstępstwa od akapitu drugiego przed dniem 1 grudnia 2019 r. substancje i mieszaniny mogą być klasyfikowane, znakowane i pakowane zgodnie z rozporządzeniem (WE) nr 1272/2008 zmienionym niniejszym rozporządzeniem.
Niniejsze rozporządzenie wiąże w całości i jest bezpośrednio stosowane we wszystkich państwach członkowskich.
Sporządzono w Brukseli dnia 16 kwietnia 2018 r.
W imieniu Komisji
Jean-Claude JUNCKER
Przewodniczący
(1) Dz.U. L 353 z 31.12.2008, s. 1.
(2) Sprostowanie do stanowiska Parlamentu Europejskiego przyjętego w pierwszym czytaniu w dniu 3 września 2008 r. w celu przyjęcia rozporządzenia Parlamentu Europejskiego i Rady (WE) nr 1272/2008 w sprawie klasyfikacji, oznakowania i pakowania substancji i mieszanin, zmieniającego i uchylającego dyrektywy 67/548/EWG i 1999/45/WE oraz zmieniającego rozporządzenie (WE) nr 1907/2006 – P6_TA(2008)0392 (COM(2007) 355 – C6-0197/2007-2007/0121 (COD)).
(3) Rozporządzenie Rady (UE) nr 1257/2010 z dnia 20 grudnia 2010 r. przedłużające obowiązywanie tymczasowych środków wprowadzonych rozporządzeniem (WE) nr 920/2005 stanowiących odstępstwo od przepisów rozporządzenia nr 1 z dnia 15 kwietnia 1958 r. w sprawie określenia systemu językowego Europejskiej Wspólnoty Gospodarczej oraz rozporządzenia nr 1 z dnia 15 kwietnia 1958 r. w sprawie określenia systemu językowego Europejskiej Wspólnoty Energii Atomowej (Dz.U. L 343 z 29.12.2010, s. 5).
(4) Dyrektywa Rady 67/548/EWG z dnia 27 czerwca 1967 r. w sprawie zbliżenia przepisów ustawodawczych, wykonawczych i administracyjnych odnoszących się do klasyfikacji, pakowania i etykietowania substancji niebezpiecznych (Dz.U. 196 z 16.8.1967, s. 1).
(5) Rozporządzenie Komisji (UE) 2016/1179 z dnia 19 lipca 2016 r. dostosowujące do postępu naukowo-technicznego rozporządzenie Parlamentu Europejskiego i Rady (WE) nr 1272/2008 w sprawie klasyfikacji, oznakowania i pakowania substancji i mieszanin (Dz.U. L 195 z 20.7.2016, s. 11).
(6) Rozporządzenie Komisji (UE) 2017/776 z dnia 4 maja 2017 r. zmieniające, w celu dostosowania do postępu naukowo-technicznego, rozporządzenie Parlamentu Europejskiego i Rady (WE) nr 1272/2008 w sprawie klasyfikacji, oznakowania i pakowania substancji i mieszanin (Dz.U. L 116 z 5.5.2017, s. 1).
(7) Rozporządzenie (WE) nr 1907/2006 Parlamentu Europejskiego i Rady z dnia 18 grudnia 2006 r. w sprawie rejestracji, oceny, udzielania zezwoleń i stosowanych ograniczeń w zakresie chemikaliów (REACH) i utworzenia Europejskiej Agencji Chemikaliów, zmieniające dyrektywę 1999/45/WE oraz uchylające rozporządzenie Rady (EWG) nr 793/93 i rozporządzenie Komisji (WE) nr 1488/94, jak również dyrektywę Rady 76/769/EWG i dyrektywy Komisji 91/155/EWG, 93/67/EWG, 93/105/WE i 2000/21/WE (Dz.U. L 396 z 30.12.2006, s. 1).
ZAŁĄCZNIK
|
Nr indeksowy |
Międzynarodowa terminologia chemiczna |
Numer WE |
Numer CAS |
Klasyfikacja |
Oznakowanie |
Specyficzne stężenia graniczne i współczynniki „M” |
Uwagi |
|||
|
Klasa zagrożenia i kody kategorii |
Kody zwrotów wskazujących rodzaj zagrożenia |
Piktogram, kody haseł ostrzegawczych |
Kody zwrotów wskazujących rodzaj zagrożenia |
Dodatkowe kody zwrotów wskazujących rodzaj zagrożenia |
||||||
|
(1) |
(2) |
(3) |
(4) |
(5) |
(6) |
(7) |
(8) |
(9) |
(10) |
(11) |
|
001-001-00-9 |
wodór |
215-605-7 |
1333-74-0 |
Flam. Gas 1 Press. Gas |
H220 |
GHS02 GHS04 Dgr |
H220 |
|
|
U |
|
001-002-00-4 |
wodorek litowo-glinowy; tetrahydroglinian litu; glinowodorek litowy |
240-877-9 |
16853-85-3 |
Water-react. 1 Skin Corr. 1A |
H260 H314 |
GHS02 GHS05 Dgr |
H260 H314 |
|
|
|
|
001-003-00-X |
wodorek sodu |
231-587-3 |
7646-69-7 |
Water-react. 1 |
H260 |
GHS02 Dgr |
H260 |
|
|
|
|
001-004-00-5 |
wodorek wapnia; diwodorek wapnia |
232-189-2 |
7789-78-8 |
Water-react. 1 |
H260 |
GHS02 Dgr |
H260 |
|
|
|
|
003-001-00-4 |
lit |
231-102-5 |
7439-93-2 |
Water-react. 1 Skin Corr. 1B |
H260 H314 |
GHS02 GHS05 Dgr |
H260 H314 |
EUH014 |
|
|
|
003-002-00-X |
n-heksylolit; heksylolit |
404-950-0 |
21369-64-2 |
Water-react. 1 Pyr. Sol. 1 Skin Corr. 1A |
H260 H250 H314 |
GHS02 GHS05 Dgr |
H260 H250 H314 |
EUH014 |
|
|
|
003-003-00-5 |
(2-metylopropylo)lit; isobutylolit |
440-620-2 |
920-36-5 |
Water-react. 1 Pyr. Liq. 1 Skin Corr. 1A STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 |
H260 H250 H314 H336 H400 H410 |
GHS02 GHS05 GHS07 GHS09 Dgr |
H260 H250 H314 H336 H410 |
EUH014 |
|
|
|
004-001-00-7 |
beryl |
231-150-7 |
7440-41-7 |
Carc. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 |
H350i H330 H301 H372 ** H319 H335 H315 H317 |
GHS06 GHS08 Dgr |
H350i H330 H301 H372 ** H319 H335 H315 H317 |
|
|
|
|
004-002-00-2 |
związki berylu, z wyjątkiem glinokrzemianów berylu i związków wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Carc. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H350i H330 H301 H372 ** H319 H335 H315 H317 H411 |
GHS06 GHS08 GHS09 Dgr |
H350i H330 H301 H372 ** H319 H335 H315 H317 H411 |
|
|
A |
|
004-003-00-8 |
tlenek berylu |
215-133-1 |
1304-56-9 |
Carc. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 |
H350i H330 H301 H372 ** H319 H335 H315 H317 |
GHS06 GHS08 Dgr |
H350i H330 H301 H372 ** H319 H335 H315 H317 |
|
|
|
|
005-001-00-X |
trifluorek boru |
231-569-5 |
7637-07-2 |
Press. Gas Acute Tox. 2 * Skin Corr. 1A |
H330 H314 |
GHS04 GHS06 GHS05 Dgr |
H330 H314 |
EUH014 |
|
U |
|
005-002-00-5 |
trichlorek boru |
233-658-4 |
10294-34-5 |
Press. Gas Acute Tox. 2 * Acute Tox. 2 * Skin Corr. 1B |
H330 H300 H314 |
GHS04 GHS06 GHS05 Dgr |
H330 H300 H314 |
EUH014 |
|
U |
|
005-003-00-0 |
tribromek boru |
233-657-9 |
10294-33-4 |
Acute Tox. 2 * Acute Tox. 2 * Skin Corr. 1A |
H330 H300 H314 |
GHS06 GHS05 Dgr |
H330 H300 H314 |
EUH014 |
|
|
|
005-004-00-6 |
trialkiloborany, substancja stała |
— |
— |
Pyr. Sol. 1 Skin Corr. 1B |
H250 H314 |
GHS02 GHS05 Dgr |
H250 H314 |
|
|
A |
|
005-004-01-3 |
trialkiloborany, ciecz |
— |
— |
Pyr. Liq. 1 Skin Corr. 1B |
H250 H314 |
GHS02 GHS05 Dgr |
H250 H314 |
|
|
A |
|
005-005-00-1 |
ortoboran trimetylu; trimetoksyboran |
204-468-9 |
121-43-7 |
Flam. Liq. 3 Acute Tox. 4 * |
H226 H312 |
GHS02 GHS07 Wng |
H226 H312 |
|
|
|
|
005-006-00-7 |
wodoroortoboran dibutylocyny(IV) |
401-040-5 |
75113-37-0 |
Repr. 1B Muta. 2 STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H360FD H341 H372** H312 H302 H318 H317 H400 H410 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H360FD H341 H372** H312 H302 H318 H317 H410 |
|
|
|
|
005-007-00-2 |
kwas borowy; [1] kwas borowy; [2] |
233-139-2 [1] 234-343-4 [2] |
10043-35-3 [1] 11113-50-1 [2] |
Repr. 1B |
H360FD |
GHS08 Dgr |
H360FD |
|
Repr.1B; H360FD: C ≥ 5,5 % |
|
|
005-008-00-8 |
tritlenek diboru; tlenek boru(III); tlenek boru |
215-125-8 |
1303-86-2 |
Repr. 1B |
H360FD |
GHS08 Dgr |
H360FD |
|
Repr.1B; H360FD:C ≥ 3,1 % |
|
|
005-009-00-3 |
butylotrifenyloboran tetrabutyloamonium |
418-080-4 |
120307-06-4 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
005-010-00-9 |
tetrakis(pentafluorofenylo)boran N, N-dimetyloanilinium |
422-050-6 |
118612-00-3 |
Carc. 2 Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 |
H351 H302 H315 H318 |
GHS08 GHS05 GHS07 Dgr |
H351 H302 H315 H318 |
|
|
|
|
005-011-00-4 |
tetraboran disodu, bezwodny; kwas borowy, sól disodowa; [1] heptatlenek disodu tetraboru, hydrat; [2] sól sodowa kwasu ortoborowego [3] |
215-540-4 [1] 235-541-3 [2] 237-560-2 [3] |
1330-43-4 [1] 12267-73-1 [2] 13840-56-7 [3] |
Repr. 1B |
H360FD |
GHS08 Dgr |
H360FD |
|
Repr. 1B; H360FD: C ≥4,5 % |
|
|
005-011-01-1 |
dekahydrat tetraboranu disodu; dekahydrat boraksu |
215-540-4 |
1303-96-4 |
Repr. 1B |
H360FD |
GHS08 Dgr |
H360FD |
|
Repr.1B; H360FD: C ≥ 8,5 % |
|
|
005-011-02-9 |
pentahydrat tetraboranu disodu; pentahydrat boraksu |
215-540-4 |
12179-04-3 |
Repr. 1B |
H360FD |
GHS08 Dgr |
H360FD |
|
Repr.B; H360FD: C ≥ 6,5 % |
|
|
005-012-00-X |
butylotrifenyloboran dietylo-{4-[1,5,5-tris(4-dietyloaminofenylo)-penta-2,4-dienylideno]cykloheksa-2,5-dienylideno}amonium |
418-070-1 |
141714-54-7 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
005-013-00-5 |
dietylometoksyboran |
425-380-9 |
7397-46-8 |
Pyr. Liq. 1 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 4 |
H250 H332 H312 H302 H373** H314 H317 H413 |
GHS02 GHS05 GHS08 GHS07 Dgr |
H250 H332 H312 H302 H373** H314 H317 H413 |
|
|
|
|
005-014-00-0 |
kwas 4-formylofenyloborowy |
438-670-5 |
87199-17-5 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
005-015-00-6 |
bis(tetrafluoroboran) 1-chlorometylo-4-fluoro-1,4-diazoniabicyklo[2.2.2]oktanu |
414-380-4 |
140681-55-6 |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H302 H318 H317 H412 |
GHS05 GHS07 Dgr |
H302 H318 H317 H412 |
|
|
|
|
005-016-00-1 |
butylo tris(4-trans-butylofenylo)boran tetrabutyloamoniowy |
431-370-5 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
005-017-00-7 |
(peroksoboran) nadboran sodu; [1] peroksometaboran sodu; [2] peroksoboran sodu; [zawierający < 0,1 % (w/w) cząstek o średnicy poniżej 50 μm] |
239-172-9 [1] 231-556-4 [2] |
15120-21-5 [1] 7632-04-4 [2] |
Ox. Sol. 2 Repr. 1B Acute Tox. 4 * STOT SE 3 Eye Dam. 1 |
H272 H360Df H302 H335 H318 |
GHS03 GHS05 GHS08 GHS07 Dgr |
H272 H360Df H302 H335 H318 |
|
Repr.1B; H360Df: C ≥9 % Repr.1B; H360 D: 6,5 % ≤ C <9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % |
|
|
005-017-01-4 |
(peroksoboran) nadboran sodu; [1] peroksometaboran sodu; [2] peroksoboran sodu; [zawierający ≥ 0,1 % (w/w) cząstek o średnicy poniżej 50 μm] |
239-172-9 [1] 231-556-4 [2] |
15120-21-5 [1] 7632-04-4 [2] |
Ox. Sol. 2 Repr. 1B Acute Tox. 3 * Acute Tox. 4 * STOT SE 3 Eye Dam. 1 |
H272 H360Df H331 H302 H335 H318 |
GHS03 GHS06 GHS05 GHS08 Dgr |
H272 H360Df H331 H302 H335 H318 |
|
Repr. 1B; H360Df: C ≥9 % Repr. 1B; H360D: 6,5 % ≤ C < 9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % |
|
|
005-018-00-2 |
sól monosodowa kwasu nadborowego (H3BO2(O2)) trójwodna; [1] czterowodna sól sodowa kwasu nadborowego; [2] czterowodna sól sodowa kwasu nadborowego (HBO(O2)); [3] sześciowodny peroksoboran sodu; [zawierający < 0,1 % (w/w) cząstek o średnicy poniżej 50 μm] |
239-172-9 [1] 234-390-0 [2] 231-556-4 [3] |
13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3] |
Repr. 1B STOT SE 3 Eye Dam. 1 |
H360Df H335 H318 |
GHS05 GHS08 GHS07 Dgr |
H360Df H335 H318 |
|
Repr. 1B; H360Df: C ≥ 14 % Repr. 1B; H360D: 10 % ≤ C < 14 % Eye Dam. 1; H318: C ≥ 36 % Eye Irrit. 2; H319: 22 % ≤ C < 36 % |
|
|
005-018-01-X |
sól monosodowa kwasu nadborowego (H3BO2(O2)) trójwodna; [1] czterowodna sól sodowa kwasu nadborowego; [2] czterowodna sól sodowa kwasu nadborowego (HBO(O2)); [3] sześciowodny peroksoboran sodu; [zawierający ≥ 0,1 % (w/w) cząstek o średnicy poniżej 50 μm] |
239-172-9 [1] 234-390-0 [2] 231-556-4 [3] |
13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3] |
Repr. 1B Acute Tox. 4 * STOT SE 3 Eye Dam. 1 |
H360Df H332 H335 H318 |
GHS05 GHS08 GHS07 Dgr |
H360Df H332 H335 H318 |
|
Repr. 1B; H360 Df: C ≥ 14 % Repr. 1B; H360D: 10 % ≤ C < 14 % Eye Dam. 1; H318: C ≥ 36 % Eye Irrit. 2; H319: 22 % ≤ C < 36 % |
|
|
005-019-00-8 |
sól sodowa kwasu nadborowego; [1] jednowodna sól sodowa kwasu nadborowego; [2] sól sodowa kwasu nadborowego (HBO(O2)) jednowodna; [3] peroksoboran sodu; [zawierający < 0,1 % (w/w) cząstek o średnicy poniżej 50 μm] |
234-390-0 [1] 234-390-0 [2] 231-556-4 [3] |
11138-47-9 [1] 12040-72-1 [2] 10332-33-9 [3] |
Ox. Sol. 3 Repr. 1B Acute Tox. 4 * STOT SE 3 Eye Dam. 1 |
H272 H360Df H302 H335 H318 |
GHS03 GHS05 GHS08 GHS07 Dgr |
H272 H360Df H302 H335 H318 |
|
Repr. 1B; H360Df: C ≥ 9 % Repr. 1B; H360D: 6,5 % ≤ C < 9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % |
|
|
005-019-01-5 |
sól sodowa kwasu nadborowego; [1] jednowodna sól sodowa kwasu nadborowego; [2] sól sodowa kwasu nadborowego (HBO(O2)) jednowodna; [3] peroksoboran sodu; [zawierający ≥ 0,1 % (w/w) cząstek o średnicy poniżej 50 μm] |
234-390-0 [1] 234-390-0 [2] 231-556-4 [3] |
11138-47-9 [1] 12040-72-1 [2] 10332-33-9 [3] |
Ox. Sol. 3 Repr. 1B Acute Tox. 3 * Acute Tox. 4 * STOT SE 3 Eye Dam. 1 |
H272 H360Df H331 H302 H335 H318 |
GHS03 GHS06 GHS05 GHS08 Dgr |
H272 H360Df H331 H302 H335 H318 |
|
Repr. 1B; H360Df: C ≥ 9 % Repr. 1B; H360D: 6,5 % ≤ C < 9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % |
|
|
006-001-00-2 |
tlenek węgla |
211-128-3 |
630-08-0 |
Flam. Gas 1 Press. Gas Repr. 1A Acute Tox. 3 * STOT RE 1 |
H220 H360D *** H331 H372 ** |
GHS02 GHS04 GHS06 GHS08 Dgr |
H220 H360D *** H331 H372 ** |
|
|
U |
|
006-002-00-8 |
fosgen; chlorek karbonylu; tlenochlorek węgla |
200-870-3 |
75-44-5 |
Press. Gas Acute Tox. 2 * Skin Corr. 1B |
H330 H314 |
GHS04 GHS06 GHS05 Dgr |
H330 H314 |
|
|
U |
|
006-003-00-3 |
disiarczek węgla |
200-843-6 |
75-15-0 |
Flam. Liq. 2 Repr. 2 STOT RE 1 Eye Irrit. 2 Skin Irrit. 2 |
H225 H361fd H372 ** H319 H315 |
GHS02 GHS08 GHS07 Dgr |
H225 H361fd H372 ** H319 H315 |
|
Repr. 2; H361fd: C ≥ 1 % STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,2 % ≤ C < 1 % |
|
|
006-004-00-9 |
węglik wapnia; karbid |
200-848-3 |
75-20-7 |
Water-react. 1 |
H260 |
GHS02 Dgr |
H260 |
|
|
T |
|
006-005-00-4 |
tiuram (ISO); disulfid tetrametylotiuramu |
205-286-2 |
137-26-8 |
Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H332 H302 H373 ** H319 H315 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H332 H302 H373 ** H319 H315 H317 H410 |
|
M = 10 |
|
|
006-006-00-X |
cyjanowodór; kwas cyjanowodorowy |
200-821-6 |
74-90-8 |
Flam. Liq. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H224 H330 H400 H410 |
GHS02 GHS06 GHS09 Dgr |
H224 H330 H410 |
|
|
|
|
006-006-01-7 |
kwas cyjanowodorowy …%; kwas pruski …% |
200-821-6 |
74-90-8 |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H330 H310 H300 H410 |
|
|
B |
|
006-007-00-5 |
sole cyjanowodoru, z wyjątkiem kompleksów cyjankowych, takich jak heksacyjanożelaziany(II) i heksacyjanożelaziany(III), oraz tlenocyjanku rtęci(II) i związków wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H330 H310 H300 H410 |
EUH032 |
|
A |
|
006-008-00-0 |
antu (ISO); (1-naftylo)tiomocznik |
201-706-3 |
86-88-4 |
Acute Tox. 2 * Carc. 2 |
H300 H351 |
GHS06 GHS08 Dgr |
H300 H351 |
|
|
|
|
006-009-00-6 |
dimetylokarbaminian 1-izopropylo-3-metylopirazol-5-ilu; izolan |
204-318-2 |
119-38-0 |
Acute Tox. 1 Acute Tox. 2 * |
H310 H300 |
GHS06 Dgr |
H310 H300 |
|
|
|
|
006-010-00-1 |
dimetylokarbaminian 5,5-dimetylo-3-oksocykloheks-1-en-1-ylu; dimetylokarbamian 5,5-dimetylo-3-oksocykloheks-1-en-1-ylu dimetan |
204-525-8 |
122-15-6 |
Acute Tox. 3 * |
H301 |
GHS06 Dgr |
H301 |
|
|
|
|
006-011-00-7 |
karbaryl (ISO); metylokarbaminian 1-naftylu |
200-555-0 |
63-25-2 |
Carc. 2 Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 |
H351 H332 H302 H400 |
GHS08 GHS07 GHS09 Wng |
H351 H332 H302 H400 |
|
M=100 |
|
|
006-012-00-2 |
ziram (ISO); bis(dimetyloditiokarbaminian) cynku |
205-288-3 |
137-30-4 |
Acute Tox. 2 * Acute Tox. 4 * STOT RE 2 * STOT SE 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H330 H302 H373 ** H335 H318 H317 H400 H410 |
GHS06 GHS08 GHS05 GHS09 Dgr |
H330 H302 H373 ** H335 H318 H317 H410 |
|
M = 100 |
|
|
006-013-00-8 |
metam sodowy (ISO); metyloditiokarbaminian sodu |
205-293-0 |
137-42-8 |
Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H314 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H302 H314 H317 H410 |
EUH031 |
|
|
|
006-014-00-3 |
nabam (ISO); etylenobis(ditiokarbaminian) disodu |
205-547-0 |
142-59-6 |
Acute Tox. 4 * STOT SE 3 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H335 H317 H410 |
GHS07 GHS09 Wng |
H302 H335 H317 H410 |
|
|
|
|
006-015-00-9 |
diuron (ISO); 3-(3,4-dichlorofenylo)-1,1-dimetylo-mocznik |
206-354-4 |
330-54-1 |
Carc. 2 Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H351 H302 H373** H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H302 H373** H410 |
|
M = 10 |
|
|
006-016-00-4 |
propoksur (ISO); metylokarbaminian 2-izopropoksyfenylu |
204-043-8 |
114-26-1 |
Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H301 H400 H410 |
GHS06 GHS09 Dgr |
H301 H410 |
|
|
|
|
006-017-00-X |
aldikarb (ISO); O-(metylokarbamoilo)oksym 2-metylo-2-(metylosulfanylo)propanalu |
204-123-2 |
116-06-3 |
Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H300 H311 H400 H410 |
GHS06 GHS09 Dgr |
H330 H300 H311 H410 |
|
|
|
|
006-018-00-5 |
aminokarb (ISO); metylokarbaminian 4-(dimetyloamino)-3-tolilu; metylokarbaminian 4-(dimetyloamino)-3-metylofenylu |
217-990-7 |
2032-59-9 |
Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H311 H301 H410 |
|
|
|
|
006-019-00-0 |
dialat (ISO); N,N-diizopropylotiokarbaminian S-2,3-dichloroallilu |
218-961-1 |
2303-16-4 |
Carc. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H351 H302 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H302 H410 |
|
|
|
|
006-020-00-6 |
barban (ISO); (3-chlorofenylo)karbaminian 4-chlorobut-2-yn-1-ylu |
202-930-4 |
101-27-9 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|
|
|
|
006-021-00-1 |
linuron (ISO); 3-(3,4-dichlorofenylo)-1-metoksy-1-metylomocznik |
206-356-5 |
330-55-2 |
Repr. 1B Carc. 2 Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H360Df H351 H302 H373 ** H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H360Df H351 H302 H373 ** H410 |
|
|
|
|
006-022-00-7 |
dekarbofuran (ISO); metylokarbaminian 2-metylo-2,3-dihydrobenzofuran-7-ylu |
— |
1563-67-3 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * |
H331 H311 H301 |
GHS06 Dgr |
H331 H311 H301 |
|
|
|
|
006-023-00-2 |
merkaptodimetur (ISO); metiokarb (ISO); metylokarbaminian 3,5-dimetylo-4-(metylotio)fenylu |
217-991-2 |
2032-65-7 |
Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H301 H400 H410 |
GHS06 GHS09 Dgr |
H301 H410 |
|
|
|
|
006-024-00-8 |
proksan sodowy (ISO); ditiokarbonian O-izopropylu-S-sodu |
205-443-5 |
140-93-2 |
Acute Tox. 4 * Skin Irrit. 2 Aquatic Chronic 2 |
H302 H315 H411 |
GHS07 GHS09 Wng |
H302 H315 H411 |
|
|
|
|
006-025-00-3 |
aletryna; (1RS,3RS;1RS,3SR)-2,2-dimetylo-3-(2-metyloprop-1-en-1-ylo)cyklopropanokarboksylan (RS)-3-allilo-2-metylo-4-oksocyklo-pent-2-en-1-ylu; bioaletryna; (1R,3R)-2,2-dimetylo-3-(2-metyloprop-1-en-1-ylo)-cyklopropanokarboksylan (RS)-3-allilo-2-metylo-4-oksocyklo-pent-2-en-1-ylu; [1] S-bioaletryna; [3] (1R,3R)-2,2-dimetylo-3-(2-metyloprop-1-en-1-ylo)cyklopropanokarboksylan (S)-3-allilo-2-metylo-4-oksocyklo-pent-2-en-1-ylu; [2] esbiotryna; (1R,3R)-2,2-dimetylo-3-(2-metyloprop-1-en-1-ylo)cyklopropanokarboksylan (RS)-3-allilo-2-metylo-4-oksocyklo-pent-2-en-1-ylu [3] |
209-542-4 [1] 249-013-5 [2]-[3] |
584-79-2 [1] 28434-00-6 [2] 84030-86-4 [3] |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H332 H302 H400 H410 |
GHS07 GHS09 Wng |
H332 H302 H410 |
|
|
C |
|
006-026-00-9 |
karbofuran (ISO); metylokarbaminian 2,2-dimetylo-2,3-dihydrobenzofuran-7-ylu |
216-353-0 |
1563-66-2 |
Acute Tox. 2 * Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H300 H400 H410 |
GHS06 GHS09 Dgr |
H330 H300 H410 |
|
|
|
|
006-028-00-X |
dinobuton (ISO); węglan 2-sec-butylo-4,6-dinitrofenylu-izopropylu |
213-546-1 |
973-21-7 |
Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H301 H400 H410 |
GHS06 GHS09 Dgr |
H301 H410 |
|
|
|
|
006-029-00-5 |
dioksakarb (ISO); metylokarbaminian 2-(1,3-dioksolan-2-ylo)fenylu |
230-253-4 |
6988-21-2 |
Acute Tox. 3 * Aquatic Chronic 2 |
H301 H411 |
GHS06 GHS09 Dgr |
H301 H411 |
|
|
|
|
006-030-00-0 |
EPTC (ISO); dipropylotiokarbaminian S-etylu |
212-073-8 |
759-94-4 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
006-031-00-6 |
formetanat (ISO); metylokarbaminian 3-[(dimetyloamino)-metylidenoamino]fenylu |
244-879-0 |
22259-30-9 |
Acute Tox. 2 * Acute Tox. 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H330 H300 H317 H400 H410 |
GHS06 GHS09 Dgr |
H330 H300 H317 H410 |
|
|
|
|
006-032-00-1 |
monolinuron (ISO); 3-(4-chlorofenylo)-1-metoksy-1-metylomocznik |
217-129-5 |
1746-81-2 |
Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373 ** H400 H410 |
GHS08 GHS07 GHS09 Wng |
H302 H373 ** H410 |
|
|
|
|
006-033-00-7 |
metoksuron (ISO); 3-(3-chloro-4-metoksyfenylo)-1,1-dimetylomocznik |
243-433-2 |
19937-59-8 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
006-034-00-2 |
pebulat (ISO); butylo(etylo)tiokarbaminian S-propylu |
214-215-4 |
1114-71-2 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
006-036-00-3 |
benzotiazuron (ISO); 1-(benzotiazol-2-ilo)-3-metylomocznik |
217-685-9 |
1929-88-0 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
006-037-00-9 |
promekarb (ISO); metylokarbaminian 3-izopropylo-5-metylofenylu |
220-113-0 |
2631-37-0 |
Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H301 H400 H410 |
GHS06 GHS09 Dgr |
H301 H410 |
|
|
|
|
006-038-00-4 |
sulfalat (ISO); dietyloditiokarbaminian 2-chloroallilu |
202-388-9 |
95-06-7 |
Carc. 1B Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H350 H302 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350 H302 H410 |
|
|
|
|
006-039-00-X |
trialat (ISO); diizopropylotiokarbaminian S-2,3,3-trichloroallilu |
218-962-7 |
2303-17-5 |
Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373 ** H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H302 H373 ** H317 H410 |
|
|
|
|
006-040-00-5 |
dimetylokarbaminian 3-metylopirazol-5-ilu; monometylan |
— |
2532-43-6 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * |
H331 H311 H301 |
GHS06 Dgr |
H331 H311 H301 |
|
|
|
|
006-041-00-0 |
chlorek dimetylokarbamoilu |
201-208-6 |
79-44-7 |
Carc. 1B Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H350 H331 H302 H319 H335 H315 |
GHS06 GHS08 Dgr |
H350 H331 H302 H319 H335 H315 |
|
Carc. 1B; H350: C ≥ 0,001 % |
|
|
006-042-00-6 |
monuron (ISO); 3-(4-chlorofenylo)-1,1-dimetylomocznik |
205-766-1 |
150-68-5 |
Carc. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H351 H302 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H302 H410 |
|
|
|
|
006-043-00-1 |
trichlorooctan 3-(4-chlorofenylo)-1,1-dimetylomocznika; monuron-TCA |
— |
140-41-0 |
Carc. 2 Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H319 H315 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H319 H315 H410 |
|
|
|
|
006-044-00-7 |
izoproturon (ISO); 3-(4-izopropylofenylo)-1,1-dimetylo-mocznik |
251-835-4 |
34123-59-6 |
Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H400 H410 |
GHS08 GHS09 Wng |
H351 H410 |
|
M = 10 |
|
|
006-045-00-2 |
metomyl (ISO); N-(metylokarbamoiloksy)acetoimidan metylu |
240-815-0 |
16752-77-5 |
Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H300 H400 H410 |
GHS06 GHS09 Dgr |
H300 H410 |
|
M=100 |
|
|
006-047-00-3 |
bufenokarb (ISO); masa poreakcyjna: N-metylokarbaminianu 3-(1-metylobutylo)fenylu i N-metylokarbaminianu 3-(1-etylopropylo)fenylu |
— |
8065-36-9 |
Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H311 H301 H410 |
|
|
|
|
006-048-00-9 |
etiofenkarb (ISO); metylokarbaminian 2-[(etylosulfanylo)-metylo]fenylu |
249-981-9 |
29973-13-5 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
006-049-00-4 |
diksantogen; ditiobis(tiomrówczan) O, O'-dietylu |
207-944-4 |
502-55-6 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
006-050-00-X |
trichlorooctan 3-fenylo-1,1-dimetylo-mocznika; fenuron-TCA |
— |
4482-55-7 |
Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H400 H410 |
GHS07 GHS09 Wng |
H315 H410 |
|
|
|
|
006-051-00-5 |
ferbam (ISO); tris(dimetyloditiokarbaminian) żelaza(III) |
238-484-2 |
14484-64-1 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H335 H315 H400 H410 |
GHS07 GHS09 Wng |
H319 H335 H315 H410 |
|
|
|
|
006-052-00-0 |
chlorowodorek formetanatu; chlorowodorek metylokarbaminianu 3-[(dimetyloamino)metylidenoamino]-fenylu |
245-656-0 |
23422-53-9 |
Acute Tox. 2 * Acute Tox. 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H330 H300 H317 H400 H410 |
GHS06 GHS09 Dgr |
H330 H300 H317 H410 |
|
|
|
|
006-053-00-6 |
izoprokarb (ISO); metylokarbaminian 2-izopropylofenylu |
220-114-6 |
2631-40-5 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
006-054-00-1 |
meksakarbat (ISO); metylokarbaminian 4-(dimetyloamino)-3,5-dimetylofenylu |
206-249-3 |
315-18-4 |
Acute Tox. 2 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H300 H312 H400 H410 |
GHS06 GHS09 Dgr |
H300 H312 H410 |
|
|
|
|
006-055-00-7 |
ksylikarb (ISO); metylokarbaminian 3,4-dimetylofenylu; metylokarbaminian 3,4-ksylilu; MPMC |
219-364-9 |
2425-10-7 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
006-056-00-2 |
metolkarb (ISO); metylokarbaminian m-tolilu; MTMC |
214-446-0 |
1129-41-5 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
006-057-00-8 |
nitrapiryna (ISO); 2-chloro-6-(trichlorometylo)pirydyna |
217-682-2 |
1929-82-4 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
006-058-00-3 |
noruron (ISO); 3-(perhydro-4,7-metanoindan-5-ylo)-1,1-dimetylomocznik |
— |
2163-79-3 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
006-059-00-9 |
oksamyl (ISO); O-(metylokarbamoilo)monooksym 2-(dimetyloamino)-1-(metylosulfanylo)-glioksalu; |
245-445-3 |
23135-22-0 |
Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 4 * Aquatic Chronic 2 |
H330 H300 H312 H411 |
GHS06 GHS09 Dgr |
H330 H300 H312 H411 |
|
|
|
|
006-060-00-4 |
oksykarboksyna (ISO); 4,4-ditlenek 2-metylo-5,6-dihydro-1,4-oksantiino-3-karboksyanilidu |
226-066-2 |
5259-88-1 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
006-061-00-X |
chlorowodorek [3-(dimetyloamino)-propylo]tiokarbaminianu S-etylu; chlorowodorek protiokarbu |
243-193-9 |
19622-19-6 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
006-062-00-5 |
(3,4-dichlorofenylo)karbaminian metylu; SWEP |
— |
1918-18-9 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
006-063-00-0 |
tiobenkarb (ISO); dietylotiokarbaminian S-4-chlorobenzylu |
248-924-5 |
28249-77-6 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
006-064-00-6 |
tiofanoks (ISO); O-(metylokarbamoilo)oksym 3,3-dimetylo-1-(metylosulfanylo)-butan-2-onu |
254-346-4 |
39196-18-4 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H310 H300 H410 |
|
|
|
|
006-065-00-1 |
O-(N-metylokarbamoilo)oksym 3-chloro-6-cyjano-bicyklo[2.2.1]heptan-2-onu; triamid |
— |
15271-41-7 |
Acute Tox. 2 * Acute Tox. 3 * Aquatic Chronic 2 |
H300 H311 H411 |
GHS06 GHS09 Dgr |
H300 H311 H411 |
|
|
|
|
006-066-00-7 |
wernolat (ISO); dipropylotiokarbaminian S-propylu; |
217-681-7 |
1929-77-7 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
006-067-00-2 |
XMC; metylokarbaminian 3,5-dimetylofenylu |
— |
2655-14-3 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
006-068-00-8 |
diazometan |
206-382-7 |
334-88-3 |
Carc. 1B |
H350 |
GHS08 Dgr |
H350 |
|
|
|
|
006-069-00-3 |
tiofanat metylowy (ISO); 1,2-di(3-metoksykarbonylo-2-tioksoureido)benzen |
245-740-7 |
23564-05-8 |
Muta. 2 Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H341 H332 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H341 H332 H317 H410 |
|
|
|
|
006-070-00-9 |
furmecykloks (ISO); N-cykloheksylo-N-metoksy-2,5-dimetylo-3-furoamid |
262-302-0 |
60568-05-0 |
Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H400 H410 |
GHS08 GHS09 Wng |
H351 H410 |
|
|
|
|
006-071-00-4 |
węglan cyklookt-4-en-1-ylu-metylu |
401-620-8 |
87731-18-8 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
006-072-00-X |
prosulfokarb (ISO); dipropylotiokarbaminian S-benzylu |
401-730-6 |
52888-80-9 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H317 H411 |
GHS07 GHS09 Wng |
H302 H317 H411 |
|
|
|
|
006-073-00-5 |
[3-(dimetyloamino)propylo]mocznik |
401-950-2 |
31506-43-1 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
006-074-00-0 |
izocyjanian 2-[3-(prop-1-en-2-ylo)fenylo]-propan-2-ylu |
402-440-2 |
2094-99-7 |
Acute Tox. 2 * Skin Corr. 1B STOT RE 2 * Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H330 H314 H373 ** H334 H317 H400 H410 |
GHS06 GHS08 GHS05 GHS09 Dgr |
H330 H314 H373 ** H334 H317 H410 |
|
|
|
|
006-076-00-1 |
mankozeb (ISO); kompleks cynku z manebem zawierający 20 % manganu i 2,5 % cynku |
— |
8018-01-7 |
Repr. 2 Skin Sens. 1 Aquatic Acute 1 |
H361d*** H317 H400 |
GHS08 GHS07 GHS09 Wng |
H361d*** H317 H400 |
|
M=10 |
|
|
006-077-00-7 |
maneb (ISO); polimeryczny etylenobis (ditiokarbaminian) manganu |
235-654-8 |
12427-38-2 |
Repr. 2 Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361d*** H332 H319 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H361d*** H332 H319 H317 H410 |
|
M=10 |
|
|
006-078-00-2 |
zineb (ISO); polimeryczny etylenobis-(ditiokarbaminian) cynku |
235-180-1 |
12122-67-7 |
STOT SE 3 Skin Sens. 1 |
H335 H317 |
GHS07 Wng |
H335 H317 |
|
|
|
|
006-079-00-8 |
disulfiram; disulfid tetraetylotiuramu |
202-607-8 |
97-77-8 |
Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373 ** H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H302 H373 ** H317 H410 |
|
|
|
|
006-080-00-3 |
monosulfid tetrametylotiuramu |
202-605-7 |
97-74-5 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H317 H411 |
GHS07 GHS09 Wng |
H302 H317 H411 |
|
|
|
|
006-081-00-9 |
bis(dibutyloditiokarbaminian) cynku |
205-232-8 |
136-23-2 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H335 H315 H317 H400 H410 |
GHS07 GHS09 Wng |
H319 H335 H315 H317 H410 |
|
|
|
|
006-082-00-4 |
bis(dietyloditiokarbaminian) cynku; bis(dietyloditiokarbamian) cynku |
238-270-9 |
14324-55-1 |
Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H319 H335 H315 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H319 H335 H315 H317 H410 |
|
|
|
|
006-083-00-X |
butokarboksym (ISO); O-[(metyloamino)karbonylo]oksym 3-(metylosulfanylo)butan-2-onu; O-metylokarbamoilooksym 3-(metylotio)butanonu |
252-139-3 |
34681-10-2 |
Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H226 H331 H311 H301 H319 H400 H410 |
GHS02 GHS06 GHS09 Dgr |
H226 H331 H311 H301 H319 H410 |
|
|
|
|
006-084-00-5 |
karbosulfan (ISO); (dibutyloaminotio)metylokarbaminian 2,3-dihydro-2,2-dimetylobenzofuran-7-ylu; (dibutyloaminosulfanylo)metylo-karbamian 2,2-dimetylo-2,3-dihydro-benzofuran-7-ylu |
259-565-9 |
55285-14-8 |
Acute Tox. 2 * Acute Tox. 3 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H330 H301 H317 H400 H410 |
GHS06 GHS09 Dgr |
H330 H301 H317 H410 |
|
|
|
|
006-085-00-0 |
fenobukarb (ISO); metylokarbaminian (RS)-2-sec-butylo-fenylu |
223-188-8 |
3766-81-2 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
006-086-00-6 |
fenoksykarb (ISO); 2-(4-fenoksyfenoksy)etylokarbaminian etylu |
276-696-7 |
72490-01-8 |
Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H400 H410 |
GHS08 GHS09 Wng |
H351 H410 |
|
M = 1 M = 10 000 |
|
|
006-087-00-1 |
furatiokarb (ISO); 2,4-dimetylo-6-oksa-5-okso-3-tia-2,4-diazadekanian 2,2-dimetylo-2,3-dihydrobenzofuran-7-ylu; N, N'-dimetylo-N, N'-tiodikarbaminian butylu-2,2-dimetylo-2,3-dihydrobenzofuran-7-ylu |
265-974-3 |
65907-30-4 |
Acute Tox. 2 * Acute Tox. 3 * STOT RE 2 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H330 H301 H373** H319 H315 H317 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H330 H301 H373** H319 H315 H317 H410 |
|
M = 100 |
|
|
006-088-00-7 |
benfurakarb (ISO); N-[2,2-dimetylo-2,3-dihydrobenzofuran-7-yloksykarbonylo(metylo)aminotio]-N-izopropylo-β-alaninian etylu; N-[2,2-dimetylo-2,3-dihydrobenzofuran-7-yloksykarbonylo(metylo)aminosulfanylo]-N-izopropylo-β-alaninian etylu |
— |
82560-54-1 |
Repr. 2 Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H361f*** H331 H302 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H361f*** H331 H302 H410 |
|
|
|
|
006-090-00-8 |
fenylokarbaminian 2-(3-jodoprop-2-yn-1-yloksy)etylu; fenylokarbamian 2-(3-jodoprop-2-yn-1-yloksy)etylu |
408-010-0 |
88558-41-2 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H332 H318 H412 |
GHS05 GHS07 Dgr |
H332 H318 H412 |
|
|
|
|
006-091-00-3 |
propineb (ISO); polimeryczny propylenobis(ditiokarbaminian) cynku |
— |
9016-72-2 |
Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 |
H332 H373** H317 H400 |
GHS08 GHS07 GHS09 Wng |
H332 H373** H317 H400 |
|
|
|
|
006-092-00-9 |
(1S)-N-[1-((2S)-2-oksiranylo)-2-fenyloetylo]karbaminian tert-butylu |
425-420-5 |
98737-29-2 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
006-093-00-4 |
2,2'-ditio di(etyloamoniowy)-bis (dibenzyloditiokarbaminian) |
427-180-7 |
— |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|
|
|
|
006-094-00-X |
N-etoksykarbonylotiokarbaminian O-izobutylu |
434-350-4 |
103122-66-3 |
Flam. Liq. 3 Carc. 1B Muta. 1B Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 |
H226 H350 H340 H302 H373** H317 H411 |
GHS02 GHS08 GHS07 GHS09 Dgr |
H226 H350 H340 H302 H373** H317 H411 |
|
|
|
|
006-095-00-5 |
fosetyl glinu (ISO); tris(etylofosfonian) glinu |
254-320-2 |
39148-24-8 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
006-096-00-0 |
chloroprofam (ISO); 3-chlorokarbanilan izopropylu |
202-925-7 |
101-21-3 |
Carc. 2 STOT RE 2 * Aquatic Chronic 2 |
H351 H373** H411 |
GHS08 GHS09 Wng |
H351 H373** H411 |
|
|
|
|
006-097-00-6 |
l-fenylo-3-(p-toluenosulfonylo)-mocznik |
424-620-1 |
13909-63-2 |
Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 3 |
H302 H373** H412 |
GHS08 GHS07 Wng |
H302 H373** H412 |
|
|
|
|
006-098-00-1 |
(lR,5S)-3-azabicyklo[3.1.0]-heks-6-ylokarbaminian tert-butylu |
429-170-8 |
134575-17-0 |
Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 |
H302 H373** H318 H317 |
GHS05 GHS08 GHS07 Dgr |
H302 H373** H318 H317 |
|
|
|
|
006-099-00-7 |
N-(p-toluenosulfonylo)-N'-(3-(p-toluenosulfonyloksy)fenylo)mocznik; 4-metylobenzenosulfonian 3-({[(4-metylofenylo)sulfonylo]karbamoilo}amino)fenylu |
520-2 |
232938-43-1 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
006-101-00-6 |
masa poreakcyjna: N, N"-(metylenodi-4,1-fenyleno)bis[N'-fenylomocznika]; N-(4-{{4-{{(fenyloamino)karbanylo]amino]fenylometylo]fenylo-N'-cykloheksylomocznika; N, N"-(metylenodi-4,1-fenyleno)bis[N'-cykloheksylomocznika] |
423-070-8 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
006-102-00-1 |
N-etoksykarbonylotiokarbaminian O-heksylu |
432-750-3 |
— |
Carc. 1B Muta. 1B Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 |
H350 H340 H302 H373** H317 H411 |
GHS08 GHS07 GHS09 Dgr |
H350 H340 H302 H373** H317 H411 |
|
|
|
|
006-103-00-7 |
N, N"-(metylenodi-4,1-fenyleno)bis[N'-oktylo]mocznik |
445-760-8 |
— |
Eye Dam. 1 Resp. Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H334 H400 H410 |
GHS05 GHS08 GHS09 Dgr |
H318 H334 H410 |
|
M=100 |
|
|
007-001-00-5 |
amoniak bezwodny |
231-635-3 |
7664-41-7 |
Flam. Gas 2 Press. Gas Acute Tox. 3 * Skin Corr. 1B Aquatic Acute 1 |
H221 H331 H314 H400 |
GHS04 GHS06 GHS05 GHS09 Dgr |
H221 H331 H314 H400 |
|
|
U |
|
007-001-01-2 |
amoniak, roztwór … % |
215-647-6 |
1336-21-6 |
Skin Corr. 1B Aquatic Acute 1 |
H314 H400 |
GHS05 GHS09 Dgr |
H314 H400 |
|
STOT SE 3; H335: C ≥ 5 % |
B |
|
007-002-00-0 |
ditlenek azotu; [1] tetratlenek diazotu [2] |
233-272-6 [1] 234-126-4 [2] |
10102-44-0 [1] 10544-72-6 [2] |
Press. Gas Ox. Gas 1 Acute Tox. 2 * Skin Corr. 1B |
H270 H330 H314 |
GHS04 GHS03 GHS06 GHS05 Dgr |
H270 H330 H314 |
|
* STOT SE 3; H335: C ≥0,5 % |
5 |
|
007-003-00-6 |
chloromekwatu chlorek (ISO); chlorek (2-chloroetylo)trimetyloamoniowy |
213-666-4 |
999-81-5 |
Acute Tox. 4 * Acute Tox. 4 * |
H312 H302 |
GHS07 Wng |
H312 H302 |
|
|
|
|
007-006-00-2 |
azotan(III) etylu |
203-722-6 |
109-95-5 |
Flam. Gas 1 Press. Gas Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H220 H332 H312 H302 |
GHS02 GHS04 GHS07 Dgr |
H220 H332 H312 H302 |
|
|
U |
|
007-007-00-8 |
azotan(V) etylu |
210-903-3 |
625-58-1 |
Unst. Expl. |
H200 |
GHS01 Dgr |
H200 |
|
|
|
|
007-008-00-3 |
hydrazyna |
206-114-9 |
302-01-2 |
Flam. Liq. 3 Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H226 H350 H331 H311 H301 H314 H317 H400 H410 |
GHS02 GHS06 GHS08 GHS05 GHS09 Dgr |
H226 H350 H331 H311 H301 H314 H317 H410 |
|
Skin Corr. 1B; H314: C ≥ 10 % Skin Irrit. 2; H315: 3 % ≤ C < 10 % Eye Irrit. 2; H319: 3 % ≤ C < 10 % |
|
|
007-009-00-9 |
azotan(III) dicykloheksyloamoniowy; azotyn dicykloheksyloamoniowy |
221-515-9 |
3129-91-7 |
Acute Tox. 4 * Acute Tox. 4 * |
H332 H302 |
GHS07 Wng |
H332 H302 |
|
* |
|
|
007-010-00-4 |
azotan(III) sodu; azotyn sodu |
231-555-9 |
7632-00-0 |
Ox. Sol. 3 Acute Tox. 3 * Aquatic Acute 1 |
H272 H301 H400 |
GHS03 GHS06 GHS09 Dgr |
H272 H301 H400 |
|
* |
|
|
007-011-00-X |
azotan(III) potasu; azotyn potasu |
231-832-4 |
7758-09-0 |
Ox. Sol. 2 Acute Tox. 3 * Aquatic Acute 1 |
H272 H301 H400 |
GHS03 GHS06 GHS09 Dgr |
H272 H301 H400 |
|
* |
|
|
007-012-00-5 |
N, N-dimetylohydrazyna |
200-316-0 |
57-14-7 |
Flam. Liq. 2 Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Aquatic Chronic 2 |
H225 H350 H331 H301 H314 H411 |
GHS02 GHS06 GHS08 GHS05 GHS09 Dgr |
H225 H350 H331 H301 H314 H411 |
|
|
|
|
007-013-00-0 |
1,2-dimetylohydrazyna |
— |
540-73-8 |
Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Chronic 2 |
H350 H331 H311 H301 H411 |
GHS06 GHS08 GHS09 Dgr |
H350 H331 H311 H301 H411 |
|
Carc. 1B; H350: C ≥ 0,01 % |
|
|
007-014-00-6 |
sole hydrazyny |
— |
— |
Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H331 H311 H301 H317 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H350 H331 H311 H301 H317 H410 |
|
|
A |
|
007-015-00-1 |
O-etylohydroksyloamina |
402-030-3 |
624-86-2 |
Flam. Liq. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 |
H225 H331 H311 H301 H372 ** H319 H317 H400 |
GHS02 GHS06 GHS08 GHS09 Dgr |
H225 H331 H311 H301 H372 ** H319 H317 H400 |
|
|
|
|
007-016-00-7 |
azotan(III) butylu; azotyn butylu |
208-862-1 |
544-16-1 |
Flam. Liq. 2 Acute Tox. 3 * Acute Tox. 3 * |
H225 H331 H301 |
GHS02 GHS06 Dgr |
H225 H331 H301 |
|
|
|
|
007-017-00-2 |
azotan(III) izobutylu; azotyn izobutylu |
208-819-7 |
542-56-3 |
Flam. Liq. 2 Carc. 1B Muta. 2 Acute Tox. 4 * Acute Tox. 4 * |
H225 H350 H341 H332 H302 |
GHS02 GHS08 GHS07 Dgr |
H225 H350 H341 H332 H302 |
|
|
|
|
007-018-00-8 |
azotan(III) sec-butylu; azotyn sec-butylu; |
213-104-8 |
924-43-6 |
Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * |
H225 H332 H302 |
GHS02 GHS07 Dgr |
H225 H332 H302 |
|
|
|
|
007-019-00-3 |
azotan(III) tert-butylu; azotyn tert-butylu; |
208-757-0 |
540-80-7 |
Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * |
H225 H332 H302 |
GHS02 GHS07 Dgr |
H225 H332 H302 |
|
|
|
|
007-020-00-9 |
azotan(III) pentylu; azotyn pentylu; [1] „azotyn amylu”, mieszanina izomerów [2] |
207-332-7 [1] 203-770-8 [2] |
463-04-7 [1] 110-46-3 [2] |
Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * |
H225 H332 H302 |
GHS02 GHS07 Dgr |
H225 H332 H302 |
|
|
|
|
007-021-00-4 |
hydrazobenzen; 1,2-difenylohydrazyna |
204-563-5 |
122-66-7 |
Carc. 1B Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H350 H302 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350 H302 H410 |
|
|
|
|
007-022-00-X |
bis(3-karboksy-4-hydroksybenzenosulfonian) hydrazyn-1,2-ium; bis(3-karboksy-4-hydroksybenzenosulfonian) hydrazyny |
405-030-1 |
— |
Carc. 1B Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 3 |
H350 H302 H314 H317 H412 |
GHS08 GHS05 GHS07 Dgr |
H350 H302 H314 H317 H412 |
|
|
|
|
007-023-00-5 |
3,5-bis[3-(2,4-di-tert-pentylofenoksy)propylokarbamoilo]benzenosulfonian sodu |
405-510-0 |
— |
Skin Irrit. 2 Skin Sens. 1 |
H315 H317 |
GHS07 Wng |
H315 H317 |
|
|
|
|
007-024-00-0 |
chlorek 2-(decylosulfanylo)etyloamoniowy; chlorek 2-(decylotio)etyloamoniowy |
405-640-8 |
36362-09-1 |
STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H373 ** H315 H318 H400 H410 |
GHS08 GHS05 GHS09 Dgr |
H373 ** H315 H318 H410 |
|
|
|
|
007-025-00-6 |
chlorowodorek (4-hydrazynofenylo)-N-metylometanosulfonoamidu |
406-090-1 |
81880-96-8 |
Muta. 2 Acute Tox. 3 * STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H341 H301 H372 ** H317 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H341 H301 H372 ** H317 H410 |
|
|
|
|
007-026-00-1 |
okso-[(2,2,6,6-tetrametylopiperydyn-4-ylo)amino]karbonyloacetohydrazyd |
413-230-5 |
122035-71-6 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
007-027-00-7 |
1,6-bis{3,3-bis[(1-metylopentylidenoimino)propylo]ureido}heksan |
420-190-2 |
771478-66-1 |
Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H373 ** H314 H317 H400 H410 |
GHS08 GHS05 GHS07 GHS09 Dgr |
H312 H302 H373 ** H314 H317 H410 |
|
|
|
|
007-028-00-2 |
azotan hydroksyloamonu |
236-691-2 |
13465-08-2 |
Expl. 1.1 **** Carc. 2 Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 |
H201 H351 H311 H302 H373** H319 H315 H317 H400 |
GHS01 GHS06 GHS08 GHS09 Dgr |
H201 H351 H311 H302 H373** H319 H315 H317 H400 |
|
|
|
|
007-029-00-8 |
wodorotlenek dietylodimetyloamoniowy |
419-400-5 |
95500-19-9 |
Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A |
H312 H302 H314 |
GHS05 GHS07 Dgr |
H312 H302 H314 |
|
|
|
|
008-001-00-8 |
tlen |
231-956-9 |
7782-44-7 |
Ox. Gas 1 Press. Gas |
H270 |
GHS03 GHS04 Dgr |
H270 |
|
|
U |
|
008-003-00-9 |
nadtlenek wodoru, roztwór … % |
231-765-0 |
7722-84-1 |
Ox. Liq. 1 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A |
H271 H332 H302 H314 |
GHS03 GHS05 GHS07 Dgr |
H271 H332 H302 H314 |
|
Ox. Liq. 1; H271: C ≥70 %**** Ox. Liq. 2; H272: 50 % ≤ C < 70 % **** * Skin Corr. 1A; H314: C ≥ 70 % Skin Corr. 1B; H314: 50 % ≤ C < 70 % Skin Irrit. 2; H315: 35 % ≤ C < 50 % Eye Dam. 1; H318: 8 % ≤ C < 50 % Eye Irrit. 2; H319: 5 % ≤ C< 8 % STOT SE 3; H335; C ≥ 35 % |
B |
|
009-001-00-0 |
fluor |
231-954-8 |
7782-41-4 |
Press. Gas Ox. Gas 1 Acute Tox. 2 * Skin Corr. 1A |
H270 H330 H314 |
GHS04 GHS03 GHS06 GHS05 Dgr |
H270 H330 H314 |
|
|
|
|
009-002-00-6 |
fluorowodór |
231-634-8 |
7664-39-3 |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Skin Corr. 1A |
H330 H310 H300 H314 |
GHS06 GHS05 Dgr |
H330 H310 H300 H314 |
|
|
|
|
009-003-00-1 |
kwas fluorowodorowy … % |
231-634-8 |
7664-39-3 |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Skin Corr. 1A |
H330 H310 H300 H314 |
GHS06 GHS05 Dgr |
H330 H310 H300 H314 |
|
Skin Corr. 1A; H314: C ≥ 7 % Skin Corr. 1B; H314: 1 % ≤ C< 7 % Eye Irrit. 2; H319: 0,1 % ≤C < 1 % |
B |
|
009-004-00-7 |
fluorek sodu |
231-667-8 |
7681-49-4 |
Acute Tox. 3 * Eye Irrit. 2 Skin Irrit. 2 |
H301 H319 H315 |
GHS06 Dgr |
H301 H319 H315 |
EUH032 |
|
|
|
009-005-00-2 |
fluorek potasu |
232-151-5 |
7789-23-3 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * |
H331 H311 H301 |
GHS06 Dgr |
H331 H311 H301 |
|
|
|
|
009-006-00-8 |
fluorek amonu |
235-185-9 |
12125-01-8 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * |
H331 H311 H301 |
GHS06 Dgr |
H331 H311 H301 |
|
|
|
|
009-007-00-3 |
fluorek sodu-fluorowodór(1/1); wodorofluorek sodu; kwaśny fluorek sodu |
215-608-3 |
1333-83-1 |
Acute Tox. 3 * Skin Corr. 1B |
H301 H314 |
GHS06 GHS05 Dgr |
H301 H314 |
|
*Skin Corr. 1B; H314: C ≥ 1 % Skin Irrit. 2; H315: 0,1 % ≤ C < % Eye Irrit. 2; H319: 0,1 % ≤ C < 1 % |
|
|
009-008-00-9 |
fluorek potasu-fluorowodór(1/1); wodorofluorek potasu; kwaśny fluorek potasu |
232-156-2 |
7789-29-9 |
Acute Tox. 3 * Skin Corr. 1B |
H301 H314 |
GHS06 GHS05 Dgr |
H301 H314 |
|
* Skin Corr. 1B; H314: C ≥ 1 % Skin Irrit. 2; H315: 0,1 % ≤ C < 1 % Eye Irrit. 2; H319: 0,1 % ≤ C < 1 % |
|
|
009-009-00-4 |
fluorek amonu-fluorowodór(1/1); wodorofluorek amonu; kwaśny fluorek amonu |
215-676-4 |
1341-49-7 |
Acute Tox. 3 * Skin Corr. 1B |
H301 H314 |
GHS06 GHS05 Dgr |
H301 H314 |
|
* Skin Corr. 1B; H314: C ≥ 1 % Skin Irrit.2; H315: 0,1 % ≤ C < 1 % Eye Irrit. 2; H319: 0,1 % ≤ C < 1 % |
|
|
009-010-00-X |
kwas tetrafluoroborowy … % |
240-898-3 |
16872-11-0 |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
|
Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 % Eye Irrit. 2; H319: 10 % ≤ C < 25 % |
B |
|
009-011-00-5 |
kwas heksafluorokrzemowy … % |
241-034-8 |
16961-83-4 |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
|
|
B |
|
009-012-00-0 |
heksafluorokrzemiany alkaliczne (sodu); [1] heksafluorokrzemiany alkaliczne (potasu); [2] heksafluorokrzemiany alkaliczne (amonu) [3] |
240-934-8 [1] 240-896-2 [2] 240-968-3 [3] |
16893-85-9 [1] 16871-90-2 [2] 16919-19-0 [3] |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * |
H331 H311 H301 |
GHS06 Dgr |
H331 H311 H301 |
|
* |
A |
|
009-013-00-6 |
heksafluorokrzemiany, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
* |
A |
|
009-014-00-1 |
heksafluorokrzemian ołowiu(II) |
247-278-1 |
25808-74-6 |
Repr. 1A Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H360Df H332 H302 H373 ** H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H360Df H332 H302 H373 ** H410 |
|
|
1 |
|
009-015-00-7 |
difluorek sulfurylu; fluorek sulfonylu; fluorek sulfurylu |
220-281-5 |
2699-79-8 |
Press. Gas Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 |
H331 H373 ** H400 |
GHS04 GHS06 GHS08 GHS09 Dgr |
H331 H373 ** H400 |
|
|
U |
|
009-016-00-2 |
heksafluoroglinian trisodu [1] heksafluorek glinu i sodu (kryolit) [2] |
237-410-6 [1] 239-148-8 [2] |
13775-53-6 [1] 15096-52-3 [2] |
STOT RE 1 Acute Tox. 4 Aquatic Chronic 2 |
H372 H332 H411 |
GHS07 GHS08 GHS09 Dgr |
H372 H332 H411 |
|
|
|
|
009-017-00-8 |
μ-fluoro-bis(trietyloglinian) potasu |
400-040-2 |
12091-08-6 |
Flam. Sol. 1 Water-react. 1 Skin Corr. 1A Acute Tox. 4 * |
H228 H270 H314 H332 |
GHS02 GHS05 GHS07 Dgr |
H228 H270 H314 H332 |
EUH014 |
|
T |
|
009-018-00-3 |
heksafluorokrzemian magnezu |
241-022-2 |
16949-65-8 |
Acute Tox. 3 * |
H301 |
GHS06 Dgr |
H301 |
|
* |
|
|
011-001-00-0 |
sód |
231-132-9 |
7440-23-5 |
Water-react. 1 Skin Corr. 1B |
H260 H314 |
GHS02 GHS05 Dgr |
H260 H314 |
EUH014 |
|
|
|
011-002-00-6 |
wodorotlenek sodu; soda kaustyczna |
215-185-5 |
1310-73-2 |
Skin Corr. 1A |
H314 |
GHS05 Dgr |
H314 |
|
Skin Corr. 1A; H314: C ≥ 5 % Skin Corr. 1B; H314 2 % ≤ C < 5 % Skin Irrit. 2; H315: 0,5 % ≤ C < 2 % Eye Irrit.2; H319: 0,5 % ≤ C < 2 % |
|
|
011-003-00-1 |
nadtlenek sodu |
215-209-4 |
1313-60-6 |
Ox. Sol. 1 Skin Corr. 1A |
H271 H314 |
GHS03 GHS05 Dgr |
H271 H314 |
|
|
|
|
011-004-00-7 |
azydek sodu |
247-852-1 |
26628-22-8 |
Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H300 H400 H410 |
GHS06 GHS09 Dgr |
H300 H400 H410 |
EUH032 |
|
|
|
011-005-00-2 |
węglan sodu; węglan disodu |
207-838-8 |
497-19-8 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
011-006-00-8 |
cyjanian sodu |
213-030-6 |
917-61-3 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
011-007-00-3 |
propoksykarbazon sodowy |
— |
181274-15-7 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
M = 10 |
|
|
012-001-00-3 |
proszek magnezowy (piroforyczny) |
231-104-6 |
7439-95-4 |
Water-react. 1 Pyr. Sol. 1 |
H260 H250 |
GHS02 Dgr |
H260 H250 |
|
|
T |
|
012-002-00-9 |
magnez, proszek lub skrawki |
231-104-6 |
— |
Flam. Sol. 1 Water-react. 2 Self-heat. 1 |
H228 H261 H252 |
GHS02 Dgr |
H228 H261 H252 |
|
|
T |
|
012-003-00-4 |
magnezu alkilowe pochodne |
— |
— |
Pyr. Liq. 1 Water-react. 1 Skin Corr. 1B |
H250 H260 H314 |
GHS02 GHS05 Dgr |
H250 H260 H314 |
EUH014 |
|
A |
|
012-004-00-X |
nadchloran węglan wodorotlenek glinu-magnezu hydrat |
422-150-1 |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
013-001-00-6 |
proszek aluminiowy (piroforyczny) |
231-072-3 |
7429-90-5 |
Water-react. 2 Pyr. Sol. 1 |
H261 H250 |
GHS02 Dgr |
H261 H250 |
|
|
T |
|
013-002-00-1 |
proszek aluminiowy stabilizowany |
231-072-3 |
7429-90-5 |
Water-react. 2 Flam. Sol. 1 |
H261 H228 |
GHS02 Dgr |
H261 H228 |
|
|
T |
|
013-003-00-7 |
trichlorek glinu, bezwodny |
231-208-1 |
7446-70-0 |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
|
|
|
|
013-004-00-2 |
glinu(III) alkilowe pochodne |
— |
— |
Pyr. Liq. 1 Water-react. 1 Skin Corr. 1B |
H250 H260 H314 |
GHS02 GHS05 Dgr |
H250 H260 H314 |
EUH014 |
|
A |
|
013-005-00-8 |
dietylo(etylodimetylosiloksy)glin(III) |
401-160-8 |
55426-95-4 |
Water-react. 1 Pyr. Liq. 1 Skin Corr. 1A |
H260 H250 H314 |
GHS02 GHS05 Dgr |
H260 H250 H314 |
EUH014 |
|
|
|
013-006-00-3 |
dimer (3-oksobutaniano-O’1,O’3etylo)-(2-dimetyloaminoetanolano)(1-metoksy-2-propanolano)glinu(III) |
402-370-2 |
— |
Flam. Liq. 3 Eye Dam. 1 |
H226 H318 |
GHS02 GHS05 Dgr |
H226 H318 |
|
|
|
|
013-007-00-9 |
poli[okso(2-butoksyetylo-3-oksobuteniano-O’1,O’3)glin] |
403-430-0 |
— |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
013-008-00-4 |
jodek dioktyloglinu |
408-190-0 |
7585-14-0 |
Pyr. Liq. 1 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H250 H314 H400 H410 |
GHS02 GHS05 GHS09 Dgr |
H250 H314 H410 |
EUH014 |
|
|
|
013-009-00-X |
(n-butylo)x(etylo)y-1,5-dihydroglinian sodu, x=0,5 y=1,5 |
418-720-2 |
— |
Flam. Sol. 1 Water-react. 1 Pyr. Sol. 1 Acute Tox. 4 * Skin Corr. 1A |
H228 H260 H250 H332 H314 |
GHS02 GHS05 GHS07 Dgr |
H228 H260 H250 H332 H314 |
EUH014 |
|
T |
|
013-010-00-5 |
bis(2,4,8,10-tetra-tert-butylo-6-hydroksy-12H-dibenzo[d, g][1.3.2] dioksafosfocyn-6-tlenek) hydroksy-glinu |
430-650-4 |
151841-65-5 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
014-001-00-9 |
trichlorosilan |
233-042-5 |
10025-78-2 |
Flam. Liq. 1 Pyr. Liq. 1 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A |
H224 H250 H332 H302 H314 |
GHS02 GHS05 GHS07 Dgr |
H224 H250 H332 H302 H314 |
EUH014 EUH029 |
* STOT SE 3; H335: C ≥ 1 % |
T |
|
014-002-00-4 |
tetrachlorosilan; tetrachlorek krzemu |
233-054-0 |
10026-04-7 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H319 H335 H315 |
GHS07 Wng |
H319 H335 H315 |
EUH014 |
|
|
|
014-003-00-X |
dichlorodimetylosilan |
200-901-0 |
75-78-5 |
Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H225 H319 H335 H315 |
GHS02 GHS07 Dgr |
H225 H319 H335 H315 |
|
|
|
|
014-004-00-5 |
trichloro(metylo)silan; metylotrichlorosilan |
200-902-6 |
75-79-6 |
Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H225 H319 H335 H315 |
GHS02 GHS07 Dgr |
H225 H319 H335 H315 |
EUH014 |
Skin Irrit.2; H315: C ≥ 1 % Eye Irrit. 2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 % |
|
|
014-005-00-0 |
tetraetoksysilan; ortokrzemian tetraetylu; krzemian etylu |
201-083-8 |
78-10-4 |
Flam. Liq. 3 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 |
H226 H332 H319 H335 |
GHS02 GHS07 Wng |
H226 H332 H319 H335 |
|
|
|
|
014-006-00-6 |
chlorowodorek bis(4-fluorofenylo)metylo[(1,2,4-triazol-4-ilo)metylo]silanu |
401-380-4 |
— |
Eye Irrit. 2 Aquatic Chronic 2 |
H319 H411 |
GHS07 GHS09 Wng |
H319 H411 |
|
|
|
|
014-007-00-1 |
trietoksy(izobutylo)silan |
402-810-3 |
17980-47-1 |
Skin Irrit. 2 |
H315 |
GHS07 Wng |
H315 |
|
|
|
|
014-008-00-7 |
(chlorometylo)bis(4-fluorofenylo)(metylo)silan |
401-200-4 |
85491-26-5 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
014-009-00-2 |
izobutylo(izopropylo)dimetoksysilan |
402-580-4 |
111439-76-0 |
Flam. Liq. 3 Acute Tox. 4 * Skin Irrit. 2 |
H226 H332 H315 |
GHS02 GHS07 Wng |
H226 H332 H315 |
|
|
|
|
014-010-00-8 |
metakrzemian disodu |
229-912-9 |
6834-92-0 |
Skin Corr. 1B STOT SE 3 |
H314 H335 |
GHS05 GHS07 Dgr |
H314 H335 |
|
|
|
|
014-011-00-3 |
cykloheksylo(dimetoksy)metylosilan |
402-140-1 |
17865-32-6 |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
014-012-00-9 |
bis[3-(trimetoksysililo)propylo]amina |
403-480-3 |
— |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|
|
|
|
014-013-00-4 |
α-hydroksypoli{metylo-[3-(2,2,6,6-tetrametylopiperydyn-4-yloksy)propylo]siloksan} |
404-920-7 |
— |
Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 |
H312 H302 H314 H411 |
GHS05 GHS07 GHS09 Dgr |
H312 H302 H314 H411 |
|
|
|
|
014-014-00-X |
etacelasil (ISO); 6-(2-chloroetylo)-6-(2-metoksyetoksy)-2,5,7,10-tetraoksa-6-silaundekan; 2-chloroetylotris(2-metoksyetoksy)silan |
253-704-7 |
37894-46-5 |
Repr. 1B Acute Tox. 4 * STOT RE 2 * |
H360D *** H302 H373 ** |
GHS08 GHS07 Dgr |
H360D *** H302 H373 ** |
|
|
|
|
014-015-00-5 |
α-trimetylosilanylo-ω-trimetylosiloksy-poli[(oksy{metylo-3-[2-(2-metoksypropoksy)propoksy]propylo}silanodiylo)-co-oksy(dimetylosilan)] |
406-420-4 |
69430-40-6 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
014-016-00-0 |
masa poreakcyjna: 1,3-di(heks-5-en-1-ylo)-1,1,3,3-tetrametylodisiloksanu; 1,3-di(heks-n-en-1-ylo)-1,1,3,3-tetrametylodisiloksanu |
406-490-6 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
014-017-00-6 |
flusilazol (ISO); bis(4-fluorofenylo)(metylo)(1H-1,2,4-triazol-1-ilometylo)silan |
— |
85509-19-9 |
Carc. 2 Repr. 1B Acute Tox. 4 * Aquatic Chronic 2 |
H351 H360D *** H302 H411 |
GHS08 GHS07 GHS09 Dgr |
H351 H360D *** H302 H411 |
|
|
|
|
014-018-00-1 |
oktametylocyklotetrasiloksan |
209-136-7 |
556-67-2 |
Repr. 2 Aquatic Chronic 4 |
H361f *** H413 |
GHS08 Wng |
H361f *** H413 |
|
|
|
|
014-019-00-7 |
masa poreakcyjna: 4-{[bis(4-fluorofenylo)metylosililo]metylo}-4H-1,2,4-triazolu; 1-{[bis(4-fluorofenylo)metylosililo]metylo}-1H-1,2,4-triazolu |
403-250-2 |
— |
Carc. 2 Repr. 1B Acute Tox. 4 * Aquatic Chronic 2 |
H351 H360D *** H302 H411 |
GHS08 GHS07 GHS09 Dgr |
H351 H360D *** H302 H411 |
|
|
|
|
014-020-00-2 |
bis(1,1-dimetyloprop-2-yn-1-yloksy)dimetylosilan |
414-960-7 |
53863-99-3 |
Acute Tox. 4 * |
H332 |
GHS07 Wng |
H332 |
|
|
|
|
014-021-00-8 |
tris(izopropenyloksy)fenylosilan |
411-340-8 |
52301-18-5 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H400 H410 |
|
|
|
|
014-022-00-3 |
produkt reakcji: 2-hydroksy-4-(prop-3-en-1-yloksy)benzofenonu i trietoksysilanu z produktem hydrolizy krzemionki i metylotrimetoksysilanu |
401-530-9 |
— |
Flam. Sol. 1 STOT SE 1 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H228 H370 ** H332 H312 H302 |
GHS02 GHS08 GHS07 Dgr |
H228 H370 ** H332 H312 H302 |
|
|
T |
|
014-023-00-9 |
α, ω-dihydroksypoli(heks-5-en-1-ylometylosiloksanu) z produktem hydrolizy krzemionki i metylotrimetoksysilanu |
408-160-7 |
125613-45-8 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
014-024-00-4 |
1-{[3-(3-chloro-4-fluorofenylo)propylo]dimetylosilanylo}-4-etoksybenzen |
412-620-2 |
121626-74-2 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
014-025-00-X |
4-[3-(dietoksymetylosililo)propoksy]-2,2,6,6-tetrametylopiperydyna |
411-400-3 |
102089-33-8 |
Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 |
H302 H373 ** H315 H318 H412 |
GHS08 GHS05 GHS07 Dgr |
H302 H373 ** H315 H318 H412 |
|
|
|
|
014-026-00-5 |
dichloro[3-(3-chloro-4-fluorofenylo)propylo]metylosilan |
407-180-3 |
770722-36-6 |
Skin Corr. 1A |
H314 |
GHS05 Dgr |
H314 |
|
|
|
|
014-027-00-0 |
chloro[3-(3-chloro-4-fluorofenylo)propylo]dimetylosilan |
410-270-5 |
770722-46-8 |
Skin Corr. 1A |
H314 |
GHS05 Dgr |
H314 |
|
|
|
|
014-028-00-6 |
α-[3-(1-oksoprop-2-enylo)-1-oksypropylo]dimetoksysililoksy-ω-[3-(1-oksoprop-2-enylo)-1-oksypropylo]dimetoksysililopoli(dimetylosiloksan) |
415-290-8 |
193159-06-7 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
014-029-00-1 |
O, O'-(etenylometylosilileno)di(oksym 4-metylopentan-2-onu) |
421-870-1 |
156145-66-3 |
Repr. 2 Acute Tox. 4 * STOT RE 2 * |
H361f *** H302 H373 ** |
GHS08 GHS07 Wng |
H361f *** H302 H373 ** |
|
|
|
|
014-030-00-7 |
[(dimetylosilileno)bis(1,2,3,3a,7a-η-1H-inden-1-ylideno)dimetylo]hafn |
422-060-0 |
137390-08-0 |
Acute Tox. 2 * |
H300 |
GHS06 Dgr |
H300 |
|
|
|
|
014-031-00-2 |
bis(1-metyloetylo)dimetoksysilan |
421-540-7 |
18230-61-0 |
Flam. Liq. 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 |
H226 H315 H317 H412 |
GHS02 GHS07 Wng |
H226 H315 H317 H412 |
|
|
|
|
014-032-00-8 |
dicyklopentylodimetoksysilan |
404-370-8 |
126990-35-0 |
Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H400 H410 |
GHS05 GHS09 Dgr |
H315 H318 H410 |
|
|
|
|
014-033-00-3 |
2-propenian 2-metylo-3-(trimetoksysililo)propylu, produkt hydrolizy z ditlenkiem krzemu |
419-030-4 |
125804-20-8 |
Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 |
H225 H319 H336 |
GHS02 GHS07 Dgr |
H225 H319 H336 |
|
|
|
|
014-034-00-9 |
3-heksyloheptametylotrisiloksan |
428-700-5 |
1873-90-1 |
Acute Tox. 4 * Aquatic Chronic 4 |
H332 H413 |
GHS07 Wng |
H332 H413 |
|
|
|
|
014-035-00-4 |
2-(3,4-epoksycykloheksylo)etylo-trietoksy silan |
425-050-4 |
10217-34-2 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
014-036-00-X |
(4-etoksyfenylo) (3-(4-fluoro-3-fenoksyfenylo)propylo)dimetylosilan |
405-020-7 |
105024-66-6 |
Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H360F*** H400 H410 |
GHS08 GHS09 Dgr |
H360F*** H410 |
|
M=1000 |
|
|
014-037-00-5 |
O, O',O''-fenylosililidynotris(oksym butan-2-onu) |
433-360-6 |
34036-80-1 |
STOT RE 2 * Skin Sens. 1 Aquatic Chronic 3 |
H373** H317 H412 |
GHS08 GHS07 Wng |
H373** H317 H412 |
|
|
|
|
014-038-00-0 |
S-(3-(trietoksysililo)propylo)sulfanylo)oktan-1-on |
436-690-9 |
220727-26-4 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
014-039-00-6 |
(2,3-dimetylobut-2-ylo)-trimetoksysilan |
439-360-2 |
142877-45-0 |
Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 |
H315 H318 H412 |
GHS05 Dgr |
H315 H318 H412 |
|
|
|
|
014-041-00-7 |
N, N-bis(trimetylosililo)aminopropylometylodietoksysilan |
445-890-5 |
201290-01-9 |
Acute Tox. 4 * Skin Sens. 1 |
H302 H317 |
GHS07 Wng |
H302 H317 |
|
|
|
|
014-042-00-2 |
masa poreakcyjna: O,O',O",O"'-silanotetrailo tetrakis(oksymu 4-metylo-2-pentanonu) (3 stereoizomery) |
423-010-0 |
— |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
014-043-00-8 |
produkt reakcji krzemionki amorficznej (50-85 %), butylo (l-metylopropylo)magnezu (3-15 %), ortokrzemianu tetraetylu (5-15 %) i tetrachlorku tytanu (5-20 %) |
432-200-2 |
— |
STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 |
H335 H315 H318 H412 |
GHS05 GHS07 Dgr |
H335 H315 H318 H412 |
|
|
|
|
014-044-00-3 |
3-[(4'-acetoksy-3 '-metoksyfenylo)propylo]trimetoksysilan |
433-050-0 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
014-045-00-9 |
fluorek krzemian magnezu sodu |
442-650-1 |
— |
STOT RE 2 * |
H373** |
GHS08 Wng |
H373** |
|
|
|
|
015-001-00-1 |
fosfor biały; tetrafosfor |
231-768-7 |
12185-10-3 |
Pyr. Sol. 1 Acute Tox. 2 * Acute Tox. 2 * Skin Corr. 1A Aquatic Acute 1 |
H250 H330 H300 H314 H400 |
GHS02 GHS06 GHS05 GHS09 Dgr |
H250 H330 H300 H314 H400 |
|
|
|
|
015-002-00-7 |
fosfor czerwony; polifosfor |
231-768-7 |
7723-14-0 |
Flam. Sol. 1 Aquatic Chronic 3 |
H228 H412 |
GHS02 Dgr |
H228 H412 |
|
|
|
|
015-004-00-8 |
fosforek glinu(III) |
244-088-0 |
20859-73-8 |
Water-react. 1 Acute Tox. 2 Acute Tox. 3 Acute Tox. 1 Aquatic Acute 1 |
H260 H300 H311 H330 H400 |
GHS02 GHS06 GHS09 Dgr |
H260 H300 H311 H330 H400 |
EUH029 EUH032 |
M = 100 |
|
|
015-005-00-3 |
fosforek magnezu(II); difosforek trimagnezu |
235-023-7 |
12057-74-8 |
Water-react. 1 Acute Tox. 2 Acute Tox. 3 Acute Tox. 1 Aquatic Acute 1 |
H260 H300 H311 H330 H400 |
GHS02 GHS06 GHS09 Dgr |
H260 H300 H311 H330 H400 |
EUH029 EUH032 |
M = 100 |
|
|
015-006-00-9 |
difosforek tricynku; fosforek cynku(II) |
215-244-5 |
1314-84-7 |
Water-react. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H260 H300 H400 H410 |
GHS02 GHS06 GHS09 Dgr |
H260 H300 H410 |
EUH029 EUH032 |
M=100 |
T |
|
015-007-00-4 |
trichlorek fosforu |
231-749-3 |
7719-12-2 |
Acute Tox. 2 * Acute Tox. 2 * STOT RE 2 * Skin Corr. 1A |
H330 H300 H373 ** H314 |
GHS06 GHS08 GHS05 Dgr |
H330 H300 H373 ** H314 |
EUH014 EUH029 |
|
|
|
015-008-00-X |
pentachlorek fosforu |
233-060-3 |
10026-13-8 |
Acute Tox. 2 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B |
H330 H302 H373 ** H314 |
GHS06 GHS08 GHS05 Dgr |
H330 H302 H373 ** H314 |
EUH014 EUH029 |
|
|
|
015-009-00-5 |
trichlorek fosforylu; trichlorektlenek fosforu; tlenochlorek fosforu |
233-046-7 |
10025-87-3 |
Acute Tox. 2 * STOT RE 1 Acute Tox. 4 * Skin Corr. 1A |
H330 H372 ** H302 H314 |
GHS06 GHS08 GHS05 Dgr |
H330 H372 ** H302 H314 |
EUH014 EUH029 |
|
|
|
015-010-00-0 |
dekatlenek tetrafosforu; pentatlenek difosforu; bezwodnik kwasu fosforowego(V); bezwodnik kwasu ortofosforowego(V) |
215-236-1 |
1314-56-3 |
Skin Corr. 1A |
H314 |
GHS05 Dgr |
H314 |
|
|
|
|
015-011-00-6 |
kwas fosforowy(V) … %, kwas ortofosorowy … % |
231-633-2 |
7664-38-2 |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
|
Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 % Eye Irrit. 2; H319: 10 % ≤ C < 25 % |
B |
|
015-012-00-1 |
trisiarczek tetrafosforu |
215-245-0 |
1314-85-8 |
Flam. Sol. 2 Water-react. 1 Acute Tox. 4 * Aquatic Acute 1 |
H228 H260 H302 H400 |
GHS02 GHS07 GHS09 Dgr |
H228 H260 H302 H400 |
|
|
T |
|
015-013-00-7 |
fosforan(V) trietylu; ortofosforan(V) trietylu |
201-114-5 |
78-40-0 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
015-014-00-2 |
fosforan(V) tributylu; ortofosforan(V) tributylu |
204-800-2 |
126-73-8 |
Carc. 2 Acute Tox. 4 * Skin Irrit. 2 |
H351 H302 H315 |
GHS08 GHS07 Wng |
H351 H302 H315 |
|
|
|
|
015-015-00-8 |
fosforan trikrezylu (o-o-o-, o-o-m-, o-o-p-, o-m-m-, o-m-p-, o-p-p-); fosforan(V) tritolilu (o-o-o-, o-o-m-, o-o-p-, o-m-m-, o-m-p-, o-p-p-); |
201-103-5 |
78-30-8 |
STOT SE 1 Aquatic Chronic 2 |
H370 ** H411 |
GHS08 GHS09 Dgr |
H370 ** H411 |
|
STOT SE 1; H370: C ≥ 1 % STOT SE 2; H371: 0,2 % ≤ C < 1 % |
C |
|
015-016-00-3 |
fosforan trikrezylu (m-m-m-, m-m-p-, m-p-p-, p-p-p-); fosforan(V) tritolilu (m-m-m-, m-m-p-, m-p-p-, p-p-p-); |
201-105-6 |
78-32-0 |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 2 |
H312 H302 H411 |
GHS07 GHS09 Wng |
H312 H302 H411 |
|
* |
C |
|
015-019-00-X |
dichlorfos (ISO); fosforan 2,2-dichlorowinylu-dimetylu |
200-547-7 |
62-73-7 |
Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * Skin Sens. 1 Aquatic Acute 1 |
H330 H311 H301 H317 H400 |
GHS06 GHS09 Dgr |
H330 H311 H301 H317 H400 |
|
M=1000 |
|
|
015-020-00-5 |
mewinfos (ISO); fosforan 2-(metoksykarbonylo)-1-metylowinylu-dimetylu |
232-095-1 |
7786-34-7 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H310 H300 H410 |
|
M = 10000 |
|
|
015-021-00-0 |
trichlorfon (ISO); 2,2,2-trichloro-1-hydroksyetylofosfonian dimetylu |
200-149-3 |
52-68-6 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H400 H410 |
|
M = 1000 |
|
|
015-022-00-6 |
fosfamidon (ISO); fosforan 2-chloro-2-(dietylokarbamoilo)-1-metylowinylu-dimetylu |
236-116-5 |
13171-21-6 |
Muta. 2 Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H341 H300 H311 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H341 H300 H311 H410 |
|
|
|
|
015-023-00-1 |
pirazokson; fosforan(V) dietylu-(3-metylo-1H-pirazol-5-ilu); ortofosforan(V) dietylu-(3-metylo-1H-pirazol-5-ilu) |
— |
108-34-9 |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * |
H330 H310 H300 |
GHS06 Dgr |
H330 H310 H300 |
|
|
|
|
015-024-00-7 |
triamifos (ISO); bis(dimetyloamid) 5-amino-3-fenylo-1H-1,2,4-triazol-1-ilofosfonowy |
— |
1031-47-6 |
Acute Tox. 1 Acute Tox. 2 * |
H310 H300 |
GHS06 Dgr |
H310 H300 |
|
|
|
|
015-025-00-2 |
TEPP (ISO); pirofosforan tetraetylu; difosforan(V) tetraetylu |
203-495-3 |
107-49-3 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 |
H310 H300 H400 |
GHS06 GHS09 Dgr |
H310 H300 H400 |
|
|
|
|
015-026-00-8 |
szradan (ISO); oktametylopirofosforotetramid |
205-801-0 |
152-16-9 |
Acute Tox. 1 Acute Tox. 2 * |
H310 H300 |
GHS06 Dgr |
H310 H300 |
|
|
|
|
015-027-00-3 |
sulfotep (ISO); ditiopirofosforan O, O,O, O-tetraetylu; 1,2-ditiodifosforan(4-) O, O,O',O'-tetraetylu |
222-995-2 |
3689-24-5 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H310 H300 H410 |
|
M = 1000 |
|
|
015-028-00-9 |
demeton-O (ISO); tiofosforan O-2-(etylosulfanylo)etylu-O,O-dietylu |
206-053-8 |
298-03-3 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 |
H310 H300 H400 |
GHS06 GHS09 Dgr |
H310 H300 H400 |
|
|
|
|
015-029-00-4 |
demeton-S (ISO); tiofosforan S-(2-etylosulfanylo)etylu-O,O-dietylu |
204-801-8 |
126-75-0 |
Acute Tox. 1 Acute Tox. 2 * |
H310 H300 |
GHS06 Dgr |
H310 H300 |
|
|
|
|
015-030-00-X |
demeton-O metylowy (ISO); tiofosforan O-2-(etylosulfanylo)etylu-O,O-dimetylu |
212-758-1 |
867-27-6 |
Acute Tox. 3 * |
H301 |
GHS06 Dgr |
H301 |
|
|
|
|
015-031-00-5 |
demeton-S metylowy (ISO); tiofosforan S-2-(etylosulfanylo)etylu-O,O-dimetylu |
213-052-6 |
919-86-8 |
Acute Tox. 3 * Acute Tox. 3 * Aquatic Chronic 2 |
H311 H301 H411 |
GHS06 GHS09 Dgr |
H311 H301 H411 |
|
|
|
|
015-032-00-0 |
protoat (ISO); ditiofosforan O,O-dietylu-S-(izopropylokarbamoilo)metylu |
218-893-2 |
2275-18-5 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Chronic 3 |
H310 H300 H412 |
GHS06 Dgr |
H310 H300 H412 |
|
|
|
|
015-033-00-6 |
forat (ISO); ditiofosforan S-(etylosulfanylo)metylu-O,O-dietylu |
206-052-2 |
298-02-2 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H310 H300 H410 |
|
M = 1000 |
|
|
015-034-00-1 |
paration (ISO); tiofosforan O,O-dietylu-O-4-nitrofenylu; |
200-271-7 |
56-38-2 |
Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H330 H300 H311 H372 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H330 H300 H311 H372 ** H410 |
|
M = 100 |
|
|
015-035-00-7 |
paration metylowy (ISO); tiofosforan O,O-dimetylu-O-4-nitrofenylu; |
206-050-1 |
298-00-0 |
Flam. Liq. 3 Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H226 H330 H300 H311 H373 ** H400 H410 |
GHS02 GHS06 GHS08 GHS09 Dgr |
H226 H330 H300 H311 H373 ** H410 |
|
M = 100 |
|
|
015-036-00-2 |
fenylotiofosfonian O-etylu-O-4-nitrofenylu; EPN |
218-276-8 |
2104-64-5 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H310 H300 H410 |
|
|
|
|
015-037-00-8 |
fenkapton (ISO); ditiofosforan S-(2,5-dichlorofenylosulfanylo)metylu-O, O-dietylu |
218-892-7 |
2275-14-1 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H331 H311 H301 H410 |
|
|
|
|
015-038-00-3 |
kumafos (ISO); tiofosforan O-3-chloro-4-metylo-2-okso-2H-chromen-7-ylu-O,O-dietylu |
200-285-3 |
56-72-4 |
Acute Tox. 2 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H300 H312 H400 H410 |
GHS06 GHS09 Dgr |
H300 H312 H410 |
|
|
|
|
015-039-00-9 |
azynofos metylowy (ISO); ditiofosforan O,O-dimetylu-S-(4-okso-3,4-dihydrobenzeno[d]-1,2,3-triazyn-3-ylo)metylu |
201-676-1 |
86-50-0 |
Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 3 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H330 H300 H311 H317 H400 H410 |
GHS06 GHS09 Dgr |
H330 H300 H311 H317 H410 |
|
|
|
|
015-040-00-4 |
diazynon (ISO); tiofosforan O,O-dietylu-O-2-izopropylo-6-metylopirymidyn-4-ylu |
206-373-8 |
333-41-5 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H400 H410 |
|
|
|
|
015-041-00-X |
malation (ISO); ditiofosforan S-1,2-bis(etoksykarbonylo)etylo-O, O-dimetylu; [zawierający ≤ 0,03 % izomalationu] |
204-497-7 |
121-75-5 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|
M=1000 |
|
|
015-042-00-5 |
chlorotion; tiofosforan O-3-chloro-4-nitrofenylu-O, O-dimetylu |
207-902-5 |
500-28-7 |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H332 H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H332 H312 H302 H410 |
|
M = 100 |
|
|
015-043-00-0 |
fosnichlor (ISO); tiofosforan O-4-chloro-3-nitrofenylu-O,O-dimetylu |
— |
5826-76-6 |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H332 H312 H302 |
GHS07 Wng |
H332 H312 H302 |
|
|
|
|
015-044-00-6 |
karbofenotion (ISO); ditiofosforan S-(4-chlorofenylosulfanylo)metylu-O, O-dietylu |
212-324-1 |
786-19-6 |
Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H311 H301 H410 |
|
|
|
|
015-045-00-1 |
mekarbam (ISO); ditiofosforan S-(N-etoksykarbonylo-N-metylokarbamoilo)metylu-O, O-dietylu |
219-993-9 |
2595-54-2 |
Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H311 H301 H400 H410 |
|
|
|
|
015-046-00-7 |
oksydemeton metylowy (ISO); tiofosforan S-(2-etylosulfinylo)etylu-O,O-dimetylu |
206-110-7 |
301-12-2 |
Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 |
H311 H301 H400 |
GHS06 GHS09 Dgr |
H311 H301 H400 |
|
|
|
|
015-047-00-2 |
etion (ISO); bis(ditiofosforan) O,O,O',O'-tetraetylu-S,S'-metylenu dietion |
209-242-3 |
563-12-2 |
Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H301 H312 H400 H410 |
GHS06 GHS09 Dgr |
H301 H312 H410 |
|
M = 10000 |
|
|
015-048-00-8 |
fention (ISO); tiofosforan O,O-dimetylu-O-3-metylo-4-(metylosulfanylo)fenylu |
200-231-9 |
55-38-9 |
Muta. 2 Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H341 H331 H312 H302 H372** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H341 H331 H312 H302 H372** H410 |
|
M=100 |
|
|
015-049-00-3 |
endotion (ISO); tiofosforan S-(5-metoksypiran-4-on-2-ylo)metylu-O,O-dimetylu |
220-472-3 |
2778-04-3 |
Acute Tox. 3 * Acute Tox. 3 * |
H311 H301 |
GHS06 Dgr |
H311 H301 |
|
|
|
|
015-050-00-9 |
tiometon (ISO); ditiofosforan S-2-(etylosulfanylo)etylu-O,O-dimetylu; |
211-362-6 |
640-15-3 |
Acute Tox. 3 * Acute Tox. 4 * |
H301 H312 |
GHS06 Dgr |
H301 H312 |
|
|
|
|
015-051-00-4 |
dimetoat (ISO); ditiofosforan S-metylokarbamoilometylu-O, O-dimetylu |
200-480-3 |
60-51-5 |
Acute Tox. 4 * Acute Tox. 4 * |
H312 H302 |
GHS07 Wng |
H312 H302 |
|
|
|
|
015-052-00-X |
fenchlorfos (ISO); tiofosforan O,O-dimetylu-O-2,4,5-trichlorofenylu |
206-082-6 |
299-84-3 |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H312 H302 H410 |
|
|
|
|
015-053-00-5 |
menazon (ISO); ditiofosforan S-(4,6-diamino-1,3,5-triazyn-2-ylo)metylu-O,O-dimetylu |
201-123-4 |
78-57-9 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
015-054-00-0 |
fenitrotion (ISO); tiofosforan O-3-metylo-4-nitrofenylu-O, O-dimetylu |
204-524-2 |
122-14-5 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
015-055-00-6 |
naled (ISO); fosforan 1,2-dibromo-2,2-dichloroetylu-dimetylu |
206-098-3 |
300-76-5 |
Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 |
H312 H302 H319 H315 H400 |
GHS07 GHS09 Wng |
H312 H302 H319 H315 H400 |
|
M = 1000 |
|
|
015-056-00-1 |
azynofos etylowy (ISO); ditiofosforan O,O-dietylu-S-(4-okso-3,4-dihydrobenzo[d]-1,2,3-triazyn-3-ylo)metylu |
220-147-6 |
2642-71-9 |
Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H300 H311 H400 H410 |
GHS06 GHS09 Dgr |
H300 H311 H410 |
|
M=100 |
|
|
015-057-00-7 |
formotion (ISO); ditiofosforan S-(N-formylo-N-metylokarbamoilo)metylu-O, O-dimetylu |
219-818-6 |
2540-82-1 |
Acute Tox. 4 * Acute Tox. 4 * |
H312 H302 |
GHS07 Wng |
H312 H302 |
|
|
|
|
015-058-00-2 |
morfotion (ISO); ditiofosforan O, O-dimetylu-S-(morfolinokarbonylo)metylu |
205-628-0 |
144-41-2 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H331 H311 H301 H410 |
|
|
|
|
015-059-00-8 |
wamidotion (ISO); tiofosforan O,O-dimetylu-S-2-[1-(metylokarbamoilo)etylosulfanylo]etylu |
218-894-8 |
2275-23-2 |
Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 |
H301 H312 H400 |
GHS06 GHS09 Dgr |
H301 H312 H400 |
|
|
|
|
015-060-00-3 |
disulfoton (ISO); ditiofosforan O,O-dietylu-S-2-(etylosulfanylo)etylu |
206-054-3 |
298-04-4 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H310 H300 H410 |
|
|
|
|
015-061-00-9 |
dimefoks (ISO); fluorek bis(dimetyloamido)fosforowy |
204-076-8 |
115-26-4 |
Acute Tox. 1 Acute Tox. 2 * |
H310 H300 |
GHS06 Dgr |
H310 H300 |
|
|
|
|
015-062-00-4 |
mipafoks (ISO); fluorek bis(izopropyloamido)fosforowy |
206-742-3 |
371-86-8 |
STOT SE 1 |
H370 ** |
GHS08 Dgr |
H370 ** |
|
|
|
|
015-063-00-X |
dioksation (ISO); bis(ditiofosforan) S,S'-1,4-dioksan-2,3-diylu-O,O,O',O'-tetraetylu |
201-107-7 |
78-34-2 |
Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H300 H311 H400 H410 |
GHS06 GHS09 Dgr |
H330 H300 H311 H410 |
|
M = 1000 |
|
|
015-064-00-5 |
bromofos etylowy (ISO); tiofosforan O-4-bromo-2,5-dichlorofenylu -O, O-dietylu |
225-399-0 |
4824-78-6 |
Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H301 H312 H400 H410 |
GHS06 GHS09 Dgr |
H301 H312 H410 |
|
|
|
|
015-065-00-0 |
ditiofosforan S-2-(etylosulfinylo)etylu-O,O-dimetylu |
— |
2703-37-9 |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Chronic 2 |
H330 H310 H300 H411 |
GHS06 GHS09 Dgr |
H330 H310 H300 H411 |
|
|
|
|
015-066-00-6 |
ometoat (ISO); tiofosforan S-(metylokarbamoilo)metylu-O, O-dimetylu |
214-197-8 |
1113-02-6 |
Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 |
H301 H312 H400 |
GHS06 GHS09 Dgr |
H301 H312 H400 |
|
|
|
|
015-067-00-1 |
fosalon (ISO); ditiofosforan S-(6-chloro-2-okso-2,3-dihydrobenzoksazol-3-ilo)metylu-O, O-dietylu |
218-996-2 |
2310-17-0 |
Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H332 H312 H317 H400 H410 |
GHS06 GHS09 Dgr |
H301 H332 H312 H317 H410 |
|
M=1000 |
|
|
015-068-00-7 |
dichlorfention (ISO); tiofosforan O-2,4-dichlorofenylu-O,O-dietylu |
202-564-5 |
97-17-6 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H400 H410 |
|
|
|
|
015-069-00-2 |
metydation (ISO); ditiofosforan S-(5-metoksy-2-okso-2,3-dihydro-1,3,4-tiadiazol-3-ilo)metylu-O,O-dimetylu |
213-449-4 |
950-37-8 |
Acute Tox. 2 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H300 H312 H400 H410 |
GHS06 GHS09 Dgr |
H300 H312 H410 |
|
|
|
|
015-070-00-8 |
cyjanotoat (ISO); tiofosforan S-[N-(1-cyjano-1-metyloetylo)karbamoilo]metylu-O,O-dietylu |
223-099-4 |
3734-95-0 |
Acute Tox. 2 * Acute Tox. 3 * |
H300 H311 |
GHS06 Dgr |
H300 H311 |
|
|
|
|
015-071-00-3 |
chlorfenwinfos (ISO); fosforan (Z, E)-2-chloro-1-(2,4-dichlorofenylo)winylu-dietylu |
207-432-0 |
470-90-6 |
Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H300 H311 H400 H410 |
GHS06 GHS09 Dgr |
H300 H311 H410 |
|
|
|
|
015-072-00-9 |
monokrotofos (ISO); fosforan dimetylu-(E)-1-metylo-2-(metylokarbamoilo)winylu |
230-042-7 |
6923-22-4 |
Muta. 2 Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H341 H330 H300 H311 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H341 H330 H300 H311 H410 |
|
|
|
|
015-073-00-4 |
dikrotofos (ISO); fosforan (E)-2-(dimetylokarbamoilo)-1-metylowinylu-dimetylu |
205-494-3 |
141-66-2 |
Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H300 H311 H400 H410 |
GHS06 GHS09 Dgr |
H300 H311 H410 |
|
|
|
|
015-074-00-X |
krufomat (ISO); N-metyloamidofosforan O-2-chloro-4-tert-butylofenylu-O-metylu |
206-083-1 |
299-86-5 |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H312 H302 H410 |
|
|
|
|
015-075-00-5 |
tiofosforan(V) S-2-(izopropylosulfinylo)etylo-O,O-dimetylu |
— |
2635-50-9 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * |
H331 H311 H301 |
GHS06 Dgr |
H331 H311 H301 |
|
|
|
|
015-076-00-0 |
potasan; tiofosforan(V) O,O-dietylu-O-4-metylo-2-okso-2H-chromen-7-ylu |
— |
299-45-6 |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H330 H310 H300 H410 |
|
M = 1000 |
|
|
015-077-00-6 |
fosforan(V) 2,2-dichlorowinylu-2-(etylosulfinylo)etylu-metylu |
— |
7076-53-1 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * |
H331 H311 H301 |
GHS06 Dgr |
H331 H311 H301 |
|
|
|
|
015-078-00-1 |
demeton-S metylosulfonowy (ISO); tiofosforan S-2-(etylosulfonylo)etylu-O,O-dimetylu |
241-109-5 |
17040-19-6 |
Acute Tox. 3 * Acute Tox. 4 * Aquatic Chronic 2 |
H301 H312 H411 |
GHS06 GHS09 Dgr |
H301 H312 H411 |
|
|
|
|
015-079-00-7 |
acefat (ISO); N-acetyloamidotiofosforan O,S-dimetylu |
250-241-2 |
30560-19-1 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
015-080-00-2 |
amidition (ISO); ditiofosforan S-[(2-metoksyetylo)karbamoilo]metylu-O, O-dimetylu |
— |
919-76-6 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
015-081-00-8 |
ditiopirofosforan O,O,O,O-tetrapropylu; 1,2-ditiodifosforan(4-) O,O,O',O'-tetrapropylu |
221-817-0 |
3244-90-4 |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H312 H302 H410 |
|
|
|
|
015-082-00-3 |
azotoat (ISO); tiofosforan O-4-(4-chlorofenyloazo)fenylu-O,O-dimetylu |
227-419-3 |
5834-96-8 |
Acute Tox. 4 * Acute Tox. 4 * |
H332 H302 |
GHS07 Wng |
H332 H302 |
|
|
|
|
015-083-00-9 |
bensulid (ISO); ditiofosforan S-2-(benzenosulfonoamido)etylu-O, O-diizopropylu |
212-010-4 |
741-58-2 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
015-084-00-4 |
chloropiryfos (ISO); tiofosforan O,O-dietylu-O-3,5,6-trichloro-2-pirydylu |
220-864-4 |
2921-88-2 |
Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H301 H400 H410 |
GHS06 GHS09 Dgr |
H301 H400 H410 |
|
M = 10000 |
|
|
015-085-00-X |
chlorofonium chlorek (ISO); chlorek tributylo(2,4-dichlorobenzylo)fosfonium |
204-105-4 |
115-78-6 |
Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 |
H301 H312 H319 H315 |
GHS06 Dgr |
H301 H312 H319 H315 |
|
|
|
|
015-086-00-5 |
kumitoat (ISO); tiofosforan O,O-dietylu-O-6-okso-7,8,9,10-tetrahydrobenzo[c]chromen-3-ylu |
— |
572-48-5 |
Acute Tox. 3 * |
H301 |
GHS06 Dgr |
H301 |
|
|
|
|
015-087-00-0 |
cyjanofos (ISO); tiofosforan O-4-cyjanofenylu-O,O-dimetylu |
220-130-3 |
2636-26-2 |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H312 H302 H410 |
|
|
|
|
015-088-00-6 |
dialifos (ISO); ditiofosforan S-2-chloro-1-ftalimidoetylu-O, O-dietylu |
233-689-3 |
10311-84-9 |
Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H300 H311 H400 H410 |
GHS06 GHS09 Dgr |
H300 H311 H400 H410 |
|
|
|
|
015-089-00-1 |
etoat-metylowy (ISO); ditiofosforan S-(etylokarbamoilo)metylu-O,O-dimetylu |
204-121-1 |
116-01-8 |
Acute Tox. 4 * Acute Tox. 4 * |
H312 H302 |
GHS07 Wng |
H312 H302 |
|
|
|
|
015-090-00-7 |
fensulfotion (ISO); tiofosforan O,O-dietylu-O-4-(metylosulfinylo)fenylu |
204-114-3 |
115-90-2 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H310 H300 H410 |
|
|
|
|
015-091-00-2 |
fonofos (ISO); etyloditiofosfonian O-etylu-S-fenylu |
213-408-0 |
944-22-9 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H310 H300 H410 |
|
|
|
|
015-092-00-8 |
fosacetym (ISO); N-acetimidoiloamidotiofosforan O,O-bis(4-chlorofenylu) |
223-874-7 |
4104-14-7 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H310 H300 H410 |
|
|
|
|
015-093-00-3 |
leptofos (ISO); fenylotiofosfonian O-4-bromo-2,5-dichlorofenylu-O-metylu |
244-472-8 |
21609-90-5 |
Acute Tox. 3 * STOT SE 1 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H301 H370 ** H312 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H301 H370 ** H312 H410 |
|
|
|
|
015-094-00-9 |
mefosfolan (ISO); N-(4-metylo-1,3-ditiolan-2-ylideno)amidofosforan dietylu |
213-447-3 |
950-10-7 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Chronic 2 |
H310 H300 H411 |
GHS06 GHS09 Dgr |
H310 H300 H411 |
|
|
|
|
015-095-00-4 |
metamidofos (ISO); amidotiofosforan O,S-dimetylu |
233-606-0 |
10265-92-6 |
Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 |
H330 H300 H311 H400 |
GHS06 GHS09 Dgr |
H330 H300 H311 H400 |
|
|
|
|
015-096-00-X |
oksydisulfoton (ISO); ditiofosforan S-2-(etylosulfinylo)etylu-O,O-dietylu |
219-679-1 |
2497-07-6 |
Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H300 H311 H400 H410 |
GHS06 GHS09 Dgr |
H300 H311 H410 |
|
M = 10 |
|
|
015-097-00-5 |
fentoat (ISO); ditiofosforan S-etoksykarbonylo(fenylo)metylu-O, O-dimetylu |
219-997-0 |
2597-03-7 |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H312 H302 H410 |
|
M = 100 |
|
|
015-098-00-0 |
trichloronat (ISO); etylotiofosfonian O-etylu-O-2,4,5-trichlorofenylu |
206-326-1 |
327-98-0 |
Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H300 H311 H400 H410 |
GHS06 GHS09 Dgr |
H300 H311 H410 |
|
|
|
|
015-099-00-6 |
pirymifos etylowy (ISO); tiofosforan O-2-dietyloamino-6-metylopirymidyn-4-ylu-O, O-dietylu |
245-704-0 |
23505-41-1 |
Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H301 H312 H400 H410 |
GHS06 GHS09 Dgr |
H301 H312 H410 |
|
|
|
|
015-100-00-X |
foksym (ISO); tiofosforan O-cyjano(fenylo)metylidenoamino-O, O-dietylu |
238-887-3 |
14816-18-3 |
Repr. 2 Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361f*** H302 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H361f*** H302 H317 H410 |
|
M=1000 |
|
|
015-101-00-5 |
fosmet (ISO); ditiofosforan S-ftalimidometylu-O, O-dimetylu |
211-987-4 |
732-11-6 |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H312 H302 H410 |
|
M = 100 |
|
|
015-102-00-0 |
fosforan(V) tris(2-chloroetylu) |
204-118-5 |
115-96-8 |
Carc. 2 Repr. 1B Acute Tox. 4 * Aquatic Chronic 2 |
H351 H360F*** H302 H411 |
GHS08 GHS07 GHS09 Dgr |
H351 H360F*** H302 H411 |
|
|
|
|
015-103-00-6 |
tribromek fosforu |
232-178-2 |
7789-60-8 |
Skin Corr. 1B STOT SE 3 |
H314 H335 |
GHS05 GHS07 Dgr |
H314 H335 |
EUH014 |
|
|
|
015-104-00-1 |
pentasiarczek difosforu; dekasiarczek tetrafosforu |
215-242-4 |
1314-80-3 |
Flam. Sol. 1 Water-react. 1 Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 |
H228 H260 H332 H302 H400 |
GHS02 GHS07 GHS09 Dgr |
H228 H260 H332 H302 H400 |
EUH029 |
|
T |
|
015-105-00-7 |
trifenoksyfosfan; trifenoksyfosfina; fosforyn trifenylu |
202-908-4 |
101-02-0 |
Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H315 H400 H410 |
GHS07 GHS09 Wng |
H319 H315 H410 |
|
Skin Irrit. 2; H315: C ≥ 5 % Eye Irrit. 2; H319: C ≥ 5 % |
|
|
015-106-00-2 |
heksametylofosforotriamid; heksametylotriamid kwasu fosforowego(V) |
211-653-8 |
680-31-9 |
Carc. 1B Muta. 1B |
H350 H340 |
GHS08 Dgr |
H350 H340 |
|
Carc. 1B; H350: C ≥ 0,01 % |
|
|
015-107-00-8 |
etoprofos (ISO); ditiofosforan O-etylu-S,S-dipropylu |
236-152-1 |
13194-48-4 |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 3 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H301 H317 H400 H410 |
GHS06 GHS09 Dgr |
H330 H310 H301 H317 H410 |
|
|
|
|
015-108-00-3 |
bromofos (ISO); tiofosforan O-4-bromo-2,5-dichlorofenylu-O,O-dimetylu |
218-277-3 |
2104-96-3 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
M = 100 |
|
|
015-109-00-9 |
krotoksyfos (ISO); fosforan dimetylu-1-metylo-2-[(1-fenyloetoksy)karbonylo]winylu |
231-720-5 |
7700-17-6 |
Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H311 H301 H410 |
|
M = 10 |
|
|
015-110-00-4 |
cyjanofenfos (ISO); fenylotiofosfonian O-4-cyjanofenylu-O-etylu |
— |
13067-93-1 |
Acute Tox. 3 * STOT SE 1 Acute Tox. 4 * Eye Irrit. 2 Aquatic Chronic 2 |
H301 H370 ** H312 H319 H411 |
GHS06 GHS08 GHS09 Dgr |
H301 H370 ** H312 H319 H411 |
|
|
|
|
015-111-00-X |
fosfolan (ISO); 1,3-ditiolan-2-ylidenoamidofosforan dietylu |
213-423-2 |
947-02-4 |
Acute Tox. 1 Acute Tox. 2 * |
H310 H300 |
GHS06 Dgr |
H310 H300 |
|
|
|
|
015-112-00-5 |
tionazyna (ISO); tiofosforan O,O-dietylu-O-pirazyn-2-ylu |
206-049-6 |
297-97-2 |
Acute Tox. 1 Acute Tox. 2 * |
H310 H300 |
GHS06 Dgr |
H310 H300 |
|
|
|
|
015-113-00-0 |
tolklofos-metyl (ISO); tiofosforan O-(2,6-dichloro-p-tolilo) O, O-dimetylu |
260-515-3 |
57018-04-9 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
015-114-00-6 |
chloromefos (ISO); ditiofosforan S-chlorometylu-O, O-dietylu |
246-538-1 |
24934-91-6 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H310 H300 H410 |
|
M = 10 |
|
|
015-115-00-1 |
chlortiofos (ISO); [izomeryczna masa poreakcyjna, w której przeważa tiofosforan O-2,5-dichloro-4-(metylo-sulfanylo)fenylu-O, O-dietylu] |
244-663-6 |
21923-23-9 |
Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H300 H311 H400 H410 |
GHS06 GHS09 Dgr |
H300 H311 H410 |
|
M = 1000 |
|
|
015-116-00-7 |
demefion-O (ISO); tiofosforan O-2-(metylosulfanylo)etylu-O, O-dimetylu |
211-666-9 |
682-80-4 |
Acute Tox. 2 * Acute Tox. 3 * |
H300 H311 |
GHS06 Dgr |
H300 H311 |
|
|
|
|
015-117-00-2 |
demefion-S (ISO); tiofosforan S-2-(metylosulfanylo)etylu-O, O-dimetylu |
219-971-9 |
2587-90-8 |
Acute Tox. 2 * Acute Tox. 3 * |
H300 H311 |
GHS06 Dgr |
H300 H311 |
|
|
|
|
015-118-00-8 |
demeton |
— |
8065-48-3 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 |
H310 H300 H400 |
GHS06 GHS09 Dgr |
H310 H300 H400 |
|
|
|
|
015-119-00-3 |
fosforan 4-(metylosulfanylo)fenylu-dimetylu |
— |
3254-63-5 |
Acute Tox. 1 Acute Tox. 2 * |
H310 H300 |
GHS06 Dgr |
H310 H300 |
|
|
|
|
015-120-00-9 |
ditalimfos (ISO); ftalimidotiofosfonian O, O-dietylu |
225-875-8 |
5131-24-8 |
Skin Irrit. 2 Skin Sens. 1 |
H315 H317 |
GHS07 Wng |
H315 H317 |
|
|
|
|
015-121-00-4 |
edifenfos (ISO); ditiofosforan O-etylu-S, S-difenylu |
241-178-1 |
17109-49-8 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H331 H301 H312 H317 H400 H410 |
GHS06 GHS09 Dgr |
H331 H301 H312 H317 H410 |
|
|
|
|
015-122-00-X |
etrymfos (ISO); tiofosforan O-6-etoksy-2-etylopirymidyn-4-ylu-O, O-dimetylu |
253-855-9 |
38260-54-7 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
M = 10 |
|
|
015-123-00-5 |
fenamifos (ISO); izopropyloamidofosforan etylu-3-metylo-4-(metylosulfanylo)fenylu |
244-848-1 |
22224-92-6 |
Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H300 H310 H330 H319 H400 H410 |
GHS06 GHS09 Dgr |
H300 H310 H330 H319 H410 |
|
M = 100 M = 100 |
|
|
015-124-00-0 |
fostietan (ISO); 1,3-ditietan-2-ylidenoamidofosforan dietylu |
244-437-7 |
21548-32-3 |
Acute Tox. 1 Acute Tox. 2 * |
H310 H300 |
GHS06 Dgr |
H310 H300 |
|
|
|
|
015-125-00-6 |
glifozyna (ISO); N, N-bis(fosfonometylo)glicyna |
219-468-4 |
2439-99-8 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
015-126-00-1 |
heptenofos (ISO); fosforan 7-chlorobicyklo[3.2.0]hepta-2,6-dien-6-ylu-dimetylu |
245-737-0 |
23560-59-0 |
Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H301 H400 H410 |
GHS06 GHS09 Dgr |
H301 H410 |
|
M = 100 |
|
|
015-127-00-7 |
iprobenfos (ISO); tiofosforan S-benzylu-O, O-diizopropylu |
247-449-0 |
26087-47-8 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
015-128-00-2 |
IPSP; ditiofosforan S-(etylosulfinylo)metylu-O, O-diizopropylu |
— |
5827-05-4 |
Acute Tox. 1 Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H310 H301 H400 H410 |
GHS06 GHS09 Dgr |
H310 H301 H410 |
|
M = 100 |
|
|
015-129-00-8 |
izofenfos (ISO); N-izopropyloamidotiofosforan O-etylu-O-2-(izopropoksykarbonylo)fenylu |
246-814-1 |
25311-71-1 |
Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H311 H301 H410 |
|
M = 100 |
|
|
015-130-00-3 |
izotioat (ISO); ditiofosforan S-2-(izopropylosulfanylo)etylu-O, O-dimetylu |
— |
36614-38-7 |
Acute Tox. 3 * Acute Tox. 3 * |
H311 H301 |
GHS06 Dgr |
H311 H301 |
|
|
|
|
015-131-00-9 |
izoksation (ISO); tiofosforan O, O-dietylu-O-5-fenyloizoksazol-3-ilu |
242-624-8 |
18854-01-8 |
Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H311 H301 H410 |
|
|
|
|
015-132-00-4 |
ditiofosforan S-(4-chlorofenylosulfanylo)metylu-O, O-dimetylu; karbofenotion metylowy |
— |
953-17-3 |
Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H311 H301 H410 |
|
M = 1000 |
|
|
015-133-00-X |
piperofos (ISO); ditiofosforan S-2-(metylopiperydynokarbonylo)metylu-O, O-dipropylu |
— |
24151-93-7 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
M = 10 |
|
|
015-134-00-5 |
pirymifos metylowy (ISO); tiofosforan O-2-(dietyloamino)-6-metylopirymidyn-4-ylu-O, O-dimetylu |
249-528-5 |
29232-93-7 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
015-135-00-0 |
profenofos (ISO); tiofosforan O-4-bromo-2-chlorofenylu-O-etylu-S-propylu |
255-255-2 |
41198-08-7 |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H332 H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H332 H312 H302 H410 |
|
M = 1000 |
|
|
015-136-00-6 |
trans-izopropylo-3-[[(etyloamino)metoksyfosfinotioil]oksy]krotonian; etyloamidotiofosforan O-[(E)-2-(izopropoksykarbonylo)-1-metylowinylu]-O-metylu; propetamfos (ISO) |
250-517-2 |
31218-83-4 |
Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H301 H400 H410 |
GHS06 GHS09 Dgr |
H301 H410 |
|
M = 100 |
|
|
015-137-00-1 |
pirazofos (ISO); tiofosforan O-6-etoksykarbonylo-5-metylopirazolo[2,3-a]pirymidyn-2-ylu-O,O-dietylu |
236-656-1 |
13457-18-6 |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H332 H302 H400 H410 |
GHS07 GHS09 Wng |
H332 H302 H410 |
|
|
|
|
015-138-00-7 |
chinalfos (ISO); tiofosforan O-chinoksalin-2-ylu-O,O-dietylu |
237-031-6 |
13593-03-8 |
Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H301 H312 H400 H410 |
GHS06 GHS09 Dgr |
H301 H312 H410 |
|
M = 1000 |
|
|
015-139-00-2 |
terbufos (ISO); ditiofosforan S-(tert-butylosulfanylo)metylu-O, O-dietylu; |
235-963-8 |
13071-79-9 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H310 H300 H410 |
|
M = 1000 |
|
|
015-140-00-8 |
triazofos (ISO); tiofosforan O, O-dietylu-O-1-fenylo-1H-1,2,4-triazol-3-ilu |
245-986-5 |
24017-47-8 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H301 H312 H400 H410 |
GHS06 GHS09 Dgr |
H331 H301 H312 H410 |
|
M=100 |
|
|
015-141-00-3 |
ditiofosforan O, O-dioktylu-S-etylenodiamoniowy, mieszanina izomerów |
400-520-1 |
— |
Skin Corr. 1B Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H314 H302 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H314 H302 H410 |
|
|
|
|
015-142-00-9 |
fosforan butylu-dialkoksy(dibutoksyfosforyloksy)tytanu(IV)-trialkoksytytanu(IV) |
401-100-0 |
— |
Flam. Liq. 2 Eye Irrit. 2 Aquatic Chronic 2 |
H225 H319 H411 |
GHS02 GHS07 GHS09 Dgr |
H225 H319 H411 |
|
|
T |
|
015-143-00-4 |
masa poreakcyjna: (2-chloroetylo)fosfonianu dialkilu oraz (2-chloropropylo)fosfonianu dialkilu, gdzie alkil: 2-chloroetyl, 2-chloropropyl lub 2-chloro-1-metyloetyl; |
401-740-0 |
— |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
015-144-00-X |
masa poreakcyjna: metylofosfinianu pentylu oraz metylofosfinianu 2-metylobutylu |
402-090-0 |
87025-52-3 |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
|
|
|
|
015-145-00-5 |
masa poreakcyjna: ditiofosforanu O, O-diizopropylu-S-miedzi(I), ditiofosforanu O-izopropylu-O-(4-metylopentan-2-ylu)-S-miedzi(I) oraz ditiofosforanu O, O-di(4-metylopentan-2-ylu)-S-miedzi(I) |
401-520-4 |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
015-146-00-0 |
ditiofosforan S-tricyklo[5.2.1.02,6]dek-3-en-8-ylu-O-alkilu-O-alkilu lub ditiofosforan S-tricyklo[5.2.1.02,6]dek-3-en-9-ylu-O-alkilu-O-alkilu, gdzie alkil to: izopropyl, izobutyl lub 2-etyloheksyl |
401-850-9 |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
015-147-00-6 |
masa poreakcyjna: tiofosforanu O, O-difenylu-S-tert-alkiloamoniowego oraz sulfidu lub disulfidu dinonylowego, gdzie grupa alkilowa ma od 12 do 14 atomów wegla |
400-930-0 |
— |
Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H315 H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H315 H318 H317 H411 |
|
|
|
|
015-148-00-1 |
kwas 2-(difosfonometylo)bursztynowy |
403-070-4 |
51395-42-7 |
Skin Corr. 1B Skin Sens. 1 |
H314 H317 |
GHS05 GHS07 Dgr |
H314 H317 |
|
|
|
|
015-149-00-7 |
masa poreakcyjna: tlenku trioktylofosfanu (tlenku trioktylofosfiny); tlenku heksylodioktylofosfanu (tlenku heksylodioktylofosfiny); tlenku diheksylooktylofosfanu (tlenku diheksylooktylofosfiny) |
403-470-9 |
— |
Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H314 H400 H410 |
GHS05 GHS09 Dgr |
H314 H410 |
|
|
|
|
015-150-00-2 |
bromek [2-(1,3-dioksolan-2-ylo)etylo]trifenylofosfonium; bromek [2-(1,3-dioksolan-2-ylo)etylo]trifenylofosfoniowy |
404-940-6 |
86608-70-0 |
Acute Tox. 4 * Eye Dam. 1 STOT RE 2 * Aquatic Chronic 3 |
H302 H318 H373 ** H412 |
GHS08 GHS05 GHS07 Dgr |
H302 H318 H373 ** H412 |
|
|
|
|
015-151-00-8 |
fosforan tris[izopropylo (lub tert-butylo)fenylu] |
405-010-2 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
015-152-00-3 |
dioksabenzofos (ISO); (RS)-2-metoksy-4H-benzo[1,3,2]dioksafosfinino-2-tion |
223-292-3 |
3811-49-2 |
Acute Tox. 3 * Acute Tox. 3 * STOT SE 1 Aquatic Chronic 2 |
H311 H301 H370 ** H411 |
GHS06 GHS08 GHS09 Dgr |
H311 H301 H370 ** H411 |
|
|
|
|
015-153-00-9 |
izazofos (ISO); tiofosforan O-(5-chloro-1-izopropylo-1H-1,2,4-triazol-3-ilu)-O, O-dietylu |
255-863-8 |
42509-80-8 |
Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H330 H311 H301 H373 ** H317 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H330 H311 H301 H373 ** H317 H410 |
|
|
|
|
015-154-00-4 |
etefon (ISO); kwas 2-chloroetylofosfonowy |
240-718-3 |
16672-87-0 |
Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 Skin Corr. 1C Aquatic Chronic 2 |
H311 H332 H302 H314 H411 |
GHS06 GHS05 GHS09 Dgr |
H311 H332 H302 H314 H411 |
EUH071 |
|
|
|
015-155-00-X |
glufosynat amonowy (ISO); 2-amino-4-(hydroksymetylofosforylo)maślan amonu; (RS)-(3-amino-3-karboksypropylo)metylofosfinian amonu; 2-amino-4-(hydroksymetylofosforylo)butanian amonu |
278-636-5 |
77182-82-2 |
Repr. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * |
H360Fd H332 H312 H302 H373** |
GHS08 GHS07 Dgr |
H360Fd H332 H312 H302 H373** |
|
|
|
|
015-156-00-5 |
tiofosforan(V) O-(2-metoksykarbonyloprop-1-enylu)-O, O-dimetylu; [1] metakryfos (ISO); tiofosforan(V) O-[(E)-(2-metoksykarbonyloprop-1-enylu)-O, O-dimetylu [2] |
250-366-9 [1]-[2] |
30864-28-9 [1] 62610-77-9 [2] |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|
|
|
|
015-157-00-0 |
kwas fosfonowy; [1] kwas ortofosforawy; kwas fosforawy [2] |
237-066-7 [1] 233-663-1 [2] |
13598-36-2 [1] 10294-56-1 [2] |
Acute Tox. 4 * Skin Corr. 1A |
H302 H314 |
GHS05 GHS07 Dgr |
H302 H314 |
|
|
|
|
015-158-00-6 |
heksafluorofosforan(1-) (η-cyklopentadienylo)(η-kumenylo)żelaza(1+) |
402-340-9 |
32760-80-8 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
015-159-00-1 |
kwas hydroksyfosfonooctowy |
405-710-8 |
23783-26-8 |
Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 |
H302 H373 ** H314 H317 |
GHS08 GHS05 GHS07 Dgr |
H302 H373 ** H314 H317 |
|
|
|
|
015-160-00-7 |
difosforan(V) wanadylu; pirofosforan(V) wanadylu |
406-260-5 |
58834-75-6 |
Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 |
H319 H317 H412 |
GHS07 Wng |
H319 H317 H412 |
|
|
|
|
015-161-00-2 |
difosforan(V) diwanadylu; pirofosforan(V) diwanadylu |
407-130-0 |
65232-89-5 |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H302 H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H317 H411 |
|
|
|
|
015-162-00-8 |
tlenek wodorofosforan(V) wanadu(IV) – 1/2 hydrat (półwodzian), z dodatkiem litu, cynku, molibdenu, żelaza i chloru |
407-350-7 |
— |
Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Aquatic Chronic 2 |
H332 H373 ** H318 H411 |
GHS08 GHS05 GHS07 GHS09 Dgr |
H332 H373 ** H318 H411 |
|
|
|
|
015-163-00-3 |
tlenek bis(2,6-dimetoksybenzoilo)-2,4,4-trimetylopentylofosfiny; bis(2,6-dimetoksybenzoilo)(2,4,4-trimetylopentylo)oksofosforan |
412-010-6 |
145052-34-2 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
015-164-00-9 |
P, P'-(1-hydroksyetyleno)bis(wodorofosfonian) wapnia – dihydrat |
400-480-5 |
36669-85-9 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
015-165-00-4 |
masa poreakcyjna: bis[heksafluorofosforanu(V)] tiobis(4,1-fenyleno)-S, S,S',S'-tetrafenylodisulfoniowego; heksafluorofosforanu(V) difenylu(4-fenylotiofenylo)sulfoniowego |
404-986-7 |
— |
Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H400 H410 |
GHS05 GHS09 Dgr |
H318 H410 |
|
|
|
|
015-166-00-X |
3,9-bis(2,6-di-tert-butylo-4-metylofenoksy)-2,4,8,10-tetraoksa-3,9-difosfaspiro[5.5]undekan |
410-290-4 |
80693-00-1 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
015-167-00-5 |
kwas 3-(hydroksyfenylofosfinylo)propanowy; kwas 3-(hydroksyfenylofosfinylo)propionowy |
411-200-6 |
14657-64-8 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
015-168-00-0 |
fostiazat (ISO); 2-okso-1,3-tiazolidyn-3-ylofosfonotian (RS)-S-sec-butylu-O-etylu; (RS)-3-[sec-butylosulfanylo(etoksy)fosfinoilo]-1,3-tiazolidyn-2-on |
— |
98886-44-3 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H331 H301 H312 H317 H400 H410 |
GHS06 GHS09 Dgr |
H331 H301 H312 H317 H410 |
EUH070 |
|
|
|
015-169-00-6 |
tetrafluoroboran tributylotetradecylofosfonium |
413-520-1 |
— |
Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373 ** H314 H317 H400 H410 |
GHS08 GHS05 GHS07 GHS09 Dgr |
H302 H373 ** H314 H317 H410 |
|
|
|
|
015-170-00-1 |
masa poreakcyjna: fosforanu(V) di(oktan-1-ylo-N, N,N-trimetyloamoniowego)-oktylu; fosforanu(V) oktan-1-ylo-N, N,N-trimetyloamoniowego-dioktylu; fosforanu(V) oktan-1-ylo-N, N,N-trimetyloamoniowego-oktylu |
407-490-9 |
— |
Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B |
H312 H302 H314 |
GHS05 GHS07 Dgr |
H312 H302 H314 |
|
|
|
|
015-171-00-7 |
fosforotian O, O,O-tris(2(lub 4)-C9-10-izoalkilofenylu) |
406-940-1 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
015-172-00-2 |
masa poreakcyjna: fosforanu(V) mono[di(4-metylopentan-2-yloksy)tiofosforotionyloizopropylu]-bis(izotridecyloamoniowego); fosforanu(V) bis[di(4-metylopentan-2-yloksy)tiofosforotionyloizopropylu]-izotridecyloamoniowego |
406-240-6 |
— |
Flam. Liq. 3 Skin Corr. 1B Aquatic Chronic 2 |
H226 H314 H411 |
GHS02 GHS05 GHS09 Dgr |
H226 H314 H411 |
|
|
|
|
015-173-00-8 |
[2-(1,1-dimetyloetylo)-6-metoksypirymidyn-4-ylo]etylofosfonotian metylu |
414-080-3 |
117291-73-3 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
015-174-00-3 |
1-chloro-N,N-dietylo-1,1-difenylo-1-(fenylometylo)fosforoamina |
411-370-1 |
82857-68-9 |
Acute Tox. 3 * Eye Dam. 1 Aquatic Chronic 2 |
H301 H318 H411 |
GHS06 GHS05 GHS09 Dgr |
H301 H318 H411 |
|
|
|
|
015-175-00-9 |
(trifenylofosforanylideno)octan tert-butylu |
412-880-7 |
35000-38-5 |
Acute Tox. 3 * STOT RE 2 * Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H301 H373 ** H319 H317 H411 |
GHS06 GHS08 GHS09 Dgr |
H301 H373 ** H319 H317 H411 |
|
|
|
|
015-176-00-4 |
P, P,P',P'-tetrakis(2-metoksyfenylo)propano-1,3-difosfina |
413-430-2 |
116163-96-3 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
015-177-00-X |
kwas [(4-fenylobutylo)hydroksyfosforylo]octowy |
412-170-7 |
83623-61-4 |
STOT RE 2 * Eye Dam. 1 Skin Sens. 1 |
H373 ** H318 H317 |
GHS08 GHS05 Dgr |
H373 ** H318 H317 |
|
|
|
|
015-178-00-5 |
(-)-(1R,2S)-(1,2-epoksypropylo)fosfonian (R)-1-fenyloetyloamoniowy, monohydrat |
418-570-8 |
25383-07-7 |
Repr. 2 Aquatic Chronic 2 |
H361f *** H411 |
GHS08 GHS09 Wng |
H361f *** H411 |
|
|
|
|
015-179-00-0 |
produkt kondensacji UVCB: chlorku tetrakishydroksymetylofosfonium, mocznika i destylowanej uwodornionej C16-18 alkiloaminy tłuszczowej |
422-720-8 |
166242-53-1 |
Carc. 2 Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H302 H373 ** H314 H317 H400 H410 |
GHS08 GHS05 GHS07 GHS09 Dgr |
H351 H302 H373 ** H314 H317 H410 |
|
|
|
|
015-180-00-6 |
sól kwasu [R-(R*,S*)]-{[2-metylo-1-(1-oksopropoksy)propoksy]-(4-fenylobutylo)fosfinylo}octowego i (-)-cynchonidyny (1:1) |
415-820-8 |
137590-32-0 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|
|
|
|
015-181-00-1 |
fosfan, fosfina |
232-260-8 |
7803-51-2 |
Flam. Gas 1 Press. Gas Acute Tox. 2 * Skin Corr. 1B Aquatic Acute 1 |
H220 H330 H314 H400 |
GHS02 GHS04 GHS06 GHS05 GHS09 Dgr |
H220 H330 H314 H400 |
|
|
U |
|
015-182-00-7 |
tetraizopropylodichlorometylen-bisfosfonian; ester diizopropylowy kwasu (dichloro-(diizopropoksy-fosforylo)metylo)fosfonowego |
430-630-5 |
10596-22-2 |
Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 |
H302 H319 H317 |
GHS07 Wng |
H302 H319 H317 |
|
|
|
|
015-183-00-2 |
kwas (1-hydroksydodecylideno)difosfonowy |
425-230-2 |
16610-63-2 |
Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H314 H400 H410 |
GHS05 GHS09 Dgr |
H314 H410 |
|
|
|
|
015-184-00-8 |
sole glifosatu, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
A |
|
015-186-00-9 |
chloropiryfos metylowy (ISO); tiofosforan O-3,5,6-trichloro-2-pirydylu-O, O-dimetylu |
227-011-5 |
5598-13-0 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
M = 10000 |
|
|
015-187-00-4 |
masa poreakcyjna: N-tlenku {[(2-hydroksyetylo)imino]bis(metyleno)}bisfosfonianu tetra sodu; N-tlenku P-tlenku [(tetrahydro-2-hydroksy-4H-1,4,2-oksazafosforyn-4-ylo)metylo]fosfonianu trisodu |
417-540-1 |
— |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|
|
|
|
015-189-00-5 |
tlenek fenylobis(2,4,6-trimetylobenzoilo)fosfanu; tlenek fenylobis(2,4,6-trimetylobenzoilo)fosfiny |
423-340-5 |
162881-26-7 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
015-190-00-0 |
difosforan(III) bis(2,4-dikumylofenylo)neopentylu; 3,9-bis[2,4-bis(l-metylo-1-fenyloetylo)fenoksy]-2,4,8,10-tetraoksa-3,9-difosfaspiro[5.5]undekan |
421-920-2 |
154862-43-8 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
015-191-00-6 |
fosforan(V) dodecylodifenylu |
431-760-5 |
27460-02-2 |
Skin Irrit. 2 Aquatic Chronic 3 |
H315 H412 |
GHS07 Wng |
H315 H412 |
|
|
|
|
015-192-00-1 |
bifosforan(V) tetrakis(2,6-dimetylofenylo)-m-fenylenu |
432-770-2 |
139189-30-3 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
015-193-00-7 |
1,1,2,2,3,3,4,4,4-nonafluoro-N-metylo-1-butanosulfonamid trifenylo(fenylometylo)fosfoniowy (1:1) |
442-960-7 |
332350-93-3 |
Acute Tox. 3 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H318 H400 H410 |
GHS05 GHS06 GHS09 Dgr |
H301 H318 H410 |
|
|
|
|
015-194-00-2 |
nonafluorobutano-1-sulfonian tetrabutylofosfoniowy |
444-440-5 |
220689-12-3 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
015-195-00-8 |
masa poreakcyjna: o-toluenofosfonianu potasu; m-toluenofosfonianu potasu; p-toluenofosfonianu potasu |
433-860-4 |
— |
Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 |
H319 H317 H412 |
GHS07 Wng |
H319 H317 H412 |
|
|
|
|
015-196-00-3 |
masa poreakcyjna: (2-(hydroksymetylokarbamoilo)etylo)fosfonianu dimetylu; (2-(hydroksymetylokarbamoilo)etylo)fosfonianu dietylu; (2-(hydroksymetylokarbamoilo)etylo)fosfonianu etylometylu |
435-960-3 |
— |
Carc. 1B Muta. 1B Skin Sens. 1 |
H350 H340 H317 |
GHS08 GHS07 Dgr |
H350 H340 H317 |
|
|
|
|
015-197-00-9 |
kwas bis(2,2,4-trimetylopentylo)ditio-fosfonowy |
420-160-9 |
107667-02-7 |
Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 |
H226 H331 H302 H314 H411 |
GHS02 GHS06 GHS05 GHS09 Dgr |
H226 H331 H302 H314 H411 |
|
|
|
|
015-198-00-4 |
kwas (4-fenylobutylo)fosfinowy |
420-450-5 |
86552-32-1 |
Carc. 2 Eye Dam. 1 |
H351 H318 |
GHS05 GHS08 Dgr |
H351 H318 |
|
|
|
|
015-199-00-X |
fosforan(V) tris(2-chloro-1-chlorometylu)-etylu |
237-159-2 |
13674-87-8 |
Carc. 2 |
H351 |
GSH08 Wng |
H351 |
|
|
|
|
015-200-00-3 |
fosforek indu |
244-959-5 |
22398-80-7 |
Carc. 1B Repr. 2 STOT RE 1 |
H350 H361f H372 (płuca) |
GHS08 Dgr |
H350 H361f H372 (płuca) |
|
STOT RE 1; H372: C ≥0,1 % Carc 1B; H350: C ≥0,01 % STOT RE 2; H373: 0,01 % ≤ C < 0,1 % |
|
|
015-201-00-9 |
fosforan triksylilu |
246-677-8 |
25155-23-1 |
Repr. 1B |
H360F |
GHS08 Dgr |
H360F |
|
|
|
|
015-202-00-4 |
fosforan(III) tris(nonylofenylu) |
247-759-6 |
26523-78-4 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
015-203-00-X |
tlenek difenylo(2,4,6-trimetylobenzoilo)fosfanu; tlenek difenylo(2,4,6-trimetylobenzoilo)fosfiny |
278-355-8 |
75980-60-8 |
Repr. 2 |
H361f (powoduje zanik jąder) |
GHS08 Wng |
H361f (powoduje zanik jąder) |
|
|
|
|
016-001-00-4 |
siarkowodór |
231-977-3 |
7783-06-4 |
Flam. Gas 1 Press. Gas Acute Tox. 2 * Aquatic Acute 1 |
H220 H330 H400 |
GHS02 GHS04 GHS06 GHS09 Dgr |
H220 H330 H400 |
|
|
U |
|
016-002-00-X |
siarczek baru |
244-214-4 |
21109-95-5 |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 |
H332 H302 H400 |
GHS07 GHS09 Wng |
H332 H302 H400 |
EUH031 |
|
|
|
016-003-00-5 |
polisiarczki baru |
256-814-3 |
50864-67-0 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 |
H319 H335 H315 H400 |
GHS07 GHS09 Wng |
H319 H335 H315 H400 |
EUH031 |
|
|
|
016-004-00-0 |
siarczek wapnia |
243-873-5 |
20548-54-3 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 |
H319 H335 H315 H400 |
GHS07 GHS09 Wng |
H319 H335 H315 H400 |
EUH031 |
|
|
|
016-005-00-6 |
polisiarczki wapnia |
215-709-2 |
1344-81-6 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 |
H319 H335 H315 H400 |
GHS07 GHS09 Wng |
H319 H335 H315 H400 |
EUH031 |
|
|
|
016-006-00-1 |
siarczek potasu; siarczek dipotasu |
215-197-0 |
1312-73-8 |
Skin Corr. 1B Aquatic Acute 1 |
H314 H400 |
GHS05 GHS09 Dgr |
H314 H400 |
EUH031 |
|
|
|
016-007-00-7 |
polisiarczki potasu |
253-390-1 |
37199-66-9 |
Skin Corr. 1B Aquatic Acute 1 |
H314 H400 |
GHS05 GHS09 Dgr |
H314 H400 |
EUH031 |
|
|
|
016-008-00-2 |
polisiarczki amonu |
232-989-1 |
9080-17-5 |
Skin Corr. 1B Aquatic Acute 1 |
H314 H400 |
GHS05 GHS09 Dgr |
H314 H400 |
EUH031 |
EUH031: C ≥1 % |
|
|
016-009-00-8 |
siarczek sodu; siarczek disodu |
215-211-5 |
1313-82-2 |
Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1B Aquatic Acute 1 |
H311 H302 H314 H400 |
GHS06 GHS05 GHS09 Dgr |
H311 H302 H314 H400 |
|
|
|
|
016-010-00-3 |
polisiarczki sodu |
215-686-9 |
1344-08-7 |
Acute Tox. 3 * Skin Corr. 1B Aquatic Acute 1 |
H301 H314 H400 |
GHS06 GHS05 GHS09 Dgr |
H301 H314 H400 |
EUH031 |
|
|
|
016-011-00-9 |
ditlenek siarki |
231-195-2 |
7446-09-5 |
Press. Gas Acute Tox. 3 * Skin Corr. 1B |
H331 H314 |
GHS04 GHS06 GHS05 Dgr |
H331 H314 |
|
* |
U5 |
|
016-012-00-4 |
dichlorek disiarki; monochlorek siarki |
233-036-2 |
10025-67-9 |
Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1A Aquatic Acute 1 |
H301 H332 H314 H400 |
GHS06 GHS05 GHS09 Dgr |
H301 H332 H314 H400 |
EUH014 EUH029 |
STOT SE 3; H335: C ≥ 1 % |
|
|
016-013-00-X |
dichlorek siarki |
234-129-0 |
10545-99-0 |
Skin Corr. 1B STOT SE 3 Aquatic Acute 1 |
H314 H335 H400 |
GHS05 GHS07 GHS09 Dgr |
H314 H335 H400 |
EUH014 |
STOT SE 3; H335: C ≥ 5 % |
|
|
016-014-00-5 |
tetrachlorek siarki |
— |
13451-08-6 |
Skin Corr. 1B Aquatic Acute 1 |
H314 H400 |
GHS05 GHS09 Dgr |
H314 H400 |
EUH014 |
STOT SE 3; H335: C ≥ 5 % |
|
|
016-015-00-0 |
dichlorek sulfinylu; dichlorek tionylu; chlorek tionylu; dichlorek tlenek siarki; tlenochlorek siarki |
231-748-8 |
7719-09-7 |
Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A |
H332 H302 H314 |
GHS05 GHS07 Dgr |
H332 H302 H314 |
EUH014 EUH029 |
STOT SE 3; H335: C ≥ 1 % |
|
|
016-016-00-6 |
dichlorek sulfonylu; dichlorek sulfurylu; chlorek sulfurylu |
232-245-6 |
7791-25-5 |
Skin Corr. 1B STOT SE 3 |
H314 H335 |
GHS05 GHS07 Dgr |
H314 H335 |
EUH014 |
|
|
|
016-017-00-1 |
kwas chlorosiarkowy(VI); kwas chlorosulfonowy |
232-234-6 |
7790-94-5 |
Skin Corr. 1A STOT SE 3 |
H314 H335 |
GHS05 GHS07 Dgr |
H314 H335 |
EUH014 |
|
|
|
016-018-00-7 |
kwas fluorosiarkowy(VI); kwas fluorosulfonowy |
232-149-4 |
7789-21-1 |
Acute Tox. 4 * Skin Corr. 1A |
H332 H314 |
GHS05 GHS07 Dgr |
H332 H314 |
|
|
|
|
016-019-00-2 |
oleum … % SO3 |
— |
— |
Skin Corr. 1A STOT SE 3 |
H314 H335 |
GHS05 GHS07 Dgr |
H314 H335 |
EUH014 |
|
B |
|
016-020-00-8 |
kwas siarkowy(VI) … % |
231-639-5 |
7664-93-9 |
Skin Corr. 1A |
H314 |
GHS05 Dgr |
H314 |
|
Skin Corr. 1A; H314: C ≥ 15 % Skin Irrit. 2; H315: 5 % ≤ C < 15 % Eye Irrit. 2; H319: 5 % ≤ C < 15 % |
B |
|
016-021-00-3 |
metanotiol; merkaptan metylowy |
200-822-1 |
74-93-1 |
Flam. Gas. 1 Press. Gas Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H220 H331 H400 H410 |
GHS02 GHS04 GHS06 GHS09 Dgr |
H220 H331 H410 |
|
|
U |
|
016-022-00-9 |
etanotiol; merkaptan etylowy |
200-837-3 |
75-08-1 |
Flam. Liq. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H225 H332 H400 H410 |
GHS02 GHS07 GHS09 Dgr |
H225 H332 H410 |
|
|
|
|
016-023-00-4 |
siarczan(VI) dimetylu |
201-058-1 |
77-78-1 |
Carc. 1B Muta. 2 Acute Tox. 2 * Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 |
H350 H341 H330 H301 H314 H317 |
GHS06 GHS08 GHS05 Dgr |
H350 H341 H330 H301 H314 H317 |
|
Carc. 1B; H350: C ≥ 0,01 % Muta. 2 H341: C ≥ 0,01 % STOT SE 3; H335: C ≥ 5 % |
|
|
016-024-00-X |
dimeksan (ISO); ditiobis(tiomrówczan) O, O-dimetylu |
215-993-8 |
1468-37-7 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
016-025-00-5 |
disul (ISO); wodorosiarczan(VI) 2-(2,4-dichlorofenoksy)etylu; 2,4-DES |
205-259-5 |
149-26-8 |
Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 |
H302 H315 H318 |
GHS05 GHS07 Dgr |
H302 H315 H318 |
|
|
|
|
016-026-00-0 |
kwas amidosiarkowy(VI); kwas sulfamidowy; kwas amidosulfonowy |
226-218-8 |
5329-14-6 |
Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 3 |
H319 H315 H412 |
GHS07 Wng |
H319 H315 H412 |
|
|
|
|
016-027-00-6 |
siarczan(VI) dietylu |
200-589-6 |
64-67-5 |
Carc. 1B Muta. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B |
H350 H340 H332 H312 H302 H314 |
GHS05 GHS08 GHS07 Dgr |
H350 H340 H332 H312 H302 H314 |
|
|
|
|
016-028-00-1 |
ditionian(III) sodu; podsiarczyn sodu |
231-890-0 |
7775-14-6 |
Self-heat. 1 Acute Tox. 4 * |
H251 H302 |
GHS02 GHS07 Dgr |
H251 H302 |
EUH031 |
|
|
|
016-029-00-7 |
kwas p-toluenosulfonowy (zawierający więcej niż 5 % H2SO4); kwas 4-metylobenzenosulfonowy (zawierający więcej niż 5 % H2SO4) |
— |
— |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
|
Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 % Eye Irrit. 2; H319: 10 % ≤ C < 25 % |
|
|
016-030-00-2 |
kwas p-toluenosulfonowy (zawierający maksymalnie 5 % H2SO4); kwas 4-metylobenzenosulfonowy (zawierający maksymalnie 5 % H2SO4) |
203-180-0 |
104-15-4 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H319 H335 H315 |
GHS07 Wng |
H319 H335 H315 |
|
STOT SE 3; H335: C ≥ 20 % |
|
|
016-031-00-8 |
1,1-ditlenek tetrahydrotiofenu; sulfolan; 1,1-dioksotetrahydrotiofen; sulfon tetrametylenu |
204-783-1 |
126-33-0 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
016-032-00-3 |
1,3-propanosulton; 2,2-dioksy-1,2-oksatiolan |
214-317-9 |
1120-71-4 |
Carc. 1B Acute Tox. 4 * Acute Tox. 4 * |
H350 H312 H302 |
GHS08 GHS07 Dgr |
H350 H312 H302 |
|
Carc. 1B; H350: C ≥ 0,01 % |
|
|
016-033-00-9 |
chlorek dimetylosulfamoilu; chlorek dimetylosulfamylu |
236-412-4 |
13360-57-1 |
Carc. 1B Acute Tox. 2 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B |
H350 H330 H312 H302 H314 |
GHS06 GHS05 GHS08 Dgr |
H350 H330 H312 H302 H314 |
|
|
|
|
016-034-00-4 |
3,3'-{piperazyno-1,4-diylobis[(6-chloro-1,3,5-triazyno-2,4-diylo)imino(2-acetamido)-4,1-fenylenoazo]}bis(naftaleno-1,5-disulfonian) tetrasodu |
400-010-9 |
81898-60-4 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
016-035-00-X |
5-anilino-3-(4-{4-[4-chloro-6-(3-sulfonianoanilino)-1,3,5-triazyno-2-yloamino]-2,5-dimetylofenyloazo}-2,5-disulfonianofenyloazo)-4-hydroksynaftaleno-2,7-disulfonian pentasodu |
400-120-7 |
— |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
016-036-00-5 |
5'-(4,6-dichloro-5-cyjanopirymidyn-2-yloamino)-4'-hydroksy-2,3'-azodinaftaleno-1,2',5,7'-disulfonian tetrasodu |
400-130-1 |
— |
Resp. Sens. 1 Aquatic Chronic 2 |
H334 H411 |
GHS08 GHS09 Dgr |
H334 H411 |
|
|
|
|
016-037-00-0 |
1-amino-4-(4-benzenosulfonoamido-3-sulfonianoanilino)-9,10-antrachinono-2-sulfonian disodu |
400-350-8 |
85153-93-1 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
016-038-00-6 |
6-[(4-chloro-6-(N-metylo-2-toluidyno)-1,3,5-triazyno-2-yloamino]-1-hydroksy-2-(4-metoksy-2-sulfonianofenyloazo)naftaleno-3-sulfonian disodu |
400-380-1 |
86393-35-3 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
016-039-00-1 |
2-(6-chloro-4-{4-[2,5-dimetylo-4-(2,5-disulfonianofenyloazo)fenyloazo]-3-ureidoanilino}-1,3,5-triazyno-2-yloamino)benzeno-1,4-disulfonian tetrasodu |
400-430-2 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
016-040-00-7 |
masa poreakcyjna: 6-(2,4-dihydroksyfenyloazo)-3-{4-[4-(2,4-dihydroksyfenyloazo)anilino]-3-sulfonianofenyloazo}-4-hydroksynaftaleno-2-sulfonianu disodu, 6-(2,4-diaminofenyloazo)-3-{4-[4-(2,4-diaminofenyloazo)anilino]-3-sulfonianofenyloazo}-4-hydroksynaftaleno-2-sulfonianu disodu i 6-(2,4-dihydroksyfenyloazo)-3-(4-{4-[7-(2,4-dihydroksyfenyloazo)-1-hydroksy-3-sulfoniano-2-naftyloazo]anilino}-3-sulfonianofenyloazo)-4-hydroksynaftaleno-2-sulfonianu disodu |
400-570-4 |
— |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
016-041-00-2 |
2,5-dichloro-4-[4-(5-chloro-4-metylo-2-sulfonianofenyloazo)-5-hydroksy-3-metylopirazol-1-ilo]benzenosulfonian wapnia |
400-710-4 |
— |
Acute Tox. 4 * |
H332 |
GHS07 Wng |
H332 |
|
|
|
|
016-042-00-8 |
5-benzamido-3-{5-[4-fluoro-6-(1-sulfoniano-2-naftyloamino)-1,3,5-triazyn-2-yloamino]-2-sulfonianofenyloazo}-4-hydroksynaftaleno-2,7-disulfonian tetrasodu |
400-790-0 |
85665-97-0 |
Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H319 H315 H317 |
GHS07 Wng |
H319 H315 H317 |
|
|
|
|
016-043-00-3 |
6-acetamido-4-hydroksy-3-{4-[2-(sulfonianooksy)etylosulfonylo]fenyloazo}naftaleno-2-sulfonian dilitu |
401-010-1 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
016-044-00-9 |
S, S'-heksano-1,6-diylobis(tiosiarczan) disodu – dihydrat |
401-320-7 |
— |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
016-045-00-4 |
4-amino-6-[5-(5-chloro-2,6-difluoropirymidyno-4-yloamino)-2-sulfonianofenyloazo]-5-hydroksy-3-{4-[2-(sulfonianooksy)etylosulfonylo]fenyloazo}naftaleno-2,7-disulfonian litu-sodu-wodoru |
401-560-2 |
108624-00-6 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
016-046-00-X |
wodorosiarczan(VI) sodu; kwaśny siarczan sodu |
231-665-7 |
7681-38-1 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
016-047-00-5 |
7-(4-{4-[4-(2,5-disulfonianoanilino)-6-fluoro-1,3,5-triazyno-2-yloamino]-2-metylofenyloazo}-7-sulfoniano-1-naftyloazo)naftaleno-1,3,5-trisulfonian heksasodu |
401-650-1 |
85665-96-9 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
016-048-00-0 |
3,5-dichloro-2-[5-cyjano-2,6-bis(3-hydroksypropyloamino)-4-metylo-3-pirydyloazo]benzenosulfonian sodu |
401-870-8 |
— |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
016-049-00-6 |
bis[dimetylo(oktadecylo)benzenosulfonian] wapnia |
402-040-8 |
— |
Skin Corr. 1B Aquatic Chronic 2 |
H314 H411 |
GHS05 GHS09 Dgr |
H314 H411 |
|
|
|
|
016-050-00-1 |
5-{4-chloro-6-[N-(4-{4-chloro-6-[5-hydroksy-2,7-disulfoniano-6-(2-sulfonianofenyloazo)-4-naftyloamino]-1,3,5-triazyno-2-yloamino}fenylo-N-metylo)amino]-1,3,5-triazyn-2-yloamino}-4-hydroksy-3-(2-sulfonianofenyloazo)naftaleno-2,7-disulfonian tripotasu-trisodu |
402-150-6 |
— |
Eye Irrit. 2 Skin Sens. 1 |
H319 H317 |
GHS07 Wng |
H319 H317 |
|
|
|
|
016-051-00-7 |
7-(4-{6-fluoro-4-[2-(2-winylosulfonyloetoksy)etyloamino]-1,3,5-triazyn-2-yloamino}-2-ureidofenyloazo)naftaleno-1,3,6-trisulfonian trisodu |
402-170-5 |
106359-91-5 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
016-052-00-2 |
4-hydroksynaftaleno-1-sulfonian benzylotributyloamoniowy |
402-240-5 |
102561-46-6 |
Acute Tox. 4 * Aquatic Chronic 2 |
H332 H411 |
GHS07 GHS09 Wng |
H332 H411 |
|
|
|
|
016-053-00-8 |
2-(dialkilokarbamoilo)benzenosulfonian dialkiloamoniowy, gdzie alkil oznacza nasycony, nierozgałęziony łańcuch zawierający 16 lub 18 atomów węgla (heksadecyl lub oktadecyl) |
402-460-1 |
— |
Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 |
H315 H317 H413 |
GHS07 Wng |
H315 H317 H413 |
|
|
|
|
016-054-00-3 |
(2,4,4-trimetyloheksanoiloksy)benzenosulfonian sodu |
400-030-8 |
— |
Acute Tox. 3 * STOT RE 1 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Sens. 1 |
H331 H372 ** H302 H319 H335 H317 |
GHS06 GHS08 Dgr |
H331 H372 ** H302 H319 H335 H317 |
|
|
|
|
016-055-00-9 |
4-amino-3,6-bis{5-[6-chloro-4-(2-hydroksyetyloamino)-1,3,5-triazyn-2-yloamino]-2-sulfonianofenyloazo}-5-hydroksy-naftaleno-2,7-disulfonian tetrasodu (zawierający > 35 % chlorku sodu i octanu sodu) |
400-510-7 |
— |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
016-056-00-4 |
wodorosiarczan(VI) potasu; kwaśny siarczan potasu |
231-594-1 |
7646-93-7 |
Skin Corr. 1B STOT SE 3 |
H314 H335 |
GHS05 GHS07 Dgr |
H314 H335 |
|
|
|
|
016-057-00-X |
chlorek styreno-4-sulfonylu |
404-770-2 |
2633-67-2 |
Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 |
H315 H318 H317 |
GHS05 GHS07 Dgr |
H315 H318 H317 |
|
|
|
|
016-058-00-5 |
produkty reakcji chlorku tionylu z 1,3,4-tiadiazolo-2,5-ditiolem, tert-nonanotiolem i C12-14-tert-alkiloaminą |
404-820-3 |
— |
Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 |
H315 H317 H412 |
GHS07 Wng |
H315 H317 H412 |
|
|
|
|
016-059-00-0 |
dichlorowodorek N, N,N',N'-tetrametyloditiobis(etyleno)diaminy |
405-300-9 |
17339-60-5 |
Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H319 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H319 H317 H410 |
|
|
|
|
016-060-00-6 |
peroksodisiarczan(VI) diamonu; nadtlenodisiarczan(VI) diamonu |
231-786-5 |
7727-54-0 |
Ox. Sol. 3 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 |
H272 H302 H319 H335 H315 H334 H317 |
GHS03 GHS08 GHS07 Dgr |
H272 H302 H319 H335 H315 H334 H317 |
|
|
|
|
016-061-00-1 |
peroksodisiarczan(VI) dipotasu; nadtlenodisiarczan(VI) dipotasu |
231-781-8 |
7727-21-1 |
Ox. Sol. 3 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 |
H272 H302 H319 H335 H315 H334 H317 |
GHS03 GHS08 GHS07 Dgr |
H272 H302 H319 H335 H315 H334 H317 |
|
|
|
|
016-062-00-7 |
bensultap (ISO); 1,3-bis(fenylosulfonylotio)-2-(N, N-dimetyloamino)propan |
— |
17606-31-4 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
016-063-00-2 |
disiarczan(IV) disodu |
231-673-0 |
7681-57-4 |
Acute Tox. 4 * Eye Dam. 1 |
H302 H318 |
GHS05 GHS07 Dgr |
H302 H318 |
EUH031 |
|
|
|
016-064-00-8 |
wodorosiarczan(IV) sodu … %; wodorosiarczyn sodu . . . % |
231-548-0 |
7631-90-5 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
EUH031 |
|
B |
|
016-065-00-3 |
1-amino-4-[2-metylo-5-(4-metylofenylosulfonyloamino)fenyloamino]antrachinono-2-sulfonian sodu |
400-100-8 |
84057-97-6 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
016-066-00-9 |
{5-[(4-amino-6-chloro-1,3,5-triazyn-2-ylo)amino]-2-[(2-hydroksy-3,5-disulfonianofenyloazo)-2-sulfonianobenzylidenohydrazyno]benzoesan}miedzian(II) tetrasodu |
404-070-7 |
116912-62-0 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
016-067-00-4 |
2,4,6-trimetylobenzenosulfonian 4-metylofenylu; mezytylenosulfonian 4-metylofenylu |
407-530-5 |
67811-06-7 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
016-068-00-X |
3,5-bis(tetradecyloksykarbonylo)benzenosulfinian sodu |
407-720-8 |
155160-86-4 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
016-069-00-5 |
kwas 3,5-bis(tetradecyloksykarbonylo)benzenosulfinowy |
407-990-7 |
141915-64-2 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
016-070-00-0 |
sulfon 4-benzyloksy-4'-(2,3-epoksy-2-metylopropoksy)difenylowy; 1-(4-benzyloksyfenylosulfonylo)-4-(2,3-epoksy-2-metylopropoksy)benzen |
408-220-2 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
016-071-00-6 |
3-amino-6,13-dichloro-10-{3-[4-chloro-6-(2-sulfofenyloamino)-1,3,5-triazyn-2-yloamino]propyloamino}trifenoksydioksazyno-4,11-disulfonian trisodu |
410-130-3 |
136248-03-8 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
016-072-00-1 |
3-amino-4-hydroksy-N-(2-metoksyetylo)benzenosulfonoamid |
411-520-6 |
112195-27-4 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H318 H317 H411 |
|
|
|
|
016-073-00-7 |
tetrakis(fenylometylo)tioperoksydi(karbotioamid) |
404-310-0 |
10591-85-2 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
016-074-00-2 |
6-fluoro-2-metylo-3-(4-metylosulfanylobenzylo)inden; 6-fluoro-2-metylo-3-(4-metylotiobenzylo)inden |
405-410-7 |
— |
Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H315 H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H315 H318 H317 H411 |
|
|
|
|
016-075-00-8 |
2,2'-diallilo-4,4'-sulfonylodifenol |
411-570-9 |
41481-66-7 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
016-076-00-3 |
2,3-bis[(2-sulfanyloetylo)sulfanylo]propano-1-tiol |
411-290-7 |
131538-00-6 |
Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373 ** H400 H410 |
GHS08 GHS07 GHS09 Wng |
H302 H373 ** H410 |
|
|
|
|
016-077-00-9 |
chlorek 2-chloro-p-toluenosulfonylu |
412-890-1 |
42413-03-6 |
Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 3 |
H314 H317 H412 |
GHS05 GHS07 Dgr |
H314 H317 H412 |
|
|
|
|
016-078-00-4 |
4-metylo-N, N-bis(2-{[(4-metylofenylo)sulfonylo]amino}etylo)benzenosulfonoamid |
413-300-5 |
56187-04-3 |
Aquatic Chronic 4 |
H413 |
— |
|
|
|
|
|
016-079-00-X |
N, N-bis[2-(p-toluenosulfonyloksy)etylo]-p-toluenosulfonoamid |
412-920-3 |
16695-22-0 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
016-080-00-5 |
2-anilino-5-[2-nitro-4-(N-fenylosulfamoilo)]anilinobenzenosulfonian sodu |
412-320-1 |
31361-99-6 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
016-081-00-0 |
N-etoksykarbonylo-N-(p-tolilosulfonylo)azanid heksahydrocyklopenta[c]pirolo-1-(1H)-amoniowy |
418-350-1 |
— |
Muta. 2 Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H341 H302 H319 H317 H411 |
GHS08 GHS07 GHS09 Wng |
H341 H302 H319 H317 H411 |
|
|
|
|
016-082-00-6 |
etoksysulfuron (ISO); 1-(4,6-dimetoksypirymidyn-2-ylo)-3-(2-etoksyfenoksysulfonylo)mocznik |
— |
126801-58-9 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
016-083-00-1 |
acybenzolar S-metylowy; benzo[1,2,3]tiadiazolo-7-karbotian S-metylu |
420-050-0 |
135158-54-2 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H335 H315 H317 H400 H410 |
GHS07 GHS09 Wng |
H319 H335 H315 H317 H410 |
|
|
|
|
016-084-00-7 |
prosulfuron (ISO); 1-(4-metoksy-6-metylo-1,3,5-triazyn-2-ylo)-3-[2-(3,3,3-trifluoropropylo)fenylosulfonylo]mocznik |
— |
94125-34-5 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
M=100 |
|
|
016-085-00-2 |
flazasulfuron (ISO); 1-(4,6-dimetoksypirymidyn-2-ylo)-3-(3-trifluorometylo-2-pirydylosulfonylo)mocznik |
— |
104040-78-0 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
016-086-00-8 |
10-amino-6,13-dichloro-3-{3-[4-(2,5-disulfonianoanilino)-6-fluoro-1,3,5-triazyn-2-yloamino]propan-3-yloamino}-5,12-dioksa-7,14-diazapentaceno-4,11-disulfonian tetrasodu |
402-590-9 |
109125-56-6 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
016-087-00-3 |
masa poreakcyjna: bisheksafluorofosforanu tiobis(4,1-fenyleno)-S, S,S',S'-tetrafenylodisulfoniowego; heksafluorofosforanu difenylu-(4-fenylotiofenylo)sulfoniowego; węglanu propylenu |
403-490-8 |
104558-95-4 |
Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H317 H400 H410 |
GHS07 GHS09 Wng |
H319 H317 H410 |
|
|
|
|
016-088-00-9 |
kwas 4-{bis[4-(dietyloamino)fenylo]-metylo}benzeno-1,2-dimetanosulfonowy |
407-280-7 |
71297-11-5 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
016-089-00-4 |
masa poreakcyjna: estrów 5,5',6,6',7,7'-heksahydroksy-3,3,3',3'-tetrametylo-1,1'-spirobiindanu i 2-diazo-1,2-dihydro-1-okso-5-sulfonaftalenu |
413-840-1 |
— |
Self-react. C **** Aquatic Chronic 4 |
H242 H413 |
GHS02 Dgr |
H242 H413 |
|
|
|
|
016-090-00-X |
4-metylo-N-(metylosulfonylo)benzenosulfonoamid |
415-040-8 |
14653-91-9 |
Acute Tox. 4 * STOT SE 3 Eye Dam. 1 |
H302 H335 H318 |
GHS05 GHS07 Dgr |
H302 H335 H318 |
|
|
|
|
016-091-00-5 |
1-amino-9,10-dihydro-9,10-diokso-4-(2,4,6-trimetyloanilino)antraceno-2-sulfonian C12-14-tert-alkiloamoniowy |
414-110-5 |
— |
Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H400 H410 |
GHS05 GHS09 Dgr |
H318 H410 |
|
|
|
|
016-092-00-0 |
masa poreakcyjna: 4,7-bis(merkaptometylo)-3,6,9-tritia-1,11-undekanoditiolu; 4,8-bis(merkaptometylo)-3,6,9-tritia-1,11-undekanoditiolu; 5,7-bis(merkaptometylo)-3,6,9-tritia-1,11-undekanoditiolu |
427-050-1 |
— |
Repr. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361f H315 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H361f H315 H317 H410 |
|
|
|
|
016-093-00-6 |
masa poreakcyjna: tris(6-diazo-5,6-dihydro-5-oksonaftaleno-1-sulfonianu) 4-(7-hydroksy-2,4,4-tri-metylochroman-2-ylo)rezorcynol-4-ilu; bis(6-diazo-5,6-dihydro-5-oksonaftaleno-1-sulfonian) 4-(7-hydroksy-2,4,4-tri-metylochroman-2-ylo)rezorcynolu (2:1) |
414-770-4 |
140698-96-0 |
Self-react. C **** Carc. 2 |
H242 H351 |
GHS02 GHS08 Dgr |
H242 H351 |
|
|
|
|
016-094-00-1 |
siarka |
231-722-6 |
7704-34-9 |
Skin Irrit. 2 |
H315 |
GHS07 Wng |
H315 |
|
|
|
|
016-095-00-7 |
masa poreakcyjna: produkt reakcji 4,4'-metylenobis-[2-(4-hydroksybenzylo)-3,6-dimetylofenolu] i 6-diazo-5,6-dihydro-5-okso-naftalenosulfonianu (1:2); produkt reakcji 4,4'-metylenobis-[2-(4-hydroksybenzylo)-3,6-dimetylofenolu] i 6-diazo-5,6-dihydro-5-okso-naftalenosulfonianu (1:3) |
417-980-4 |
— |
Self-react. C **** Carc. 2 |
H242 H351 |
GHS02 GHS08 Dgr |
H242 H351 |
|
|
|
|
016-096-00-2 |
tifensulfuron metylowy (ISO); 3-(4-metoksy-6-metylo-1,3,5-triazyn-2-ylokarbamoilosulfoamoilo)tiofeno-2-karboksylan metylu |
— |
79277-27-3 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
016-097-00-8 |
chlorowodorek 1-amino-2-metylo-2-propanotiolu |
434-480-1 |
32047-53-3 |
Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 3 |
H302 H314 H317 H412 |
GHS05 GHS07 Dgr |
H302 H314 H317 H412 |
|
|
|
|
017-001-00-7 |
chlor |
231-959-5 |
7782-50-5 |
Ox. Gas 1 Press. Gas Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 |
H270 H331 H319 H335 H315 H400 |
GHS03 GHS04 GHS06 GHS09 Dgr |
H270 H331 H319 H335 H315 H400 |
|
M = 100 |
U |
|
017-002-00-2 |
chlorowodór |
231-595-7 |
7647-01-0 |
Press. Gas Acute Tox. 3 * Skin Corr. 1A |
H331 H314 |
GHS04 GHS06 GHS05 Dgr |
H331 H314 |
|
|
U5 |
|
017-002-01-X |
kwas chlorowodorowy … %; kwas solny … % |
231-595-7 |
— |
Skin Corr. 1B STOT SE 3 |
H314 H335 |
GHS05 GHS07 Dgr |
H314 H335 |
|
Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 % EyeIrrit. 2; H319: 10 % ≤ C < 25 % STOT SE 3; H335: C ≥ 10 % |
B |
|
017-003-00-8 |
chloran(V) baru |
236-760-7 |
13477-00-4 |
Ox. Sol. 1 Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 2 |
H271 H332 H302 H411 |
GHS03 GHS07 GHS09 Dgr |
H271 H332 H302 H411 |
|
|
|
|
017-004-00-3 |
chloran(V) potasu |
223-289-7 |
3811-04-9 |
Ox. Sol. 1 Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 2 |
H271 H332 H302 H411 |
GHS03 GHS07 GHS09 Dgr |
H271 H332 H302 H411 |
|
|
|
|
017-005-00-9 |
chloran(V) sodu |
231-887-4 |
7775-09-9 |
Ox. Sol. 1 Acute Tox. 4 * Aquatic Chronic 2 |
H271 H302 H411 |
GHS03 GHS07 GHS09 Dgr |
H271 H302 H411 |
|
|
|
|
017-006-00-4 |
kwas chlorowy(VII) … %; kwas nadchlorowy …% |
231-512-4 |
7601-90-3 |
Ox. Liq. 1 Skin Corr. 1A |
H271 H314 |
GHS03 GHS05 Dgr |
H271 H314 |
|
Skin Corr. 1A; H314: C ≥ 50 % Skin Corr. 1B; H314: 10 % ≤ C < 50 % Skin Irrit. 2; H315: 1 % ≤ C < 10 % Eye Irrit. 2; H319: 1 % ≤ C < 10 % Ox. Liq. 1; H271: C > 50 %: Ox. Liq. 2; H272: C ≤ 50 %: |
B |
|
017-007-00-X |
chloran(VII) baru; nadchloran baru |
236-710-4 |
13465-95-7 |
Ox. Sol. 1 Acute Tox. 4 * Acute Tox. 4 * |
H271 H332 H302 |
GHS03 GHS07 Dgr |
H271 H332 H302 |
|
|
|
|
017-008-00-5 |
chloran(VII) potasu; nadchloran potasu |
231-912-9 |
7778-74-7 |
Ox. Sol. 1 Acute Tox. 4 * |
H271 H302 |
GHS03 GHS07 Dgr |
H271 H302 |
|
|
|
|
017-009-00-0 |
nadchloran amonu; chloran(VII) amonu |
232-235-1 |
7790-98-9 |
Expl. 1.1 Ox. Sol. 1 |
H201 H271 |
GHS01 Dgr |
H201 H271 |
|
|
T |
|
017-010-00-6 |
chloran(VII) sodu; nadchloran sodu |
231-511-9 |
7601-89-0 |
Ox. Sol. 1 Acute Tox. 4 * |
H271 H302 |
GHS03 GHS07 Dgr |
H271 H302 |
|
|
|
|
017-011-00-1 |
chloran(I) sodu, roztwór zawierający … % aktywnego Cl |
231-668-3 |
7681-52-9 |
Skin Corr. 1B Aquatic Acute 1 |
H314 H400 |
GHS05 GHS09 Dgr |
H314 H400 |
EUH031 |
EUH031: C ≥5 % |
B |
|
017-012-00-7 |
podchloryn wapnia; chloran(I) wapnia |
231-908-7 |
7778-54-3 |
Ox. Sol. 2 Acute Tox. 4 * Skin Corr. 1B Aquatic Acute 1 |
H272 H302 H314 H400 |
GHS03 GHS05 GHS07 GHS09 Dgr |
H272 H302 H314 H400 |
EUH031 |
Skin Corr. 1B; H314: C ≥ 5 % Skin Irrit. 2; H315: 1 % ≤ C < 5 % Eye Dam.1; H318: 3 % ≤ C < 5 % Eye Irrit. 2; H319: 0,5 % ≤ C < 3 % M = 10 |
T |
|
017-013-00-2 |
chlorek wapnia |
233-140-8 |
10043-52-4 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
017-014-00-8 |
chlorek amonu |
235-186-4 |
12125-02-9 |
Acute Tox. 4 * Eye Irrit. 2 |
H302 H319 |
GHS07 Wng |
H302 H319 |
|
|
|
|
017-015-00-3 |
chlorowodorek chlorku [2-(aminometylo)fenylo]acetylu |
417-410-4 |
61807-67-8 |
Acute Tox. 4 * Skin Corr. 1A Skin Sens. 1 |
H302 H314 H317 |
GHS05 GHS07 Dgr |
H302 H314 H317 |
|
|
|
|
017-016-00-9 |
chlorek metylotrifenylofosfonium |
418-400-2 |
1031-15-8 |
Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 |
H312 H302 H315 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H312 H302 H315 H318 H411 |
|
|
|
|
017-017-00-4 |
chlorek (Z)-dokoz-13-enylo-N, N-bis(2-hydroksyetylo)-N-metyloamoniowy |
426-210-6 |
120086-58-0 |
Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H314 H400 H410 |
GHS05 GHS09 Dgr |
H314 H410 |
|
|
|
|
017-018-00-X |
chlorek N, N,N-trimetylo-2,3-bis(stearoiloksy)propyloamoniowy |
405-660-7 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
017-019-00-5 |
chlorowodorek (R)-1,2,3,4-tetrahydro-6,7-dimetoksy-1-weratryloizochinoliny; chlorowodorek (R)-1,2,3,4-tetrahydro-6,7-dimetoksy-1-(3,4-dimetoksyfenylometylo)izochinoliny |
415-110-8 |
54417-53-7 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
017-020-00-0 |
chlorek etylopropoksyglinu |
421-790-7 |
13014-29-4 |
Water-react. 1 Skin Corr. 1A |
H260 H314 |
GHS02 GHS05 Dgr |
H260 H314 |
EUH014 |
|
|
|
017-021-00-6 |
chlorek (behenamidopropylo)dimetylo-(dihydroksypropylo)amoniowy; chlorek (dokozanoamidopropylo)dimetylo(dihydroksypropylo)amoniowy |
423-420-1 |
136920-10-0 |
Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H318 H317 H410 |
|
|
|
|
017-023-00-7 |
trichlorki [fosfinylidenotris(oksy)] tris[3-aminopropylo-2-hydroksy-N, N-dimetylo-N-(C6-18)-alkilu] |
425-520-9 |
197179-61-6 |
Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H400 H410 |
GHS05 GHS09 Dgr |
H318 H410 |
|
|
|
|
017-026-00-3 |
ditlenek chloru |
233-162-8 |
10049-04-4 |
Press. Gas Ox. Gas 1 Acute Tox. 2 * Skin Corr. 1B Aquatic Acute 1 |
H270 H330 H314 H400 |
GHS04 GHS03 GHS06 GHS05 GHS09 Dgr |
H270 H330 H314 H400 |
|
M = 10 |
5 |
|
017-026-01-0 |
ditlenek chloru … % |
233-162-8 |
10049-04-4 |
Acute Tox. 3 * Skin Corr. 1B Aquatic Acute 1 |
H301 H314 H400 |
GHS06 GHS05 GHS09 Dgr |
H301 H314 H400 |
|
Skin Corr. 1B; H314: C ≥ 5 % Skin Irrit. 2; H315: 1 % ≤ C < 5 % Eye Dam.1; H318: 3 % ≤ C < 5 % Eye Irrit. 2; H319: 0,3 % ≤ C < 3 % STOT SE 3; H335: C ≥ 3 % M = 10 |
B |
|
019-001-00-2 |
potas |
231-119-8 |
7440-09-7 |
Water-react. 1 Skin Corr. 1B |
H260 H314 |
GHS02 GHS05 Dgr |
H260 H314 |
EUH014 |
|
|
|
019-002-00-8 |
wodorotlenek potasu; potaż żrący |
215-181-3 |
1310-58-3 |
Acute Tox. 4 * Skin Corr. 1A |
H302 H314 |
GHS05 GHS07 Dgr |
H302 H314 |
|
Skin Corr. 1A; H314: C ≥ 5 % Skin Corr. 1B; H314: 2 % ≤ C < 5 % Skin Irrit. 2; H315: 0,5 % ≤ C < 2 % Eye Irrit. 2; H319: 0,5 % ≤ C < 2 % |
|
|
020-001-00-X |
wapń |
231-179-5 |
7440-70-2 |
Water-react. 2 |
H261 |
GHS02 Dgr |
H261 |
|
|
|
|
020-002-00-5 |
cyjanek wapnia; dicyjanek wapnia |
209-740-0 |
592-01-8 |
Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H300 H400 H410 |
GHS06 GHS09 Dgr |
H300 H410 |
EUH032 |
|
|
|
020-003-00-0 |
masa poreakcyjna: [bis(2-hydroksy-5-tetrapropenylofenylometylo)metyloamino]diwodorotlenku diwapnia; [tris(2-hydroksy-5-tetrapropenylofenylometylo)metyloamino]triwodorotlenku triwapnia; poli{[(2-hydroksy-5-tetrapropenylofenylometylo)metyloamino]wodorotlenku wapnia} |
420-470-4 |
— |
Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H319 H315 H317 |
GHS07 Wng |
H319 H315 H317 |
|
|
|
|
022-001-00-5 |
chlorek tytanu(IV); tetrachlorek tytanu |
231-441-9 |
7550-45-0 |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
EUH014 |
|
|
|
022-002-00-0 |
szczawian tytanu(IV) |
403-260-7 |
— |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
022-003-00-6 |
bis(η5-cyklopentadienylo)-bis[2,6-difluoro-3-(pirol-1-ilo)fenylo]tytan |
412-000-1 |
125051-32-3 |
Flam. Sol. 1 Repr. 2 STOT RE 2 * Aquatic Chronic 2 |
H228 H361f *** H373 ** H411 |
GHS02 GHS08 GHS09 Dgr |
H228 H361f *** H373 ** H411 |
|
|
T |
|
022-004-00-1 |
tlenek potasowo-tytanowy (K2Ti6O13) |
432-240-0 |
12056-51-8 |
Carc. 2 |
H351 |
GHS08 Wng |
H351 |
|
|
|
|
022-005-00-7 |
[N-(1,1-dimetyloetylo)-1,1-dimetylo-1-[(1,2,3,4,5-η)-2,3,4,5-tetrametylo-2,4-cyclopentadien-1-ylo]silanoamino(2-)-κN][1,2,3,4-η)-1,3-pentadieno]-tytan |
419-840-8 |
169104-71-6 |
Flam. Sol. 1**** Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 4 |
H228 H314 H317 H413 |
GHS02 GHS05 GHS07 Dgr |
H228 H314 H317 H413 |
|
|
|
|
023-001-00-8 |
pentatlenek diwanadu; pentatlenek wanadu; tlenek wanadu(V) |
215-239-8 |
1314-62-1 |
Muta. 2 Repr. 2 STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Aquatic Chronic 2 |
H341 H361d *** H372 ** H332 H302 H335 H411 |
GHS08 GHS07 GHS09 Dgr |
H341 H361d *** H372 ** H332 H302 H335 H411 |
|
|
|
|
024-001-00-0 |
tlenek chromu(VI); tritlenek chromu; bezwodnik chromowy |
215-607-8 |
1333-82-0 |
Ox. Sol. 1 Carc. 1A Muta. 1B Repr. 2 Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Skin Corr. 1A Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H271 H350 H340 H361f *** H330 H311 H301 H372 ** H314 H334 H317 H400 H410 |
GHS03 GHS06 GHS08 GHS05 GHS09 Dgr |
H271 H350 H340 H361f *** H330 H311 H301 H372 ** H314 H334 H317 H410 |
|
STOT SE 3; H335: C ≥ 1 % |
|
|
024-002-00-6 |
dichromian(VI) potasu |
231-906-6 |
7778-50-9 |
Ox. Sol. 2 Carc. 1B Muta. 1B Repr. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Acute Tox. 4 * Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H272 H350 H340 H360FD H330 H301 H372 ** H312 H314 H334 H317 H400 H410 |
GHS03 GHS06 GHS08 GHS05 GHS09 Dgr |
H272 H350 H340 H360FD H330 H301 H372 ** H312 H314 H334 H317 H410 |
|
STOT SE 3; H335: C ≥ 5 % |
3 |
|
024-003-00-1 |
dichromian(VI) amonu |
232-143-1 |
7789-09-5 |
Ox. Sol. 2 **** Carc. 1B Muta. 1B Repr. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Acute Tox. 4 * Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H272 H350 H340 H360FD H330 H301 H372 ** H312 H314 H334 H317 H400 H410 |
GHS03 GHS06 GHS08 GHS05 GHS09 Dgr |
H272 H350 H340 H360FD H330 H301 H372 ** H312 H314 H334 H317 H410 |
|
STOT SE 3; H335: C ≥ 5 % Resp. Sens.; H334: C ≥0,2 % Skin Sens.; H317:C ≥0,2 % |
G3 |
|
024-004-00-7 |
dichromian(VI) sodu |
234-190-3 |
10588-01-9 |
Ox. Sol. 2 Carc. 1B Muta. 1B Repr. 1B Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 4 * STOT RE 1 Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H272 H350 H340 H360FD H330 H301 H312 H372** H314 H334 H317 H400 H410 |
GHS03 GHS06 GHS05 GHS08 GHS09 Dgr |
H272 H350 H340 H360FD H330 H301 H312 H372** H314 H334 H317 H410 |
|
Resp. Sens. 1; H334: C ≥ 0,2 % Skin Sens. 1; H317:C ≥0,2 % STOT SE 3; H335: C ≥ 5 % |
3 |
|
024-005-00-2 |
dichlorek ditlenek chromu; chlorek chromylu; dichlorek chromylu; tlenochlorek chromu |
239-056-8 |
14977-61-8 |
Ox. Liq. 1 Carc. 1B Muta. 1B Skin Corr. 1A Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H271 H350i H340 H314 H317 H400 H410 |
GHS03 GHS08 GHS05 GHS07 GHS09 Dgr |
H271 H350i H340 H314 H317 H410 |
|
Skin Corr. 1A; H314: C ≥ 10 % Skin Corr. 1B; H314: 5 % ≤ C < 10 % Skin Irrit. 2; H315: 0,5 % ≤ C < 5 % Eye Irrit. 2; H319: 0,5 % ≤ C < 5 % STOT SE 3; H335: 0,5 % ≤ C < 5 % Skin Sens. 1; H317: C ≥ 0,5 % |
T3 |
|
024-006-00-8 |
chromian(VI) potasu |
232-140-5 |
7789-00-6 |
Carc. 1B Muta. 1B Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H340 H319 H335 H315 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H340 H319 H335 H315 H317 H410 |
|
Skin Sens. 1; H317:C ≥ 0,5 % |
3 |
|
024-007-00-3 |
chromiany(VI) cynku łącznie z chromianem(VI) cynku-potasu |
— |
— |
Carc. 1A Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H302 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350 H302 H317 H410 |
|
|
A |
|
024-008-00-9 |
chromian(VI) wapnia |
237-366-8 |
13765-19-0 |
Carc. 1B Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H350 H302 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350 H302 H410 |
|
|
|
|
024-009-00-4 |
chromian(VI) strontu |
232-142-6 |
7789-06-2 |
Carc. 1B Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H350 H302 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350 H302 H400 H410 |
|
|
|
|
024-010-00-X |
chromian(VI) chromu(III); chromian chromu(III); chromian chromowy |
246-356-2 |
24613-89-6 |
Ox. Sol. 1 Carc. 1B Skin Corr. 1A Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H271 H350 H314 H317 H400 H410 |
GHS03 GHS08 GHS05 GHS07 GHS09 Dgr |
H271 H350 H314 H317 H410 |
|
|
T |
|
024-011-00-5 |
bis[1-(3,5-dinitro-2-oksydofenyloazo)-3-(N-fenylokarbamoilo)-2-naftolano]chromian(III) amonu |
400-110-2 |
109125-51-1 |
Self-react. C **** Aquatic Acute 1 Aquatic Chronic 1 |
H242 H400 H410 |
GHS02 GHS09 Dgr |
H242 H410 |
|
|
|
|
024-012-00-0 |
bis[7-acetamido-2-(4-nitro-2-oksydofenyloazo)-3-sulfoniano-1-naftolano]chromian(III) trisodu |
400-810-8 |
— |
Muta. 2 |
H341 |
GHS08 Wng |
H341 |
|
|
|
|
024-013-00-6 |
[6-anilino-2-(5-nitro-2-oksydofenyloazo)-3-sulfoniano-1-naftolano](4-sulfoniano-1,1'-azodi-2,2`-naftolano)chromian(III) trisodu |
402-500-8 |
— |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|
|
|
|
024-014-00-1 |
bis[2-(5-chloro-4-nitro-2-oksydofenyloazo)-5-sulfoniano-1-naftolano]chromian(III) trisodu |
402-870-0 |
93952-24-0 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
024-015-00-7 |
[3-metylo-4-(5-nitro-2-oksydofenyloazo)-1-fenyloazopirazolano][1-(3-nitro-2-oksydo-5-sulfonianofenyloazo)-2-naftolano]chromian(III) disodu |
404-930-1 |
— |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H332 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H332 H318 H411 |
|
|
|
|
024-016-00-2 |
bis[1-(5-chloro-2-oksydofenyloazo)-2-naftolano]chromian (III) tetradecyloamoniowy |
405-110-6 |
88377-66-6 |
STOT RE 2 * Aquatic Chronic 4 |
H373 ** H413 |
GHS08 Wng |
H373 ** H413 |
|
|
|
|
024-017-00-8 |
związki chromu(VI), z wyjątkiem chromianu(VI) baru i związków wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Carc. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H317 H410 |
|
|
A |
|
024-018-00-3 |
chromian(VI) sodu; chromian(VI) disodu |
231-889-5 |
7775-11-3 |
Carc. 1B Muta. 1B Repr. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Acute Tox. 4 * Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H340 H360FD H330 H301 H372 ** H312 H314 H334 H317 H400 H410 |
GHS06 GHS08 GHS05 GHS09 Dgr |
H350 H340 H360FD H330 H301 H372 ** H312 H314 H334 H317 H410 |
|
Resp. Sens.; H334: C ≥ 0,2 % Skin Sens.; H317:C ≥ 0,2 % |
3 |
|
024-019-00-9 |
główny składnik: anilid kwasu acetooctowego / 3-amino-1-hydroksybenzen (ATAN-MAP): {6-[(2 lub 3 lub 4)-amino-(4 lub 5 lub 6)-hydroksyfenyloazo]-5'-(fenylosulfamoilo)-3-sulfonianonaftaleno-2-azobenzeno-1,2'-diolano}-{6''-[1-(fenylokarbamoilo)etyloazo]-5'''-(fenylosulfamoilo)-3''-sulfonianonaftaleno-2''-azobenzeno-1'',2'''-diolano}chromian(III) trisodu; produkt uboczny 1: anilid kwasu acetooctowego / anilid kwasu acetooctowego (ATAN-ATAN): bis{6-[1-(fenylokarbamoilo)etyloazo]-5'-(fenylosulfonylo)-3-sulfonianonaftaleno-2-azobenzeno-1,2'-diolano}chromian(III) trisodu; produkt uboczny 2: 3-amino-1-hydroksybenzen / 3-amino-1-hydroksybenzen (MAP-MAP): bis{6-[(2 lub 3 lub 4)-amino-(4 lub 5 lub 6)-hydroksyfenyloazo]-5'-(fenylosulfamoilo)-3-sulfonianonaftaleno-2-azobenzeno-1,2'-diolano}chromian(III) trisodu |
419-230-1 |
— |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
024-020-00-4 |
bis[(3'-nitro-5'-sulfoniano{6-amino-2-[4-(2-hydroksy-1-naftyloazo)fenylosulfonyloamino]pirymidyno-5-azo}benzeno-2',4-diolano)]chromian(III) trisodu |
418-220-4 |
— |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
024-021-00-X |
bis[(N, N'-n)-1'-(fenylokarbamoilo)-3,5-disulfonianobenzenoazo-1'-prop-1'-eno-2,2'-diolato]chromian (III) potasu i tetrasodu |
425-830-4 |
— |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
025-001-00-3 |
tlenek manganu(IV); ditlenek manganu |
215-202-6 |
1313-13-9 |
Acute Tox. 4 * Acute Tox. 4 * |
H332 H302 |
GHS07 Wng |
H332 H302 |
|
|
|
|
025-002-00-9 |
manganian(VII) potasu; nadmanganian potasu |
231-760-3 |
7722-64-7 |
Ox. Sol. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H272 H302 H400 H410 |
GHS03 GHS07 GHS09 Dgr |
H272 H302 H410 |
|
|
|
|
025-003-00-4 |
siarczan(VI) manganu(II) |
232-089-9 |
7785-87-7 |
STOT RE 2 * Aquatic Chronic 2 |
H373 ** H411 |
GHS08 GHS09 Wng |
H373 ** H411 |
|
|
|
|
025-004-00-X |
di(heksafluorofosforan) bis(N, N',N''-trimetylo-1,4,7-triazacyklononano)trioksodimanganu(IV) – monohydrat |
411-760-1 |
116633-53-5 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
025-005-00-5 |
masa poreakcyjna: [29H,31H-ftalocyjanino-C, C,C-trisulfoniano(6-)-N29,N30,N31,N32]manganianu(3-) trisodu; [29H,31H-ftalocyjanino-C, C,C, C-tetrasulfoniano(6-)-N29,N30,N31,N32]manganianu(3-) tetrasodu; [29H,31H-ftalocyjanino-C, C,C, C,C-pentasulfoniano(6-)-N29,N30,N31,N32]manganianu(3-) pentasodu |
417-660-4 |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
026-001-00-6 |
heksafluorostiboran (η-kumen)-(η-cyklopentadienylo)żelaza(II) |
407-840-0 |
100011-37-8 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H302 H318 H412 |
GHS05 GHS07 Dgr |
H302 H318 H412 |
|
|
|
|
026-002-00-1 |
trifluorometanosulfonian (η-kumen)-(η-cyklopentadienylo)żelaza(II) |
407-880-9 |
117549-13-0 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
026-003-00-7 |
siarczan żelaza(II) |
231-753-5 |
7720-78-7 |
Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 |
H302 H319 H315 |
GHS07 Wng |
H302 H319 H315 |
|
|
|
|
026-003-01-4 |
siarczan żelaza(II) (1:1) heptahydrat; kwas siarkowy (VI), sól żelaza(II) (1:1), heptahydrat; siarczan żelazawy heptahydrat |
231-753-5 |
7782-63-0 |
Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 |
H302 H319 H315 |
GHS07 Wng |
H302 H319 H315 |
|
Skin Irrit.2; H315: C ≥ 25 % |
|
|
026-004-00-2 |
żelazian potasu |
430-010-4 |
12160-44-0 |
Skin Corr. 1B Skin Sens. 1 |
H314 H317 |
GHS05 GHS07 Dgr |
H314 H317 |
|
|
|
|
027-001-00-9 |
kobalt |
231-158-0 |
7440-48-4 |
Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 4 |
H334 H317 H413 |
GHS08 Dgr |
H334 H317 H413 |
|
|
|
|
027-002-00-4 |
tlenek kobaltu(II) |
215-154-6 |
1307-96-6 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|
M=10 |
|
|
027-003-00-X |
siarczek kobaltu(II) |
215-273-3 |
1317-42-6 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
M=10 |
|
|
027-004-00-5 |
dichlorek kobaltu |
231-589-4 |
7646-79-9 |
Carc. 1B Muta. 2 Repr. 1B Acute Tox. 4 * Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360F*** H302 H334 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H341 H360F*** H302 H334 H317 H410 |
|
Carc. 1B; H350i: C ≥ 0,01 % M=10 |
1 |
|
027-005-00-0 |
siarczan kobaltu; siarczan(VI) kobaltu |
233-334-2 |
10124-43-3 |
Carc. 1B Muta. 2 Repr. 1B Acute Tox. 4 * Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360F*** H302 H334 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H341 H360F*** H302 H334 H317 H410 |
|
Carc. 1B; H350i: C ≥ 0,01 % M=10 |
1 |
|
027-006-00-6 |
octan kobaltu(II) |
200-755-8 |
71-48-7 |
Carc. 1B Muta. 2 Repr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360F*** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360F*** H334 H317 H410 |
|
Carc. 1B; H350i: C ≥ 0,01 % M = 10 |
1 |
|
027-007-00-1 |
heksacyjanokobaltan(III) cynku, kompleks trzeciorzędowego alkoholu butylowego/ glikolu polipropylenowego |
425-240-7 |
— |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|
|
|
|
027-008-00-7 |
kompleks kobalto(III)-bis(N-fenylo-4-(5-etylosulfonylo-2-hydroksyfenyloazo)-3-hydroksynaftyloamid), uwodniony (n H2O, 2<n<3) |
427-390-9 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
027-009-00-2 |
azotan(V) kobaltu(II) |
233-402-1 |
10141-05-6 |
Carc. 1B Muta. 2 Repr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360F*** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360F*** H334 H317 H410 |
|
Carc. 1B; H350i: C ≥ 0,01 % M = 10 |
1 |
|
027-010-00-8 |
węglan kobaltu(II) |
208-169-4 |
513-79-1 |
Carc. 1B Muta. 2 Repr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360F*** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360F*** H334 H317 H410 |
|
Carc. 1B; H350i: C ≥ 0,01 % M=10 |
1 |
|
028-001-00-1 |
tetrakarbonylonikiel; tetrakarbonylek niklu |
236-669-2 |
13463-39-3 |
Flam. Liq. 2 Carc. 2 Repr. 1B Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H225 H351 H360D *** H330 H400 H410 |
GHS02 GHS06 GHS08 GHS09 Dgr |
H225 H351 H360D *** H330 H410 |
|
|
|
|
028-002-00-7 |
nikiel |
231-111-4 |
7440-02-0 |
Carc. 2 STOT RE 1 Skin Sens. 1 |
H351 H372** H317 |
GHS08 GHS07 Dgr |
H351 H372** H317 |
|
|
S7 |
|
028-002-01-4 |
proszek niklowy; [średnica cząstek < 1 mm] |
231-111-4 |
7440-02-0 |
Carc. 2 STOT RE 1 Skin Sens. 1 Aquatic Chronic 3 |
H351 H372** H317 H412 |
GHS08 GHS07 Dgr |
H351 H372** H317 H412 |
|
|
|
|
028-003-00-2 |
tlenek niklawy; [1] tlenek niklu(II); [2] bunsenit [3] |
215-215-7[1] 234-323-5[2]-[3] |
1313-99-1 [1] 11099-02-8 [2] 34492-97-2 [3] |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Chronic 4 |
H350i H372** H317 H413 |
GHS08 GHS07 Dgr |
H350i H372** H317 H413 |
|
|
|
|
028-004-00-8 |
ditlenek niklu; tlenek niklu(IV) |
234-823-3 |
12035-36-8 |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Chronic 4 |
H350i H372** H317 H413 |
GHS08 GHS07 Dgr |
H350i H372** H317 H413 |
|
|
|
|
028-005-00-3 |
tritlenek diniklu |
215-217-8 |
1314-06-3 |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Chronic 4 |
H350i H372** H317 H413 |
GHS08 GHS07 Dgr |
H350i H372** H317 H413 |
|
|
|
|
028-006-00-9 |
siarczek niklu(II); [1] siarczek niklowy; [2] millerit [3] |
240-841-2[1] 234-349-7[2]-[3] |
16812-54-7 [1] 11113-75-0 [2] 1314-04-1 [3] |
Carc. 1A Muta. 2 STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H341 H372** H317 H410 |
|
|
|
|
028-007-00-4 |
disiarczek triniklu; [1] hazlełudyt [2] |
234-829-6[1] -[2] |
12035-72-2 [1] 12035-71-1 [2] |
Carc. 1A Muta. 2 STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H341 H372** H317 H410 |
|
|
|
|
028-008-00-X |
wodorotlenek niklu(II); [1] wodorotlenek niklawy [2] |
235-008-5 [1] 234-348-1 [2] |
12054-48-7 [1] 11113-74-9 [2] |
Carc. 1A Repr. 1B Muta. 2 STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H360D*** H341 H372** H332 H302 H315 H334 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H360D*** H341 H372** H332 H302 H315 H334 H317 H410 |
|
|
|
|
028-009-00-5 |
siarczan(VI) niklu(II) |
232-104-9 |
7786-81-4 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H332 H302 H315 H334 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H341 H360D*** H372** H332 H302 H315 H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Irrit. 2; H315: C ≥ 20 % Skin Sens. 1; H317: C ≥ 0,01 % M = 1 |
|
|
028-010-00-0 |
węglan niklu; zasadowy węglan niklu; kwas węglowy, sól niklowa (2+); [1] kwasu węglowego, sól niklowa; [2] [μ-[karbonato(2-)-O:O’]] dihydroksy trinikiel; [3] [karbonato(2-)] tetrahydroksytrinikiel [4] |
222-068-2 [1] 240-408-8 [2] 265-748-4 [3] 235-715-9 [4] |
3333-67-3 [1] 16337-84-1 [2] 65405-96-1 [3] 12607-70-4 [4] |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H332 H302 H315 H334 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H341 H360D*** H372** H332 H302 H315 H334 H317 H410 |
|
|
|
|
028-011-00-6 |
dichlorek niklu(II) |
231-743-0 |
7718-54-9 |
Carc. 1A Muta. 2 Repr. 1B Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H331 H301 H372** H315 H334 H317 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H350i H341 H360D*** H331 H301 H372** H315 H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % < C < 1 % Skin Irrit. 2; H315: C ≥ 20 % Skin Sens. 1; H317: C ≥ 0,01 % M = 1 |
|
|
028-012-00-1 |
diazotan niklu; [1] kwas azotowy(V), sól niklowa [2] |
236-068-5 [1] 238-076-4 [2] |
13138-45-9 [1] 14216-75-2 [2] |
Ox. Sol. 2 Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H272 H350i H341 H360D*** H372** H332 H302 H315 H318 H334 H317 H400 H410 |
GHS03 GHS05 GHS08 GHS07 GHS09 Dgr |
H272 H350i H341 H360D*** H372** H332 H302 H315 H318 H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % < C < 1 % Skin Irrit. 2; H315: C ≥ 20 % Skin Sens. 1; H317 C ≥0,01 % M = 1 |
|
|
028-013-00-7 |
kamień niklowy |
273-749-6 |
69012-50-6 |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
|
|
|
|
028-014-00-2 |
szlamy i osady powstające w procesie elektrolitycznej rafinacji miedzi, odmiedziowane, siarczan (VI) niklu |
295-859-3 |
92129-57-2 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H332 H302 H315 H334 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H341 H360D*** H372** H332 H302 H315 H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373:0,1 % ≤ C < % Skin Sens. 1; H317:C ≥ 0,01 % M=1 |
|
|
028-015-00-8 |
szlamy i osady powstające w procesie elektrolitycznej rafinacji miedzi, odmiedziowane |
305-433-1 |
94551-87-8 |
Carc. 1A Muta. 2 Repr. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
|
|
|
|
028-016-00-3 |
dichloran(VII) niklu; sól niklu(II) kwasu chlorowego(VII) |
237-124-1 |
13637-71-3 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H314 H334 H317 H400 H410 |
GHS05 GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H314 H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
|
|
028-017-00-9 |
bis(siarcznan) dipotasu i niklu; [1] bis(siarczan) diamonu i niklu [2] |
237-563-9 [1] 239-793-2 [2] |
13842-46-1 [1] 15699-18-0 [2] |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H332 H302 H334 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H341 H360D*** H372** H332 H302 H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373:0,1 % ≤ C < 1 % Skin Sens. 1; H317:C ≥ 0,01 % M=1 |
|
|
028-018-00-4 |
bis(sulfamidian) niklu; amidosulfoniam niklu |
237-396-1 |
13770-89-3 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C ≥ 0,01 % M=1 |
|
|
028-019-00-X |
bis(tetrafluoroboran) niklu |
238-753-4 |
14708-14-6 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥0,01 % M=1 |
|
|
028-021-00-0 |
dimrówczan niklu; [1] sól niklowa kwasu mrówkowego; [2] sól miedzi i niklu kwasu mrówkowego [3] |
222-101-0 [1] 239-946-6 [2] 268-755-0 [3] |
3349-06-2 [1] 15843-02-4 [2] 68134-59-8 [3] |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C ≥0,01 % M=1 |
|
|
028-022-00-6 |
di(octan) niklu; [1] octan niklu [2] |
206-761-7 [1] 239-086-1 [2] |
373-02-4 [1] 14998-37-9 [2] |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H332 H302 H334 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H341 H360D*** H372** H332 H302 H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C≥ 0,01 % M = 1 |
|
|
028-024-00-7 |
dibenzoesan niklu |
209-046-8 |
553-71-9 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C≥ 0,01 % M=1 |
|
|
028-025-00-2 |
bis(4-cykloheksylomaślan) niklu |
223-463-2 |
3906-55-6 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C ≥0,01 % M=1 |
|
|
028-026-00-8 |
stearynian niklu(II); oktadekanian niklu(II) |
218-744-1 |
2223-95-2 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373:0,1 % ≤ C < 1 % Skin Sens. 1; H317:C;≥0,01 % M=1 |
|
|
028-027-00-3 |
dimleczan niklu |
— |
16039-61-5 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
|
STOT RE 1; H372:C ≥ 1 % STOT RE 2; H373:0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
|
|
028-028-00-9 |
oktanian niklu(II) |
225-656-7 |
4995-91-9 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Skin Corr. 1A Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H314 H334 H317 H400 H410 |
GHS05 GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H314 H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
|
|
028-029-00-4 |
difluorek niklu; [1] dibromek niklu; [2] dijodek niklu; [3] fluorek niklowo-potasowy [4] |
233-071-3 [1] 236-665-0 [2] 236-666-6 [3] -[4] |
10028-18-9 [1] 13462-88-9 [2] 13462-90-3 [3] 11132-10-8 [4] |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥0,01 % M=1 |
|
|
028-030-00-X |
heksafluorokrzemian niklu |
247-430-7 |
26043-11-8 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C ≥ 0,01 % M=1 |
|
|
028-031-00-5 |
selenian(VI) niklu |
239-125-2 |
15060-62-5 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C≥0,01 % M=1 |
|
|
028-032-00-0 |
wodorofosforan niklu; [1] bis(diwodorofosforan) niklu; [2] bis(ortofosforan) triniklu; [3] difosforan diniklu; [4] bis(fosfininian) niklu; [5] fosfinian niklu; [6] sól wapniowo-niklowa kwasu fosforowego(V); [7] sól niklowa(II) kwasu difosorowego [8] |
238-278-2 [1] 242-522-3 [2] 233-844-5 [3] 238-426-6 [4] 238-511-8 [5] 252-840-4 [6] -[7] -[8] |
14332-34-4 [1] 18718-11-1 [2] 10381-36-9 [3] 14448-18-1 [4] 14507-36-9 [5] 36026-88-7 [6] 17169-61-8 [7] 19372-20-4 [8] |
Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H372** H334 H317 H410 |
|
|
|
|
028-033-00-6 |
heksacyjanożelazian diamonowo-niklowy |
— |
74195-78-1 |
Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H372** H334 H317 H410 |
|
|
|
|
028-034-00-1 |
dicyjanian niklu |
209-160-8 |
557-19-7 |
Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H372** H334 H317 H410 |
EUH032 |
|
|
|
028-035-00-7 |
chromian(VI) niklu |
238-766-5 |
14721-18-7 |
Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H372** H334 H317 H410 |
|
|
|
|
028-036-00-2 |
krzemian niklu(II); [1] ortokrzemian diniklu; [2] krzemian niklu (3:4); [3] sól niklowa kwasu krzemowego; [4] triwodorohydroksybis[ortokrzemian(4-)] triniklu(3-) [5] |
244-578-4 [1] 237-411-1 [2] 250-788-7 [3] 253-461-7 [4] 235-688-3 [5] |
21784-78-1 [1] 13775-54-7 [2] 31748-25-1 [3] 37321-15-6 [4] 12519-85-6 [5] |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
|
|
|
|
028-037-00-8 |
heksacyjanożelazian diniklu |
238-946-3 |
14874-78-3 |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
|
|
|
|
028-038-00-3 |
bis(arsenian(V)) triniklu; arsenian niklu(II) |
236-771-7 |
13477-70-8 |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350 H372** H317 H410 |
|
|
|
|
028-039-00-9 |
szczawian niklu; [1] sól niklowa kwasu szczawiowego [2] |
208-933-7 [1] 243-867-2 [2] |
547-67-1 [1] 20543-06-0 [2] |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
|
|
|
|
028-040-00-4 |
tellurek niklu |
235-260-6 |
12142-88-0 |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
|
|
|
|
028-041-00-X |
tetrasiarczek triniklu |
— |
12137-12-1 |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
|
|
|
|
028-042-00-5 |
bis(arsenian(III)) triniklu |
— |
74646-29-0 |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
|
|
|
|
028-043-00-0 |
szary peryklaz kobaltu i niklu; C.I. Pigment Black 25; czerń pigmentowa 25; C.I. 77332; [1] ditlenek kobaltu i niklu; [2] tlenek kobaltu i niklu [3] |
269-051-6 [1] 261-346-8 [2] -[3] |
68186-89-0 [1] 58591-45-0 [2] 12737-30-3 [3] |
Carc. 1A STOT RE 1 Skin Sens. 1 |
H350i H372** H317 |
GHS08 GHS07 Dgr |
H350i H372** H317 |
|
|
|
|
028-044-00-6 |
tritlenek niklu cyny; cynian(IV) niklu |
234-824-9 |
12035-38-0 |
Carc. 1A STOT RE 1 Skin Sens. 1 |
H350i H372** H317 |
GHS08 GHS07 Dgr |
H350i H372** H317 |
|
|
|
|
028-045-00-1 |
dekatlenek niklu i triuranu |
239-876-6 |
15780-33-3 |
Carc. 1A STOT RE 1 Skin Sens. 1 |
H350i H372** H317 |
GHS08 GHS07 Dgr |
H350i H372** H317 |
|
|
|
|
028-046-00-7 |
ditiocyjanian niklu |
237-205-1 |
13689-92-4 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
EUH032 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C≥0,01 % M=1 |
|
|
028-047-00-2 |
dichromian(VI) niklu |
239-646-5 |
15586-38-6 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
|
STOT RE 1; H372:C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317:C≥0,01 % M=1 |
|
|
028-048-00-8 |
selenian niklu(II) |
233-263-7 |
10101-96-9 |
Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H372** H334 H317 H410 |
|
|
|
|
028-049-00-3 |
selenek niklu |
215-216-2 |
1314-05-2 |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
|
|
|
|
028-050-00-9 |
sól ołowiu i niklu kwasu krzemowego |
— |
68130-19-8 |
Carc. 1A Repr. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H360Df H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H360Df H372** H317 H410 |
|
|
|
|
028-051-00-4 |
diarsenek niklu; [1] arsenek niklu [2] |
235-103-1 [1] 248-169-1 [2] |
12068-61-0 [1] 27016-75-7 [2] |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
|
|
|
|
028-052-00-X |
priderit niklu, baru i tytanu; C.I. Pigment Yellow 157; żółcień pigmentowa 157; C.I. 77900 |
271-853-6 |
68610-24-2 |
Carc. 1A STOT RE 1 Skin Sens. 1 |
H350i H372** H317 |
GHS08 GHS07 Dgr |
H350i H372** H317 |
|
|
|
|
028-053-00-5 |
dichloran(V) niklu; [1] dibromian(V) niklu; [2] sól niklowa(II) wodorosiarczanu etylu [3] |
267-897-0 [1] 238-596-1 [2] 275-897-7 [3] |
67952-43-6 [1] 14550-87-9 [2] 71720-48-4 [3] |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < % Skin Sens. 1; H317:C≥0,01 %1 M=1 |
|
|
028-054-00-0 |
trifluorooctan niklu(II); [1] propionian niklu(II); [2] bis(benzenosulfonian) niklu; [3] wodorocytrynian niklu(II); [4] sól amonowo-niklowa kwasu cytrynowego; [5] sól niklowa kwasu cytrynowego; [6] bis(2-etyloheksanian) niklu; [7] sól niklowa kwasu 2-etyloheksanowego; [8] sól niklowa kwasu dimetyloheksanowego; [9] izooktanian niklu(II); [10] izooktanian niklu; [11] bis(izononanian) niklu; [12] neononanian niklu(II); [13] izodekanian niklu(II); [14] neodekanian niklu(II); [15] sól niklowa kwasu neodekanowego; [16] neoundekanian niklu(II); [17] bis(D-glukonian-O1,O2)niklu; [18] 3,5-bis(tert-butylo)-4-hydroksybenzoesan niklu (2:1); [19] palmitynian niklu(II); [20] (2-etyloheksaniano-O)(izononaniano-O)nikiel; [21] (izononaniano-O)(izooktaniano-O) nikiel; [22] (izooktaniano-O)(neodekaniano-O) nikiel; [23] (2-etyloheksaniano-O)(izodekaniano-O)nikiel; [24] (2-etyloheksaniano-O)(neodekaniano-O)nikiel; [25] (izodekaniano-O)(izooktaniano-O)nikiel; [26] (izodekaniano-O)(izononaniano-O)nikiel; [27] (isononaniano-O)(neodekaniano-O)nikiel; [28] sole niklowe kwasów tłuszczowych C6-19 o łańcuchach rozgałęzionych; [29] sole niklowe kwasów tłuszczowych o łańcuchach C8-18 i nienasyconych C18; [30] sól niklowa(II) kwasu 2,7-naftalenodisulfonowego; [31] |
240-235-8 [1] 222-102-6 [2] 254-642-3 [3] 242-533-3 [4] 242-161-1 [5] 245-119-0 [6] 224-699-9 [7] 231-480-1 [8] 301-323-2 [9] 249-555-2 [10] 248-585-3 [11] 284-349-6 [12] 300-094-6 [13] 287-468-1 [14] 287-469-7 [15] 257-447-1 [16] 300-093-0 [17] 276-205-6 [18] 258-051-1 [19] 294-302-1 [29] 283-972-0 [30] -[31] 237-138-8 [20] 287-470-2 [21] 287-471-8 [22] 284-347-5 [23] 284-351-7 [24] 285-698-7 [25] 285-909-2 [26] 284-348-0 [27] 287-592-6 [28] |
16083-14-0 [1] 3349-08-4 [2] 39819-65-3 [3] 18721-51-2 [4] 18283-82-4 [5] 22605-92-1 [6] 4454-16-4 [7] 7580-31-6 [8] 93983-68-7 [9] 29317-63-3 [10] 27637-46-3 [11] 84852-37-9 [12] 93920-10-6 [13] 85508-43-6 [14] 85508-44-7 [15] 51818-56-5 [16] 93920-09-3 [17] 71957-07-8 [18] 52625-25-9 [19] 13654-40-5 [20] 85508-45-8 [21] 85508-46-9 [22] 84852-35-7 [23] 84852-39-1 [24] 85135-77-9 [25] 85166-19-4 [26] 84852-36-8 [27] 85551-28-6 [28] 91697-41-5 [29] 84776-45-4 [30] 72319-19-8 [31] |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
|
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
|
|
028-055-00-6 |
siarczan(IV) niklu(II); [1] tritlenek niklu i telluru; [2] tetratlenek niklu i telluru; [3] fosforan tlenek wodorotlenek molibdenu i niklu [4] |
231-827-7 [1] 239-967-0 [2] 239-974-9 [3] 268-585-7 [4] |
7757-95-1 [1] 15851-52-2 [2] 15852-21-8 [3] 68130-36-9 [4] |
Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H372** H334 H317 H410 |
|
|
|
|
028-056-00-1 |
borek niklu (NiB); [1] borek diniklu; [2] brek triniklu; [3] borek niklu; [4] krzemek diniklu; [5] dikrzemek niklu; [6] fosforek diniklu; [7] fosforek niklu i boru [8] |
234-493-0 [1] 234-494-6 [2] 234-495-1 [3] 235-723-2 [4] 235-033-1 [5] 235-379-3 [6] 234-828-0 [7] -[8] |
12007-00-0 [1] 12007-01-1 [2] 12007-02-2 [3] 12619-90-8 [4] 12059-14-2 [5] 12201-89-7 [6] 12035-64-2 [7] 65229-23-4 [8] |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
|
|
|
|
028-057-00-7 |
tetratlenek diglinu i niklu; [1] tritlenek niklu i tytanu; [2] tlenek niklu i tytanu; [3] heksatlenek niklu i diwanadu; [4] oktatlenek kobaltu, dimolibdenu i niklu; [5] tritlnek niklu i cyrkonu; [6] tetratlenek molibdenu i niklu; [7] tetratlenek niklu i wolframu; [8] oliwin, zieleń niklowa; [9] ditlenek litu i niklu; [10] tlenek molibdenu i niklu; [11] |
234-454-8 [1] 234-825-4 [2] 235-752-0 [3] 257-970-5 [4] 268-169-5 [5] 274-755-1 [6] 238-034-5 [7] 238-032-4 [8] 271-112-7 [9] -[10] -[11] |
12004-35-2 [1] 12035-39-1 [2] 12653-76-8 [3] 52502-12-2 [4] 68016-03-5 [5] 70692-93-2 [6] 14177-55-0 [7] 14177-51-6 [8] 68515-84-4 [9] 12031-65-1 [10] 12673-58-4 [11] |
Carc. 1A STOT RE 1 Skin Sens. 1 |
H350i H372** H317 |
GHS08 GHS07 Dgr |
H350i H372** H317 |
|
|
|
|
028-058-00-2 |
tlenek kobaltu, litu i niklu |
442-750-5 |
— |
Carc. 1A Acute Tox. 2 * STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H330 H372** H317 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H350i H330 H372** H317 H410 |
|
|
|
|
029-001-00-4 |
chlorek miedzi(I); chlorek miedziawy |
231-842-9 |
7758-89-6 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H400 H410 |
|
|
|
|
029-003-00-5 |
sole miedziowe kwasów naftenowych; naftenian miedzi |
215-657-0 |
1338-02-9 |
Flam. Liq. 3 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H226 H302 H400 H410 |
GHS02 GHS07 GHS09 Wng |
H226 H302 H410 |
|
|
|
|
029-004-00-0 |
siarczan(VI) miedzi(II); siarczan miedziowy |
231-847-6 |
7758-98-7 |
Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H319 H315 H400 H410 |
GHS07 GHS09 Wng |
H302 H319 H315 H410 |
|
|
|
|
029-005-00-6 |
[tris(chlorometylo)ftalocyjaniano]miedzi(II), produkt reakcji z N-metylopiperyzyną i kwasem metoksyoctowym; turkus kartasol |
401-260-1 |
— |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
029-006-00-1 |
(trisulfonianoftalocyjaniano)miedzian(II) tris(oktadek-9-enyloamoniowy) |
403-210-4 |
— |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|
|
|
|
029-007-00-7 |
wodorotlenek [2-{3-[6-(2-chloro-5-sulfoniano)anilino]-4-(3-karboksypirydynio)-1,3,5-triazyn-2-yloamino]-2-oksydo-5-sulfonianofenyloazofenylometyloazo}-4-sulfonianobenzoesano]miedzian(3-) trisodu |
404-670-9 |
89797-01-3 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
G |
|
029-008-00-2 |
metanosulfonian miedzi(II) |
405-400-2 |
54253-62-2 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H318 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H410 |
|
|
|
|
029-009-00-8 |
kompleks ftalocyjanino-N-[3-(dietylo-amino)propylo]sulfonoamidu z miedzią |
413-650-9 |
93971-95-0 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
029-010-00-3 |
masa poreakcyjna związków od [dodekakis(p-tolilosulfanylo)ftalocyjaniano]miedzi(II) do [heksadekakis(p-tolilosulfanylo)ftalocyjaniano]miedzi(II); |
407-700-9 |
101408-30-4 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
029-011-00-9 |
kompleks [29H,31H-ftalocyjaniano-(2-)-N29,N30,N31,N32]-({3-[N-metylo-N-(2-hydroksyetylo)amino]propylo}amino)sulfonylosulfonianu sodu z miedzią |
412-730-0 |
150522-10-4 |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
|
|
|
|
029-012-00-4 |
{[N-(3-trimetyloamoniopropylo)sulfamoilo]metylosulfonianoftalocyjaniniano}miedzian(II) sodu |
407-340-2 |
124719-24-0 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
029-013-00-X |
(2-{α-[3-(4-chloro-6-{2-[2-(winylosulfonylo)etoksy]etyloamino}-1,3,5-triazyn-2-yloamino)-2-oksydo-5-sulfonianofenyloazo]benzylidenohydrazyno}-4-sulfonianobenzoesano)miedzian(II) trisodu |
407-580-8 |
130201-51-3 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
029-014-00-5 |
masa poreakcyjna: kompleksu 2,2'-[[cis-1,2-cykloheksanodylobis(nitrylometylidyno)]bis[fenolanu]](2-)N, N',O, O'-miedzi i kompleksu 2,2'-[[trans-1,2-cykloheksanodylobis(nitrylometylidyno)]bis[fenolanu]](2-)N, N',O, O'-miedzi |
419-610-7 |
171866-24-3 |
STOT RE 2 * Aquatic Chronic 2 |
H373** H411 |
GHS08 GHS09 Wng |
H373** H411 |
|
|
|
|
030-001-00-1 |
proszek cynkowy – pył cynkowy (piroforyczny) |
231-175-3 |
7440-66-6 |
Water-react. 1 Pyr. Sol. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H260 H250 H400 H410 |
GHS02 GHS09 Dgr |
H260 H250 H410 |
|
|
T |
|
030-001-01-9 |
proszek cynkowy – pył cynkowy (stabilizowany) |
231-175-3 |
7440-66-6 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
030-003-00-2 |
chlorek cynku(II); dichlorek cynku |
231-592-0 |
7646-85-7 |
Acute Tox. 4 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H302 H314 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H302 H314 H410 |
|
STOT SE 3; H335: C ≥ 5 % |
|
|
030-004-00-8 |
dimetylocynk; [1] dietylocynk [2] |
208-884-1 [1] 209-161-3 [2] |
544-97-8 [1] 557-20-0 [2] |
Pyr. Liq. 1 Water-react. 1 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H250 H260 H314 H400 H410 |
GHS02 GHS05 GHS09 Dgr |
H250 H260 H314 H410 |
EUH014 |
|
|
|
030-005-00-3 |
diaminabis(izocyjaniano)cynk(II) |
401-610-3 |
— |
Acute Tox. 4 * Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 |
H302 H318 H334 H317 H400 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H302 H318 H334 H317 H400 |
|
|
|
|
030-006-00-9 |
siarczan(VI) cynku(II) (uwodniony) (monohydrat, heksahydrat, heptahydrat); [1] siarczan(VI) cynku(II) (bezwodny) [2] |
231-793-3 [1] 231-793-3 [2] |
7446-19-7 [1] 7733-02-0 [2] |
Acute Tox. 4 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H318 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H410 |
|
|
|
|
030-007-00-4 |
bis(3,5-di-tert-butylosalicylano-O1,O2)cynk |
403-360-0 |
42405-40-3 |
Flam. Sol. 1 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H228 H302 H400 H410 |
GHS02 GHS07 GHS09 Dgr |
H228 H302 H410 |
|
|
T |
|
030-008-00-X |
wodorotlenek 2-(benzenosulfonamido)benzoesan cynku(II) |
403-750-0 |
113036-91-2 |
Acute Tox. 4 * Aquatic Chronic 2 |
H332 H411 |
GHS07 GHS09 Wng |
H332 H411 |
|
|
|
|
030-009-00-5 |
bis(4-(n-oktyloksykarbonyloamino) salicylan) cynku dihydrat |
417-130-2 |
— |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|
|
|
|
030-010-00-0 |
kwas 2-dodec-1-enylobutanodiowy, sól cynkowa estru 4-metylowego |
430-740-3 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
030-011-00-6 |
bis[ortofosforan(V)] tricynku |
231-944-3 |
7779-90-0 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
030-012-00-1 |
wodorotlenek węglan glinu, magnezu i cynku |
423-570-6 |
169314-88-9 |
Aquatic Chronic 4 |
H413 |
|
H413 |
|
|
|
|
030-013-00-7 |
tlenek cynku |
215-222-5 |
1314-13-2 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
030-015-00-8 |
bis(heksacyjanokobaltano(3+))dioctano tetracynk(2+) |
440-060-9 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
033-001-00-X |
arsen |
231-148-6 |
7440-38-2 |
Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H301 H400 H410 |
GHS06 GHS09 Dgr |
H331 H301 H410 |
|
|
|
|
033-002-00-5 |
związki arsenu, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H301 H400 H410 |
GHS06 GHS09 Dgr |
H331 H301 H410 |
|
* |
A1 |
|
033-003-00-0 |
tlenek arsenu(III); tritlenek arsenu; arszenik; tlenek arsenawy |
215-481-4 |
1327-53-3 |
Carc. 1A Acute Tox. 2 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H350 H300 H314 H400 H410 |
GHS06 GHS08 GHS05 GHS09 Dgr |
H350 H300 H314 H410 |
|
|
|
|
033-004-00-6 |
pentatlenek arsenu; tlenek arsenu(V); tlenek arsenowy |
215-116-9 |
1303-28-2 |
Carc. 1A Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H350 H331 H301 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H350 H331 H301 H410 |
|
|
|
|
033-005-00-1 |
kwas arsenowy i jego sole, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Carc. 1A Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H350 H331 H301 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H350 H331 H301 H410 |
|
|
A |
|
033-006-00-7 |
arsan; arsenowodór; arsyna |
232-066-3 |
7784-42-1 |
Flam. Gas 1 Press. Gas Acute Tox. 2 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H220 H330 H373 ** H400 H410 |
GHS02 GHS04 GHS06 GHS08 GHS09 Dgr |
H220 H330 H373 ** H410 |
|
|
U |
|
033-007-00-2 |
tert-butyloarsan |
423-320-6 |
4262-43-5 |
Pyr. Liq. 1 Acute Tox. 2 * |
H250 H330 |
GHS02 GHS06 Dgr |
H250 H330 |
|
|
|
|
034-001-00-2 |
selen |
231-957-4 |
7782-49-2 |
Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 4 |
H331 H301 H373 ** H413 |
GHS06 GHS08 Dgr |
H331 H301 H373 ** H413 |
|
|
|
|
034-002-00-8 |
związki selenu, z wyjątkiem selenku siarczku kadmu oraz związków wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H331 H301 H373** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H331 H301 H373** H410 |
|
|
A |
|
034-003-00-3 |
selenin sodu |
233-267-9 |
10102-18-8 |
Acute Tox. 2 * Acute Tox. 3 * Skin Sens. 1 Aquatic Chronic 2 |
H300 H331 H317 H411 |
GHS06 GHS09 Dgr |
H300 H331 H317 H411 |
EUH031 |
|
|
|
035-001-00-5 |
brom |
231-778-1 |
7726-95-6 |
Acute Tox. 2 * Skin Corr. 1A Aquatic Acute 1 |
H330 H314 H400 |
GHS06 GHS05 GHS09 Dgr |
H330 H314 H400 |
|
|
|
|
035-002-00-0 |
bromowodór |
233-113-0 |
10035-10-6 |
Press. Gas Skin Corr. 1A STOT SE 3 |
H314 H335 |
GHS04 GHS05 GHS07 Dgr |
H314 H335 |
|
|
U |
|
035-002-01-8 |
kwas bromowodorowy … % |
— |
— |
Skin Corr. 1B STOT SE 3 |
H314 H335 |
GHS05 GHS07 Dgr |
H314 H335 |
|
Skin Corr. 1B; H314: C ≥ 40 % Skin Irrit. 2; H315: 10 % ≤ C < 40 % Eye Irrit. 2; H319: 10 % ≤ C < 40 % STOT SE 3; H335: C ≥ 10 % |
B |
|
035-003-00-6 |
bromian(V) potasu |
231-829-8 |
7758-01-2 |
Ox. Sol. 1 Carc. 1B Acute Tox. 3 * |
H271 H350 H301 |
GHS03 GHS06 GHS08 Dgr |
H271 H350 H301 |
|
|
|
|
035-004-00-1 |
bromian(VII) 2-hydroksyetyloamoniowy |
407-440-6 |
— |
Ox. Sol. 2 **** Acute Tox. 4 * Skin Corr. 1A Skin Sens. 1 Aquatic Acute 1 |
H272 H302 H314 H317 H400 |
GHS03 GHS05 GHS07 GHS09 Dgr |
H272 H302 H314 H317 H400 |
|
|
|
|
040-001-00-3 |
proszek cyrkonowy (piroforyczny) |
231-176-9 |
7440-67-7 |
Water-react. 1 Pyr. Sol. 1 |
H260 H250 |
GHS02 Dgr |
H260 H250 |
|
|
T |
|
040-002-00-9 |
proszek cyrkonowy, suchy, (niepiroforyczny) |
— |
— |
Self-heat. 1 |
H251 |
GHS02 Dgr |
H251 |
|
|
T |
|
040-003-00-4 |
produkt reakcji kwasu 3,5-di-tert-butylosalicylowego i tlenochlorku cyrkonu, odwodniony, zasadowy Zr: DTBS = 1,0:1,0 do 1,0:1,5 |
430-610-6 |
226996-19-6 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
042-001-00-9 |
tritlenek molibdenu; tlenek molibdenu(VI) |
215-204-7 |
1313-27-5 |
Carc. 2 Eye Irrit. 2 STOT SE 3 |
H351 H319 H335 |
GHS08 GHS07 Wng |
H351 H319 H335 |
|
|
|
|
042-002-00-4 |
oktamolibdenian(4-) tetrakis(dimetyloditetradecyloamoniowy) |
404-760-8 |
117342-25-3 |
Acute Tox. 3 * Eye Dam. 1 |
H331 H318 |
GHS06 GHS05 Dgr |
H331 H318 |
|
|
|
|
042-003-00-X |
oktamolibdenian(4-) tetrakis(trimetyloheksadecyloamoniowy) |
404-860-1 |
116810-46-9 |
Flam. Sol. 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H228 H318 H400 H410 |
GHS02 GHS05 GHS09 Dgr |
H228 H318 H410 |
|
|
T |
|
042-004-00-5 |
produkt reakcji molibdenianu(VI) amonu i C12-C24-dioksyetylenowanej alkiloaminy (1:5-1:3) |
412-780-3 |
— |
Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H315 H317 H411 |
GHS07 GHS09 Wng |
H315 H317 H411 |
|
|
|
|
042-005-00-0 |
masa poreakcyjna: mono-i digliceroli oleju canola; rozgałęzionego 1,3-propanodiamino,N-[3-(tridecylooksy)-propylo] amidu kwasu pochodzącego z oleju canola; kompleksu N, N-diorgano-ditiokarbaminianomolibdenu |
434-240-6 |
— |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
046-001-00-X |
wodorowęglan tetraamminopalladu(II) |
425-270-0 |
134620-00-1 |
Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373** H318 H317 H400 H410 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H302 H373** H318 H317 H410 |
|
|
|
|
047-001-00-2 |
azotan(V) srebra |
231-853-9 |
7761-88-8 |
Ox. Sol. 2 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H272 H314 H400 H410 |
GHS03 GHS05 GHS09 Dgr |
H272 H314 H410 |
|
|
|
|
047-002-00-8 |
kwas polifosforowy, sól miedzi, sodu, magnezu, wapnia, srebra i cynku |
416-850-4 |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
048-001-00-5 |
związki kadmu, z wyjątkiem selenku siarczku kadmu (xCdS.yCdSe), masy poreakcyjnej siarczku kadmu z siarczkiem cynku (xCdS.yZnS), mieszaniny siarczku kadmu z siarczkiem rtęci(II) (xCdS.yHgS) i związków wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H332 H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H332 H312 H302 H410 |
|
* |
A1 |
|
048-002-00-0 |
kadm (niepiroforyczny); [1] tlenek kadmu(II) (niepiroforyczny) [2] |
231-152-8 [1] 215-146-2 [2] |
7440-43-9 [1] 1306-19-0 [2] |
Carc. 1B Muta. 2 Repr. 2 Acute Tox. 2 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H341 H361fd H330 H372 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H350 H341 H361fd H330 H372 ** H410 |
|
|
|
|
048-003-00-6 |
dimrówczan kadmu; mrówczan kadmu |
224-729-0 |
4464-23-7 |
Acute Tox. 3 * Acute Tox. 3 * Carc. 2 STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H301 H351 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H331 H301 H351 H373 ** H410 |
|
* STOT RE 2; H373: C ≥0,25 % |
|
|
048-004-00-1 |
dicyjanek kadmu |
208-829-1 |
542-83-6 |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Carc. 2 STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H300 H351 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H330 H310 H300 H351 H373 ** H410 |
EUH032 |
STOT RE 2; H373: C ≥0,1 % EUH032:C≥1 % |
|
|
048-005-00-7 |
heksafluorokrzemian(2-) kadmu; fluorokrzemian kadmu |
241-084-0 |
17010-21-8 |
Acute Tox. 3 * Acute Tox. 3 * Carc. 2 STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H301 H351 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H331 H301 H351 H373 ** H410 |
|
* STOT RE 2; H373: C ≥0,1 % |
|
|
048-006-00-2 |
fluorek kadmu(II) |
232-222-0 |
7790-79-6 |
Carc. 1B Muta. 1B Repr. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H340 H360FD H330 H301 H372 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H350 H340 H360FD H330 H301 H372 ** H410 |
|
Carc. 1B; H350: C ≥ 0,01 % * oral STOT RE 1; H372: C ≥ 7 % STOT RE 2: 0,1 % ≤ C <7 % |
|
|
048-007-00-8 |
jodek kadmu(II) |
232-223-6 |
7790-80-9 |
Acute Tox. 3 * Acute Tox. 3 * Carc. 2 STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H301 H351 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H331 H301 H351 H373 ** H410 |
|
* STOT RE 2; H373: C ≥ 0,1 % |
|
|
048-008-00-3 |
chlorek kadmu(II) |
233-296-7 |
10108-64-2 |
Carc. 1B Muta. 1B Repr. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H340 H360FD H330 H301 H372 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H350 H340 H360FD H330 H301 H372 ** H410 |
|
Carc. 1B; H350: C ≥ 0,01 % * oral STOT RE 1; H372: C ≥ 7 % STOT RE 2; H373: 0,1 % ≤ C < 7 % |
|
|
048-009-00-9 |
siarczan(VI) kadmu(II) |
233-331-6 |
10124-36-4 |
Carc. 1B Muta. 1B Repr. 1B Acute Tox. 2 * Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H340 H360FD H330 H301 H372 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H350 H340 H360FD H330 H301 H372 ** H410 |
|
Carc. 1B; H350: C ≥ 0,01 % * oral STOT RE 1; H372: C ≥ 7 % STOT RE 2; H373 0,1 % ≤ C < 7 % |
|
|
048-010-00-4 |
siarczek kadmu(II) |
215-147-8 |
1306-23-6 |
Carc. 1B Muta. 2 Repr. 2 STOT RE 1 Acute Tox. 4 * Aquatic Chronic 4 |
H350 H341 H361fd H372 ** H302 H413 |
GHS08 GHS07 Dgr |
H350 H341 H361fd H372 ** H302 H413 |
|
* STOT RE 1; H372: C ≥ 10 % STOT RE 2; H373: 0,1 % ≤ C < 10 % |
1 |
|
048-011-00-X |
kadm (piroforyczny) |
231-152-8 |
7440-43-9 |
Pyr. Sol. 1 Carc. 1B Muta. 2 Repr. 2 Acute Tox. 2 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H250 H350 H341 H361fd H330 H372 ** H400 H410 |
GHS02 GHS06 GHS08 GHS09 Dgr |
H250 H350 H341 H361fd H330 H372 ** H410 |
|
|
|
|
050-001-00-5 |
tetrachlorek cyny; chlorek cynowy; chlorek cyny(IV) |
231-588-9 |
7646-78-8 |
Skin Corr. 1B Aquatic Chronic 3 |
H314 H412 |
GHS05 Dgr |
H314 H412 |
|
STOT SE 3; H335:C≥5 % |
|
|
050-002-00-0 |
cyheksatyna (ISO); hydroksytri(cykloheksylo)stannan; wodorotlenek tri(cykloheksylo)cyny |
236-049-1 |
13121-70-5 |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H332 H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H332 H312 H302 H410 |
|
M=1000 |
|
|
050-003-00-6 |
fentyny octan (ISO); octan trifenylocyny; |
212-984-0 |
900-95-8 |
Carc. 2 Repr. 2 Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H361d*** H330 H311 H301 H372** H335 H315 H318 H400 H410 |
GHS06 GHS05 GHS08 GHS09 Dgr |
H351 H361d*** H330 H311 H301 H372** H335 H315 H318 H410 |
|
M=10 |
|
|
050-004-00-1 |
fentyny wodorotlenek (ISO); wodorotlenek trifenylocyny |
200-990-6 |
76-87-9 |
Carc. 2 Repr. 2 Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H361d*** H330 H311 H301 H372** H335 H315 H318 H400 H410 |
GHS06 GHS05 GHS08 GHS09 Dgr |
H351 H361d*** H330 H311 H301 H372** H335 H315 H318 H410 |
|
M=10 |
|
|
050-005-00-7 |
związki trimetylocyny, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H330 H310 H300 H410 |
|
* |
A1 |
|
050-006-00-2 |
związki trietylocyny, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H330 H310 H300 H410 |
|
* |
A1 |
|
050-007-00-8 |
związki tripropylocyny, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H331 H311 H301 H410 |
|
* |
A1 |
|
050-009-00-9 |
fluorotripentylostannan;[1] heksapentylodistannoksan [2] |
243-546-7 [1] 247-143-7 [2] |
20153-49-5 [1] 25637-27-8 [2] |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H332 H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H332 H312 H302 H410 |
|
* |
1 |
|
050-010-00-4 |
fluorotriheksylostannan |
243-547-2 |
20153-50-8 |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H332 H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H332 H312 H302 H410 |
|
* |
1 |
|
050-011-00-X |
związki trifenylocyny, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H331 H311 H301 H410 |
|
* M=100 |
A1 |
|
050-012-00-5 |
tetracykloheksylostannan; [1] chlorotricykloheksylostannan; [2] butylotricykloheksylostannan [3] |
215-910-5 [1] 221-437-5 [2] 230-358-5 [3] |
1449-55-4 [1] 3091-32-5 [2] 7067-44-9 [3] |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H332 H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H332 H312 H302 H410 |
|
* |
A1 |
|
050-013-00-0 |
związki trioktylocyny, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Chronic 4 |
H319 H335 H315 H413 |
GHS07 Wng |
H319 H335 H315 H413 |
|
Skin Irrit. 2; H315: C ≥ 1 % Eye Irrit.2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 % |
A1 |
|
050-017-00-2 |
fenbutacyny tlenek (ISO); tlenek bis[tris(2-fenylo-2-metylopropylo)cyny] |
236-407-7 |
13356-08-6 |
Acute Tox. 2 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H330 H319 H315 H400 H410 |
GHS06 GHS09 Dgr |
H330 H319 H315 H410 |
|
|
|
|
050-018-00-8 |
bis(metanosulfonian) cyny |
401-640-7 |
53408-94-9 |
Skin Corr. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H314 H302 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H314 H302 H317 H411 |
|
|
|
|
050-019-00-3 |
azocyklocyna (ISO); 1-(tricykloheksylostannylo)-1H-1,2,4-triazol; tricykloheksylo-1H-1,2,4-triazol-1-ilocyna |
255-209-1 |
41083-11-8 |
Acute Tox. 2 * Acute Tox. 3 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H330 H301 H335 H315 H318 H400 H410 |
GHS06 GHS05 GHS09 Dgr |
H330 H301 H335 H315 H318 H410 |
|
|
|
|
050-020-00-9 |
trioktylostannan |
413-320-4 |
869-59-0 |
STOT RE 1 Skin Irrit. 2 Aquatic Chronic 4 |
H372 ** H315 H413 |
GHS08 GHS07 Dgr |
H372 ** H315 H413 |
|
|
|
|
050-021-00-4 |
dichlorodioktylocyna |
222-583-2 |
3542-36-7 |
Acute Tox. 3 * STOT RE 1 Aquatic Chronic 3 |
H331 H372** H412 |
GHS06 GHS08 Dgr |
H331 H372** H412 |
|
|
|
|
050-022-00-X |
dichlorek dibutylocyny; (DBTC) |
211-670-0 |
683-18-1 |
Muta. 2 Repr. 1B Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 4 * STOT RE 1 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H341 H360FD H330 H301 H312 H372** H314 H400 H410 |
GHS06 GHS05 GHS08 GHS09 Dgr |
H341 H360FD H330 H301 H312 H372** H314 H410 |
|
Skin Corr. 1B; H314: C ≥ 5 % Skin Irrit. 2; H315: 0,01 % ≤ C < 5 % Eye Dam.1; H318: 3 % ≤ C < 5 % Eye Irrit. 2; H319: 0,01 % ≤ C < 3 % M=10 |
|
|
050-023-00-5 |
masa poreakcyjna: bis[(2-etylo-1-oksoheksylo)oksy]dioktylowodorku cyny; tlenku bis[((2-etylo-1-oksoheksylo)oksy)dioktylocyny]; bis(1-fenylo-1,3-dekanodionylo)dioktylowodorku cyny; ((2-etylo-1-oksoheksylo)oksy)-(1-fenylo-1,3-dekanodionylo)dioktylo wodorku cyny; bis(1-fenylo-1,3-dekanodionylo)dioktylowodorku cyny; |
422-920-5 |
— |
STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H373** H400 H410 |
GHS08 GHS09 Wng |
H373** H410 |
|
M=10 |
|
|
050-024-00-0 |
masa poreakcyjna: wodorotlenku tri-p-tolilocyny; heksa-p-tolilodistannoksanu |
432-230-6 |
— |
STOT RE 1 Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H372** H302 H315 H318 H317 H400 H410 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H372** H302 H315 H318 H317 H410 |
|
|
|
|
050-025-00-6 |
trichlorometylostannan |
213-608-8 |
993-16-8 |
Repr. 2 |
H361d |
GHS08 Wng |
H361d |
|
|
|
|
050-026-00-1 |
10-etylo-4-[[2-[(2-etyloheksylo)oksy]-2-oksoetylo]tio]-4-metylo-7-okso-8-oksa-3,5-ditia-4-cynianotetradekanonian 2-etyloheksylu |
260-828-5 |
57583-34-3 |
Repr. 2 |
H361d |
GHS08 Wng |
H361d |
|
|
|
|
050-027-00-7 |
10-etylo-4,4-dioktylo-7-okso-8-oksa-3,5-ditia-4-cynianotetradekanonian 2-etyloheksylu |
239-622-4 |
15571-58-1 |
Repr. 1B |
H360D |
GHS08 Dgr |
H360D |
|
|
|
|
050-028-00-2 |
10-etylo-4,4-dimetylo-7-okso-8-oksa-3,5-ditia-4-cynianotetradekanonian 2-etyloheksylu |
260-829-0 |
57583-35-4 |
Repr. 2 Acute Tox. 4 STOT RE 1 Skin Sens. 1A |
H361d H302 H372 (układ nerwowy, układ odpornościowy) H317 |
GHS08 GHS07 Dgr |
H361d H302 H372 (układ nerwowy, układ odpornościowy) H317 |
|
|
|
|
050-029-00-8 |
dichlorek dimetylocyny |
212-039-2 |
753-73-1 |
Repr. 2 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 STOT RE 1 Skin Corr. 1B |
H361d H330 H301 H311 H372 (układ nerwowy, układ odpornościowy) H314 |
GHS08 GHS06 GHS05 Dgr |
H361d H330 H301 H311 H372 (układ nerwowy, układ odpornościowy) H314 |
EUH071 |
|
|
|
051-001-00-8 |
chlorek antymonu(III); trichlorek antymonu; chlorek antymonawy |
233-047-2 |
10025-91-9 |
Skin Corr. 1B Aquatic Chronic 2 |
H314 H411 |
GHS05 GHS09 Dgr |
H314 H411 |
|
STOT SE3; H335: C ≥ 5 % |
|
|
051-002-00-3 |
chlorek antymonu(V); pentachlorek antymonu; chlorek antymonowy |
231-601-8 |
7647-18-9 |
Skin Corr. 1B Aquatic Chronic 2 |
H314 H411 |
GHS05 GHS09 Dgr |
H314 H411 |
|
STOT SE 3; H335: C ≥ 5 % |
|
|
051-003-00-9 |
związki antymonu, z wyjątkiem: tetratlenku (Sb2O4), pentatlenku (Sb2O5), trisiarczku (Sb2S3), pentasiarczku (Sb2S5) i związków wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 2 |
H332 H302 H411 |
GHS07 GHS09 Wng |
H332 H302 H411 |
|
* |
A1 |
|
051-004-00-4 |
fluorek antymonu(III); trifluorek antymonu; fluorek antymonawy |
232-009-2 |
7783-56-4 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Chronic 2 |
H331 H311 H301 H411 |
GHS06 GHS09 Dgr |
H331 H311 H301 H411 |
|
|
|
|
051-005-00-X |
tlenek antymonu(III); tritlenek antymonu; tlenek antymonawy |
215-175-0 |
1309-64-4 |
Carc. 2 |
H351 |
GHS08 Wng |
H351 |
|
|
|
|
051-006-00-5 |
heksafluoroantymonian difenylo(4-fenylotiofenylo)sulfoniowy |
403-500-0 |
— |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
051-007-00-0 |
heksafluoroantymonian bis(4-dodecylofenylo)jodonium |
404-420-9 |
71786-70-4 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
053-001-00-3 |
jod |
231-442-4 |
7553-56-2 |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 |
H332 H312 H400 |
GHS07 GHS09 Wng |
H332 H312 H400 |
|
|
|
|
053-002-00-9 |
jodowodór |
233-109-9 |
10034-85-2 |
Press. Gas Skin Corr. 1A |
H314 |
GHS04 GHS05 Dgr |
H314 |
|
Skin Corr. 1A; H314: C ≥ 10 % Skin Corr. 1B; H314: 0,2 % ≤ C < 10 % Skin Irrit. 2; H315: 0,02 % ≤ C < 0,2 % Eye Irrit. 2; H319: 0,02 % ≤ C < 0,2 % STOT SE 3; H335: C ≥0,02 % |
U5 |
|
053-002-01-6 |
kwas jodowodorowy … % |
— |
— |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
|
|
Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 % Eye Irrit. 2; H319: 10 % ≤ C < 25 % |
B |
|
053-003-00-4 |
jodylobenzen |
— |
696-33-3 |
Expl. **** |
**** |
**** |
**** |
|
|
|
|
053-004-00-X |
bis(jodylobenzoesan) wapnia |
— |
— |
Expl. **** |
**** |
**** |
**** |
|
|
C |
|
053-005-00-5 |
tetrakis(pentafluorofenylo)boran(1-) [4-(1-metyloetylo)fenylo]-(4-metylofenylo)jodonium |
422-960-3 |
178233-72-2 |
Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H373 ** H400 H410 |
GHS08 GHS07 GHS09 Wng |
H312 H302 H373 ** H410 |
|
|
|
|
056-001-00-1 |
nadtlenek baru(II) |
215-128-4 |
1304-29-6 |
Ox. Sol. 2 Acute Tox. 4 * Acute Tox. 4 * |
H272 H332 H302 |
GHS03 GHS07 Dgr |
H272 H332 H302 |
|
|
|
|
056-002-00-7 |
sole baru, z wyjątkiem siarczanu(VI) baru, soli kwasu 1-azo-2-hydroksynaftalenyloarylosulfonowego i soli wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 4 * Acute Tox. 4 * |
H332 H302 |
GHS07 Wng |
H332 H302 |
|
* |
A1 |
|
056-003-00-2 |
węglan baru |
208-167-3 |
513-77-9 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
056-004-00-8 |
chlorek baru; dichlorek baru |
233-788-1 |
10361-37-2 |
Acute Tox. 3 * Acute Tox. 4 * |
H301 H332 |
GHS06 Dgr |
H301 H332 |
|
|
|
|
064-001-00-8 |
trójwodny wodorosiarczan(IV) gadolinu(III) |
456-900-2 |
51285-81-5 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
072-001-00-4 |
tetrabutoksyd hafnu; tetrabutanolan hafnu; |
411-740-2 |
22411-22-9 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
074-001-00-X |
diwodorododekawolframian heksasodu |
412-770-9 |
12141-67-2 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H302 H318 H412 |
GHS05 GHS07 Dgr |
H302 H318 H412 |
|
|
|
|
074-002-00-5 |
produkt reakcji heksachlorku wolframu z 2-metylopropan-2-olem, nonylofenolem i pentano-2,4-dionem |
408-250-6 |
— |
Flam. Liq. 2 Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H225 H332 H314 H317 H400 H410 |
GHS02 GHS05 GHS07 GHS09 Dgr |
H225 H332 H314 H317 H410 |
|
|
|
|
076-001-00-5 |
tetratlenek osmu; tlenek osmu(VIII) |
244-058-7 |
20816-12-0 |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Skin Corr. 1B |
H330 H310 H300 H314 |
GHS06 GHS05 Dgr |
H330 H310 H300 H314 |
|
|
|
|
078-001-00-0 |
tetrachloroplatyniany(II), z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 3 * Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H301 H318 H334 H317 |
GHS06 GHS05 GHS08 Dgr |
H301 H318 H334 H317 |
|
|
A |
|
078-002-00-6 |
tetrachloroplatynian(II) diamonu |
237-499-1 |
13820-41-2 |
Acute Tox. 3 * Skin Irrit. 2 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H301 H315 H318 H334 H317 |
GHS06 GHS05 GHS08 Dgr |
H301 H315 H318 H334 H317 |
|
|
|
|
078-003-00-1 |
tetrachloroplatynian(II) disodu |
233-051-4 |
10026-00-3 |
Acute Tox. 3 * Skin Irrit. 2 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H301 H315 H318 H334 H317 |
GHS06 GHS05 GHS08 Dgr |
H301 H315 H318 H334 H317 |
|
|
|
|
078-004-00-7 |
tetrachloroplatynian(II) dipotasu |
233-050-9 |
10025-99-7 |
Acute Tox. 3 * Skin Irrit. 2 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H301 H315 H318 H334 H317 |
GHS06 GHS05 GHS08 Dgr |
H301 H315 H318 H334 H317 |
|
|
|
|
078-005-00-2 |
heksachloroplatyniany(IV), z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 3 * Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H301 H318 H334 H317 |
GHS06 GHS05 GHS08 Dgr |
H301 H318 H334 H317 |
|
|
A |
|
078-006-00-8 |
heksachloroplatynian(IV) disodu |
240-983-5 |
16923-58-3 |
Acute Tox. 3 * Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H301 H318 H334 H317 |
GHS06 GHS05 GHS08 Dgr |
H301 H318 H334 H317 |
|
|
|
|
078-007-00-3 |
heksachloroplatynian(IV) dipotasu |
240-979-3 |
16921-30-5 |
Acute Tox. 3 * Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H301 H318 H334 H317 |
GHS06 GHS05 GHS08 Dgr |
H301 H318 H334 H317 |
|
|
|
|
078-008-00-9 |
heksachloroplatynian(IV) diamonu |
240-973-0 |
16919-58-7 |
Acute Tox. 3 * Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H301 H318 H334 H317 |
GHS06 GHS05 GHS08 Dgr |
H301 H318 H334 H317 |
|
|
|
|
078-009-00-4 |
kwas heksachloroplatynowy(IV) |
241-010-7 |
16941-12-1 |
Acute Tox. 3 * Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 |
H301 H314 H334 H317 |
GHS06 GHS05 GHS08 Dgr |
H301 H314 H334 H317 |
|
|
|
|
078-010-00-X |
wodorowęglan tetraaminoplatyny(II) |
426-730-3 |
123439-82-7 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H302 H318 H412 |
GHS05 GHS07 Dgr |
H302 H318 H412 |
|
|
|
|
078-011-00-5 |
kwas hydroksydisiarczanoplatynowy(II) |
423-310-1 |
61420-92-6 |
Acute Tox. 4 * STOT RE 2 * Skin Corr. 1A Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 3 |
H302 H373 H314 H334 H317 H412 |
GHS05 GHS08 GHS07 Dgr |
H302 H373 H314 H334 H317 H412 |
|
|
|
|
078-012-00-0 |
roztwór azotanu(V) platyny(IV) / kwasu azotowego(V) |
432-400-1 |
— |
Skin Corr. 1A Aquatic Acute 1 Aquatic Chronic 1 |
H314 H400 H410 |
GHS05 GHS09 Dgr |
H314 H410 |
|
|
|
|
080-001-00-0 |
rtęć |
231-106-7 |
7439-97-6 |
Repr. 1B Acute Tox. 2 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H360D*** H330 H372** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H360D*** H330 H372** H410 |
|
|
|
|
080-002-00-6 |
związki nieorganiczne rtęci, z wyjątkiem siarczku rtęci(II) i związków wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H300 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H330 H310 H300 H373 ** H410 |
|
* STOT RE 2; H373: C ≥ 0,1 % |
A1 |
|
080-003-00-1 |
dichlorek dirteci; chlorek rteci(I); kalomel; chlorek rtęciawy |
233-307-5 |
10112-91-1 |
Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H319 H335 H315 H400 H410 |
GHS07 GHS09 Wng |
H302 H319 H335 H315 H410 |
|
|
|
|
080-004-00-7 |
związki organiczne rtęci, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H300 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H330 H310 H300 H373 ** H410 |
|
* STOT RE 2; H373: C ≥0,1 % |
A1 |
|
080-005-00-2 |
piorunian rtęci(II); fulminian rtęci(II); fulminian rtęciowy |
211-057-8 |
628-86-4 |
Unst. Expl. Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H200 H331 H311 H301 H373 ** H400 H410 |
GHS01 GHS06 GHS08 GHS09 Dgr |
H200 H331 H311 H301 H373 ** H400 H410 |
|
|
|
|
080-005-01-X |
piorunian rtęci(II); fulminian rtęci(II); fulminian rtęciowy [≥ 20 % flegmatyzatora] |
211-057-8 |
628-86-4 |
Expl. 1.1 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H201 H331 H311 H301 H373 ** H400 H410 |
GHS01 GHS06 GHS08 GHS09 Dgr |
H201 H331 H311 H301 H373 ** H400 H410 |
|
|
|
|
080-006-00-8 |
dicyjank tlenek dirtęci(II); dicyjanek tlenek dirtęci; tlenocyjanek rtęci |
215-629-8 |
1335-31-5 |
Expl. 1.1 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H201 H331 H311 H301 H373** H400 H410 |
GHS01 GHS06 GHS08 GHS09 Dgr |
H201 H331 H311 H301 H373** H410 |
|
|
|
|
080-007-00-3 |
dimetylortęć; [1] dietylortęć [2] |
209-805-3 [1] 211-000-7 [2] |
593-74-8 [1] 627-44-1 [2] |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H300 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H330 H310 H300 H373 ** H410 |
|
* STOT RE 2; H373: C ≥0,05 % |
1 |
|
080-008-00-9 |
azotan(V) fenylortęci(II); [1] wodorotlenek fenylortęci(II); [2] zasadowy azotan fenylortęci; azotan(V) wodorotlenek fenylortęci(II) [3] |
200-242-9 [1] 202-866-7 [2] -[3] |
55-68-5 [1] 100-57-2 [2] 8003-05-2 [3] |
Acute Tox. 3 * STOT RE 1 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H301 H372 ** H314 H400 H410 |
GHS06 GHS08 GHS05 GHS09 Dgr |
H301 H372 ** H314 H410 |
|
|
|
|
080-009-00-4 |
chlorek (2-metoksyetylo)rtęci(II) |
204-659-7 |
123-88-6 |
Acute Tox. 3 * STOT RE 1 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H301 H372 ** H314 H400 H410 |
GHS06 GHS08 GHS05 GHS09 Dgr |
H301 H372 ** H314 H410 |
|
|
|
|
080-010-00-X |
dichlorek rtęci; chlorek rtęci(II); chlorek rtęciowy; sublimat |
231-299-8 |
7487-94-7 |
Muta. 2 Repr. 2 Acute Tox. 2 * STOT RE 1 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H341 H361f*** H300 H372** H314 H400 H410 |
GHS06 GHS05 GHS08 GHS09 Dgr |
H341 H361f*** H300 H372** H314 H410 |
|
|
|
|
080-011-00-5 |
octan fenylortęci(II) |
200-532-5 |
62-38-4 |
Acute Tox. 3 * STOT RE 1 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H301 H372 ** H314 H400 H410 |
GHS06 GHS08 GHS05 GHS09 Dgr |
H301 H372 ** H314 H410 |
|
|
|
|
081-001-00-3 |
tal |
231-138-1 |
7440-28-0 |
Acute Tox. 2 * Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 4 |
H330 H300 H373 ** H413 |
GHS06 GHS08 Dgr |
H330 H300 H373 ** H413 |
|
|
|
|
081-002-00-9 |
związki talu, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 2 * Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 2 |
H330 H300 H373 ** H411 |
GHS06 GHS08 GHS09 Dgr |
H330 H300 H373 ** H411 |
|
|
A |
|
081-003-00-4 |
siarczan(VI) talu(I); siarczan(VI) ditalu; siarczan talawy |
231-201-3 |
7446-18-6 |
Acute Tox. 2 * STOT RE 1 Skin Irrit. 2 Aquatic Chronic 2 |
H300 H372 ** H315 H411 |
GHS06 GHS08 GHS09 Dgr |
H300 H372 ** H315 H411 |
|
|
|
|
082-001-00-6 |
związki ołowiu, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Repr. 1A Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H360Df H332 H302 H373 ** H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H360Df H332 H302 H373 ** H410 |
|
Repr.2 H361f: C ≥ 2,5 % * STOT RE 2; H373: C ≥0,5 % |
A1 |
|
082-002-00-1 |
ołowiu alkilowe pochodne |
— |
— |
Repr. 1A Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H360Df H330 H310 H300 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H360Df H330 H310 H300 H373 ** H410 |
|
Repr.1A; H360D: C≥ 0,1 % * STOT RE 2; H373: C ≥0,05 % |
A1 |
|
082-003-00-7 |
diazydek ołowiu; azydek ołowiu(II); azydek ołowiawy |
236-542-1 |
13424-46-9 |
Unst. Expl. Repr. 1A Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H200 H360Df H332 H302 H373 ** H400 H410 |
GHS01 GHS08 GHS07 GHS09 Dgr |
H200 H360Df H332 H302 H373 ** H410 |
|
|
1 |
|
082-003-01-4 |
diazydek ołowiu; azydek ołowiu(II) [≥ 20 % flegmatyzatora] |
236-542-1 |
13424-46-9 |
Expl. 1.1 Repr. 1A Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H201 H360Df H332 H302 H373 ** H400 H410 |
GHS01 GHS08 GHS07 GHS09 Dgr |
H201 H360Df H332 H302 H373 ** H410 |
|
|
1 |
|
082-004-00-2 |
chromian(VI) ołowiu(II); chromian ołowiawy |
231-846-0 |
7758-97-6 |
Carc. 1B Repr. 1A STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H360Df H373** H400 H410 |
GHS08 GHS09 Dgr |
H350 H360Df H373** H410 |
|
|
1 |
|
082-005-00-8 |
octan ołowiu(II); dioctan ołowiu; octan ołowiawy |
206-104-4 |
301-04-2 |
Repr. 1A STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H360Df H373 ** H400 H410 |
GHS08 GHS09 Dgr |
H360Df H373 ** H410 |
|
|
1 |
|
082-006-00-3 |
fosforan(V) ołowiu(II); fosforan ołowiawy; diortofosforan(V) triołowiu |
231-205-5 |
7446-27-7 |
Repr. 1A STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H360Df H373 ** H400 H410 |
GHS08 GHS09 Dgr |
H360Df H373 ** H410 |
|
|
1 |
|
082-007-00-9 |
octan wodorotlenek ołowiu(II); zasadowy octan ołowiawy |
215-630-3 |
1335-32-6 |
Carc. 2 Repr. 1A STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H351 H360Df H373 ** H400 H410 |
GHS08 GHS09 Dgr |
H351 H360Df H373 ** H410 |
|
|
1 |
|
082-008-00-4 |
bis(metanosulfonian) ołowiu |
401-750-5 |
17570-76-2 |
Repr. 1A Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 |
H360Df H332 H302 H373 ** H315 H318 |
GHS08 GHS05 GHS07 Dgr |
H360Df H332 H302 H373 ** H315 H318 |
|
|
1 |
|
082-009-00-X |
żółty sulfochromian ołowiu; C.I. Pigment Yellow 34; żółcień pigmentowa 34; [Substancja ta została wpisana do Colour Index przez Colour Constitution pod numerem C.I. 77603.] |
215-693-7 |
1344-37-2 |
Carc. 1B Repr. 1A STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H360Df H373** H400 H410 |
GHS08 GHS09 Dgr |
H350 H360Df H373** H410 |
|
|
1 |
|
082-010-00-5 |
czerwony chromian molibdenian siarczan ołowiu; C.I. Pigment Red 104; czerwień pigmentowa 104; [Substancja ta została wpisana do Colour Index przez Colour Constitution pod numerem C.I. 77605.] |
235-759-9 |
12656-85-8 |
Carc. 1B Repr. 1A STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H360Df H373** H400 H410 |
GHS08 GHS09 Dgr |
H350 H360Df H373** H410 |
|
|
1 |
|
082-011-00-0 |
wodoroarsenian(V) ołowiu(II) |
232-064-2 |
7784-40-9 |
Carc. 1A Repr. 1A Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H350 H360Df H331 H301 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H350 H360Df H331 H301 H373 ** H410 |
|
|
1 |
|
082-012-00-6 |
bromek, chlorek, fluorek, jodek baru, wapnia, cezu, ołowiu, samaru i strontu z dodatkiem europu |
431-780-4 |
199876-46-5 |
Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 2 |
H302 H373** H411 |
GHS08 GHS07 GHS09 Wng |
H302 H373** H411 |
|
|
|
|
092-001-00-8 |
uran |
231-170-6 |
7440-61-1 |
Acute Tox. 2 * Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 4 |
H330 H300 H373 ** H413 |
GHS06 GHS08 Dgr |
H330 H300 H373 ** H413 |
|
|
|
|
092-002-00-3 |
związki uranu, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 2 * Acute Tox. 2 * STOT RE 2 Aquatic Chronic 2 |
H330 H300 H373** H411 |
GHS06 GHS08 GHS09 Dgr |
H330 H300 H373** H411 |
|
|
A |
|
601-001-00-4 |
metan |
200-812-7 |
74-82-8 |
Flam. Gas 1 Press. Gas |
H220 |
GHS02 GHS04 Dgr |
H220 |
|
|
U |
|
601-002-00-X |
etan |
200-814-8 |
74-84-0 |
Flam. Gas 1 Press. Gas |
H220 |
GHS02 GHS04 Dgr |
H220 |
|
|
U |
|
601-003-00-5 |
propan |
200-827-9 |
74-98-6 |
Flam. Gas 1 Press. Gas |
H220 |
GHS02 GHS04 Dgr |
H220 |
|
|
U |
|
601-004-00-0 |
butan; [1] i izobutan [2] |
203-448-7 [1] 200-857-2 [2] |
106-97-8 [1] 75-28-5 [2] |
Flam. Gas 1 Press. Gas |
H220 |
GHS02 GHS04 Dgr |
H220 |
|
|
C U |
|
601-004-01-8 |
butan (zawierający ≥ 0,1 % butadienu (numer WE 203-450-8)); [1] izobutan (zawierający ≥ 0,1 % butadienu (numer WE 203-450-8)) [2] |
203-448-7 [1] 200-857-2 [2] |
106-97-8 [1] 75-28-5 [2] |
Flam. Gas 1 Press. Gas Carc. 1A Muta. 1B |
H220 H350 H340 |
GHS02 GHS04 GHS08 Dgr |
H220 H350 H340 |
|
|
C S U |
|
601-005-00-6 |
2,2-dimetylopropan; neopentan |
207-343-7 |
463-82-1 |
Flam. Gas 1 Press. Gas Aquatic Chronic 2 |
H220 H411 |
GHS02 GHS04 GHS09 Dgr |
H220 H411 |
|
|
U |
|
601-006-00-1 |
pentan |
203-692-4 |
109-66-0 |
Flam. Liq. 2 Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2 |
H225 H304 H336 H411 |
GHS02 GHS08 GHS07 GHS09 Dgr |
H225 H304 H336 H411 |
EUH066 |
|
C |
|
601-007-00-7 |
heksan (zawierający < 5 % n-heksanu (numer WE 203-777-6)); 2-metylopentan;[1] 3-metylopentan; [2] 2,2-dimetylobutan; [3] 2,3-dimetylobutan [4] |
203-523-4 [1] 202-481-4 [2] 200-906-8 [3] 201-193-6 [4] |
107-83-5 [1] 96-14-0 [2] 75-83-2 [3] 79-29-8 [4] |
Flam. Liq. 2 Asp. Tox. 1 Skin Irrit. 2 STOT SE 3 Aquatic Chronic 2 |
H225 H304 H315 H336 H411 |
GHS02 GHS08 GHS07 GHS09 Dgr |
H225 H304 H315 H336 H411 |
|
|
C |
|
601-008-00-2 |
heptan; n-heptan; [1] 2,4-dimetylopentan; [2] 2,2,3-trimetylobutan; [3] 3,3-dimetylopentan; [4] 2,3-dimetylopentan; [5] 3-metyloheksan; [6] 2,2-dimetylopentan; [7] 2-metyloheksan; [8] 3-etylopentan; [9] izoheptan; [10] |
205-563-8 [1] 203-548-0 [2] 207-346-3 [3] 209-230-8 [4] 209-280-0 [5] 209-643-3 [6] 209-680-5 [7] 209-730-6 [8] 210-529-0 [9] 250-610-8 [10] |
142-82-5 [1] 108-08-7 [2] 464-06-2 [3] 562-49-2 [4] 565-59-3 [5] 589-34-4 [6] 590-35-2 [7] 591-76-4 [8] 617-78-7 [9] 31394-54-4 [10] |
Flam. Liq. 2 Asp. Tox. 1 Skin Irrit. 2 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 |
H225 H304 H315 H336 H400 H410 |
GHS02 GHS08 GHS07 GHS09 Dgr |
H225 H304 H315 H336 H410 |
|
|
C |
|
601-009-00-8 |
oktan; n-oktan; [1] 2,2,4-trimetylopentan; [2] 2,3,3-trimetylopentan; [3] 3,3-dimetyloheksan; [4] 2,2,3-trimetylopentan; [5] 2,3,4-trimetylopentan; [6] 3,4-dimetyloheksan; [7] 2,3-dimetyloheksan; [8] 2,4-dimetyloheksan; [9] 4-metyloheptan; [10] 3-metyloheptan; [11] 2,2-dimetyloheksan; [12] 2,5-dimetyloheksan; [13] 2-metyloheptan; [14] 2,2,3,3-tetrametylobutan; [15] 3-etylo-2-metylopentan; [16] 3-etyloheksan; [17] 3-etylo-3-metylopentan; [18] izooktan; [19] |
203-892-1 [1] 208-759-1 [2] 209-207-2 [3] 209-243-9 [4] 209-266-4 [5] 209-292-6 [6] 209-504-7 [7] 209-547-1 [8] 209-649-6 [9] 209-650-1 [10] 209-660-6 [11] 209-689-4 [12] 209-745-8 [13] 209-747-9 [14] 209-855-6 [15] 210-187-2 [16] 210-621-0 [17] 213-923-0 [18] 247-861-0 [19] |
111-65-9 [1] 540-84-1 [2] 560-21-4 [3] 563-16-6 [4] 564-02-3 [5] 565-75-3 [6] 583-48-2 [7] 584-94-1 [8] 589-43-5 [9] 589-53-7 [10] 589-81-1 [11] 590-73-8 [12] 592-13-2 [13] 592-27-8 [14] 594-82-1 [15] 609-26-7 [16] 619-99-8 [17] 1067-08-9 [18] 26635-64-3 [19] |
Flam. Liq. 2 Asp. Tox. 1 Skin Irrit. 2 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 |
H225 H304 H315 H336 H400 H410 |
GHS02 GHS08 GHS07 GHS09 Dgr |
H225 H304 H315 H336 H410 |
|
|
C |
|
601-010-00-3 |
eten; etylen |
200-815-3 |
74-85-1 |
Flam. Gas 1 Press. Gas STOT SE 3 |
H220 H336 |
GHS02 GHS04 GHS07 Dgr |
H220 H336 |
|
|
U |
|
601-011-00-9 |
propen; propylen |
204-062-1 |
115-07-1 |
Flam. Gas 1 Press. Gas |
H220 |
GHS02 GHS04 Dgr |
H220 |
|
|
U |
|
601-012-00-4 |
but-1-en; butylen-1; [1] buten – mieszanina izomerów 1-i 2-; [2] 2-metylopropen; izobutylen; [3] (Z)-but-2-en; cis-butylen-2; [4] (E)-but-2-en; trans-butylen-2 [5] |
203-449-2 [1] 203-452-9 [2] 204-066-3 [3] 209-673-7 [4] 210-855-3 [5] |
106-98-9 [1] 107-01-7 [2] 115-11-7 [3] 590-18-1 [4] 624-64-6 [5] |
Flam. Gas 1 Press. Gas |
H220 |
GHS02 GHS04 Dgr |
H220 |
|
|
C U |
|
601-013-00-X |
1,3-butadien; buta-1,3-dien |
203-450-8 |
106-99-0 |
Flam. Gas 1 Press. Gas Carc. 1A Muta. 1B |
H220 H350 H340 |
GHS02 GHS04 GHS08 Dgr |
H220 H350 H340 |
|
|
D U |
|
601-014-00-5 |
izopren (stabilizowany); 2-metylo-1,3-butadien |
201-143-3 |
78-79-5 |
Flam. Liq. 1 Carc. 1B Muta. 2 Aquatic Chronic 3 |
H224 H350 H341 H412 |
GHS02 GHS08 Dgr |
H224 H350 H341 H412 |
|
|
D |
|
601-016-00-6 |
cyklopropan |
200-847-8 |
75-19-4 |
Flam. Gas 1 Press. Gas |
H220 |
GHS02 GHS04 Dgr |
H220 |
|
|
U |
|
601-017-00-1 |
cykloheksan |
203-806-2 |
110-82-7 |
Flam. Liq. 2 Asp. Tox. 1 Skin Irrit. 2 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 |
H225 H304 H315 H336 H400 H410 |
GHS02 GHS08 GHS07 GHS09 Dgr |
H225 H304 H315 H336 H410 |
|
|
|
|
601-018-00-7 |
metylocykloheksan |
203-624-3 |
108-87-2 |
Flam. Liq. 2 Asp. Tox. 1 Skin Irrit. 2 STOT SE 3 Aquatic Chronic 2 |
H225 H304 H315 H336 H411 |
GHS02 GHS08 GHS07 GHS09 Dgr |
H225 H304 H315 H336 H411 |
|
|
|
|
601-019-00-2 |
1,4-dimetylocyckoheksan |
209-663-2 |
589-90-2 |
Flam. Liq. 2 Asp. Tox. 1 Skin Irrit. 2 STOT SE 3 Aquatic Chronic 2 |
H225 H304 H315 H336 H411 |
GHS02 GHS08 GHS07 GHS09 Dgr |
H225 H304 H315 H336 H411 |
|
|
|
|
601-020-00-8 |
benzen |
200-753-7 |
71-43-2 |
Flam. Liq. 2 Carc. 1a Muta. 1B STOT RE 1 Asp. Tox. 1 Eye Irrit. 2 Skin Irrit. 2 |
H225 H350 H340 H372 ** H304 H319 H315 |
GHS02 GHS08 GHS07 Dgr |
H225 H350 H340 H372 ** H304 H319 H315 |
|
|
E |
|
601-021-00-3 |
toluen; metylobenzen |
203-625-9 |
108-88-3 |
Flam. Liq. 2 Repr. 2 Asp. Tox. 1 STOT RE 2 * Skin Irrit. 2 STOT SE 3 |
H225 H361d *** H304 H373 ** H315 H336 |
GHS02 GHS08 GHS07 Dgr |
H225 H361d *** H304 H373 ** H315 H336 |
|
|
|
|
601-022-00-9 |
o-ksylen; 1,2-dimetylobenzen; [1] p-ksylen; 1,4-dimetylobenzen; [2] m-ksylen; 1,3-dimetylobenzen; [3] ksylen; dimetylobenzen [4] |
202-422-2 [1] 203-396-5 [2] 203-576-3 [3] 215-535-7 [4] |
95-47-6 [1] 106-42-3 [2] 108-38-3 [3] 1330-20-7 [4] |
Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 |
H226 H332 H312 H315 |
GHS02 GHS07 Wng |
H226 H332 H312 H315 |
|
* |
C |
|
601-023-00-4 |
etylobenzen; fenyloetan |
202-849-4 |
100-41-4 |
Flam. Liq. 2 Acute Tox. 4* STOT RE 2 Asp. Tox. 1 |
H225 H332 H373 (narządy słuchu) H304 |
GHS02 GHS07 GHS08 Dgr |
H225 H332 H373 (narządy słuchu) H304 |
|
|
|
|
601-024-00-X |
kumen; izopropylobenzen; [1] propylobenzen; 1-fenylopropan [2] |
202-704-5 [1] 203-132-9 [2] |
98-82-8 [1] 103-65-1 [2] |
Flam. Liq. 3 Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2 |
H226 H304 H335 H411 |
GHS02 GHS08 GHS07 GHS09 Dgr |
H226 H304 H335 H411 |
|
|
C |
|
601-025-00-5 |
mezytylen; 1,3,5-trimetylobenzen |
203-604-4 |
108-67-8 |
Flam. Liq. 3 STOT SE 3 Aquatic Chronic 2 |
H226 H335 H411 |
GHS02 GHS07 GHS09 Wng |
H226 H335 H411 |
|
STOT SE 3; H335: C ≥ 25 % |
|
|
601-026-00-0 |
styren; winylobenzen |
202-851-5 |
100-42-5 |
Flam. Liq. 3 Repr. 2 Acute Tox. 4* STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 |
H226 H361d H332 H372 (narządy słuchu) H315 H319 |
GHS02 GHS08 GHS07 Dgr |
H226 H361d H332 H372 (narządy słuchu) H315 H319 |
|
* |
D |
|
601-027-00-6 |
2-fenyloprop-1-en; propen-2-ylobenzen; izopropenylobenzen α-metylostyren |
202-705-0 |
98-83-9 |
Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 Aquatic Chronic 2 |
H226 H319 H335 H411 |
GHS02 GHS07 GHS09 Wng |
H226 H319 H335 H411 |
|
STOT SE 3; H335: C ≥ 25 % |
|
|
601-028-00-1 |
2-metylostyren; 2-winylotoluen |
210-256-7 |
611-15-4 |
Acute Tox. 4 * Aquatic Chronic 2 |
H332 H411 |
GHS07 GHS09 Wng |
H332 H411 |
|
|
|
|
601-029-00-7 |
dipenten; limonen;[1] (R)-p-menta-1,8-dien; d-limonene; [2] (S)-p-menta-1,8-dien; l-limonene; [3] trans-1-metylo-4-(1-metylowinylo)cykloheksen; [4] (±)-1-metylo-4-(1-metylowinylo)cykloheksen [5] |
205-341-0 [1] 227-813-5 [2] 227-815-6 [3] 229-977-3 [4] 231-732-0 [5] |
138-86-3 [1] 5989-27-5 [2] 5989-54-8 [3] 6876-12-6 [4] 7705-14-8 [5] |
Flam. Liq. 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H226 H315 H317 H400 H410 |
GHS02 GHS07 GHS09 Wng |
H226 H315 H317 H410 |
|
|
C |
|
601-030-00-2 |
cyklopentan |
206-016-6 |
287-92-3 |
Flam. Liq. 2 Aquatic Chronic 3 |
H225 H412 |
GHS02 Dgr |
H225 H412 |
|
|
|
|
601-031-00-8 |
2,4,4-trimetylopent-1-en; diizobutylen |
203-486-4 |
107-39-1 |
Flam. Liq. 2 Aquatic Chronic 2 |
H225 H411 |
GHS02 GHS09 Dgr |
H225 H411 |
|
|
|
|
601-032-00-3 |
benzo[a]piren; benzo[d, e,f]chryzen |
200-028-5 |
50-32-8 |
Carc. 1B Muta. 1B Repr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H340 H360FD H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350 H340 H360FD H317 H410 |
|
Carc. 1B; H350: C ≥ 0,01 % |
|
|
601-033-00-9 |
benzo[a]antracen |
200-280-6 |
56-55-3 |
Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H350 H400 H410 |
GHS08 GHS09 Dgr |
H350 H410 |
|
M=100 |
|
|
601-034-00-4 |
benzo[b]fluoranten; benzo[e]acefenantrylen |
205-911-9 |
205-99-2 |
Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H350 H400 H410 |
GHS08 GHS09 Dgr |
H350 H410 |
|
|
|
|
601-035-00-X |
benzo[j]fluoranten |
205-910-3 |
205-82-3 |
Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H350 H400 H410 |
GHS08 GHS09 Dgr |
H350 H410 |
|
|
|
|
601-036-00-5 |
benzo[k]fluoranten |
205-916-6 |
207-08-9 |
Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H350 H400 H410 |
GHS08 GHS09 Dgr |
H350 H410 |
|
|
|
|
601-037-00-0 |
n-heksan |
203-777-6 |
110-54-3 |
Flam. Liq. 2 Repr. 2 Asp. Tox. 1 STOT RE 2 * Skin Irrit. 2 STOT SE 3 Aquatic Chronic 2 |
H225 H361f *** H304 H373 ** H315 H336 H411 |
GHS02 GHS08 GHS07 GHS09 Dgr |
H225 H361f *** H304 H373 ** H315 H336 H411 |
|
STOT RE 2; H373: C ≥ 5 % |
|
|
601-041-00-2 |
dibenzo[a, h]antracen |
200-181-8 |
53-70-3 |
Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H350 H400 H410 |
GHS08 GHS09 Dgr |
H350 H410 |
|
Carc. 1B; H350: C ≥ 0,01 % M=100 |
|
|
601-042-00-8 |
bifenyl; fenylobenzen |
202-163-5 |
92-52-4 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H335 H315 H400 H410 |
GHS07 GHS09 Wng |
H319 H335 H315 H410 |
|
|
|
|
601-043-00-3 |
1,2,4-trimetylobenzen |
202-436-9 |
95-63-6 |
Flam. Liq. 3 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Chronic 2 |
H226 H332 H319 H335 H315 H411 |
GHS02 GHS07 GHS09 Wng |
H226 H332 H319 H335 H315 H411 |
|
|
|
|
601-044-00-9 |
3a,4,7,7a-tetrahydro-4,7-metanoinden; dicyklopentadien |
201-052-9 |
77-73-6 |
Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Chronic 2 |
H225 H332 H302 H319 H335 H315 H411 |
GHS02 GHS07 GHS09 Dgr |
H225 H332 H302 H319 H335 H315 H411 |
|
|
|
|
601-045-00-4 |
1,2,3,4-tetrahydronaftalen; tetralina |
204-340-2 |
119-64-2 |
Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 |
H319 H315 H411 |
GHS07 GHS09 Wng |
H319 H315 H411 |
EUH019 |
|
|
|
601-046-00-X |
7-metylookta-1,6-dien |
404-210-7 |
42152-47-6 |
Flam. Liq. 3 Aquatic Acute 1 Aquatic Chronic 1 |
H226 H400 H410 |
GHS02 GHS09 Wng |
H226 H410 |
|
|
|
|
601-047-00-5 |
m-menta-1,3(8)-dien |
404-150-1 |
17092-80-7 |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
601-048-00-0 |
chryzen |
205-923-4 |
218-01-9 |
Carc. 1B Muta. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H341 H400 H410 |
GHS08 GHS09 Dgr |
H350 H341 H410 |
|
|
|
|
601-049-00-6 |
benzo[e]piren |
205-892-7 |
192-97-2 |
Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H350 H400 H410 |
GHS08 GHS09 Dgr |
H350 H410 |
|
|
|
|
601-051-00-7 |
4-fenylobut-1-en |
405-980-7 |
768-56-9 |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
601-052-00-2 |
naftalen |
202-049-5 |
91-20-3 |
Carc. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H351 H302 H400 H410 |
GHS07 GHS08 GHS09 Wng |
H351 H302 H410 |
|
|
|
|
601-053-00-8 |
nonylofenol; [1] rozgałęziony 4-nonylofenol [2] |
246-672-0 [1] 284-325-5 [2] |
25154-52-3 [1] 84852-15-3 [2] |
Repr. 2 Acute Tox. 4 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H361fd H302 H314 H400 H410 |
GHS08 GHS05 GHS07 GHS09 Dgr |
H361fd H302 H314 H410 |
|
|
|
|
601-054-00-3 |
masa poreakcyjna izomerów: dibenzylobenzenu; dibenzylo(metylo)benzenu; dibenzylo(dimetylo)benzenu; dibenzylo(trimetylo)benzenu |
405-570-8 |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
601-055-00-9 |
masa poreakcyjna izomerów: mono(tetradekan-2-ylo)naftalenów; di(tetradekan-2-ylo)naftalenów; tri(tetradekan-2-ylo)naftalenów |
410-190-0 |
132983-41-6 |
Eye Irrit. 2 Aquatic Chronic 4 |
H319 H413 |
GHS07 Wng |
H319 H413 |
|
|
|
|
601-056-00-4 |
masa poreakcyjna izomerów: metylodifenylometanu; dimetylodifenylometanu |
405-470-4 |
73807-39-3 |
Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H400 H410 |
GHS07 GHS09 Wng |
H315 H410 |
|
|
|
|
601-057-00-X |
tosylan N-dodecylo-N-{3-[4-(dimetyloamino)-benzamido]propylo}-N, N-dimetyloamoniowy |
421-130-8 |
156679-41-3 |
Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H318 H317 H410 |
|
|
|
|
601-058-00-5 |
di-L-p-menten |
417-870-6 |
83648-84-4 |
Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H317 H400 H410 |
GHS07 GHS09 Wng |
H315 H317 H410 |
|
|
|
|
601-059-00-0 |
2-benzylideno-3-oksomaślan metylu |
420-940-9 |
15768-07-7 |
Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 |
H319 H315 H411 |
GHS07 GHS09 Wng |
H319 H315 H411 |
|
|
|
|
601-060-00-6 |
1,2-bis[4-fluoro-6-{4-sulfo-5-[2-(4-sulfonaftalen-3-yloazo)-1-hydroksy-3,6-disulfo-8-aminonaftalen-7-yloazo]fenyloamino}-1,3,5-triazyn-2-yloamino]etan – sole x-sodu, y-potasu, gdzie x=7,755 y=0,245 |
417-610-1 |
155522-09-1 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
601-061-00-1 |
(etyloetano-1,2-diylo)[2-({[(2-hydroksyetylo)metyloamino]acetylo}propylo)-ω-(nonylofenoksy)poli]oksy(metyloetano-1,2-diyl) |
418-960-8 |
— |
Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 |
H314 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H314 H317 H411 |
|
|
|
|
601-062-00-7 |
masa poreakcyjna: rozgałęzionych triakontanów; rozgałęzionych dotriakontanów; rozgałęzionych tetratriakontanów; rozgałęzionych heksatriakontanów |
417-030-9 |
151006-59-6 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
601-063-00-2 |
masa poreakcyjna rozgałęzionych izomerów tetrakozanu |
417-060-2 |
151006-61-0 |
Acute Tox. 4 * Aquatic Chronic 4 |
H332 H413 |
GHS07 Wng |
H332 H413 |
|
|
|
|
601-064-00-8 |
rozgałęzione heksatriakontany |
417-070-7 |
151006-62-1 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
601-065-00-3 |
masa poreakcyjna: (1'α,3'α,6'α)-2,2,3',7',7'-pentametylospiro(1,3-dioksano-5,2'-norkaranu); (1'α,3'β,6'α)-2,2,3',7',7'-pentametylospiro(1,3-dioksano-5,2'-norkaranu) |
416-930-9 |
— |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
601-066-00-9 |
1-[4-(trans-4-heptylocykloheksylo)fenylo]etan |
426-820-2 |
78531-60-9 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
601-067-00-4 |
arsenian(V) trietylu |
427-700-2 |
15606-95-8 |
Carc. 1A Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H350 H331 H301 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H350 H331 H301 H410 |
|
|
|
|
601-068-00-X |
1,2-diacetoksybut-3-en |
421-720-5 |
18085-02-4 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
601-069-00-5 |
bromek 2-etylo-1-[2-(1,3-dioksanylo)etylo]pirydyniowy |
422-680-1 |
287933-44-2 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
601-070-00-0 |
masa poreakcyjna: ikozanu (eikozanu) o rozgałęzionym łańcuchu; dokozanu o rozgałęzionym łańcuchu; tetrakozanu o rozgałęzionym łańcuchu |
417-050-8 |
151006-58-5 |
Acute Tox. 4 * Aquatic Chronic 4 |
H332 H413 |
GHS07 Wng |
H332 H413 |
|
|
|
|
601-071-00-6 |
1-dimetoksymetylo-2-nitrobenzen |
423-830-9 |
20627-73-0 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
601-072-00-1 |
masa poreakcyjna: 1-(4-izopropylofenylo)-1-fenyloetanu; 1-(3-izopropylofenylo)-1-fenyloetanu; 1-(2-izopropylofenylo)-1-fenyloetanu |
430-690-2 |
52783-21-8 |
Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H400 H410 |
GHS07 GHS09 Wng |
H315 H410 |
|
|
|
|
601-073-00-7 |
1-bromo-3,5-difluorobenzen |
416-710-2 |
461-96-1 |
Flam. Liq. 3 Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H226 H302 H373 ** H315 H317 H400 H410 |
GHS02 GHS08 GHS07 GHS09 Wng |
H226 H302 H373 ** H315 H317 H410 |
|
|
|
|
601-074-00-2 |
masa poreakcyjna: 4-(2,2,3-trimetylocyklopent-3-en-1-ylo)-1-metylo-2-oksabicyklo[2.2.2]oktanu; 1-(2,2,3-trimetylocyklopent-3-en-1-ylo)-5-metylo-6-oksabicyklo[3.2.1]oktanu; spiro[cykloheks-3-en-1-ylo-(4,5,6,6a-tetrahydro-3,6',6',6'a-tetrametylo)-1,3'(3'aH)-(2H)cyklopenta[b]furanu]; spiro[cykloheks-3-en-1-ylo-(4,5,6,6a-tetrahydro-4,6',6',6'a-tetrametylo)-1,3'(3'aH)-(2H)cyklopenta[b]furanu; |
422-040-1 |
— |
Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 |
H319 H315 H411 |
GHS07 GHS09 Wng |
H319 H315 H411 |
|
|
|
|
601-075-00-8 |
4,4'-bis(N-karbamoilo-4-metylobenzenosulfonamido)difenylometan |
418-770-5 |
151882-81-4 |
Carc. 2 |
H351 |
GHS08 Wng |
H351 |
|
|
|
|
601-076-00-3 |
cyklopropan etynylu |
425-430-1 |
6746-94-7 |
Flam. Liq. 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 |
H225 H315 H318 H412 |
GHS02 GHS05 Dgr |
H225 H315 H318 H412 |
|
|
|
|
601-077-00-9 |
masa poreakcyjna: 1-heptylo-4-etylo-2,6,7-trioksabicyklo[2.2.2]oktanu; 1-nonylo-4-etylo-2,6,7-trioksabicyklo[2.2.2]oktanu |
426-510-7 |
196965-91-0 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
601-078-00-4 |
masa poreakcyjna: 1,7-dimetylo-2-[(3-metylobicyklo[2.2.1]hept-2-ylo)metylo]bicyklo[2.2.1]heptanu; 2,3-dimetylo-2-[(3-metylobicyklo[2.2.1]hept-2-ylo)metylo]bicyklo[2.2.1]heptanu |
427-040-5 |
— |
Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H314 H400 H410 |
GHS05 GHS09 Dgr |
H314 H410 |
|
|
|
|
601-079-00-X |
masa poreakcyjna: trans-trans-cykloheksadeka-1,9-dienu; cis-trans-cykloheksadeka-1,9-dienu |
429-620-3 |
— |
Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 |
H315 H317 H413 |
GHS07 Wng |
H315 H317 H413 |
|
|
|
|
601-080-00-5 |
masa poreakcyjna: izomerów sec-butylofenylo(fenylo)metanu; mieszanych izomerów 1-(sec-butylofenylo(fenylo)-2-fenyloetanu; mieszanych izomerów 1-(sec-butylofenylo)-1-fenyloetanu |
431-100-6 |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
601-081-00-0 |
cykloheksadeka-1,9-dien |
431-730-1 |
4277-06-9 |
Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 |
H315 H317 H413 |
GHS07 Wng |
H315 H317 H413 |
|
|
|
|
601-082-00-6 |
masa poreakcyjna: endo-2-metylo-egzo-3-metylo-egzo-2-[(egzo-3-metylobicyklo[2.2.1]hept-egzo-2-ylo)metylo]bicyklo[2.2.1]heptanu; egzo-2-metylo-egzo-3-metylo-endo-2-[(endo-3-metylobicyklo[2.2.1]hept-egzo-2-ylo)metylo]bicyklo [2.2.1]heptanu |
434-420-4 |
— |
Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H400 H410 |
GHS05 GHS09 Dgr |
H315 H318 H410 |
|
|
|
|
601-083-00-1 |
5-endo-heksylo-bicyklo[2.2.1]hept-2-en |
435-000-3 |
22094-83-3 |
Asp. Tox. 1 Skin Irrit. 2 Aquatic Chronic 4 |
H304 H315 H413 |
GHS08 GHS07 Dgr |
H304 H315 H413 |
|
|
|
|
601-084-00-7 |
masa poreakcyjna 5-endo-butylo-bicyklo[2.2.1]hept-2-enu; 5-egzo-butylo-bicyklo[2.2.1]hept-2-enu (80:20) |
435-180-3 |
— |
Asp. Tox. 1 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H304 H315 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H304 H315 H410 |
|
|
|
|
601-085-00-2 |
izopentan; 2-metylobutan |
201-142-8 |
78-78-4 |
Flam. Liq. 1 Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2 |
H224 H304 H336 H411 |
GHS02 GHS08 GHS07 GHS09 Dgr |
H224 H304 H336 H411 |
EUH066 |
|
|
|
601-087-00-3 |
2,4,4-trimetylopent-1-en; diizobutylen |
246-690-9 |
25167-70-8 |
Flam. Liq. 2 Asp. Tox. 1 STOT SE 3 |
H225 H304 H336 |
GHS02 GHS07 GHS08 Dgr |
H225 H304 H336 |
|
|
D |
|
601-088-00-9 |
2-winylocykloheksen |
202-848-9 |
100-40-3 |
Carc. 2 |
H351 |
GHS08 Wng |
H351 |
|
|
|
|
601-089-00-4 |
muskalur cis-tricoz-9-en |
248-505-7 |
27519-02-4 |
Skin Sens. 1B |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
602-001-00-7 |
chlorometan; chlorek metylu |
200-817-4 |
74-87-3 |
Flam. Gas 1 Press. Gas Carc. 2 STOT RE 2 * |
H220 H351 H373 ** |
GHS02 GHS04 GHS08 Dgr |
H220 H351 H373 ** |
|
|
U |
|
602-002-00-2 |
bromometan; bromek metylu |
200-813-2 |
74-83-9 |
Press. Gas Muta. 2 Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Ozone 1 |
H341 H331 H301 H373** H319 H335 H315 H400 H420 |
GHS04 GHS06 GHS08 GHS09 Dgr |
H341 H331 H301 H373 ** H319 H335 H315 H400 H420 |
|
|
U |
|
602-003-00-8 |
dibromometan; dibromek metylenu; bromek metylenu |
200-824-2 |
74-95-3 |
Acute Tox. 4 * Aquatic Chronic 3 |
H332 H412 |
GHS07 Wng |
H332 H412 |
|
* |
|
|
602-004-00-3 |
dichlorometan; dichlorek metylenu; chlorek metylenu |
200-838-9 |
75-09-2 |
Carc. 2 |
H351 |
GHS08 Wng |
H351 |
|
|
|
|
602-005-00-9 |
jodek metylu; jodometan |
200-819-5 |
74-88-4 |
Carc. 2 Acute Tox. 4 * Acute Tox. 3 * Acute Tox. 3 * STOT SE 3 Skin Irrit. 2 |
H351 H312 H331 H301 H335 H315 |
GHS06 GHS08 Dgr |
H351 H312 H331 H301 H335 H315 |
|
|
|
|
602-006-00-4 |
chloroform; trichlorometan |
200-663-8 |
67-66-3 |
Carc. 2 Repr. 2 Acute Tox. 3 Acute Tox. 4 STOT RE 1 Eye Irrit. 2 Skin Irrit. 2 |
H351 H361d H331 H302 H372 H319 H315 |
GHS06 GHS08 Dgr |
H351 H361d H331 H302 H372 H319 H315 |
|
|
|
|
602-007-00-X |
bromoform; tribromometan |
200-854-6 |
75-25-2 |
Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 |
H331 H302 H319 H315 H411 |
GHS06 GHS09 Dgr |
H331 H302 H319 H315 H411 |
|
|
|
|
602-008-00-5 |
tetrachlorek węgla; czterochlorek węgla; tetrachlorometan |
200-262-8 |
56-23-5 |
Carc. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Aquatic Chronic 3 Ozone 1 |
H351 H331 H311 H301 H372** H412 H420 |
GHS06 GHS08 Dgr |
H351 H331 H311 H301 H372 ** H412 H420 |
|
* STOT RE 1; H372:C≥1 % STOT RE 2; H373:0,2 % ≤C < 1 % |
|
|
602-009-00-0 |
chloroetan; chlorek etylu |
200-830-5 |
75-00-3 |
Flam. Gas 1 Press. Gas Carc. 2 Aquatic Chronic 3 |
H220 H351 H412 |
GHS02 GHS04 GHS08 Dgr |
H220 H351 H412 |
|
|
U |
|
602-010-00-6 |
1,2-dibromoetan; dibromek etylenu; bromek etylenu |
203-444-5 |
106-93-4 |
Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Chronic 2 |
H350 H331 H311 H301 H319 H335 H315 H411 |
GHS06 GHS08 GHS09 Dgr |
H350 H331 H311 H301 H319 H335 H315 H411 |
|
* |
|
|
602-011-00-1 |
1,1-dichloroetan; chlorek etylidenu; dichlorek etylidenu |
200-863-5 |
75-34-3 |
Flam. Liq. 2 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Aquatic Chronic 3 |
H225 H302 H319 H335 H412 |
GHS02 GHS07 Dgr |
H225 H302 H319 H335 H412 |
|
* |
|
|
602-012-00-7 |
1,2-dichloroetan; dichlorek etylenu; chlorek etylenu |
203-458-1 |
107-06-2 |
Flam. Liq. 2 Carc. 1B Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H225 H350 H302 H319 H335 H315 |
GHS02 GHS08 GHS07 Dgr |
H225 H350 H302 H319 H335 H315 |
|
|
|
|
602-013-00-2 |
1,1,1-trichloroetan; metylochloroform |
200-756-3 |
71-55-6 |
Acute Tox. 4 * Ozone 1 |
H332 H420 |
GHS07 Wng |
H332 H420 |
|
|
F |
|
602-014-00-8 |
1,1,2-trichloroetan |
201-166-9 |
79-00-5 |
Carc. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H351 H332 H312 H302 |
GHS08 GHS07 Wng |
H351 H332 H312 H302 |
EUH066 |
* |
|
|
602-015-00-3 |
1,1,2,2-tetrachloroetan; tetrachlorek acetylenu |
201-197-8 |
79-34-5 |
Acute Tox. 2 * Acute Tox. 1 Aquatic Chronic 2 |
H330 H310 H411 |
GHS06 GHS09 Dgr |
H330 H310 H411 |
|
|
|
|
602-016-00-9 |
1,1,2,2-tetrabromoetan; tetrabromek acetylenu |
201-191-5 |
79-27-6 |
Acute Tox. 2 * Eye Irrit. 2 Aquatic Chronic 3 |
H330 H319 H412 |
GHS06 Dgr |
H330 H319 H412 |
|
|
|
|
602-017-00-4 |
pentachloroetan |
200-925-1 |
76-01-7 |
Carc. 2 STOT RE 1 Aquatic Chronic 2 |
H351 H372 ** H411 |
GHS08 GHS09 Dgr |
H351 H372 ** H411 |
|
STOT RE 1; H372: C≥ 1 % STOT RE 2; H373: 0,2 % ≤ C < 1 % |
|
|
602-018-00-X |
1-chloropropan; chlorek propylu; [1] 2-chloropropan; chlorek izopropylu [2] |
208-749-7 [1] 200-858-8 [2] |
540-54-5 [1] 75-29-6 [2] |
Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H225 H332 H312 H302 |
GHS02 GHS07 Dgr |
H225 H332 H312 H302 |
|
|
C |
|
602-019-00-5 |
1-bromopropan; bromek propylu |
203-445-0 |
106-94-5 |
Flam. Liq. 2 Repr. 1B STOT RE 2 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 STOT SE 3 |
H225 H360FD H373 ** H319 H335 H315 H336 |
GHS02 GHS08 GHS07 Dgr |
H225 H360FD H373 ** H319 H335 H315 H336 |
|
|
|
|
602-021-00-6 |
1,2-dibromo-3-chloropropan |
202-479-3 |
96-12-8 |
Carc. 1B Muta. 1B Repr. 1A Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 |
H350 H340 H360F *** H301 H373 ** H412 |
GHS06 GHS08 Dgr |
H350 H340 H360F *** H301 H373 ** H412 |
|
|
|
|
602-022-00-1 |
1-chloropentan; chlorek pentylu; [1] 2-chloropentan; chlorek pentylu; [2] 3-chloropentan [3] |
208-846-4 [1] 210-885-7 [2] 210-467-4 [3] |
543-59-9 [1] 625-29-6 [2] 616-20-6 [3] |
Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H225 H332 H312 H302 |
GHS02 GHS07 Dgr |
H225 H332 H312 H302 |
|
|
C |
|
602-023-00-7 |
chlorek winylu; chloroeten; chloroetylen |
200-831-0 |
75-01-4 |
Press. Gas Flam. Gas 1 Carc. 1A |
H220 H350 |
GHS02 GHS08 Dgr |
H220 H350 |
|
|
D U |
|
602-024-00-2 |
bromoeten; bromek winylu; bromoetylen |
209-800-6 |
593-60-2 |
Press. Gas Flam. Gas 1 Carc. 1B |
H220 H350 |
GHS02 GHS08 Dgr |
H220 H350 |
|
|
U |
|
602-025-00-8 |
1,1-dichloroeten; chlorek winylidenu |
200-864-0 |
75-35-4 |
Flam. Liq. 1 Carc. 2 Acute Tox. 4 * |
H224 H351 H332 |
GHS02 GHS08 GHS07 Dgr |
H224 H351 H332 |
|
* |
D |
|
602-026-00-3 |
1,2-dichloroeten; 1,2-dichloroetylen; dichlorek acetylenu; [1] cis-1,2-dichloroeten; [2] trans-1,2-dichloroeten [3] |
208-750-2 [1] 205-859-7 [2] 205-860-2 [3] |
540-59-0 [1] 156-59-2 [2] 156-60-5 [3] |
Flam. Liq. 2 Acute Tox. 4 * Aquatic Chronic 3 |
H225 H332 H412 |
GHS02 GHS07 Dgr |
H225 H332 H412 |
|
* |
C |
|
602-027-00-9 |
trichloroetylen; trichloroeten |
201-167-4 |
79-01-6 |
Carc. 1B Muta. 2 Eye Irrit. 2 Skin Irrit. 2 STOT SE 3 Aquatic Chronic 3 |
H350 H341 H319 H315 H336 H412 |
GHS08 GHS07 Dgr |
H350 H341 H319 H315 H336 H412 |
|
|
|
|
602-028-00-4 |
tetrachloroeten; tetrachloroetylen; perchloroetylen |
204-825-9 |
127-18-4 |
Carc. 2 Aquatic Chronic 2 |
H351 H411 |
GHS08 GHS09 Wng |
H351 H411 |
|
|
|
|
602-029-00-X |
3-chloropropen; chlorek allilu |
203-457-6 |
107-05-1 |
Flam. Liq. 2 Carc. 2 Muta. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 |
H225 H351 H341 H332 H312 H302 H373 ** H319 H335 H315 H400 |
GHS02 GHS08 GHS07 GHS09 Dgr |
H225 H351 H341 H332 H312 H302 H373 ** H319 H335 H315 H400 |
|
|
D |
|
602-030-00-5 |
1,3-dichloropropen; [1] (Z)-1,3-dichloropropen [2] |
208-826-5 [1] 233-195-8 [2] |
542-75-6 [1] 10061-01-5 [2] |
Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * Asp. Tox. 1 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H226 H311 H301 H332 H304 H319 H335 H315 H317 H400 H410 |
GHS02 GHS06 GHS08 GHS09 Dgr |
H226 H311 H301 H332 H304 H319 H335 H315 H317 H410 |
|
|
C D |
|
602-031-00-0 |
1,1-dichloropropen |
209-253-3 |
563-58-6 |
Flam. Liq. 2 Acute Tox. 3 * Aquatic Chronic 3 |
H225 H301 H412 |
GHS02 GHS06 Dgr |
H225 H301 H412 |
|
|
|
|
602-032-00-6 |
3-chloro-2-metylopropen; chlorek 2-metyloallilu |
209-251-2 |
563-47-3 |
Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 |
H225 H332 H302 H314 H317 H411 |
GHS02 GHS05 GHS07 GHS09 Dgr |
H225 H332 H302 H314 H317 H411 |
|
|
|
|
602-034-00-7 |
1,2-dichlorobenzen; o-dichlorobenzen |
202-425-9 |
95-50-1 |
Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H319 H335 H315 H400 H410 |
GHS07 GHS09 Wng |
H302 H319 H335 H315 H410 |
|
* |
|
|
602-035-00-2 |
1,4-dichlorobenzen; p-dichlorobenzen |
203-400-5 |
106-46-7 |
Carc. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H319 H400 H410 |
GHS08 GHS09 Wng |
H351 H319 H410 |
|
|
|
|
602-036-00-8 |
chloropren (stabilizowany); 2-chlorobuta-1,3-dien (stabilizowany) |
204-818-0 |
126-99-8 |
Flam. Liq. 2 Carc. 1B Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H225 H350 H332 H302 H373 ** H319 H335 H315 |
GHS02 GHS08 GHS07 Dgr |
H225 H350 H332 H302 H373 ** H319 H335 H315 |
|
|
D |
|
602-037-00-3 |
α-chlorotoluen (chlorometylo)benzen; chlorek benzylu; chloro(fenylo)metan |
202-853-6 |
100-44-7 |
Carc. 1B Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 |
H350 H331 H302 H373 ** H335 H315 H318 |
GHS06 GHS08 GHS05 Dgr |
H350 H331 H302 H373 ** H335 H315 H318 |
|
|
|
|
602-038-00-9 |
α, α,α-trichlorotoluen; (trichlorometylo)benzen; fenylochloroform |
202-634-5 |
98-07-7 |
Carc. 1B Acute Tox. 3 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 |
H350 H331 H302 H335 H315 H318 |
GHS06 GHS08 GHS05 Dgr |
H350 H331 H302 H335 H315 H318 |
|
|
|
|
602-039-00-4 |
polichlorowane bifenyle; PCB |
215-648-1 |
1336-36-3 |
STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H373 ** H400 H410 |
GHS08 GHS09 Wng |
H373 ** H410 |
|
STOT RE 2; H373: C ≥ 0,005 % |
C |
|
602-040-00-X |
2-chlorotoluen; o-chlorotoluen; [1] 3-chlorotoluen; o-chlorotoluen; [2] 4-chlorotoluen; o-chlorotoluen; [3] chlorotoluen [4] |
202-424-3 [1] 203-580-5 [2] 203-397-0 [3] 246-698-2 [4] |
95-49-8 [1] 108-41-8 [2] 106-43-4 [3] 25168-05-2 [4] |
Acute Tox. 4 * Aquatic Chronic 2 |
H332 H411 |
GHS07 GHS09 Wng |
H332 H411 |
|
|
C |
|
602-041-00-5 |
pentachloronaftalen |
215-320-8 |
1321-64-8 |
Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H319 H315 H400 H410 |
GHS07 GHS09 Wng |
H312 H302 H319 H315 H410 |
|
|
C |
|
602-042-00-0 |
1,2,3,4,5,6-heksachlorocykloheksany, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Carc. 2 Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H351 H301 H312 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H351 H301 H312 H410 |
|
|
A C |
|
602-043-00-6 |
lindan (ISO); γ-HCH lub γ-BHC; γ-1,2,3,4,5,6-heksachlorocykloheksan |
200-401-2 |
58-89-9 |
Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Lact. Aquatic Acute 1 Aquatic Chronic 1 |
H301 H332 H312 H373 ** H362 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H301 H332 H312 H373 ** H362 H410 |
|
M=10 |
|
|
602-044-00-1 |
kamfechlor (ISO); toksafen; |
232-283-3 |
8001-35-2 |
Carc. 2 Acute Tox. 3 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H301 H312 H335 H315 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H351 H301 H312 H335 H315 H410 |
|
|
|
|
602-045-00-7 |
DDT (ISO); klofenotan (INN); dikofan; 1,1,1-trichloro-2,2-bis(4-chlorofenylo)etan; dichlorodifenylotrichloroetan |
200-024-3 |
50-29-3 |
Carc. 2 Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H301 H372 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H351 H301 H372 ** H410 |
|
|
|
|
602-046-00-2 |
heptachlor (ISO); 1,4,5,6,7,8,8-heptachloro-3a,4,7,7a-tetrahydro-4,7-metanoinden |
200-962-3 |
76-44-8 |
Carc. 2 Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H351 H311 H301 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H351 H311 H301 H373 ** H410 |
|
|
|
|
602-047-00-8 |
chlordan (ISO); 1,2,4,5,6,7,8,8-oktachloro-3a,4,7,7a-tetrahydro-4,7-metanoindan |
200-349-0 |
57-74-9 |
Carc. 2 Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H351 H312 H302 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H312 H302 H410 |
|
|
|
|
602-048-00-3 |
aldryna (ISO) |
206-215-8 |
309-00-2 |
Carc. 2 Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H311 H301 H372 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H351 H311 H301 H372 ** H410 |
|
|
|
|
602-049-00-9 |
dieldryna (ISO) |
200-484-5 |
60-57-1 |
Carc. 2 Acute Tox. 1 Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H310 H301 H372 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H351 H310 H301 H372 ** H410 |
|
|
|
|
602-050-00-4 |
izodryna; (1α,4α,4aβ,5β,8β,8aβ)-1,2,3,4,10,10-heksachloro-1,4,4a,5,8,8a-heksahydro-1,4:5,8-dimetanonaftalen |
207-366-2 |
465-73-6 |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H330 H310 H300 H410 |
|
M=100 |
|
|
602-051-00-X |
endryna (ISO); rel-(1R,4S,4aS,5S,6S,7R,8R,8aR)-1,2,3,4,10,10-heksachloro-6,7-epoksy-1,4,4a,5,6,7,8,8a-oktahydro-1,4:5,8-dimetanonaftalen |
200-775-7 |
72-20-8 |
Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H300 H311 H400 H410 |
GHS06 GHS09 Dgr |
H300 H311 H410 |
|
|
|
|
602-052-00-5 |
endosulfan (ISO); siarczyn 1,4,5,6,7,7-heksachloro-8,9,10-trinorborn-5-en-2,3-ylenodimetylu); siarczyn 1,4,5,6,7,7-heksachloro-8,9,10-trinorborn-5-en-2,3-ylenodimetylu) |
204-079-4 |
115-29-7 |
Acute Tox. 2 * Acute Tox. 2 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H300 H312 H400 H410 |
GHS06 GHS09 Dgr |
H330 H300 H312 H410 |
|
|
|
|
602-053-00-0 |
izobenzan (ISO); 1,3,4,5,6,7,8,8-oktachloro-1,3,3a,4,7,7a-heksahydro-4,7-metanoizobenzofuran |
206-045-4 |
297-78-9 |
Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 |
H310 H300 H400 |
GHS06 GHS09 Dgr |
H310 H300 H400 |
|
|
|
|
602-054-00-6 |
3-jodopropen; jodek allilu |
209-130-4 |
556-56-9 |
Flam. Liq. 2 Skin Corr. 1B |
H225 H314 |
GHS02 GHS05 Dgr |
H225 H314 |
|
|
|
|
602-055-00-1 |
bromoetan; bromek etylu |
200-825-8 |
74-96-4 |
Flam. Liq. 2 Carc. 2 Acute Tox. 4 * Acute Tox. 4 * |
H225 H351 H332 H302 |
GHS02 GHS08 GHS07 Dgr |
H225 H351 H332 H302 |
|
|
|
|
602-056-00-7 |
α, α, α-trifluorotoluen; trifluoro(fenylo)metan; (trifluorometylo)benzen; fenylofluoroform |
202-635-0 |
98-08-8 |
Flam. Liq. 2 Aquatic Chronic 2 |
H225 H411 |
GHS02 GHS09 Dgr |
H225 H411 |
|
|
|
|
602-057-00-2 |
α-bromotoluen; (bromometylo)benzen; bromek benzylu; bromo(fenylo)metan |
202-847-3 |
100-39-0 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H319 H335 H315 |
GHS07 Wng |
H319 H335 H315 |
|
|
|
|
602-058-00-8 |
α, α-dichlorotoluen; chlorek benzylidenu; (dichlorometylo)benzen |
202-709-2 |
98-87-3 |
Carc. 2 Acute Tox. 3 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 |
H351 H331 H302 H335 H315 H318 |
GHS06 GHS08 GHS05 Dgr |
H351 H331 H302 H335 H315 H318 |
|
|
|
|
602-059-00-3 |
1-chlorobutan; chlorek butylu |
203-696-6 |
109-69-3 |
Flam. Liq. 2 |
H225 |
GHS02 Dgr |
H225 |
|
|
|
|
602-060-00-9 |
bromobenzen |
203-623-8 |
108-86-1 |
Flam. Liq. 3 Skin Irrit. 2 Aquatic Chronic 2 |
H226 H315 H411 |
GHS02 GHS07 GHS09 Wng |
H226 H315 H411 |
|
|
|
|
602-061-00-4 |
heksafluoropropen; heksafluoropropylen; perfluoropropylen |
204-127-4 |
116-15-4 |
Press. Gas Acute Tox. 4 * STOT SE 3 |
H332 H335 |
GHS07 Wng |
H332 H335 |
|
|
U |
|
602-062-00-X |
1,2,3-trichloropropan |
202-486-1 |
96-18-4 |
Carc. 1B Repr. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H350 H360F *** H332 H312 H302 |
GHS08 GHS07 Dgr |
H350 H360F *** H332 H312 H302 |
|
|
D |
|
602-063-00-5 |
tlenek heptachloru; 1,4,5,6,7,8,8-heptachloro-2,3-epoksy-3a,4,7,7a-tetrahydro-4,7-metanoindan |
213-831-0 |
1024-57-3 |
Carc. 2 Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H351 H301 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H351 H301 H373 ** H410 |
|
|
|
|
602-064-00-0 |
1,3-dichloropropan-2-ol; alkohol dichloroizopropylowy |
202-491-9 |
96-23-1 |
Carc. 1B Acute Tox. 3 * Acute Tox. 4 * |
H350 H301 H312 |
GHS06 GHS08 Dgr |
H350 H301 H312 |
|
|
|
|
602-065-00-6 |
heksachlorobenzen |
204-273-9 |
118-74-1 |
Carc. 1B STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H372 ** H400 H410 |
GHS08 GHS09 Dgr |
H350 H372 ** H410 |
|
|
|
|
602-066-00-1 |
tetrachloro-p-benzochinon; tetrachloro-1,4-benzochinon; chloranil |
204-274-4 |
118-75-2 |
Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H315 H400 H410 |
GHS07 GHS09 Wng |
H319 H315 H410 |
|
|
|
|
602-067-00-7 |
1,3-dichlorobenzen |
208-792-1 |
541-73-1 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
602-068-00-2 |
bis(trichloroctan) etylenu |
219-732-9 |
2514-53-6 |
Skin Irrit. 2 |
H315 |
GHS07 Wng |
H315 |
|
|
|
|
602-069-00-8 |
dichloroacetylen |
— |
7572-29-4 |
Unst. Expl. Carc. 2 STOT RE 2 * |
H200 H351 H373 ** |
GHS01 GHS08 Wng |
H200 H351 H373 ** |
|
|
|
|
602-070-00-3 |
3-chloro-α, α,α,4,5-pentafluorotoluen; 1-chloro-2,3-difluoro-5-(trifluorometylo)benzen |
401-930-3 |
77227-99-7 |
Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 |
H226 H332 H302 H400 |
GHS02 GHS07 GHS09 Wng |
H226 H332 H302 H400 |
|
|
|
|
602-071-00-9 |
(bromobenzylo)bromotoluen – masa poreakcyjna izomerów |
402-210-1 |
99688-47-8 |
STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H373 ** H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H373 ** H317 H410 |
|
|
|
|
602-072-00-4 |
dichloro(dichlorobenzylo)toluen – masa poreakcyjna izomerów; (dichlorofenylo)(dichlorotolilo)metan – masa poreakcyjna izomerów (IUPAC) |
278-404-3 |
76253-60-6 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
602-073-00-X |
1,4-dichlorobut-2-en |
212-121-8 |
764-41-0 |
Carc. 1B Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H350 H330 H311 H301 H314 H400 H410 |
GHS06 GHS08 GHS05 GHS09 Dgr |
H350 H330 H311 H301 H314 H410 |
|
Carc. 1B; H350: C ≥ 0,01 % STOT SE 3; H335:C≥5 % |
|
|
602-074-00-5 |
pentachlorobenzen |
210-172-0 |
608-93-5 |
Flam. Sol. 1 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H228 H302 H400 H410 |
GHS02 GHS07 GHS09 Dgr |
H228 H302 H410 |
|
|
T |
|
602-075-00-0 |
4,4,5,5-tetrachloro-1,3-dioksolan-2-on |
404-060-2 |
22432-68-4 |
Acute Tox. 2 * Acute Tox. 4 * Skin Corr. 1B |
H330 H302 H314 |
GHS06 GHS05 Dgr |
H330 H302 H314 |
|
|
|
|
602-076-00-6 |
2,3,4-trichlorobut-1-en |
219-397-9 |
2431-50-7 |
Carc. 2 Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H331 H302 H319 H335 H315 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H351 H331 H302 H319 H335 H315 H410 |
|
Carc. 2; H351: C ≥ 0,1 % |
|
|
602-077-00-1 |
dodekachloropentacyklo[5.2.1.02,6.03,9.05,8]dekan; mirex |
219-196-6 |
2385-85-5 |
Carc. 2 Repr. 2 Lact. Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H351 H361fd H362 H312 H302 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H361fd H362 H312 H302 H410 |
|
|
|
|
602-078-00-7 |
heksachlorocyklopentadien |
201-029-3 |
77-47-4 |
Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H330 H311 H302 H314 H400 H410 |
GHS06 GHS05 GHS09 Dgr |
H330 H311 H302 H314 H410 |
|
|
|
|
602-079-00-2 |
2,3-dichloropropen; 2,3-dichloropropylen |
201-153-8 |
78-88-6 |
Flam. Liq. 2 Muta. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 |
H225 H341 H332 H312 H302 H335 H315 H318 H412 |
GHS02 GHS08 GHS05 GHS07 Dgr |
H225 H341 H332 H312 H302 H335 H315 H318 H412 |
|
|
|
|
602-080-00-8 |
chloroalkany C10-13 chlorowane parafiny, C10-13 |
287-476-5 |
85535-84-8 |
Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H400 H410 |
GHS08 GHS09 Wng |
H351 H410 |
EUH066 |
|
|
|
602-081-00-3 |
kwas 2-chloro-4,5-difluorobenzoesowy |
405-380-5 |
— |
Acute Tox. 4 * Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 |
H312 H302 H318 H317 |
GHS05 GHS07 Dgr |
H312 H302 H318 H317 |
|
|
|
|
602-082-00-9 |
2,2,6,6-tetrakis(bromometylo)-4-oksaheptano-1,7-diol |
408-020-5 |
109678-33-3 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
602-083-00-4 |
pochodne pentabromowe eteru difenylowego; eter pentabromodifenylowy |
251-084-2 |
32534-81-9 |
STOT RE 2 * Lact. Aquatic Acute 1 Aquatic Chronic 1 |
H373 ** H362 H400 H410 |
GHS08 GHS09 Wng |
H373 ** H362 H410 |
|
|
|
|
602-084-00-X |
1,1-dichloro-1-fluoroetan |
404-080-1 |
1717-00-6 |
Aquatic Chronic 3 Ozone 1 |
H412 H420 |
GHS07 Wng |
H412 H420 |
|
|
|
|
602-085-00-5 |
2-bromopropan |
200-855-1 |
75-26-3 |
Flam. Liq. 2 Repr. 1a STOT RE 2 * |
H225 H360F *** H373 ** |
GHS02 GHS08 Dgr |
H225 H360F *** H373 ** |
EUH066 |
|
|
|
602-086-00-0 |
trifluorojodometan; jodek trifluorometylu |
219-014-5 |
2314-97-8 |
Muta. 2 |
H341 |
GHS08 Wng |
H341 |
|
|
|
|
602-087-00-6 |
1,2,4-trichlorobenzen |
204-428-0 |
120-82-1 |
Acute Tox. 4 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H315 H400 H410 |
GHS07 GHS09 Wng |
H302 H315 H410 |
|
|
|
|
602-088-00-1 |
2,3-dibromopropan-1-ol; 2,3-dibromo-1-propanol |
202-480-9 |
96-13-9 |
Carc. 1B Repr. 2 Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 3 |
H350 H361f *** H311 H332 H302 H412 |
GHS08 GHS07 Dgr |
H350 H361f *** H311 H332 H302 H412 |
|
|
|
|
602-089-00-7 |
4-bromo-2-chloro-1-fluorobenzen |
405-580-2 |
60811-21-4 |
Acute Tox. 4 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H315 H400 H410 |
GHS07 GHS09 Wng |
H302 H315 H410 |
|
|
|
|
602-090-00-2 |
1-allilo-3-chloro-4-fluorobenzen; 4-allilo-2-chloro-1-fluorobenzen |
406-630-6 |
121626-73-1 |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
602-091-00-8 |
1,3-dichloro-4-fluorobenzen; 2,4-dichloro-1-fluorobenzen |
406-160-1 |
1435-48-9 |
Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 |
H302 H373 ** H315 H411 |
GHS08 GHS07 Wng |
H302 H373 ** H315 H411 |
|
|
|
|
602-092-00-3 |
1-bromo-3,4,5-trifluorobenzen; 5-bromo-1,2,3-trifluorobenzen |
418-480-9 |
138526-69-9 |
Flam. Liq. 3 Carc. 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 |
H226 H351 H315 H318 H411 |
GHS02 GHS08 GHS05 GHS09 Dgr |
H226 H351 H315 H318 H411 |
|
|
|
|
602-093-00-9 |
α, α,α,4-tetrachlorotoluen; trichlorek p-chlorobenzylidynu |
226-009-1 |
5216-25-1 |
Carc. 1B Repr. 2 STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 |
H350 H361f *** H372 ** H312 H302 H335 H315 |
GHS08 GHS07 Dgr |
H350 H361f *** H372 ** H312 H302 H335 H315 |
|
|
|
|
602-094-00-4 |
pochodna oktabromowa eteru difenylowego |
251-087-9 |
32536-52-0 |
Repr. 1B |
H360Df |
GHS08 Dgr |
H360Df |
|
|
|
|
602-095-00-X |
chloroalkany, C14-17; chlorowane parafiny, C14-17 |
287-477-0 |
85535-85-9 |
Lact. Aquatic Acute 1 Aquatic Chronic 1 |
H362 H400 H410 |
GHS09 Wng |
H362 H410 |
EUH066 |
|
|
|
602-096-00-5 |
chlorowodorek zieleni malachitowej; [1] szczawian zieleni malachitowej [2] |
209-322-8 [1] 219-441-7 [2] |
569-64-2 [1] 2437-29-8 [2] |
Repr. 2 Acute Tox. 4 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361d *** H302 H318 H400 H410 |
GHS08 GHS05 GHS07 GHS09 Dgr |
H361d *** H302 H318 H410 |
|
|
|
|
602-097-00-0 |
1-bromo-9-(4,4,5,5,5-pentafluoro-pentylotio)nonan; 1-bromo-9-(4,4,5,5,5-pentafluoro-pentylosulfanylo)nonan |
422-850-5 |
148757-89-5 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
602-098-00-6 |
2-(3-bromofenoksy)tetrahydro-2H-piran |
429-030-6 |
57999-49-2 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
602-099-00-1 |
chlorek 3-(4-fluorofenylo)-2-metylopropionylu |
426-370-7 |
— |
Skin Corr. 1A Acute Tox. 4 * Aquatic Chronic 3 |
H314 H302 H412 |
GHS05 GHS07 Dgr |
H314 H302 H412 |
EUH014 EUH029 |
|
|
|
602-100-00-5 |
masa poreakcyjna: (R, R)-1,1,1,2,2,3,4,5,5,5-dekafluoropentanu; (S, S)-1,1,1,2,2,3,4,5,5,5-dekafluoropentanu |
420-640-8 |
— |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
602-101-00-0 |
2-chloro-4-fluoro-5-nitrofenylo (izobutylo)węglan; węglan 2-chloro-4-fluoro-5-nitrofenylo (izobutylu) |
427-020-6 |
141772-37-4 |
STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H373** H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H373** H317 H410 |
|
|
|
|
602-102-00-6 |
1,1,1,3,3-pentafluorobutan |
430-250-1 |
406-58-6 |
Flam. Liq. 2 |
H225 |
GHS02 Dgr |
H225 |
|
|
|
|
602-103-00-1 |
1-(chlorofenylometylo)-2-metylobenzen |
431-450-1 |
41870-52-4 |
Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H400 H410 |
GHS07 GHS09 Wng |
H315 H410 |
|
|
|
|
602-104-00-7 |
1,1,2,2,3,3,4-heptafluorocyklopentan |
430-710-1 |
15290-77-4 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
602-105-00-2 |
1,1,2,2,3,3,4,4,4-nonafluoro-1-butanosulfinian sodu |
422-100-7 |
102061-82-5 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
602-106-00-8 |
2-bromo-4,6-difluoroanilina |
429-430-0 |
444-14-4 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
602-107-00-3 |
3,3,4,4-tetrafluoro-4-jodo-1-buten |
439-500-2 |
33831-83-3 |
Acute Tox. 4 * Skin Irrit. 2 Aquatic Chronic 2 |
H302 H315 H411 |
GHS07 GHS09 Wng |
H302 H315 H411 |
|
|
|
|
602-108-00-9 |
(2,3,5,6-tetrafluorofenylo)metanol |
443-840-7 |
4084-38-2 |
Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 |
H302 H319 H317 |
GHS07 Wng |
H302 H319 H317 |
|
|
|
|
602-109-00-4 |
heksabromocyklododekan [1] 1,2,5,6,9,10-heksabromocyklododekan [2] |
247-148-4 [1] 221-695-9[2] |
25637-99-4[1] 3194-55-6[2] |
Repr. 2 Lact. |
H361 H362 |
GHS08 Wng |
H361 H362 |
|
|
|
|
603-001-00-X |
metanol |
200-659-6 |
67-56-1 |
Flam. Liq. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT SE 1 |
H225 H331 H311 H301 H370 ** |
GHS02 GHS06 GHS08 Dgr |
H225 H331 H311 H301 H370 ** |
|
* STOT SE 1; H370: C≥10 % STOT SE 2; H371: 3 % ≤ C<10 % |
|
|
603-002-00-5 |
etanol; alkohol etylowy |
200-578-6 |
64-17-5 |
Flam. Liq. 2 |
H225 |
GHS02 Dgr |
H225 |
|
|
|
|
603-003-00-0 |
propan-1-ol; n-propanol |
200-746-9 |
71-23-8 |
Flam. Liq. 2 Eye Dam. 1 STOT SE 3 |
H225 H318 H336 |
GHS02 GHS05 GHS07 Dgr |
H225 H318 H336 |
|
|
|
|
603-004-00-6 |
butan-1-ol; n-butanol |
200-751-6 |
71-36-3 |
Flam. Liq. 3 Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 STOT SE 3 |
H226 H302 H335 H315 H318 H336 |
GHS02 GHS05 GHS07 Dgr |
H226 H302 H335 H315 H318 H336 |
|
|
|
|
603-005-00-1 |
2-metylopropan-2-ol; alkohol tert-butylowy |
200-889-7 |
75-65-0 |
Flam. Liq. 2 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 |
H225 H332 H319 H335 |
GHS02 GHS07 Dgr |
H225 H332 H319 H335 |
|
|
|
|
603-006-00-7 |
izomery pentanolu, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
250-378-8 |
|
Flam. Liq. 3 Acute Tox. 4 * STOT SE 3 |
H226 H332 H335 |
GHS02 GHS07 Wng |
H226 H332 H335 |
EUH066 |
|
C |
|
603-007-00-2 |
2-metylobutan-2-ol; tert-pentanol |
200-908-9 |
75-85-4 |
Flam. Liq. 2 Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 |
H225 H332 H335 H315 |
GHS02 GHS07 Dgr |
H225 H332 H335 H315 |
|
|
|
|
603-008-00-8 |
4-metylopentan-2-ol; metyloizobutylokarbinol; alkohol metyloamylowy |
203-551-7 |
108-11-2 |
Flam. Liq. 3 STOT SE 3 |
H226 H335 |
GHS02 GHS07 Wng |
H226 H335 |
|
STOT SE 3; H335: C ≥ 25 % |
|
|
603-009-00-3 |
cykloheksanol |
203-630-6 |
108-93-0 |
Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 |
H332 H302 H335 H315 |
GHS07 Wng |
H332 H302 H335 H315 |
|
|
|
|
603-010-00-9 |
2-metylocykloheksanol, mieszanina izomerów; [1] cis-2-metylocykloheksanol; [2] trans-2-metylocykloheksanol [3] |
209-512-0 [1] 231-187-9 [2] 231-186-3 [3] |
583-59-5 [1] 7443-70-1 [2] 7443-52-9 [3] |
Acute Tox. 4 * |
H332 |
GHS07 Wng |
H332 |
|
|
C |
|
603-011-00-4 |
2-metoksyetanol; eter monometylowy glikolu etylenowego; cellosolw metylowy |
203-713-7 |
109-86-4 |
Flam. Liq. 3 Repr. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H226 H360FD H332 H312 H302 |
GHS02 GHS08 GHS07 Dgr |
H226 H360FD H332 H312 H302 |
|
|
|
|
603-012-00-X |
2-etoksyetanol; eter monoetylowy glikolu etylenowego; cellosolw etylowy |
203-804-1 |
110-80-5 |
Flam. Liq. 3 Repr. 1B Acute Tox. 3 Acute Tox. 4 |
H226 H360FD H331 H302 |
GHS02 GHS08 GHS06 Dgr |
H226 H360FD H331 H302 |
|
|
|
|
603-013-00-5 |
2-izopropoksyetanol; eter monoizopropylowy glikolu etylenowego; cellosolw izopropylowy |
203-685-6 |
109-59-1 |
Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 |
H332 H312 H319 |
GHS07 Wng |
H332 H312 H319 |
|
|
|
|
603-014-00-0 |
2-butoksyetanol; eter monobutylowy glikolu etylenowego; cellosolw butylowy |
203-905-0 |
111-76-2 |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 |
H332 H312 H302 H319 H315 |
GHS07 Wng |
H332 H312 H302 H319 H315 |
|
|
|
|
603-015-00-6 |
alkohol allilowy; prop-2-en-1-ol |
203-470-7 |
107-18-6 |
Flam. Liq. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 |
H225 H331 H311 H301 H319 H335 H315 H400 |
GHS02 GHS06 GHS09 Dgr |
H225 H331 H311 H301 H319 H335 H315 H400 |
|
|
|
|
603-016-00-1 |
4-hydroksy-4-metylopentan-2-on; alkohol diacetonowy |
204-626-7 |
123-42-2 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
Eye Irrit. 2; H319: C≥ 10 % |
|
|
603-018-00-2 |
alkohol furfurylowy; 2-furylometanol |
202-626-1 |
98-00-0 |
Carc. 2 Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 STOT SE 3 |
H351 H331 H312 H302 H373** H319 H335 |
GHS06 GHS08 Dgr |
H351 H331 H312 H302 H373** H319 H335 |
|
|
|
|
603-019-00-8 |
eter dimetylowy; metoksymetan; tlenek metylu |
204-065-8 |
115-10-6 |
Flam. Gas 1 Press. Gas |
H220 |
GHS02 GHS04 Dgr |
H220 |
|
|
U |
|
603-020-00-3 |
eter etylowo-metylowy; metoksyetan; metoksyetylen |
— |
540-67-0 |
Flam. Gas 1 Press. Gas |
H220 |
GHS02 GHS04 Dgr |
H220 |
|
|
U |
|
603-021-00-9 |
eter metylowo-winylowy; metoksyeten |
203-475-4 |
107-25-5 |
Flam. Gas 1 Press. Gas |
H220 |
GHS02 GHS04 Dgr |
H220 |
|
|
D U |
|
603-022-00-4 |
eter dietylowy; eter |
200-467-2 |
60-29-7 |
Flam. Liq. 1 Acute Tox. 4 * STOT SE 3 |
H224 H302 H336 |
GHS02 GHS07 Dgr |
H224 H302 H336 |
EUH019 EUH066 |
|
|
|
603-023-00-X |
tlenek etylenu; epoksyetan oksiran |
200-849-9 |
75-21-8 |
Press. Gas Flam. Gas 1 Carc. 1B Muta. 1B Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H220 H350 H340 H331 H319 H335 H315 |
GHS02 GHS04 GHS06 GHS08 Dgr |
H220 H350 H340 H331 H319 H335 H315 |
|
|
U |
|
603-024-00-5 |
1,4-dioksan |
204-661-8 |
123-91-1 |
Flam. Liq. 2 Carc. 2 Eye Irrit. 2 STOT SE 3 |
H225 H351 H319 H335 |
GHS02 GHS08 GHS07 Dgr |
H225 H351 H319 H335 |
EUH019 EUH066 |
|
D |
|
603-025-00-0 |
tetrahydrofuran |
203-726-8 |
109-99-9 |
Flam. Liq. 2 Carc. 2 Eye Irrit. 2 STOT SE 3 |
H225 H351 H319 H335 |
GHS02 GHS07 GHS08 Dgr |
H225 H351 H319 H335 |
EUH019 |
STOT SE 3; H335: C≥25 % Eye Irrit.2; H319: C ≥ 25 % |
|
|
603-026-00-6 |
1-chloro-2,3-epoksypropan; epichlorohydryna; tlenek 2-chloropropylenu |
203-439-8 |
106-89-8 |
Flam. Liq. 3 Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 |
H226 H350 H331 H311 H301 H314 H317 |
GHS02 GHS06 GHS08 GHS05 Dgr |
H226 H350 H331 H311 H301 H314 H317 |
|
* |
|
|
603-027-00-1 |
etano-1,2-diol; glikol etylenowy |
203-473-3 |
107-21-1 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
603-028-00-7 |
2-chloroetanol; chlorohydryna etylenu; etylenochlorohydryna; alkohol 2-chloroetylowy |
203-459-7 |
107-07-3 |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * |
H330 H310 H300 |
GHS06 Dgr |
H330 H310 H300 |
|
|
|
|
603-029-00-2 |
eter bis(2-chloroetylowy); eter 2,2'-dichlorodietylowy |
203-870-1 |
111-44-4 |
Carc. 2 Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * |
H351 H330 H310 H300 |
GHS06 GHS08 Dgr |
H351 H330 H310 H300 |
|
|
|
|
603-030-00-8 |
2-aminoetanol; etanoloamina |
205-483-3 |
141-43-5 |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B |
H332 H312 H302 H314 |
GHS05 GHS07 Dgr |
H332 H312 H302 H314 |
|
STOT SE 3; H335: C ≥ 5 % |
|
|
603-031-00-3 |
1,2-dimetoksyetan; eter dimetylowy glikolu etylenowego; EGDME |
203-794-9 |
110-71-4 |
Flam. Liq. 2 Repr. 1B Acute Tox. 4 * |
H225 H360FD H332 |
GHS02 GHS08 GHS07 Dgr |
H225 H360FD H332 |
EUH019 |
|
|
|
603-032-00-9 |
diazotan(V) etylenu; diazotan(V) glikolu etylenowego |
211-063-0 |
628-96-6 |
Unst. Expl. Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 |
H200 H330 H310 H300 H373** |
GHS01 GHS06 GHS08 Dgr |
H200 H330 H310 H300 H373** |
|
|
|
|
603-033-00-4 |
diazotan(V) 3-oksapentano-1,5-diylu; diazotan(V) glikolu dietylenowego |
211-745-8 |
693-21-0 |
Unst. Expl Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 3 |
H200 H330 H310 H300 H373 ** H412 |
GHS01 GHS06 GHS08 Dgr |
H200 H330 H310 H300 H373 ** H412 |
|
|
|
|
603-033-01-1 |
diazotan(V) 3-oksapentano-1,5-diylu; diazotan(V) glikolu dietylenowego; [> 25 % flegmatyzatora] |
211-745-8 |
693-21-0 |
Expl. 1.1 Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 3 |
H201 H330 H310 H300 H373 ** H412 |
GHS01 GHS06 GHS08 Dgr |
H201 H330 H310 H300 H373 ** H412 |
|
|
|
|
603-034-00-X |
triazotan(V) glicerolu; nitrogliceryna |
200-240-8 |
55-63-0 |
Unst. Expl. Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 2 |
H200 H330 H310 H300 H373 ** H411 |
GHS01 GHS06 GHS08 GHS09 Dgr |
H200 H330 H310 H300 H373 ** H411 |
|
|
|
|
603-034-01-7 |
triazotan(V) glicerolu; nitrogliceryn; [>40 % flegmatyzatora] |
200-240-8 |
55-63-0 |
Expl. 1.1 Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 2 |
H201 H330 H310 H300 H373 ** H411 |
GHS01 GHS06 GHS08 GHS09 Dgr |
H201 H330 H310 H300 H373 ** H411 |
|
|
|
|
603-035-00-5 |
tetraazotan(V) pentaerytrytolu; tetraazotan(V) pentaerytrytu; pentryt |
201-084-3 |
78-11-5 |
Unst. Expl. |
H200 |
GHS01 Dgr |
H200 |
|
|
|
|
603-035-01-2 |
tetraazotan(V) pentaerytrytolu; tetraazotan(V) pentaerytrytu; pentryt; [>20 % flegmatyzatora] |
201-084-3 |
78-11-5 |
Expl. 1.1 |
H201 |
GHS01 Dgr |
H201 |
|
|
T |
|
603-036-00-0 |
heksaazotan(V) heksano-1,2,3,4,5,6-heksaolu; nitromannit; heksaazotan(V) mannitu |
239-924-6 |
15825-70-4 |
Unst. Expl. |
H200 |
GHS01 Dgr |
H200 |
|
|
|
|
603-036-01-8 |
heksaazotan(V) heksano-1,2,3,4,5,6-heksaolu; nitromannit; heksaazotan(V) mannitu; [>40 % flegmatyzatora] |
239-924-6 |
15825-70-4 |
Expl. 1.1 |
H201 |
GHS01 Dgr |
H201 |
|
|
|
|
603-037-00-6 |
azotan celulozy; nitroceluloza |
— |
— |
Expl. 1.1 |
H201 |
GHS01 Dgr |
H201 |
|
|
T |
|
603-038-00-1 |
eter allilowo-glicydowy; 3-(2,3-epoksypropoksy)propen; eter prop-2-en-1-ylo-2,3-epoksypropylowy |
203-442-4 |
106-92-3 |
Flam. Liq. 3 Carc. 2 Muta. 2 Repr. 2 Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H226 H351 H341 H361f *** H332 H302 H335 H315 H318 H317 H412 |
GHS02 GHS08 GHS05 GHS07 Dgr |
H226 H351 H341 H361f *** H332 H302 H335 H315 H318 H317 H412 |
|
|
|
|
603-039-00-7 |
eter butylowo-glicydowy; 1-butoksy-2,3-epoksypropan |
219-376-4 |
2426-08-6 |
Flam. Liq. 3 Carc. 2 Muta. 2 Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Sens. 1 Aquatic Chronic 3 |
H226 H351 H341 H332 H302 H335 H317 H412 |
GHS02 GHS08 GHS07 Wng |
H226 H351 H341 H332 H302 H335 H317 H412 |
|
|
|
|
603-040-00-2 |
metanolan sodu; metoksylan sodu; [1] metanolan potasu; metoksylan potasu; [2] metanolan litu; metoksylan litu [3] |
204-699-5 [1] 212-736-1 [2] 212-737-7 [3] |
124-41-4 [1] 865-33-8 [2] 865-34-9 [3] |
Self-heat 1 Skin Corr. 1B |
H251 H314 |
GHS02 GHS05 Dgr |
H251 H314 |
EUH014 |
|
T |
|
603-041-00-8 |
etanolan potasu; etoksylan potasu; [1] etanolan sodu; etoksylan sodu [2] |
213-029-0 [1] 205-487-5 [2] |
917-58-8 [1] 141-52-6 [2] |
Self-heat 1 Skin Corr. 1B |
H251 H314 |
GHS02 GHS05 Dgr |
H251 H314 |
EUH014 |
|
T |
|
603-042-00-3 |
triizopropanolan glinu; triizopropoksylan glinu |
209-090-8 |
555-31-7 |
Flam. Sol. 1 |
H228 |
GHS02 Dgr |
H228 |
|
|
T |
|
603-043-00-9 |
triarymol (ISO); alkohol 2,4'-dichloro-α-(pirymidyn-5-ylo)benzhydrylowy |
— |
26766-27-8 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
603-044-00-4 |
dikofol (ISO); 2,2,2-trichloro-1,1-bis(4-chlorofenylo)etanol |
204-082-0 |
115-32-2 |
Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H315 H317 H400 H410 |
GHS07 GHS09 Wng |
H312 H302 H315 H317 H410 |
|
|
|
|
603-045-00-X |
eter diizopropylowy; [1] eter dipropylowy [2] |
203-560-6 [1] 203-869-6 [2] |
108-20-3 [1] 111-43-3 [2] |
Flam. Liq. 2 STOT SE 3 |
H225 H336 |
GHS02 GHS07 Dgr |
H225 H336 |
EUH019 EUH066 |
|
C |
|
603-046-00-5 |
eter bis(chlorometylowy); oksybis(chlorometan) |
208-832-8 |
542-88-1 |
Flam. Liq. 2 Carc. 1A Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 4 * |
H225 H350 H330 H311 H302 |
GHS02 GHS06 GHS08 Dgr |
H225 H350 H330 H311 H302 |
|
Carc. 1A; H350: C ≥ 0,001 % |
|
|
603-047-00-0 |
2-(dimetyloamino)etanol; N,N-dimetyloetanoloamina |
203-542-8 |
108-01-0 |
Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B |
H226 H332 H312 H302 H314 |
GHS02 GHS05 GHS07 Dgr |
H226 H332 H312 H302 H314 |
|
STOT SE 3; H335: C≥5 % |
|
|
603-048-00-6 |
2-(dietyloamino)etanol; N,N-dietyloetanoloamina |
202-845-2 |
100-37-8 |
Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B |
H226 H332 H312 H302 H314 |
GHS02 GHS05 GHS07 GHS09 Dgr |
H226 H332 H312 H302 H314 |
|
STOT SE 3; H335: C≥5 % |
|
|
603-049-00-1 |
chlorofenetol (ISO); 1,1-bis(4-chlorofenylo)etanol |
201-246-3 |
80-06-8 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
603-050-00-7 |
1-(2-butoksypropoksy)propan-2-ol |
246-011-6 |
24083-03-2 |
Acute Tox. 4 * Acute Tox. 4 * |
H312 H302 |
GHS07 Wng |
H312 H302 |
|
|
|
|
603-051-00-2 |
2-etylobutan-1-ol; alkohol 2-etylobutylowy |
202-621-4 |
97-95-0 |
Acute Tox. 4 * Acute Tox. 4 * |
H312 H302 |
GHS07 Wng |
H312 H302 |
|
|
|
|
603-052-00-8 |
3-butoksypropan-2-ol; eter monobutylowy glikolu propylenowego |
225-878-4 |
5131-66-8 |
Eye Irrit. 2 Skin Irrit. 2 |
H319 H315 |
GHS07 Wng |
H319 H315 |
|
|
|
|
603-053-00-3 |
2-metylopentano-2,4-diol; glikol heksylenowy |
203-489-0 |
107-41-5 |
Eye Irrit. 2 Skin Irrit. 2 |
H319 H315 |
GHS07 Wng |
H319 H315 |
|
|
|
|
603-054-00-9 |
eter di-n-butylowy; eter dibutylowy |
205-575-3 |
142-96-1 |
Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Chronic 3 |
H226 H319 H335 H315 H412 |
GHS02 GHS07 Wng |
H226 H319 H335 H315 H412 |
|
STOT SE 3; H335: C≥10 % |
|
|
603-056-00-X |
[(p-toliloksy)metylo]oksiran; eter 2,3-epoksypropylowo-p-tolilowy; eter glicydowo-p-tolilowy; [1] [(m-toliloksy)metylo]oksiran; eter 2,3-epoksypropylowo-m-tolilowy; eter glicydowo-m-tolilowy; [2] eter 2,3-epoksypropylowo-o-tolilowy; eter glicydowo-o-tolilowy; [3] [(toliloksy)metylo]oksiran; 1,2-epoksy-3-(metylofenoksy)propan; eter glicydowo-tolilowy [4] |
218-574-8 [1] 218-575-3 [2] 218-645-3 [3] 247-711-4 [4] |
2186-24-5 [1] 2186-25-6 [2] 2210-79-9 [3] 26447-14-3 [4] |
Muta. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H341 H315 H317 H411 |
GHS08 GHS07 GHS09 Wng |
H341 H315 H317 H411 |
|
|
C |
|
603-057-00-5 |
fenylometanol; alkohol benzylowy; fenylokarbinol |
202-859-9 |
100-51-6 |
Acute Tox. 4 * Acute Tox. 4 * |
H332 H302 |
GHS07 Wng |
H332 H302 |
|
|
|
|
603-058-00-0 |
1,3-epoksypropan |
207-964-3 |
503-30-0 |
Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H225 H332 H312 H302 |
GHS02 GHS07 Dgr |
H225 H332 H312 H302 |
|
|
|
|
603-059-00-6 |
heksan-1-ol; alkohol heksylowy |
203-852-3 |
111-27-3 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
603-060-00-1 |
2,2'-bioksiran; 1,2:3,4-diepoksybutan; ditlenek butadienu |
215-979-1 |
1464-53-5 |
Carc. 1B Muta. 1B Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B |
H350 H340 H330 H311 H301 H314 |
GHS06 GHS08 GHS05 Dgr |
H350 H340 H330 H311 H301 H314 |
|
|
|
|
603-061-00-7 |
tetrahydro-2-furylometanol; alkohol tetrahydrofurfurylowy; 2-(hydroksymetylo)oksolan |
202-625-6 |
97-99-4 |
Repr. 1B Eye Irrit. 2 |
H360Df H319 |
GHS08 GHS07 Dgr |
H360Df H319 |
|
|
|
|
603-062-00-2 |
tetrahydrofurano-2,5-diylodimetanol; 2,5-bis(hydroksymetylo)oksolan; 2,5-bis(hydroksymetylo)tetrahydrofuran |
203-239-0 |
104-80-3 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H319 H335 H315 |
GHS07 Wng |
H319 H335 H315 |
|
STOT SE 3; H335: C ≥10 % |
|
|
603-063-00-8 |
2,3-epoksypropan-1-ol; alkohol glicydowy; oksiranylometanol; glicydol |
209-128-3 |
556-52-5 |
Carc. 1B Muta. 2 Repr. 1B Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H350 H341 H360F *** H331 H312 H302 H319 H335 H315 |
GHS06 GHS08 Dgr |
H350 H341 H360F *** H331 H312 H302 H319 H335 H315 |
|
|
|
|
603-064-00-3 |
1-metoksypropan-2-ol; eter monometylowy glikolu propylenowego |
203-539-1 |
107-98-2 |
Flam. Liq. 3 STOT SE 3 |
H226 H336 |
GHS02 GHS07 Wng |
H226 H336 |
|
|
|
|
603-065-00-9 |
eter diglicydowy rezorcynolu; eter diglicydowy rezorcyny; 1,3-bis(2,3-epoksypropoksy)benzen |
202-987-5 |
101-90-6 |
Carc. 2 Muta. 2 Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 |
H351 H341 H312 H302 H319 H315 H317 H412 |
GHS08 GHS07 Wng |
H351 H341 H312 H302 H319 H315 H317 H412 |
|
|
|
|
603-066-00-4 |
1,2-epoksy-4-(epoksyetylo)cykloheksan; diepoksy-4-winylocykloheksen |
203-437-7 |
106-87-6 |
Carc. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * |
H351 H331 H311 H301 |
GHS06 GHS08 Dgr |
H351 H331 H311 H301 |
|
* |
|
|
603-067-00-X |
eter fenylowo-glicydowy; eter 2,3-epoksypropylowo-fenylowy; 1,2-epoksy-3-fenoksypropan |
204-557-2 |
122-60-1 |
Carc. 1B Muta. 2 Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 |
H350 H341 H332 H335 H315 H317 H412 |
GHS08 GHS07 Dgr |
H350 H341 H332 H335 H315 H317 H412 |
|
|
|
|
603-068-00-5 |
1,2-epoksy-3-(2-etylocykloheksanoksy)propan; eter 2-etylocykloheksanowo-glicydowy |
— |
130014-35-6 |
Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H319 H315 H317 |
GHS07 Wng |
H319 H315 H317 |
|
|
|
|
603-069-00-0 |
2,4,6-tris(dimetyloaminometylo)fenol |
202-013-9 |
90-72-2 |
Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 |
H302 H319 H315 |
GHS07 Wng |
H302 H319 H315 |
|
|
|
|
603-070-00-6 |
2-amino-2-metylopropan-1-ol; izobutanoloamina |
204-709-8 |
124-68-5 |
Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 3 |
H319 H315 H412 |
GHS07 Wng |
H319 H315 H412 |
|
|
|
|
603-071-00-1 |
2,2'-iminodietanol; dietanoloamina |
203-868-0 |
111-42-2 |
Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 |
H302 H373 ** H315 H318 |
GHS08 GHS05 GHS07 Dgr |
H302 H373 ** H315 H318 |
|
|
|
|
603-072-00-7 |
1,4-bis(2,3-epoksypropoksy)butan; eter diglicydowy butano-1,4-diolu |
219-371-7 |
2425-79-8 |
Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H332 H312 H319 H315 H317 |
GHS07 Wng |
H332 H312 H319 H315 H317 |
|
|
|
|
603-073-00-2 |
2,2-bis[4-(2,3-epoksypropoksy)fenylo]propan |
216-823-5 |
1675-54-3 |
Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H319 H315 H317 |
GHS07 Wng |
H319 H315 H317 |
|
Eye Irrit. 2; H319: C≥ 5 % Skin Irrit. 2; H315: C≥5 % |
|
|
603-074-00-8 |
produkt reakcji: bisfenol A z epichlorohydryną; żywica epoksydowa (średnia masa cząsteczkowa ≤ 700) |
500-033-5 |
25068-38-6 |
Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H319 H315 H317 H411 |
GHS07 GHS09 Wng |
H319 H315 H317 H411 |
|
Eye Irrit. 2; H319: C ≥ 5 % Skin Irrit 2; H315: C≥ 5 % |
|
|
603-075-00-3 |
eter chlorometylowo-metylowy; chloro(metoksy)metan |
203-480-1 |
107-30-2 |
Flam. Liq. 2 Carc. 1A Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H225 H350 H332 H312 H302 |
GHS02 GHS08 GHS07 Dgr |
H225 H350 H332 H312 H302 |
|
|
|
|
603-076-00-9 |
but-2-yno-1,4-diol; 2-butyno-1,4-diol |
203-788-6 |
110-65-6 |
Skin Corr. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 |
H314 H331 H301 H312 H373 ** H317 |
GHS06 GHS05 GHS08 Dgr |
H314 H331 H301 H312 H373 ** H317 |
|
Skin Corr. 1B; H314: C≥50 % Skin Irrit. 2; H315: 25 %≤ C < 50 % Eye Irrit. 2; H319: 25 %≤ C<50 % |
D |
|
603-077-00-4 |
1-(dimetyloamino)propan-2-ol; dimepranol (INN); N, N-dimetyloizopropanoloamina |
203-556-4 |
108-16-7 |
Flam. Liq. 3 Acute Tox. 4 * Skin Corr. 1B |
H226 H302 H314 |
GHS02 GHS05 GHS07 Dgr |
H226 H302 H314 |
|
|
|
|
603-078-00-X |
prop-2-yn-1-ol; alkohol propargilowy |
203-471-2 |
107-19-7 |
Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Aquatic Chronic 2 |
H226 H331 H311 H301 H314 H411 |
GHS02 GHS06 GHS05 GHS09 Dgr |
H226 H331 H311 H301 H314 H411 |
|
|
|
|
603-079-00-5 |
2,2'-metyloiminodietanol; N-metylodietanoloamina; |
203-312-7 |
105-59-9 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
603-080-00-0 |
2-(metyloamino)etanol; N-metyloetanoloamina; N-metylo-2-etanoloamina N-metylo-2-aminoetanol |
203-710-0 |
109-83-1 |
Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B |
H312 H302 H314 |
GHS05 GHS07 Dgr |
H312 H302 H314 |
|
STOT SE 3; H335: C≥5 % |
|
|
603-081-00-6 |
2,2'-sulfanodiylodietanol; tiodiglikol; 2,2'-tiodietanol; siarczek di(2-hydroksyetylu) |
203-874-3 |
111-48-8 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
603-082-00-1 |
1-aminopropan-2-ol; izopropanoloamina |
201-162-7 |
78-96-6 |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
|
|
|
|
603-083-00-7 |
1,1'-iminodipropan-2-ol; diizopropanoloamina |
203-820-9 |
110-97-4 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
603-084-00-2 |
tlenek styrenu; (epoksyetylo)benzen; fenylooksiran |
202-476-7 |
96-09-3 |
Carc. 1B Acute Tox. 4 * Eye Irrit. 2 |
H350 H312 H319 |
GHS08 GHS07 Dgr |
H350 H312 H319 |
|
|
|
|
603-085-00-8 |
bronopol (INN); 2-bromo-2-nitropropano-1,3-diol |
200-143-0 |
52-51-7 |
Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 |
H312 H302 H335 H315 H318 H400 |
GHS05 GHS07 GHS09 Dgr |
H312 H302 H335 H315 H318 H400 |
|
M=10 |
|
|
603-086-00-3 |
etyrymol (ISO); 5-butylo-2-etyloamino-6-metylopirymidyn-4-ol |
245-949-3 |
23947-60-6 |
Acute Tox. 4 * |
H312 |
GHS07 Wng |
H312 |
|
|
|
|
603-087-00-9 |
2-etyloheksano-1,3-diol; glikol oktylenowy |
202-377-9 |
94-96-2 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
603-088-00-4 |
2-(oktylosulfanylo)etanol; sulfid 2-hydroksyetylowo-oktylowy |
222-598-4 |
3547-33-9 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
603-089-00-X |
7,7-dimetylo-3-oksa-6-azaoktan-1-ol |
400-390-6 |
— |
Skin Corr. 1A Acute Tox. 4 * |
H314 H302 |
GHS05 GHS07 Dgr |
H314 H302 |
|
|
|
|
603-090-00-5 |
2-(2-bromoetoksy)anizol |
402-010-4 |
4463-59-6 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
603-091-00-0 |
egzo-1-metylo-4-(1-metyloetylo)-7-oksabicyklo[2.2.1]heptan-2-ol; egzo-4-izopropylo-1-metylo-1,4-epoksycykloheksan-2-ol |
402-470-6 |
87172-89-2 |
Acute Tox. 4 * Eye Dam. 1 |
H302 H318 |
GHS05 GHS07 Dgr |
H302 H318 |
|
|
|
|
603-092-00-6 |
2-metylo-4-fenylopentanol |
402-770-7 |
92585-24-5 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
603-093-00-1 |
cinmetylina (ISO); egzo-(±)-1-metylo-4-(1-metyloetylo)-2-[(2-metylofenylo)metoksy]-7-oksabicyklo[2.2.1]heptan; egzo-(±)-4-izopropylo-1-metylo-2-(2-metylobenzyloksy)-1,4-epoksycykloheksan |
402-410-9 |
87818-31-3 |
Acute Tox. 4 * Aquatic Chronic 2 |
H332 H411 |
GHS07 GHS09 Dgr |
H332 H411 |
|
|
|
|
603-094-00-7 |
1,3-bis(2,3-epoksypropoksy)-2,2-dimetylopropan |
241-536-7 |
17557-23-2 |
Skin Irrit. 2 Skin Sens. 1 |
H315 H317 |
GHS07 Wng |
H315 H317 |
|
|
|
|
603-095-00-2 |
2-propoksyetanol; eter monopropylowy glikolu etylenowego |
220-548-6 |
2807-30-9 |
Acute Tox. 4 * Eye Irrit. 2 |
H312 H319 |
GHS07 Wng |
H312 H319 |
|
|
|
|
603-096-00-8 |
2-(2-butoksyetoksy)etanol; eter monobutylowy glikolu dietylenowego |
203-961-6 |
112-34-5 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
603-097-00-3 |
1,1',1''-nitrylotripropan-2-ol; triizopropanoloamina |
204-528-4 |
122-20-3 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
603-098-00-9 |
2-fenoksyetanol; eter monofenylowy glikolu etylenowego |
204-589-7 |
122-99-6 |
Acute Tox. 4 * Eye Irrit. 2 |
H302 H319 |
GHS07 Wng |
H302 H319 |
|
|
|
|
603-099-00-4 |
chlorowodorek 3-[N-metylo-N-(4-metyloamino-3-nitrofenylo)amino]propano-1,2-diolu |
403-440-5 |
93633-79-5 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
603-100-00-8 |
1,2-dimetoksypropan |
404-630-0 |
7778-85-0 |
Flam. Liq. 2 |
H225 |
GHS02 Dgr |
H225 |
EUH019 |
|
|
|
603-101-00-3 |
2-izobutylo-4-metylotetrahydropiran-4-ol, mieszanina izomerów cis i trans |
405-040-6 |
— |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
603-103-00-4 |
pochodne mono[(C12-14-alkiloksy)metylowe] oksiranu; [(C12-14-alkiloksy)metylo]oksiran; eter (C12-14-alkilowo)-glicydowy. |
271-846-8 |
68609-97-2 |
Skin Irrit. 2 Skin Sens. 1 |
H315 H317 |
GHS07 Wng |
H315 H317 |
|
|
|
|
603-104-00-X |
fenarymol (ISO); alkohol 2,4'-dichloro-α-(pirymidyn-5-ylo)benzhydrylowy |
262-095-7 |
60168-88-9 |
Repr. 2 Lact. Aquatic Chronic 2 |
H361fd H362 H411 |
GHS08 GHS09 Wng |
H361fd H362 H411 |
|
|
|
|
603-105-00-5 |
furan |
203-727-3 |
110-00-9 |
Flam. Liq. 1 Carc. 1B Muta. 2 Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Aquatic Chronic 3 |
H224 H350 H341 H332 H302 H373 ** H315 H412 |
GHS02 GHS08 GHS07 Dgr |
H224 H350 H341 H332 H302 H373 ** H315 H412 |
EUH019 |
|
|
|
603-106-00-0 |
2-metoksypropan-1-ol |
216-455-5 |
1589-47-5 |
Flam. Liq. 3 Repr. 1B STOT SE 3 Skin Irrit. 2 Eye Dam. 1 |
H226 H360D *** H335 H315 H318 |
GHS02 GHS08 GHS05 GHS07 Dgr |
H226 H360D *** H335 H315 H318 |
|
|
|
|
603-107-00-6 |
2-(2-metoksyetoksy)etanol; eter monometylowy glikolu dietylenowego; 3,6-dioksaheptan-1-on |
203-906-6 |
111-77-3 |
Repr. 2 |
H361d *** |
GHS08 Wng |
H361d *** |
|
|
|
|
603-108-00-1 |
2-metylopropan-1-ol; izobutanol; alkohol izobutylowy |
201-148-0 |
78-83-1 |
Flam. Liq. 3 STOT SE 3 Skin Irrit. 2 Eye Dam. 1 STOT SE 3 |
H226 H335 H315 H318 H336 |
GHS02 GHS05 GHS07 Dgr |
H226 H335 H315 H318 H336 |
|
|
|
|
603-109-00-7 |
masa poreakcyjna: 1-etoksy-1,1,2,3,3,3-heksafluoro-2-(trifluorometylo)propanu; 1-etoksy-1,1,2,2,3,3,4,4,4-nonafluorobutanu |
425-340-0 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
603-110-00-2 |
masa poreakcyjna: cis-2-izobutylo-5-metylo 1,3-dioksanu; trans-2-izobutylo-5-metylo 1,3-dioksanu |
426-130-1 |
166301-21-9 |
Skin Irrit. 2 Aquatic Chronic 3 |
H315 H412 |
GHS07 Wng |
H315 H412 |
|
|
|
|
603-111-00-8 |
masa poreakcyjna: 1-(1,1-dimetylopropylo)-4-etoksy-cis-cykloheksanu; 1-(1,1-dimetylopropylo)-4-etoksy-trans-cykloheksanu |
426-530-6 |
— |
Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H400 H410 |
GHS07 GHS09 Wng |
H315 H410 |
|
|
|
|
603-112-00-3 |
2-fenyloetoksycyklopentan; eter cyklopentylowo-2-fenyloetylowy |
428-340-9 |
— |
Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H400 H410 |
GHS07 GHS09 Wng |
H315 H410 |
|
|
|
|
603-113-00-9 |
6-glicydyloksynaf-1-ylo oksymetylooksiran |
429-960-2 |
27610-48-6 |
Muta. 2 Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 |
H341 H312 H315 H317 H412 |
GHS08 GHS07 Wng |
H341 H312 H315 H317 H412 |
|
|
|
|
603-114-00-4 |
9-(2-propenyloksy)tricyklo[5.2.1.0(2,6)]dek-3(lub-4-)-en |
430-830-2 |
26912-64-1 |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
603-115-00-X |
masa poreakcyjna: O, O',O''-(metylosilanotriylo)tris(4-metylo-2-pentanono oksymu) (3 stereoizomery); |
423-580-0 |
— |
STOT RE 2 * Aquatic Chronic 4 |
H373** H413 |
GHS08 Wng |
H373** H413 |
|
|
|
|
603-116-00-5 |
monochlorowodorek (Z)-(2,4-difluorofenylo)piperydyn-4-ylometanono oksymu |
424-740-2 |
138271-16-6 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H302 H318 H412 |
GHS05 GHS07 Dgr |
H302 H318 H412 |
|
|
|
|
603-117-00-0 |
propan-2-ol; alkohol izopropylowy; izopropanol |
200-661-7 |
67-63-0 |
Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 |
H225 H319 H336 |
GHS02 GHS07 Dgr |
H225 H319 H336 |
|
|
|
|
603-118-00-6 |
6-dimetyloaminoheksan-1-ol |
404-680-3 |
1862-07-3 |
Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 3 |
H302 H314 H412 |
GHS05 GHS07 Dgr |
H302 H314 H412 |
|
|
|
|
603-119-00-1 |
1,1'-(1,3-fenylenodioksy)bis{3-[2-(prop-2-en-1-ylo)fenoksy]propan-2-ol} |
405-840-5 |
— |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
603-120-00-7 |
2-metylo-5-fenylopentan-1-ol |
405-890-8 |
25634-93-9 |
Eye Irrit. 2 Skin Irrit. 2 |
H319 H315 |
GHS07 Wng |
H319 H315 |
|
|
|
|
603-121-00-2 |
4-[4-(1,3-dihydroksypropan-2-ylo)fenyloamino]-1,8-dihydroksy-5-nitroantrachinon |
406-057-1 |
114565-66-1 |
Carc. 2 Skin Sens. 1 Aquatic Chronic 4 |
H351 H317 H413 |
GHS08 GHS07 Wng |
H351 H317 H413 |
|
|
|
|
603-122-00-8 |
2-etyloheksan-1-olan sodu |
406-150-7 |
38411-13-1 |
Flam. Sol. 1 Skin Corr. 1B Aquatic Chronic 3 |
H228 H314 H412 |
GHS02 GHS05 Dgr |
H228 H314 H412 |
|
|
T |
|
603-123-00-3 |
4-metylo-8-metylidenotricyklo[3.3.1.13,7]dekan-2-ol |
406-330-5 |
122760-84-3 |
Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H315 H317 H411 |
GHS07 GHS09 Wng |
H315 H317 H411 |
|
|
|
|
603-124-00-9 |
1,4-bis[2-(winyloksy)etoksy]benzen |
406-900-3 |
84563-49-5 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
603-125-00-4 |
2-(2,4-dichlorofenylo)-1-(1H—1,2,4-triazol-1-ilo)pent-4-en-2-ol |
407-850-5 |
89544-40-1 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|
|
|
|
603-126-00-X |
2-[(4-metylo-2-nitrofenylo)amino]etanol |
408-090-7 |
100418-33-5 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 |
H302 H317 H412 |
GHS07 Wng |
H302 H317 H412 |
|
|
|
|
603-127-00-5 |
butan-2-ol; [1] (S)-butan-2-ol; [2] (R)-butan-2-ol; [3] (±)-butan-2-ol [4] |
201-158-5 [1] 224-168-1 [2] 238-967-8 [3] 240-029-8 [4] |
78-92-2 [1] 4221-99-2 [2] 14898-79-4 [3] 15892-23-6 [4] |
Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 STOT SE 3 |
H226 H319 H335 H336 |
GHS02 GHS07 Wng |
H226 H319 H335 H336 |
|
|
C |
|
603-128-00-0 |
2-(fenylometoksy)naftalen |
405-490-3 |
613-62-7 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
603-129-00-6 |
1-tert-butoksypropan-2-ol |
406-180-0 |
57018-52-7 |
Flam. Liq. 3 Eye Dam. 1 |
H226 H318 |
GHS02 GHS05 Dgr |
H226 H318 |
|
|
|
|
603-130-00-1 |
masa poreakcyjna izomerów: α-[(dimetylo)bifenylo]-ω-hydroksypoli(oksyetylenu) |
406-325-8 |
— |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
603-131-00-7 |
masa poreakcyjna: 1-dezoksy-1-[metylo(1-oksododecylo)amino]-D-glucitolu; 1-dezoksy-1-[metylo(1-oksotetradecylo)amino]-D-glucitolu (3:1) |
407-290-1 |
— |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
603-132-00-2 |
2-hydroksymetylo-9-metylo-6-(1-metyloetylo)-1,4-dioksaspiro[4.5]dekan |
408-200-3 |
63187-91-7 |
Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 |
H315 H318 H412 |
GHS05 Dgr |
H315 H318 H412 |
|
|
|
|
603-133-00-8 |
masa poreakcyjna: 3-[(4-amino-2-chloro-5-nitrofenylo)amino]propano-1,2-diolu; 3,3'-(2-chloro-5-nitro-1,4-fenylenodiimino)bis(propano-1,2-diolu) |
408-240-1 |
— |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
603-134-00-3 |
masa poreakcyjna podstawionych dodecylem i/lub tetradecylem eterów difenylowych. Produkt reakcji Friedela Craftsa. Katalizator jest usuwany z produktu. Eter difenylowy jest podstawiony grupami alkilowymi C1-C10. Grupy alkilowe są rozłożone losowo pomiędzy węgle C1 i C6. Stosuje się grupy o prostym łańcuchu węglowym zawierające 12 i 14 atomów węgla w stosunku 50/50. |
410-450-3 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
603-135-00-9 |
bis{[2,2',2''-nitrylotris(etanolano)]-1-N, O}bis[2-(2-metoksyetoksy)etoksy]tytan |
410-500-4 |
— |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|
|
|
|
603-136-00-4 |
3-({4-[bis(2-hydroksyetylo)amino]-2-nitrofenylo}amino)propan-1-ol |
410-910-3 |
104226-19-9 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
603-137-00-X |
masa poreakcyjna: 1-dezoksy-1-[metylo(1-oksoheksadecylo)amino]-D-glucitolu; 1-deoksy-1-[metylo-(1-oksooktadecylo)amino]-D-glucitolu |
411-130-6 |
— |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
603-138-00-5 |
3-(2,2-dimetylo-3-hydroksypropylo)toluen; 2,2-dimetylo-3-(3-metylofenylo)propan-1-ol |
403-140-4 |
103694-68-4 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
603-139-00-0 |
eter bis(2-metoksyetylowy) |
203-924-4 |
111-96-6 |
Flam. Liq. 3 Repr. 1B |
H226 H360FD |
GHS02 GHS08 Dgr |
H226 H360FD |
EUH019 |
|
|
|
603-140-00-6 |
2,2'-oksybisetanol; glikol dietylenowy |
203-872-2 |
111-46-6 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
603-141-00-1 |
masa poreakcyjna: dodecyloksy-1-metylo-1-[oksypoli(2-hydroksymetyloetanoksy)]pentadekanu; dodecyloksy-1-metylo-1-[oksypoli(2-hydroksymetyloetanoksy)]heptadekanu |
413-780-6 |
— |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
603-142-00-7 |
2-[2-(2-hydroksyetoksy)etylo]-2-azabicyklo[2.2.1]heptan |
407-360-1 |
116230-20-7 |
Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 |
H312 H302 H373 ** H315 H318 |
GHS06 GHS08 GHS05 Dgr |
H312 H302 H373 ** H315 H318 |
|
|
|
|
603-143-00-2 |
R-2,3-epoksypropan-1-ol |
404-660-4 |
57044-25-4 |
Self-react. C **** Carc. 1B Muta. 2 Repr. 1B Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B |
H242 H350 H341 H360F *** H331 H312 H302 H314 |
GHS02 GHS06 GHS08 GHS05 Dgr |
H242 H350 H341 H360F *** H331 H312 H302 H314 |
|
|
|
|
603-144-00-8 |
masa poreakcyjna: 2,6,9-trimetylocyklododeka-2,5,9-trien-1-olu; 6,9-dimetylo-2-metylenocyklododeka-5,9-dien-1-olu |
413-530-6 |
111850-00-1 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
603-145-00-3 |
2-izopropylo-2-(1-metylobutylo)-1,3-dimetoksypropan |
406-970-5 |
129228-11-1 |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
603-146-00-9 |
2-({2-[2-(dimetyloamino)etoksy]etylo}metyloamino)etanol |
406-080-7 |
83016-70-0 |
Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 3 |
H302 H314 H412 |
GHS05 GHS07 Dgr |
H302 H314 H412 |
|
|
|
|
603-147-00-4 |
(-)-trans-4-(4'-fluorofenylo)-3-hydroksymetylo-N-metylopiperydyna |
406-030-4 |
105812-81-5 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|
|
|
|
603-148-00-X |
1,4-bis[(winyloksy)metylo]cykloheksan |
413-370-7 |
17351-75-6 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
603-149-00-5 |
masa poreakcyjna: diastereoizomerów 1-(1-hydroksyetylo)-4-(1-metyloetylo)cykloheksanu |
407-640-3 |
63767-86-2 |
Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 |
H319 H315 H411 |
GHS07 GHS09 Wng |
H319 H315 H411 |
|
|
|
|
603-150-00-0 |
(±)-trans-3,3-dimetylo-5-(2,2,3-trimetylocyklopent-3-en-1-ylo)pent-4-en-2-ol |
411-580-3 |
107898-54-4 |
Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H400 H410 |
GHS07 GHS09 Wng |
H315 H410 |
|
|
|
|
603-151-00-6 |
(±)-2-(2,4-dichlorofenylo)-3-(1H-1,2,4-triazol-1-ilo)propan-1-ol |
413-570-4 |
— |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
603-152-00-1 |
2-(4-tert-butylofenylo)etanol |
410-020-5 |
5406-86-0 |
Repr. 2 STOT RE 2 * Eye Dam. 1 Aquatic Chronic 2 |
H361f *** H373 ** H318 H411 |
GHS08 GHS05 GHS09 Dgr |
H361f *** H373 ** H318 H411 |
|
|
|
|
603-153-00-7 |
3-{[2-nitro-4-(trifluorometylo)fenylo]amino}propano-1,2-diol |
410-010-0 |
104333-00-8 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
603-154-00-2 |
1-[(2-tert-butylo)cykloheksyloksy]butan-2-ol |
412-300-2 |
139504-68-0 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
603-156-00-3 |
2-(2,4-dichlorofenylo)-2-allilooksiran; 2-(2,4-dichlorofenylo)-2-(prop-2-en-1-ylo)oksiran |
411-210-0 |
89544-48-9 |
Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H317 H400 H410 |
GHS07 GHS09 Wng |
H315 H317 H410 |
|
|
|
|
603-157-00-9 |
6,9-bis(heksadecyloksymetylo)-4,7-dioksanonano-1,2,9-triol |
411-450-6 |
143747-72-2 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
603-158-00-4 |
masa poreakcyjna: 4 diastereoizomerów 2,7-dimetylo-10-(1-metyloetylo)-1-oksaspiro[4.5]deka-3,6-dienu |
412-460-3 |
— |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
603-159-00-X |
2-cyklododecylopropan-1-ol |
411-410-8 |
118562-73-5 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
603-160-00-5 |
1,2-dietoksypropan |
412-180-1 |
10221-57-5 |
Flam. Liq. 2 |
H225 |
GHS02 Dgr |
H225 |
EUH019 |
|
|
|
603-161-00-0 |
1,3-dietoksypropan |
413-140-6 |
3459-83-4 |
Flam. Liq. 3 |
H226 |
GHS02 Wng |
H226 |
|
|
|
|
603-162-00-6 |
α-[2-({[(2-hydroksyetylo)metyloamino]acetylo}amino)propylo]-ω-(nonylofenoksy)poli[okso(metyloetano-1,2-diyl)] |
413-420-8 |
144736-29-8 |
Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 |
H314 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H314 H317 H411 |
|
|
|
|
603-163-00-1 |
2-fenylopropano-1,3-diol |
411-810-2 |
1570-95-2 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
603-164-00-7 |
2-butylo-4-chloro-5-hydroksymetylo-1-[2'-(2-trifenylometylo-2H-1,2,3,4-tetrazol-5-ilo)-1,1'-bifenylo-4-metylo]-4,5-dihydro-1H-imidazol |
412-420-5 |
133909-99-6 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
603-165-00-2 |
masa poreakcyjna: 4-allilo-2,6-bis(2,3-epoksypropylo)fenolu; 4-allilo-6-(3-{6-[3-(6-{3-[4-allilo-2,6-bis(2,3-epoksypropylo)fenoksy]-2-hydroksypropylo}-4-allilo-2-(2,3-epoksypropylo)fenoksy)-2-hydroksypropylo]-4-allilo-2-(2,3-epoksypropylo)fenoksy}-2-hydroksypropylo)-2-(2,3-epoksypropylo)fenolu; 4-allilo-6-{3-[4-allilo-2,6-bis(2,3-epoksypropylo)fenoksy]-2-hydroksypropylo}-2-(2,3-epoksypropylo)fenolu; 4-allilo-6-[3-(6-{3-[4-allilo-2,6-bis-(2,3-epoksypropylo)fenoksy]-2-hydroksypropylo}-4-allilo-2-(2,3-epoksypropylo)fenoksy)-2-hydroksypropylo]-2-(2,3-epoksypropylo)fenolu |
417-470-1 |
— |
Muta. 2 Skin Sens. 1 |
H341 H317 |
GHS08 GHS07 Wng |
H341 H317 |
|
|
|
|
603-166-00-8 |
R-1-chloro-2,3-epoksypropan |
424-280-2 |
51594-55-9 |
Flam. Liq. 3 Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 |
H226 H350 H331 H311 H301 H314 H317 |
GHS02 GHS06 GHS08 GHS05 Dgr |
H226 H350 H331 H311 H301 H314 H317 |
|
|
|
|
603-167-00-3 |
3,3',5,5'-tetra-tert-butylobifenylo-2,2'-diol |
407-920-5 |
6390-69-8 |
Aquatic Chronic 4 |
H413 |
GHS05 Dgr |
H413 |
|
|
|
|
603-168-00-9 |
3-(2-etyloheksyloksy)propano-1,2-diol |
408-080-2 |
70445-33-9 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
603-169-00-4 |
(±)-trans-4-(4-fluorofenylo)-3-hydroksymetylo-N-metylopiperydyna |
415-550-0 |
109887-53-8 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|
|
|
|
603-170-00-X |
masa poreakcyjna: 2-metylo-1-(6-metylobicyklo[2.2.1]hept-5-en-2-ylo)pent-1-en-3-olu; 2-metylo-1-(1-metylobicyklo[2.2.1]hept-5-en-2-ylo)pent-1-en-3-olu; 2-metylo-1-(5-metylobicyklo[2.2.1]hept-5-en-2-ylo)pent-1-en-3-olu |
415-990-3 |
67739-11-1 |
Eye Irrit. 2 Aquatic Chronic 2 |
H319 H411 |
GHS07 GHS09 Wng |
H319 H411 |
|
|
|
|
603-171-00-5 |
tiazol-5-ilometanol |
414-780-9 |
38585-74-9 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
603-172-00-0 |
trans-butenodian mono-2-{2-[4-(dibenzo[b, f][1,4]tiazepin-11-ylo)-piperazynium-1-ylo]etoksy}etanolu |
415-180-1 |
773058-82-5 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|
|
|
|
603-173-00-6 |
4,4-dimetylo-3,5,8-trioksa-bicyklo[5.1.0]oktan |
421-750-9 |
57280-22-5 |
Eye Irrit. 2 Skin Sens. 1 |
H319 H317 |
GHS07 Wng |
H319 H317 |
|
|
|
|
603-174-00-1 |
4-cykloheksylo-2-metylobutan-2-ol |
420-630-3 |
83926-73-2 |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|
|
|
|
603-175-00-7 |
2-(2-heksyloksyetoksy)etanol; DEGHE; eter monoheksylowy glikolu dietylenowego; 3,6-dioksa-1-dodekanol; karbitol heksylowy; 3,6-dioksadodekan-1-ol |
203-988-3 |
112-59-4 |
Acute Tox. 4 * Eye Dam. 1 |
H312 H318 |
GHS05 GHS07 Dgr |
H312 H318 |
|
|
|
|
603-176-00-2 |
1,2-bis(2-metoksyetoksy)etan; TEGDME; eter dimetylowy glikolu trietylenowego |
203-977-3 |
112-49-2 |
Repr. 1B |
H360Df |
GHS08 Dgr |
H360Df |
EUH019 |
|
|
|
603-177-00-8 |
1-etoksypropan-2-ol; 2PG1EE; 1-etoksy-2-propanol; eter monoetylowy glikolu propylenowego; [1] octan 2-etoksy-1-metyloetylu; 2PG1EEA [2] |
216-374-5 [1] 259-370-9 [2] |
1569-02-4 [1] 54839-24-6 [2] |
Flam. Liq. 3 STOT SE 3 |
H226 H336 |
GHS02 GHS07 Wng |
H226 H336 |
|
|
|
|
603-178-00-3 |
2-heksyloksyetanol; eter monoheksylowy glikolu etylenowego; n-heksyloglikol |
203-951-1 |
112-25-4 |
Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B |
H312 H302 H314 |
GHS05 GHS07 Dgr |
H312 H302 H314 |
|
|
|
|
603-179-00-9 |
ergokalcyferol (ISO); witamina D2 |
200-014-9 |
50-14-6 |
Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 |
H330 H311 H301 H372 ** |
GHS06 GHS08 Dgr |
H330 H311 H301 H372 ** |
|
|
|
|
603-180-00-4 |
cholekalcyferol; witamina D3 |
200-673-2 |
67-97-0 |
Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 |
H330 H311 H301 H372 ** |
GHS06 GHS08 Dgr |
H330 H311 H301 H372 ** |
|
|
|
|
603-181-00-X |
eter tert-butylowo-metylowy; MTBE; 2-metoksy-2-metylopropan |
216-653-1 |
1634-04-4 |
Flam. Liq. 2 Skin Irrit. 2 |
H225 H315 |
GHS02 GHS07 Dgr |
H225 H315 |
|
|
|
|
603-182-00-5 |
produkt reakcji: nasyconych, jednonienasyconych i wielonienasyconych, częściowo estryfikowanych alkoholi o długich łańcuchach pochodzenia roślinnego (Brassica napus L., Brassica rapa L., Helianthus annuus L., Glycine hispida, Gossypium hirsutum L., Cocos nucifera L., Elaeis guineensis) z O,O-diizobutyloditio-fosforanem i 2-etyloheksylaminą oraz nadtlenkiem wodoru |
428-630-5 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
603-183-00-0 |
2-[2-(2-butoksyetoksy)etoksy]etanol; TEGBE; eter monobutylowy glikolu trietylenowego; glikol butoksytrietylenowy |
205-592-6 |
143-22-6 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
Eye Dam.1; H318: C≥30 % Eye Irrit. 2; H319: 20 % ≤C< 30 % |
|
|
603-184-00-6 |
2-(hydroksymetylo)-2-{[2-hydroksy-3-(izooktadecyloksy)propoksy]metylo}-propano-1,3-diol |
416-380-1 |
146925-83-9 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
603-185-00-1 |
2,4-dichloro-3-etylo-6-nitrofenol |
420-740-1 |
99817-36-4 |
Acute Tox. 3 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H318 H317 H400 H410 |
GHS06 GHS05 GHS09 Dgr |
H301 H318 H317 H410 |
|
|
|
|
603-186-00-7 |
trans-(5RS,6SR)-6-amino-2,2-dimetylo-1,3-dioksepan-5-ol |
419-050-3 |
79944-37-9 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
603-187-00-2 |
dichlorek 2-[(4,6-bis{4-[2-(1-metylo-pyridinium-4-ylo)winylo]fenyloamino}-1,3,5-triazyn-2-ylo)(2-hydroksyetylo)-amino]etanolu |
419-360-9 |
163661-77-6 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
603-188-00-8 |
masa poreakcyjna: 6,7-epoksy-1,2,3,4,5,6,7,8-oktahydro-1,1,2,4,4,7-heksametylonaftalenu; 7,8-epoksy-1,2,3,4,6,7,8,8a-oktahydro-1,1,2,4,4,7-heksametylonaftalenu |
426-970-9 |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
603-189-00-3 |
masa poreakcyjna związków kompleksowych: tytanu, 2,2'-oksydietanolu, mleczanu amonu, nitrylotris(propan-2-olu) i glikolu etylenowego |
405-250-8 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
603-190-00-9 |
8,8-dimetylo-7-isopropylo-6,10-dioksaspiro[4,5]dekan |
424-030-2 |
62406-73-9 |
Skin Irrit. 2 Aquatic Chronic 3 |
H315 H412 |
GHS07 Wng |
H315 H412 |
|
|
|
|
603-191-00-4 |
2-[4,6-bis(2,4-dimetylofenylo)-1,3,5-triazyn-2-ylo]-5-{3-[(2-etyloheksylo)oksy]-2-hydroksypropoksy}fenol |
419-740-4 |
137658-79-8 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
603-192-00-X |
(E,E)-3,7,11-trimetylododeka-1,4,6,10-tetraen-3-ol |
423-240-1 |
125474-34-2 |
Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H315 H318 H317 H410 |
|
|
|
|
603-193-00-5 |
9,10-antracenoditlenek disodu |
426-030-8 |
46492-07-3 |
Skin Corr. 1A |
H314 |
GHS05 Dgr |
H314 |
|
|
|
|
603-194-00-0 |
2-(2-aminoetyloamino)etanol; (AEEA) |
203-867-5 |
111-41-1 |
Repr. 1B Skin Corr. 1B Skin Sens. 1 |
H360Df H314 H317 |
GHS05 GHS08 GHS07 Dgr |
H360Df H314 H317 |
|
STOT SE 3; H335: C≥5 % |
|
|
603-195-00-6 |
2-[4-(4-metoksyfenylo)-6-fenylo-1,3,5-triazyn-2-ylo]fenol |
430-810-3 |
154825-62-4 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
603-196-00-1 |
2-(7-etylo-1H-indol-3-ilo)etanol |
431-020-1 |
41340-36-7 |
Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 2 |
H302 H373 ** H411 |
GHS08 GHS07 GHS09 Wng |
H302 H373 ** H411 |
|
|
|
|
603-199-00-8 |
etoksazol (ISO); (RS)-5-tert-butylo-2-[2-(2,6-difluorofenylo)-4,5-dihydro-1,3-oksazol-4-ilo]fenetol |
— |
153233-91-1 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
M = 100 |
|
|
603-200-00-1 |
1-pentanol; [1] 3-pentanol [2] |
200-752-1 [1] 209-526-7 [2] |
71-41-0 [1] 584-02-1 [2] |
Flam. Liq. 3 Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 |
H226 H332 H335 H315 |
GHS02 GHS07 Wng |
H226 H332 H335 H315 |
|
|
|
|
603-201-00-7 |
(E)-(7R,11R)-3,7,11,15-tetrametyloheksadek-2-en-1-ol |
416-120-5 |
— |
Skin Irrit. 2 Aquatic Chronic 4 |
H315 H413 |
GHS07 Wng |
H315 H413 |
|
|
|
|
603-202-00-2 |
4,4,5,5,5-pentafluoropentan-1-ol |
421-360-9 |
148043-73-6 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
603-203-00-8 |
(1R,3S,7R,8R,10R,13R)-5,5,7,9,9,13-heksametylo-4,6-dioksatetracyklo[6.5.1.01,10.03,7] tetradekan |
427-580-1 |
— |
Skin Irrit. 2 |
H315 |
GHS07 Wng |
H315 |
|
|
|
|
603-204-00-3 |
masa poreakcyjna: 2,2'-(heptano-1,7-diylo)bis-1,3-dioksolanu; 2,2'-(heptano-1,6-diylo)bis-1,3-dioksolanu |
428-110-8 |
— |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
603-205-00-9 |
chlorowodorek (1S-cis)-4-(2-amino-6-chloro-9H-puryn-9-ylo)-2-cyklopenteno-1-metanolu |
426-200-1 |
172015-79-1 |
STOT RE 1 Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H372** H302 H318 H317 H412 |
GHS05 GHS08 GHS07 Dgr |
H372** H302 H318 H317 H412 |
|
|
|
|
603-206-00-4 |
2,2-dichloro-1,3-benzodioksol |
426-850-6 |
2032-75-9 |
Flam. Liq. 3 Skin Corr. 1A Acute Tox. 4 * Skin Sens. 1 |
H226 H314 H302 H317 |
GHS02 GHS05 GHS07 Dgr |
H226 H314 H302 H317 |
EUH014 |
|
|
|
603-207-00-X |
2-izobutylo-2-izopropylo-1,3-dimetoksypropan |
430-800-9 |
129228-21-3 |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
603-208-00-5 |
1,2-dietoksyetan |
211-076-1 |
629-14-1 |
Flam. Liq. 2 Repr. 1A Eye Irrit. 2 |
H225 H360Df H319 |
GHS02 GHS08 GHS07 Dgr |
H225 H360Df H319 |
EUH019 |
|
|
|
603-209-00-0 |
spinosad (ISO) (masa poreakcyjna spinosydu A i spinosydu D w proporcjach 95:5 – 50:50); masa poreakcyjna: 50-95 % (2R,3aS,5aR,5bS,9S,13S,14R,16aS,16bR)-2-(6-deoksy-2,3,4-tri-O-metylo-α-L-mannopiranosiloksy)-13-(4-dimetyloamino-2,3,4,6-tetradeoksy-β-D-erytropiranosiloksy)-9-etylo-2,3,3a,5a,5b,6,7,9,10,11,12,13,14,15,16a,16b-heksadekahydro-14-metylo-1H-8-oksacyklododeka[b]as-indacen-7,15-dionu i 50-5 % (2S,3aR,5aS,5bS,9S,13S,14R,16aS,16bS)-2-(6-deoksy-2,3,4-tri-O-metylo-α-L-mannopiranosiloksy)-13-(4-dimetyloamino-2,3,4,6-tetradeoksy-β-D-erytropiranosilosky)-9-etylo-2,3,3a,5a,5b,6,7,9,10,11,12,13,14,15,16a,16b-heksadekahydro-4,14-dimetylo-1H-8-oksacyklododeka[b]as-indacen-7,15-dionu; [1] spinosyd A; [2] spinosyd D [3] |
-[1] -[2] -[3] |
-[1] 131929-60-7 [2] 131929-63-0 [3] |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
M=10 |
|
|
603-210-00-6 |
2,4-dietylo-1,5-pentanodiol |
429-310-8 |
57987-55-0 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
603-211-00-1 |
chlorek 2,3-epoksypropylotrimetyloamoniowy …%; chlorek glicydylotrimetyloamoniowy …%; |
221-221-0 |
3033-77-0 |
Carc. 1B Muta. 2 Repr. 2 Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H350 H341 H361f*** H312 H302 H373** H318 H317 H412 |
GHS05 GHS08 GHS07 Dgr |
H350 H341 H361f*** H312 H302 H373** H318 H317 H412 |
|
|
B |
|
603-212-00-7 |
1,3,4,6,7,8-heksahydro-4,6,6,7,8,8-heksametyloindeno[5,6-c]piran; galaxolid; (HHCB) |
214-946-9 |
1222-05-5 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
603-213-00-2 |
2-metoksy-2-metylobutan; eter tert-amylowometylowy |
213-611-4 |
994-05-8 |
Flam. Liq. 2 Acute Tox. 4 * STOT SE 3 |
H225 H302 H336 |
GHS02 GHS07 Dgr |
H225 H302 H336 |
|
|
|
|
603-214-00-8 |
1,1-diizopropoksycykloheksan |
413-740-8 |
1132-95-2 |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
|
|
|
|
603-215-00-3 |
bis(tetrafluoroboran) 1-hydroksy-4-fluoro-1,4-diazoniobicyklo[2.2.2]octanu |
418-330-2 |
162241-33-0 |
Expl. 1.1**** Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H201 H302 H373** H318 H317 H400 H410 |
GHS01 GHS05 GHS08 GHS07 GHS09 Dgr |
H201 H302 H373** H318 H317 H410 |
|
|
|
|
603-216-00-9 |
cis-1-amino-2,3-dihydro-1H-inden-2-ol |
422-660-2 |
7480-35-5 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|
|
|
|
603-217-00-4 |
2-butylo-2-etylo-1,3-propanodiolofosforan(III) 2,4,6-tri-tert-butylofenylu |
423-560-1 |
161717-32-4 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
603-220-00-0 |
1-{benzylo[2-(2-metoksyfenoksy)etylo]amino}-3-(9H-karbazol-4-ilooksy)propan-2-ol |
432-890-5 |
72955-94-3 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
603-221-00-6 |
chlorowodorek 1-(2-amino-5-chlorofenylo)-2,2,2-trifluoro-1,1-etanodiolu; [zawierający < 0,1 % 4-chloroaniliny (Nr WE 203-401-0)] |
433-580-2 |
214353-17-0 |
Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 |
H302 H314 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H314 H411 |
|
|
|
|
603-221-01-3 |
chlorowodorek 1-(2-amino-5-chlorofenylo)-2,2,2-trifluoro-1,1-etanodiolu; [zawierający ≥ 0,1 % 4-chloroaniliny (Nr WE 203-401-0)] |
433-580-2 |
214353-17-0 |
Carc. 1B Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 |
H350 H302 H314 H411 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H350 H302 H314 H411 |
|
|
|
|
603-222-00-1 |
(2R,3S,4R,5R,7R,9R,10R,11S,12S,13R)10-[(4-dimetyloamino-3-hydroksy-6-metylotetrahydropiran-2-ylo)oksy]-2-etylo-3,4,12-trihydroksy-9-metoksy-3,5,7,9,11,13-heksametylo-6,14-diokso-1-oksacyklotetradekan |
433-820-6 |
118058-74-5 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
603-223-00-7 |
2-cyklopentylidenocyklopentanol; 1,1'-bi(cyklopentyliden)-2-ol |
434-270-1 |
6261-30-9 |
Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 |
H315 H318 H412 |
GHS05 Dgr |
H315 H318 H412 |
|
|
|
|
603-224-00-2 |
3-etoksy-1,1,1,2,3,4,4,5,5,6,6,6-dodekafluoro-2-(trifluorometylo)-heksan |
435-790-1 |
297730-93-9 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
603-225-00-8 |
A9-oksym erytromycyny(E); (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-((2,6,-didezoksy-3-C-metylo-3-O-metylo-α-L-rybo-heksopiranozylo)oksy)-14-etylo-7,12,13-trihydroksy-3,5,7,9,11,13-heksametylo-6-((3,4,6-tridezoksy-3-dimetyloamino-β-D-ksyloheksapiranozylo)oksy)oksacyklotetradekan-2-ono-10-oksym (E) |
437-070-0 |
13127-18-9 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
603-226-00-3 |
4,4'(4-(4-metoksyfenylo)-1,3,5-triazyn-2,4-diylo)bisbenzeno-1,3-diol |
444-500-0 |
1440-00-2 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
603-227-00-9 |
eter α-hydro-ω-[[[(1,1-dimetyloetylo)dioksy]karbonylo]oksy]-poli[oksy(metylo-1,2-etanodiylu)] z 2,2-bis(hydroksymetylo)-1,3-propanodiolem (4:1) produkt reakcji: eteru α-hydro-ω-((chlorokarbonylo)oksy)-poli(oksy(metylo-1,2-etanodiylu)) z 2,2-bis(hydroksymetylo)-1,3-propanodiolem i 1,1-dimetyloetylonadszczawianem potasu |
445-060-2 |
203574-04-3 |
**** Aquatic Acute 1 Aquatic Chronic 1 |
**** H400 H410 |
**** GHS09 Wng |
**** H410 |
|
|
|
|
603-228-00-4 |
(+/-)-(R*R*)-6-fluoro-3,4-dihydro-2-oksiranylo-2H-1-benzopiran |
419-620-1 |
— |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
603-229-00-X |
(Z)-3-chloro-3-(4-chlorofenylo)-1-hydroksy-2-propeno-1-sulfonian sodu |
420-800-7 |
— |
Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H315 H318 H317 H410 |
|
|
|
|
603-230-00-5 |
2,6,6,7,8,8-heksametylodekahydro-2H-indeno[4,5-b]furan |
440-030-5 |
— |
Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 4 |
H315 H318 H413 |
GHS05 Dgr |
H315 H318 H413 |
|
|
|
|
603-231-00-0 |
(S)-1,1-difenylo-1,2-propanodiol |
443-220-6 |
— |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
603-232-00-6 |
3,3,8,8,10,10-heksametylo-9-[1-(4-oksiranylometoksy-fenylo)-etoksy]-1,5-dioksa-9-aza-spiro[5.5]undekan |
444-420-6 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
603-233-00-1 |
masa poreakcyjna: 4-(1,3a,4,6,7,7a-heksahydro-4,7-metanoinden-5-ylideno)-3-metylobutan-2-olu; 4-(3,3a,4,6,7,7a-heksahydro-4,7-metanoinden-5-ylideno)-3-metylobutan-2-olu; 1-(1,3a,4,6,7,7a-heksahydro-4,7-metanoinden-5-ylideno)pentan-3-olu; 1-(3,3a,4,6,7,7a-heksahydro-4,7-metanoinden-5-ylideno)pentan-3-olu; (E)-4-(3a,4,5,6,7,7a-heksahydro-1H-4,7-metanoinden-5-ylo)-3-metylobut-3-en-2-ol; (E)-4-(3a,4,5,6,7,7a-heksahydro-3H-4,7-metanoinden-5-ylo)-3-metylobut-3-en-2-olu |
444-430-0 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
603-234-00-7 |
(1R,4R)-4-metoksy-2,2,7,7-tetrametylotricyklo(6.2.1.0(1,6))undek-5-en |
444-480-3 |
— |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
604-001-00-2 |
fenol; hydroksybenzen; monohydroksybenzen; alkohol fenylowy |
203-632-7 |
108-95-2 |
Muta. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Skin Corr. 1B |
H341 H331 H311 H301 H373 ** H314 |
GHS06 GHS08 GHS05 Dgr |
H341 H331 H311 H301 H373 ** H314 |
|
* Skin Corr. 1B; H314: C ≥ 3 % Skin Irrit. 2; H315 1 % ≤ C<3 % Eye Irrit. 2; H319:1 % ≤C<3 % |
|
|
604-002-00-8 |
pentachlorofenol |
201-778-6 |
87-86-5 |
Carc. 2 Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H330 H311 H301 H319 H335 H315 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H351 H330 H311 H301 H319 H335 H315 H410 |
|
|
|
|
604-003-00-3 |
pentachlorofenolan sodu; [1] pentachlorofenolan potasu [2] |
205-025-2 [1] 231-911-3 [2] |
131-52-2 [1] 7778-73-6 [2] |
Carc. 2 Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H330 H311 H301 H319 H335 H315 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H351 H330 H311 H301 H319 H335 H315 H410 |
|
|
|
|
604-004-00-9 |
m-krezol; 3-krezol; 3-metylofenol; 3-hydroksytoluen; m-hydroksytoluen; m-metylofenol [1] o-krezol; 2-krezol; 2-metylofenol; 2-hydroksytoluen; o-hydroksytoluen; o-metylofenol [2] p-krezol; 4-krezol; 4-metylofenol; 4-hydroksytoluen; p-metylofenol; p-hydroksytoluen [3] krezol, mieszanina izomerów [4] |
203-577-9 [1] 202-423-8 [2] 203-398-6 [3] 215-293-2 [4] |
108-39-4 [1] 95-48-7 [2] 106-44-5 [3] 1319-77-3 [4] |
Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B |
H311 H301 H314 |
GHS06 GHS05 Dgr |
H311 H301 H314 |
|
* |
C |
|
604-005-00-4 |
1,4-dihydroksybenzen; hydrochinon; chinol |
204-617-8 |
123-31-9 |
Carc. 2 Muta. 2 Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 |
H351 H341 H302 H318 H317 H400 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H351 H341 H302 H318 H317 H400 |
|
M=10 |
|
|
604-006-00-X |
3,4-ksylenol; 3,4-dimetylofenol; [1] 2,5-ksylenol; 2,5-dimetylofenol; [2] 2,4-ksylenol; 2,5-dimetylofenol; [3] 2,3-ksylenol; 2,5-dimetylofenol; [4] 2,6-ksylenol; 2,5-dimetylofenol; [5] ksylenol; dimetylofenol; [6] 2,4(lub 2,5)-ksylenol; 2,4(lub 2,5)-dimetylofenol [7] |
202-439-5 [1] 202-461-5 [2] 203-321-6 [3] 208-395-3 [4] 209-400-1 [5] 215-089-3 [6] 276-245-4 [7] |
95-65-8 [1] 95-87-4 [2] 105-67-9 [3] 526-75-0 [4] 576-26-1 [5] 1300-71-6 [6] 71975-58-1 [7] |
Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Aquatic Chronic 2 |
H311 H301 H314 H411 |
GHS06 GHS05 GHS09 Dgr |
H311 H301 H314 H411 |
|
|
C |
|
604-007-00-5 |
2-naftol; 2-hydroksynaftalen |
205-182-7 |
135-19-3 |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 |
H332 H302 H400 |
GHS07 GHS09 Wng |
H332 H302 H400 |
|
|
|
|
604-008-00-0 |
2-chlorofenol; o-chlorofenol; [1] 4-chlorofenol; p-chlorofenol; [2] 3-chlorofenol; m-chlorofenol; [3] chlorofenol [4] |
202-433-2 [1] 203-402-6 [2] 203-582-6 [3] 246-691-4 [4] |
95-57-8 [1] 106-48-9 [2] 108-43-0 [3] 25167-80-0 [4] |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 2 |
H332 H312 H302 H411 |
GHS07 GHS09 Wng |
H332 H312 H302 H411 |
|
|
C |
|
604-009-00-6 |
pirogalol; 1,2,3-trihydroksybenzen |
201-762-9 |
87-66-1 |
Muta. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 3 |
H341 H332 H312 H302 H412 |
GHS08 GHS07 Wng |
H341 H332 H312 H302 H412 |
|
* |
|
|
604-010-00-1 |
rezorcynol; rezorcyna; benzeno-1,3-diol; 1,3-dihydroksybenzen |
203-585-2 |
108-46-3 |
Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 |
H302 H319 H315 H400 |
GHS07 GHS09 Wng |
H302 H319 H315 H400 |
|
* |
|
|
604-011-00-7 |
2,4-dichlorofenol |
204-429-6 |
120-83-2 |
Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 |
H311 H302 H314 H411 |
GHS06 GHS05 GHS09 Dgr |
H311 H302 H314 H411 |
|
|
|
|
604-012-00-2 |
4-chloro-o-krezol; 4-chloro-2-metylofenol |
216-381-3 |
1570-64-5 |
Acute Tox. 3 * Skin Corr. 1A Aquatic Acute 1 |
H331 H314 H400 |
GHS06 GHS05 GHS09 Dgr |
H331 H314 H400 |
|
STOT SE 3; H335: C≥1 % |
|
|
604-013-00-8 |
2,3,4,6-tetrachlorofenol |
200-402-8 |
58-90-2 |
Acute Tox. 3 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H319 H315 H400 H410 |
GHS06 GHS09 Dgr |
H301 H319 H315 H410 |
|
* Eye Irrit. 2; H319:C≥5 % Skin Irrit. 2; H315: C≥5 % |
|
|
604-014-00-3 |
chlorokrezol; 4-chloro-m-krezol; 4-chloro-3-metylofenol |
200-431-6 |
59-50-7 |
Acute Tox. 4 * Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 |
H312 H302 H318 H317 H400 |
GHS05 GHS07 GHS09 Dgr |
H312 H302 H318 H317 H400 |
|
* |
|
|
604-015-00-9 |
2,2'-metylenobis(3,4,6-trichlorofenol); heksachlorofen |
200-733-8 |
70-30-4 |
Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H311 H301 H410 |
|
* |
|
|
604-016-00-4 |
1,2-dihydroksybenzen; pirokatechol; pirokatechina |
204-427-5 |
120-80-9 |
Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 |
H312 H302 H319 H315 |
GHS07 Wng |
H312 H302 H319 H315 |
|
|
|
|
604-017-00-X |
2,4,5-trichlorofenol |
202-467-8 |
95-95-4 |
Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H319 H315 H400 H410 |
GHS07 GHS09 Wng |
H302 H319 H315 H410 |
|
* Eye Irrit. 2; H319: C≥5 % Skin Irrit.2; H315: C ≥5 % |
|
|
604-018-00-5 |
2,4,6-trichlorofenol |
201-795-9 |
88-06-2 |
Carc. 2 Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H302 H319 H315 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H302 H319 H315 H410 |
|
|
|
|
604-019-00-0 |
dichlorofen (ISO); 4,4'-dichloro-2,2'-metylenodifenol; 2,2'-metylenobis(4-chlorofenol) |
202-567-1 |
97-23-4 |
Acute Tox. 4 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H319 H400 H410 |
GHS07 GHS09 Wng |
H302 H319 H410 |
|
|
|
|
604-020-00-6 |
2-fenylofenol (ISO); bifenyl-2-ol; 2-hydroksybifenyl; |
201-993-5 |
90-43-7 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 |
H319 H335 H315 H400 |
GHS07 GHS09 Wng |
H319 H335 H315 H400 |
|
|
|
|
604-021-00-1 |
bifenyl-2-olan sodu; 2-fenylofenolan sodu |
205-055-6 |
132-27-4 |
Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 |
H302 H335 H315 H318 H400 |
GHS05 GHS07 GHS09 Wng |
H302 H335 H315 H318 H400 |
|
|
|
|
604-022-00-7 |
2,2-dimetylo-1,3-benzodioksol-4-ol |
400-900-7 |
22961-82-6 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
604-023-00-2 |
2,4-dichloro-3-etylofenol |
401-060-4 |
— |
Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H314 H400 H410 |
GHS05 GHS09 Dgr |
H314 H410 |
|
|
|
|
604-024-00-8 |
4,4'-(4-metylopentano-2,2-diylo)difenol; 4,4'-izobutyloetylidenodifenol; 2,2-bis(4-hydroksyfenylo)-4-metylopentan |
401-720-1 |
6807-17-6 |
Repr. 1B Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H360F *** H319 H400 H410 |
GHS08 GHS09 Dgr |
H360F *** H319 H410 |
|
|
|
|
604-025-00-3 |
2,5-bis(2-metylopentan-2-ylo)hydrochinon |
400-220-0 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
604-026-00-9 |
2,2'-spirobi(6-hydroksy-4,4,7-trimetylochroman) |
400-270-3 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
604-027-00-4 |
2-metylo-5-(1,1,3,3-tetrametylobutylo)hydrochinon |
400-530-6 |
— |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H318 H317 H411 |
|
|
|
|
604-028-00-X |
4-amino-3-fluorofenol; 4-hydroksy-2-fluoroanilina |
402-230-0 |
399-95-1 |
Carc. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H350 H302 H317 H411 |
GHS08 GHS07 GHS09 Dgr |
H350 H302 H317 H411 |
|
|
|
|
604-029-00-5 |
1-naftol; 1-hydroksynaftalen |
201-969-4 |
90-15-3 |
Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 |
H312 H302 H335 H315 H318 |
GHS05 GHS07 Dgr |
H312 H302 H335 H315 H318 |
|
|
|
|
604-031-00-6 |
gwajakol; 2-metoksyfenol; 2-hydroksyanizol |
201-964-7 |
90-05-1 |
Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 |
H302 H319 H315 |
GHS07 Wng |
H302 H319 H315 |
|
|
|
|
604-032-00-1 |
tymol; 2-izopropylo-5-metylofenol |
201-944-8 |
89-83-8 |
Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 |
H302 H314 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H314 H411 |
|
|
|
|
604-033-00-7 |
but-3-enian izobutylu |
401-170-2 |
24342-03-8 |
Flam. Liq. 3 |
H226 |
GHS02 Wng |
H226 |
|
|
|
|
604-034-00-2 |
4,4'-tiodi-o-krezol |
403-330-7 |
24197-34-0 |
Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H400 H410 |
GHS05 GHS09 Dgr |
H318 H410 |
|
|
|
|
604-035-00-8 |
produkty reakcji 4-nonylofenolu z formaldehydem i dodekano-1-tiolem |
404-160-6 |
— |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
604-036-00-3 |
4,4'-oksybis(etylenotio)difenol |
404-590-4 |
90884-29-0 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
604-037-00-9 |
3,5-ksylenol; 3,5-dimetylofenol |
203-606-5 |
108-68-9 |
Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B |
H311 H301 H314 |
GHS06 GHS05 Dgr |
H311 H301 H314 |
|
|
|
|
604-038-00-4 |
4-chloro-3,5-dimetylofenol; [1] chloroksylenol [2] |
201-793-8 [1] 215-316-6 [2] |
88-04-0 [1] 1321-23-9 [2] |
Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H302 H319 H315 H317 |
GHS07 Wng |
H302 H319 H315 H317 |
|
|
|
|
604-039-00-X |
2-[4-(6-chlorobenzoksazol-2-iloksy)fenoksy]propanian etylu fenoksaprop etylowy (ISO) |
266-362-9 |
66441-23-4 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
604-040-00-5 |
fomesafen (ISO); 5-[2-chloro-4-(trifluorometylo)fenoksy]-N-metylosulfonylo-2-nitrobenzamid |
276-439-9 |
72178-02-0 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
604-041-00-0 |
acifluorofen (ISO); kwas 5-[2-chloro-4-(trifluorometylo)fenoksy]-2-nitrobenzoesowy [1] 5-[2-chloro-4-(trifluorometylo)fenoksy]-2-nitrobenzoesan sodu; acifluorofen sodowy [2] |
256-634-5 [1] 263-560-7 [2] |
50594-66-6 [1] 62476-59-9 [2] |
Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H315 H318 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H302 H315 H318 H410 |
|
|
|
|
604-042-00-6 |
4-nitrozofenol |
203-251-6 |
104-91-6 |
Muta. 2 Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H341 H302 H318 H411 |
GHS08 GHS05 GHS07 GHS09 Dgr |
H341 H302 H318 H411 |
|
|
|
|
604-043-00-1 |
monobenzon; eter benzylowo-4-hydroksyfenylowy; eter monobenzylowy hydrochinonu; 4-benzyloksyfenol |
203-083-3 |
103-16-2 |
Eye Irrit. 2 Skin Sens. 1 |
H319 H317 |
GHS07 Wng |
H319 H317 |
|
|
|
|
604-044-00-7 |
mekwinol; 4-metoksyfenol; eter monometylowy hydrochinonu; eter 4-hydroksyfenylowo-metylowy |
205-769-8 |
150-76-5 |
Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 |
H302 H319 H317 |
GHS07 Wng |
H302 H319 H317 |
|
|
|
|
604-045-00-2 |
2,3,5-trimetylohydrochinon |
211-838-3 |
700-13-0 |
Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H332 H335 H315 H318 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H332 H335 H315 H318 H317 H410 |
|
|
|
|
604-046-00-8 |
4-(4-izopropoksyfenylosulfonylo)fenol |
405-520-5 |
95235-30-6 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
604-047-00-3 |
4-(4-toliloksy)bifenyl |
405-730-7 |
51601-57-1 |
STOT RE 2 * Aquatic Chronic 4 |
H373 ** H413 |
GHS08 Wng |
H373 ** H413 |
|
|
|
|
604-048-00-9 |
4,4',4''-(etano-1,1,1-triylo)trifenol |
405-800-7 |
27955-94-8 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
604-049-00-4 |
4,4'-metylenobis(oksyetylenotio)difenol; 4,4'-metylenobis(oksyetylenosulfanylo)difenol |
407-480-4 |
93589-69-6 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
604-051-00-5 |
3,5-bis(3,5-di-tert-butylo-4-hydroksybenzylo)-2,4,6-trimetylofenol |
401-110-5 |
87113-78-8 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
604-052-00-0 |
2,2'-metylenobis[6-(2H-benzotriazol-2-ilo)-4-(1,1,3,3-tetrametylobutylo)fenol] |
403-800-1 |
103597-45-1 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
604-053-00-6 |
2-metylo-4-tert-butylo-6-(1-metylopentadecylo)fenol |
410-760-9 |
157661-93-3 |
Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H317 H400 H410 |
GHS07 GHS09 Wng |
H315 H317 H410 |
|
|
|
|
604-054-00-1 |
masa poreakcyjna: 2-metoksy-4-(tetrahydro-4-metyleno-2H-piran-2-ylo)-fenolu; 4-(3,6-dihydro-4-metylo-2H-piran-2-ylo)-2-metoksyfenolu |
412-020-0 |
— |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
604-055-00-7 |
2,2'-((3,3',5,5'-tetrametylo-(1,1'-bifenylo)-4,4'-diylo)-bis(oksymetyleno))bisoksyran |
413-900-7 |
85954-11-6 |
Carc. 2 Skin Sens. 1 |
H351 H317 |
GHS08 GHS07 Wng |
H351 H317 |
|
|
|
|
604-056-00-2 |
2-(2-hydroksy-3,5-dinitroanilino)etanol |
412-520-9 |
99610-72-7 |
Flam. Sol. 2 Repr. 2 Acute Tox. 4 * |
H228 H361f *** H302 |
GHS02 GHS07 GHS08 Dgr |
H228 H361f *** H302 |
|
|
|
|
604-058-00-3 |
1,2-bis(3-metylofenoksy)etan |
402-730-9 |
54914-85-1 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
604-059-00-9 |
2-heksadecylohydrochinon |
406-400-5 |
— |
STOT RE 2 * Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 |
H373 ** H315 H317 H413 |
GHS08 GHS07 Wng |
H373 ** H315 H317 H413 |
|
|
|
|
604-060-00-4 |
9,9-bis(4-hydroksyfenylo)fluoren |
406-950-6 |
3236-71-3 |
Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H315 H400 H410 |
GHS07 GHS09 Wng |
H319 H315 H410 |
|
|
|
|
604-061-00-X |
masa poreakcyjna: 2-chloro-5-sec-tetradecylohydrochinonów, gdzie sec-tetradecyl = 1-metylotridecyl; 1-etylododecyl; 1-propyloundecyl; 1-butylodecyl; 1-pentylononyl; 1-heksylooktyl |
407-740-7 |
— |
Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 |
H315 H317 H412 |
GHS07 Wng |
H315 H317 H412 |
|
|
|
|
604-062-00-5 |
2,4-dimetylo-6-(1-metylopentadecylo)fenol |
411-220-5 |
— |
Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H317 H400 H410 |
GHS07 GHS09 Wng |
H315 H317 H410 |
|
|
|
|
604-063-00-0 |
5,6-dihydroksyindol |
412-130-9 |
3131-52-0 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|
|
|
|
604-064-00-6 |
2-(4,6-difenylo-1,3,5-triazyn-2-ylo)-5-(heksyloksy)fenol |
411-380-6 |
147315-50-2 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
604-065-00-1 |
4,4',4''-(1-metylopropan-1-ylo-3-ylideno)-tris(2-cykloheksylo-5-metylofenol) |
407-460-5 |
111850-25-0 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
604-066-00-7 |
masa poreakcyjna: 6-(1,1-dimetyloetylo)-4-tetrapropylo-2-[(2-hydroksy-5-tetrapropylofenylo)-metylo]fenolu (związek C41) i 2,2'-bis[6-(1,1-dimetyloetylo)-1-hydroksy-4-tetrapropylofenylo]metanu (związek C45); 2,6-bis(1,1-dimetyloetylo)-4-tetrapropylofenolu i 2-(1,1-dimetyloetylo)-4-tetrapropylofenolu; 2,6-bis[(6-(1,1-dimetyloetylo)-1-hydroksy-4-tetrapropylofenylo)metylo]-4-(tetra-propylo)fenolu i 2-[(6-(1,1-dimetyloetylo)-1-hydroksy-4-tetrapropylofenylometylo]-6-[(1-hydroksy-4-tetrapropylofenylo)-metylo]-4-(tetrapropylo)fenolu |
414-550-8 |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
604-067-00-2 |
masa poreakcyjna: 2,2'-[(2-hydroksyetylo)imino]bis-(metyleno)bis[4-dodecylofenolu]; formaldehydu, oligomeru z 4-dodecylofenolem i 2-aminoetanolem (n=2); formaldehydu, oligomeru z 4-dodecylofenolem i 2-aminoetanolem (n=3, 4 i powyżej) |
414-520-4 |
— |
Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H400 H410 |
GHS05 GHS09 Dgr |
H315 H318 H410 |
|
|
|
|
604-068-00-8 |
chlorowodorek (±)-4-(2-{[3-(4-hydroksyfenylo)-1-metylopropylo]amino}-1-hydroksyetylo)fenolu |
415-170-5 |
90274-24-1 |
Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 |
H332 H302 H317 |
GHS07 Wng |
H332 H302 H317 |
|
|
|
|
604-069-00-3 |
2-(1-metylopropylo)-4-tert-butylofenol |
421-740-4 |
51390-14-8 |
Skin Corr. 1B Aquatic Chronic 2 |
H314 H411 |
GHS05 GHS09 Dgr |
H314 H411 |
|
|
|
|
604-070-00-9 |
triklosan; eter 2,4,4'-trichloro-2'-hydroksydifenylowy; 5-chloro-2-(2,4-dichlorofenoksy)fenol |
222-182-2 |
3380-34-5 |
Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H315 H400 H410 |
GHS07 GHS09 Wng |
H319 H315 H410 |
|
M = 100 |
|
|
604-071-00-4 |
4,4'-(1-{4-[1-(4-hydroksyfenylo)-1-metyloetylo]fenylo}etylideno)difenol |
425-600-3 |
110726-28-8 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
604-072-00-X |
1,2-bis(fenoksymetylo)benzen |
428-620-0 |
10403-74-4 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
604-073-00-5 |
(E)-3-[1-[4-[2-(dimetyloamino)etoksy]fenylo]-2-fenylobut-1-enylo]fenol |
428-010-4 |
82413-20-5 |
Carc. 2 Repr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H360F*** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H351 H360F*** H317 H410 |
|
|
|
|
604-074-00-0 |
tetrabromobisfenol-A; 2,2',6,6'-tetrabromo-4,4'-izopropylidenodifenol |
201-236-9 |
79-94-7 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
604-075-00-6 |
4-(1,1,3,3-tetrametylobutylo)fenol; 4-tert-oktylofenol |
205-426-2 |
140-66-9 |
Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H400 H410 |
GHS05 GHS09 Dgr |
H315 H318 H410 |
|
M=10 |
|
|
604-076-00-1 |
fenoloftaleina |
201-004-7 |
77-09-8 |
Carc. 1B Muta. 2 Repr. 2 |
H350 H341 H361f*** |
GHS08 Dgr |
H350 H341 H361f*** |
|
Carc. 1B; H350: C ≥1 % |
|
|
604-077-00-7 |
2-benzotriazol-2-ilo-4-metylo-6-(2-metyloallilo)fenol |
419-750-9 |
98809-58-6 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
604-079-00-8 |
4,4'-(1,3-fenyleno-bis(1-metyloetylideno))bis-fenol |
428-970-4 |
13595-25-0 |
Repr. 2 Skin Sens. 1 Aquatic Chronic 2 |
H361f*** H317 H411 |
GHS08 GHS07 GHS09 Wng |
H361f*** H317 H411 |
|
|
|
|
604-080-00-3 |
4-fluoro-3-trifluorometylofenol |
432-560-0 |
61721-07-1 |
Acute Tox. 4 * Skin Corr. 1A Skin Sens. 1 Aquatic Chronic 2 |
H332 H314 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H332 H314 H317 H411 |
|
|
|
|
604-081-00-9 |
1,1-bis(4-hydroksyfenylo)-1-fenyloetan |
433-130-5 |
1571-75-1 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
604-082-00-4 |
2-chloro-6-fluoro-fenol |
433-890-8 |
2040-90-6 |
Muta. 1B Repr. 2 Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 |
H340 H361f*** H302 H314 H317 H411 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H340 H361f*** H302 H314 H317 H411 |
|
|
|
|
604-083-00-X |
polimer 4,4'-sulfonylobisfenolu z chlorkiem amonu (NH4Cl), pentachlorofosforanem i fenolem |
439-270-3 |
260408-02-4 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
604-084-00-5 |
1-etoksy-2,3-difluorobenzen |
441-000-4 |
121219-07-6 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
604-087-00-1 |
masa poreakcyjna: monoestru 1,2-naftochinonodiazydo-5-sulfochlorku (lub kwasu sulfonowego) z 4,4'-(l-(4-(l-(4-hydroksyfenylo)-1-metyloetylo)-fenylo)etylideno)bisfenolem; diestru 1,2-naftochinonodiazydo-5-sulfochlorku (lub kwasu sulfonowego) z 4,4'-(l-(4-(l-(4-hydroksyfenylo)-1-metyloetylo)-fenylo)etylideno)bisfenolem; triestru 1,2-naftochinonodiazydo-5-sulfochlorku (lub kwasu sulfonowego) z 4,4'-(l-(4-(l-(4-hydroksyfenylo)-1-metyloetylo)-fenylo)etylideno)bisfenolem |
433-640-8 |
— |
Pyr. Sol. 1 Aquatic Chronic 4 |
H250 H413 |
GHS02 Dgr |
H250 H413 |
EUH044 |
|
|
|
604-089-00-2 |
2-metylo-5-tert-butylotiofenol; |
444-970-7 |
— |
Flam. Liq. 3 Repr. 2 STOT RE 2 * Asp. Tox. 1 Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 |
H226 H361d*** H373** H304 H319 H315 H317 H336 H400 H410 |
GHS02 GHS08 GHS07 GHS09 Dgr |
H226 H361d*** H373** H304 H319 H315 H317 H336 H410 |
|
|
|
|
604-090-00-8 |
4-tert-butylofenol |
202-679-0 |
98-54-4 |
Repr. 2 Skin Irrit. 2 Eye Dam. 1 |
H361f H315 H318 |
GHS08 GHS05 Dgr |
H361f H315 H318 |
|
|
|
|
604-091-00-3 |
etofenproks (ISO); eter 3-fenoksybenzylo-2-(4-etoksyfenylo)-2-metylopropylowy |
407-980-2 |
80844-07-1 |
Lact. Aquatic Acute 1 Aquatic Chronic 1 |
H362 H400 H410 |
GHS09 Wng |
H362 H410 |
|
M = 100 M = 1 000 |
|
|
605-001-00-5 |
formaldehyd …%; aldehyd mrówkowy …% |
200-001-8 |
50-00-0 |
Carc. 1B Muta. 2 Acute Tox. 3* Acute Tox. 3* Acute Tox. 3* Skin Corr. 1B Skin Sens. 1 |
H350 H341 H301 H311 H331 H314 H317 |
GHS08 GHS06 GHS05 Dgr |
H350 H341 H301 H311 H331 H314 H317 |
|
* Skin Corr. 1B; H314: C ≥25 % Skin Irrit. 2; H315: 5 % ≤C < 25 % Eye Irrit. 2; H319: 5 % ≤ C <25 % STOT SE 3; H335: C ≥ 5 % SkinSens.; H317: C ≥ 0,2 % |
B, D |
|
605-002-00-0 |
1,3,5-trioksan; trioksymetylen |
203-812-5 |
110-88-3 |
Flam. Sol. 1 Repr. 2 STOT SE 3 |
H228 H361d *** H335 |
GHS02 GHS08 GHS07 Dgr |
H228 H361d *** H335 |
|
|
T |
|
605-003-00-6 |
acetaldehyd; aldehyd octowy etanal |
200-836-8 |
75-07-0 |
Flam. Liq. 1 Carc. 2 Eye Irrit. 2 STOT SE 3 |
H224 H351 H319 H335 |
GHS02 GHS08 GHS07 Dgr |
H224 H351 H319 H335 |
|
|
|
|
605-004-00-1 |
2,4,6-trimetylo-1,3,5-trioksan; paraldehyd |
204-639-8 |
123-63-7 |
Flam. Liq. 3 |
H226 |
GHS02 Wng |
H226 |
|
|
|
|
605-005-00-7 |
2,4,6,8-tetrametylo-1,3,5,7-tetroksokan; metaldehyd |
203-600-2 |
108-62-3 |
Flam. Sol. 2 Acute Tox. 4 * |
H228 H302 |
GHS02 GHS07 Wng |
H228 H302 |
|
|
|
|
605-006-00-2 |
butanal; aldehyd masłowy |
204-646-6 |
123-72-8 |
Flam. Liq. 2 |
H225 |
GHS02 Dgr |
H225 |
|
|
|
|
605-007-00-8 |
1,1-dimetoksyetan; acetal dimetylowy acetaldehydu |
208-589-8 |
534-15-6 |
Flam. Liq. 2 |
H225 |
GHS02 Dgr |
H225 |
|
|
|
|
605-008-00-3 |
akroleina; prop-2-enal; akrylaldehyd; aldehyd akrylowy |
203-453-4 |
107-02-8 |
Flam. Liq. 2 Acute Tox. 1 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H225 H330 H300 H311 H314 H400 H410 |
GHS02 GHS06 GHS05 GHS09 Dgr |
H225 H330 H300 H311 H314 H410 |
EUH071 |
Skin Corr. 1B; H314:C≥ 0,1 % M = 100 M = 1 |
D |
|
605-009-00-9 |
aldehyd krotonowy; but-2-enal; [1] (E)-but-2-enal; (E)-aldehyd krotonowy [2] |
224-030-0 [1] 204-647-1 [2] |
4170-30-3 [1] 123-73-9 [2] |
Flam. Liq. 2 Muta. 2 Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 |
H225 H341 H330 H311 H301 H373 ** H335 H315 H318 H400 |
GHS02 GHS06 GHS08 GHS05 GHS09 Dgr |
H225 H341 H330 H311 H301 H373 ** H335 H315 H318 H400 |
|
|
|
|
605-010-00-4 |
2-furaldehyd |
202-627-7 |
98-01-1 |
Carc. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H351 H331 H301 H312 H319 H335 H315 |
GHS06 GHS08 Dgr |
H351 H331 H301 H312 H319 H335 H315 |
|
|
|
|
605-011-00-X |
2-chlorobenzaldehyd; o-chlorobenzaldehyd; aldehyd o-chlorobenzoesowy |
201-956-3 |
89-98-5 |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
|
|
|
|
605-012-00-5 |
benzaldehyd; aldehyd benzoesowy |
202-860-4 |
100-52-7 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
605-014-00-6 |
hydrat chloralu; hydrat trichloroetanalu; wodzian chloralu; 2,2,2-trichloroetano-1,1-diol |
206-117-5 |
302-17-0 |
Acute Tox. 3 * Eye Irrit. 2 Skin Irrit. 2 |
H301 H319 H315 |
GHS06 Dgr |
H301 H319 H315 |
|
|
|
|
605-015-00-1 |
1,1-dietoksyetan; acetal |
203-310-6 |
105-57-7 |
Flam. Liq. 2 Eye Irrit. 2 Skin Irrit. 2 |
H225 H319 H315 |
GHS02 GHS07 Dgr |
H225 H319 H315 |
|
|
|
|
605-016-00-7 |
glioksal …%; etanodial …% |
203-474-9 |
107-22-2 |
Muta. 2 Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H341 H332 H319 H315 H317 |
GHS07 GHS08 Wng |
H341 H332 H319 H315 H317 |
|
* |
B |
|
605-017-00-2 |
1,3-dioksolan |
211-463-5 |
646-06-0 |
Flam. Liq. 2 |
H225 |
GHS02 Dgr |
H225 |
|
|
|
|
605-018-00-8 |
propanal; aldehyd propionowy |
204-623-0 |
123-38-6 |
Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H225 H319 H335 H315 |
GHS02 GHS07 Dgr |
H225 H319 H335 H315 |
|
|
|
|
605-019-00-3 |
cytral α i cytral ß; geranial i neral; (E)-3,7-dimetylookta-2,6-dienal i (Z)-3,7-dimetylookta-2,6-dienal |
226-394-6 |
5392-40-5 |
Skin Irrit. 2 Skin Sens. 1 |
H315 H317 |
GHS07 Wng |
H315 H317 |
|
|
|
|
605-020-00-9 |
safrol; 5-allilo-1,3-benzodioksol |
202-345-4 |
94-59-7 |
Carc. 1B Muta. 2 Acute Tox. 4 * |
H350 H341 H302 |
GHS08 GHS07 Dgr |
H350 H341 H302 |
|
|
|
|
605-021-00-4 |
produkty reakcji formaldehydu z butylofenolem |
294-145-9 |
91673-30-2 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
605-024-00-0 |
2-bromo-5-hydroksy-4-metoksybenzaldehyd |
426-540-0 |
2973-59-3 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
605-025-00-6 |
chloroacetaldehyd |
203-472-8 |
107-20-0 |
Carc. 2 Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Aquatic Acute 1 |
H351 H330 H311 H301 H314 H400 |
GHS06 GHS08 GHS05 GHS09 Dgr |
H351 H330 H311 H301 H314 H400 |
|
STOT SE 3; H335: C≥ 5 % |
|
|
605-026-00-1 |
2,5,7,7-tetrametylooktanal |
405-690-0 |
114119-97-0 |
Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H315 H317 H411 |
GHS07 GHS09 Wng |
H315 H317 H411 |
|
|
|
|
605-027-00-7 |
masa poreakcyjna: 3a,4,5,6,7,7a-heksahydro-4,7-metano-1H-indeno-6-karboaldehydu; 3a,4,5,6,7,7a-heksahydro-4,7-metano-1H-indeno-5-karboaldehydu |
410-480-7 |
— |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
605-028-00-2 |
β-metylo-3-(1-metyloetylo)benzenopropanal |
412-050-4 |
125109-85-5 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
605-029-00-8 |
2-cykloheksylopropanal |
412-270-0 |
2109-22-0 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
605-030-00-3 |
oksym 1-(4-metoksyfenylo)acetaldehydu |
411-510-1 |
3353-51-3 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
605-031-00-9 |
masa poreakcyjna: 2,2-dimetoksyetanalu (ten związek jest uważany za bezwodny pod względem tożsamości, struktury i składu, jednak 2,2-dimetoksyetanal będzie występował w formie uwodnionej. 60 % postaci bezwodnej jest równoważne z 70,4 % hydratu); woda (włączając wodę niezwiązaną i wodę w uwodnionym 2,2-dimetoksyetanalu); |
421-890-0 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
605-032-00-4 |
3-[3-(4-fluorofenylo)-1-(1-metyloetylo)-1H-indol-2-ylo]-(E)-2-propenal |
425-370-4 |
93957-50-7 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
605-033-00-X |
masa poreakcyjna: 3,7,11-trimetylo-cis-6,10-dodekadienalu; 3,7,11-trimetylo-trans-6,10-dodekadienalu |
425-910-9 |
32480-08-3 |
Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H400 H410 |
GHS07 GHS09 Wng |
H315 H410 |
|
|
|
|
605-034-00-5 |
masa poreakcyjna: (1RS,2RS,3SR,6RS,9SR)-9-metoksytricyklo[5.2.1.0(2,6)]dekano-3-karboaldehydu; (1RS,2RS,3RS,6RS,8SR)-8-metoksytricyklo[5.2.1.0(2,6)]dekano-3-karboaldehydu; (1RS,2RS,4SR,6RS,8SR)-8-metoksytricyklo[5.2.1.0(2,6)]dekano-4-karboaldehydu |
429-860-9 |
— |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
605-035-00-0 |
(E)-3-(4-(4-fluorofenylo)-5-metoksymetylo-2,6-bis(1-metoksymetylo)pirydyn-3-ylo)prop-2-enal |
426-330-9 |
177964-68-0 |
Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 |
H319 H317 H413 |
GHS07 Wng |
H319 H317 H413 |
|
|
|
|
605-036-00-6 |
2-bromomalonoaldehyd |
430-470-6 |
2065-75-0 |
Acute Tox. 4 * Eye Dam. 1 |
H302 H318 |
GHS05 GHS07 Dgr |
H302 H318 |
|
|
|
|
605-037-00-1 |
trans-3-[2-(7-chloro-2-chinolinylo)winylo]benzaldehyd; 3-[(E)-2-(7-chloro-2-chinolinylo)winylo]benzaldehyd |
421-800-1 |
120578-03-2 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
605-038-00-7 |
3-metylo-5-fenylopentan-1-al |
433-900-0 |
55066-49-4 |
Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H302 H315 H317 H411 |
GHS07 GHS09 Wng |
H302 H315 H317 H411 |
|
|
|
|
605-039-00-2 |
3,4-dihydroksy-5-nitrobenzaldehyd |
441-810-8 |
116313-85-0 |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 |
H302 H318 H317 |
GHS05 GHS07 Dgr |
H302 H318 H317 |
|
|
|
|
606-001-00-8 |
aceton; propan-2-on; propanon; keton dimetylowy |
200-662-2 |
67-64-1 |
Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 |
H225 H319 H336 |
GHS02 GHS07 Dgr |
H225 H319 H336 |
EUH066 |
|
|
|
606-002-00-3 |
butanon; keton etylowo-metylowy |
201-159-0 |
78-93-3 |
Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 |
H225 H319 H336 |
GHS02 GHS07 Dgr |
H225 H319 H336 |
EUH066 |
|
|
|
606-003-00-9 |
heptan-3-on; keton butylowo-etylowy |
203-388-1 |
106-35-4 |
Flam. Liq. 3 Acute Tox. 4 * Eye Irrit. 2 |
H226 H332 H319 |
GHS02 GHS07 Wng |
H226 H332 H319 |
|
|
|
|
606-004-00-4 |
4-metylopentan-2-on; keton izobutylowo-metylowy; hekson |
203-550-1 |
108-10-1 |
Flam. Liq. 2 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 |
H225 H332 H319 H335 |
GHS02 GHS07 Dgr |
H225 H332 H319 H335 |
EUH066 |
|
|
|
606-005-00-X |
2,6-dimetyloheptan-4-on; keton diizobutylowy |
203-620-1 |
108-83-8 |
Flam. Liq. 3 STOT SE 3 |
H226 H335 |
GHS02 GHS07 Wng |
H226 H335 |
|
STOT SE 3; H335: C ≥ 10 % |
|
|
606-006-00-5 |
pentan-3-on; keton dietylowy; dimetyloaceton |
202-490-3 |
96-22-0 |
Flam. Liq. 2 STOT SE 3 STOT SE 3 |
H225 H335 H336 |
GHS02 GHS07 Dgr |
H225 H335 H336 |
EUH066 |
|
|
|
606-007-00-0 |
3-metylobutan-2-on; keton izopropylowo-metylowy |
209-264-3 |
563-80-4 |
Flam. Liq. 2 |
H225 |
GHS02 Dgr |
H225 |
|
|
|
|
606-009-00-1 |
4-metylopent-3-en-2-on; tlenek mezytylu |
205-502-5 |
141-79-7 |
Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H226 H332 H312 H302 |
GHS02 GHS07 Wng |
H226 H332 H312 H302 |
|
* |
|
|
606-010-00-7 |
cykloheksanon |
203-631-1 |
108-94-1 |
Flam. Liq. 3 Acute Tox. 4 * |
H226 H332 |
GHS02 GHS07 Wng |
H226 H332 |
|
|
|
|
606-011-00-2 |
2-metylocykloheksanon |
209-513-6 |
583-60-8 |
Flam. Liq. 3 Acute Tox. 4 * |
H226 H332 |
GHS02 GHS07 Wng |
H226 H332 |
|
|
|
|
606-012-00-8 |
3,5,5-trimetylocykloheks-2-en-1-on; izoforon |
201-126-0 |
78-59-1 |
Carc. 2 Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 |
H351 H312 H302 H319 H335 |
GHS08 GHS07 Wng |
H351 H312 H302 H319 H335 |
|
STOT SE 3; H335: C ≥10 % |
|
|
606-013-00-3 |
p-benzochinon; 1,4-benzochinon; chinon |
203-405-2 |
106-51-4 |
Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 |
H331 H301 H319 H335 H315 H400 |
GHS06 GHS09 Dgr |
H331 H301 H319 H335 H315 H400 |
|
M=10 |
|
|
606-016-00-X |
piwal (ISO); 2-piwaloiloindano-1,3-dion; 2-(trimetyloacetylo)indano-1,3-dion; pindone |
201-462-8 |
83-26-1 |
Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H372 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H301 H372 ** H410 |
|
|
|
|
606-017-00-5 |
diketen; 4-metylidenooksetan-2-on |
211-617-1 |
674-82-8 |
Flam. Liq. 3 Acute Tox. 4 * |
H226 H332 |
GHS02 GHS07 Wng |
H226 H332 |
|
|
D |
|
606-018-00-0 |
dichlon (ISO); 2,3-dichloro-1,4-naftochinon |
204-210-5 |
117-80-6 |
Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H319 H315 H400 H410 |
GHS07 GHS09 Wng |
H302 H319 H315 H410 |
|
|
|
|
606-019-00-6 |
chlordekon (ISO); perchloropentacyklo[5,3,0,0,2,6,0,3,90,4,8]dekan-5-on; dekachloropentacyklo[5,2,1,02,6,03,9,05,8]dekan-4-on |
205-601-3 |
143-50-0 |
Carc. 2 Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H351 H311 H301 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H351 H311 H301 H410 |
|
|
|
|
606-020-00-1 |
5-metyloheptan-3-on; keton etylowo-sec-amylowy; etylo-sec-amyloketon |
208-793-7 |
541-85-5 |
Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 |
H226 H319 H335 |
GHS02 GHS07 Wng |
H226 H319 H335 |
|
STOT SE 3; H335: C≥10 % |
|
|
606-022-00-2 |
1-fenylopirazolidyn-3-on |
202-155-1 |
92-43-3 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
606-023-00-8 |
4-metoksy-4-metylopentan-2-on |
203-512-4 |
107-70-0 |
Flam. Liq. 3 Acute Tox. 4 * |
H226 H332 |
GHS02 GHS07 Wng |
H226 H332 |
|
|
|
|
606-024-00-3 |
heptan-2-on; keton metylowo-pentylowy; keton metylowo-n-amylowy; metyloamyloketon |
203-767-1 |
110-43-0 |
Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * |
H226 H332 H302 |
GHS02 GHS07 Wng |
H226 H332 H302 |
|
|
|
|
606-025-00-9 |
cyklopentanon |
204-435-9 |
120-92-3 |
Flam. Liq. 3 Eye Irrit. 2 Skin Irrit. 2 |
H226 H319 H315 |
GHS02 GHS07 Wng |
H226 H319 H315 |
|
|
|
|
606-026-00-4 |
5-metyloheksan-2-on; keton izopentylowo-metylowy; keton metylowo-izoamylowy; metyloizoamyloketon |
203-737-8 |
110-12-3 |
Flam. Liq. 3 Acute Tox. 4 * |
H226 H332 |
GHS02 GHS07 Wng |
H226 H332 |
|
|
|
|
606-027-00-X |
heptan-4-on; keton dipropylowy |
204-608-9 |
123-19-3 |
Flam. Liq. 3 Acute Tox. 4 * |
H226 H332 |
GHS02 GHS07 Wng |
H226 H332 |
|
|
|
|
606-028-00-5 |
2,4-dimetylopentan-3-on; keton diizopropylowy |
209-294-7 |
565-80-0 |
Flam. Liq. 2 Acute Tox. 4 * |
H225 H332 |
GHS02 GHS07 Dgr |
H225 H332 |
|
|
|
|
606-029-00-0 |
pentano-2,4-dion; acetyloaceton |
204-634-0 |
123-54-6 |
Flam. Liq. 3 Acute Tox. 4 * |
H226 H302 |
GHS02 GHS07 Wng |
H226 H302 |
|
|
|
|
606-030-00-6 |
heksan-2-on; metylobutyloketon; keton butylowo-metylowy; keton metylo-n-butylowy |
209-731-1 |
591-78-6 |
Flam. Liq. 3 Repr. 2 STOT RE 1 STOT SE 3 |
H226 H361f *** H372 ** H336 |
GHS02 GHS08 GHS07 Dgr |
H226 H361f *** H372 ** H336 |
|
|
|
|
606-031-00-1 |
propano-3-lakton; 1,3-propiolakton; oksetan-2-on; ß-propiolakton; lakton kwasu 3-hydroksypropionowego |
200-340-1 |
57-57-8 |
Carc. 1B Acute Tox. 2 * Eye Irrit. 2 Skin Irrit. 2 |
H350 H330 H319 H315 |
GHS06 GHS08 Dgr |
H350 H330 H319 H315 |
|
|
|
|
606-032-00-7 |
heksachloroaceton; heksachloropropan-2-on; heksachloropropanon |
204-129-5 |
116-16-5 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
606-033-00-2 |
2-(3,4-dichlorofenylo)-4-metylo-1,2,4-oksadiazolidyno-3,5-dion; metazol (ISO) |
243-761-6 |
20354-26-1 |
Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 |
H312 H302 H319 H315 H411 |
GHS07 GHS09 Wng |
H312 H302 H319 H315 H411 |
|
|
|
|
606-034-00-8 |
metrybuzyna (ISO); 4-amino-6-tert-butylo-3-metylotio-1,2,4-triazyn-5(4H)-on; 4-amino-6-(1,1-dimetyloetylo)-3-metylotio-4,5-dihydro-1,2,4-triazyn-5-on |
244-209-7 |
21087-64-9 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
M=10 |
|
|
606-035-00-3 |
chlorydazon (ISO); 5-amino-4-chloro-2-fenylopirydazyn-3(2H)-on; pirazon |
216-920-2 |
1698-60-8 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
606-036-00-9 |
chinometionat (ISO); 6-metylo-1,3-ditiolano[4,5-b]chinoksalin-2-on |
219-455-3 |
2439-01-2 |
Repr. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361f *** H332 H312 H302 H373 ** H319 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H361f *** H332 H312 H302 H373 ** H319 H317 H410 |
|
|
|
|
606-037-00-4 |
triadimefon (ISO); 1-(4-chlorofenoksy)-3,3-dimetylo-1-(1H-1,2,4-triazol-1-ilo)butan-2-on |
256-103-8 |
43121-43-3 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H317 H411 |
GHS07 GHS09 Wng |
H302 H317 H411 |
|
|
|
|
606-038-00-X |
difacynon (ISO); 2-(difenyloacetylo)indano-1,3-dion |
201-434-5 |
82-66-6 |
Acute Tox. 2 * STOT RE 1 |
H300 H372 ** |
GHS06 GHS08 Dgr |
H300 H372 ** |
|
|
|
|
606-039-00-5 |
5(lub 6)-tert-butylo-2'-chloro-6'-etyloamino-3',7'-dimetylospiro[izobenzofurano-1(1H),9'-ksanten]-3-on |
400-680-2 |
— |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H332 H400 H410 |
GHS07 GHS09 Wng |
H332 H410 |
|
|
|
|
606-040-00-0 |
chlorek benzylo(etylo)[(3-hydroksybenzoilo)metylo]ammonium; chlorek benzylo(etylo)[(3-hydroksybenzoilo)metylo]amoniowy |
401-840-4 |
55845-90-4 |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|
|
|
|
606-042-00-1 |
acetofenon |
202-708-7 |
98-86-2 |
Acute Tox. 4 * Eye Irrit. 2 |
H302 H319 |
GHS07 Wng |
H302 H319 |
|
|
|
|
606-043-00-7 |
2,4-di-tert-butylocykloheksanon; |
405-340-7 |
13019-04-0 |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
606-044-00-2 |
2,4,6-trimetylobenzofenon |
403-150-9 |
954-16-5 |
Acute Tox. 4 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H319 H400 H410 |
GHS07 GHS09 Wng |
H302 H319 H410 |
|
|
|
|
606-045-00-8 |
oksadiazon (ISO); 3-[2,4-dichloro-5-(1-metyloetoksy)fenylo]-5-(1,1-dimetyloetylo)-1,3,4-oksadiazolo-2(3H)-on; 5-tert-butylo-3-(2,4-dichloro-5-izopropoksyfenylo-1,3,4-oksadiazolo-2(3H)-on |
243-215-7 |
19666-30-9 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
606-046-00-3 |
cykloheksadec-8-en-1-on, masa poreakcyjna izomerów cis-i trans- |
401-700-2 |
3100-36-5 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
606-047-00-9 |
2-benzylo-2-dimetyloamino-4`-morfolinobutyrofenon |
404-360-3 |
119313-12-1 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
606-048-00-4 |
2'-anilino-3'-metylo-6'-dipentyloaminospiro[izobenzofuran-1(1H),9'-ksanten]-3-on |
406-480-1 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
606-049-00-X |
4-(trans-4-propylocykloheksylo)acetofenon |
406-700-6 |
78531-61-0 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
606-050-00-5 |
6-anilino-1-benzoilo-4-(4-tert-pentylofenoksy)nafto[1,2,3-d, e]chinolino-2,7-(3H)-dion |
412-480-2 |
72453-58-8 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
606-051-00-0 |
4-pentylocykloheksanon |
406-670-4 |
61203-83-6 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
606-052-00-6 |
4-(N,N-dibutylamino)-2-hydroksy-2'-karboksybenzofenon |
410-410-5 |
54574-82-2 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
606-053-00-1 |
flurtamon (ISO); (RS)-5-metyloamino-2-fenylo-4-(3-trifluorometylofenylo)furan-3(2H)-on |
— |
96525-23-4 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
606-055-00-2 |
1-[1,3,3,6-tetrametylo-1-(1-metyloetylo)-2,3-dihydro-1H-inden-5-ylo]etanon |
411-180-9 |
92836-10-7 |
Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 2 |
H302 H373 ** H411 |
GHS08 GHS07 GHS09 Wng |
H302 H373 ** H411 |
|
|
|
|
606-056-00-8 |
4-chloro-3',4'-dimetoksybenzofenon |
404-610-1 |
116412-83-0 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
606-057-00-3 |
4-propylocykloheksanon |
406-810-4 |
40649-36-3 |
Skin Irrit. 2 Aquatic Chronic 3 |
H315 H412 |
GHS07 Wng |
H315 H412 |
|
|
|
|
606-058-00-9 |
4'-fluoro-2,2-dimetoksyacetofenon |
407-500-1 |
21983-80-2 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
606-059-00-4 |
chlorowodorek 2,4-difluoro-α-(1H-1,2,4-triazol-1-ilo)acetofenonu |
412-390-3 |
86386-75-6 |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 |
H302 H318 H317 |
GHS05 GHS07 Dgr |
H302 H318 H317 |
|
|
|
|
606-060-00-X |
masa poreakcyjna: izomerów trans- i cis-2,4-dimetylo-2-(5,5,8,8-tetrametylo-5,6,7,8-tetrahydro-2-naftylo)-1,3-dioksolanu |
412-950-7 |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
606-061-00-5 |
(3-chlorofenylo)(4-metoksy-3-nitrofenylo)metanon |
423-290-4 |
66938-41-8 |
Muta. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H341 H400 H410 |
GHS08 GHS09 Wng |
H341 H410 |
|
|
|
|
606-062-00-0 |
tetrahydrotiopirano-3-karboaldehyd |
407-330-8 |
61571-06-0 |
Repr. 1B Eye Dam. 1 Aquatic Chronic 3 |
H360D *** H318 H412 |
GHS08 GHS05 Dgr |
H360D *** H318 H412 |
|
|
|
|
606-063-00-6 |
(E)-3-(2-chlorofenylo)-2-(4-fluorofenylo)propenal |
410-980-5 |
112704-51-5 |
Eye Irrit. 2 Skin Sens. 1 |
H319 H317 |
GHS07 Wng |
H319 H317 |
|
|
|
|
606-064-00-1 |
bis(ketal etylenowy) pregn-5-eno-3,20-dionu |
407-450-0 |
7093-55-2 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
606-065-00-7 |
1-(4-morfolinofenylo)butan-1-on |
413-790-0 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
606-066-00-2 |
(E)-5-[(4-chlorofenylo)metyleno]-2,2-dimetylocyklopentanon |
410-440-9 |
164058-20-2 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
606-067-00-8 |
masa poreakcyjna: 1-(2,3,6,7,8,9-heksahydro-1,1-dimetylo-1H-benzo[g]inden-4-ylo)etanonu; 1-(2,3,5,6,7,8-heksahydro-1,1-dimetylo-1H-benzo[f]inden-4-ylo)etanonu; 1-(2,3,6,7,8,9-heksahydro-1,1-dimetylo-1H-benzo[g]inden-5-ylo)etanonu; 1-(2,3,6,7,8,9-heksahydro-3,3-dimetylo-1H-benzo[g]inden-5-ylo)etanonu |
414-870-8 |
96792-67-5 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
606-068-00-3 |
2,7,11-trimetylo-13-(2,6,6-trimetylocykloheks-1-en-1-ylo)trideka-2,4,6,8,10,12-heksaenal |
415-770-7 |
1638-05-7 |
STOT RE 2 * Skin Sens. 1 Aquatic Chronic 3 |
H373 ** H317 H412 |
GHS08 GHS07 Wng |
H373 ** H317 H412 |
|
|
|
|
606-069-00-9 |
spiro[1,3-dioksolano-2,5'-(4',4',8',8'-tetrametyloheksahydro-3',9'-metanonaftalen)] |
415-460-1 |
154171-76-3 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
606-070-00-4 |
butroksydym (ISO); 5-(3-butyrylo-2,4,6-trimetylofenylo)-2-[1-(etoksyimino)propylo]-3-hydroksycykloheks-2-en-1-on |
414-790-3 |
138164-12-2 |
Repr. 2 Acute Tox. 4 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H361fd H302 H315 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H361fd H302 H315 H410 |
|
|
|
|
606-071-00-X |
17-spiro(5,5-dimetylo-1,3-dioksan-2-ylo)androsta-1,4-dien-3-on |
421-050-3 |
13258-43-0 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
606-072-00-5 |
3-acetylo-1-fenylopirolidyno-2,4-dion |
421-600-2 |
719-86-8 |
STOT RE 2 * Aquatic Chronic 2 |
H373 ** H411 |
GHS08 GHS09 Wng |
H373 ** H411 |
|
|
|
|
606-073-00-0 |
4,4'-bis(dimetyloamino)benzofenon; keton Michlera |
202-027-5 |
90-94-8 |
Carc. 1B Muta. 2 Eye Dam. 1 |
H350 H341 H318 |
GHS08 GHS05 Dgr |
H350 H341 H318 |
|
|
|
|
606-074-00-6 |
masa poreakcyjna: (1R*,2S*)-2-acetylo-1,2,3,4,5,6,7,8-oktahydro-1,2,8,8-tetrametylonaftalenu; (2R*,3S*)-2-acetylo-1,2,3,4,5,6,7,8-oktahydro-2,3,8,8-tetrametylonaftalenu |
425-570-1 |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
606-075-00-1 |
1-benzylo-5-etoksyimidazolidyno-2,4-dion |
417-340-4 |
65855-02-9 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
606-076-00-7 |
1-(2-chinolilokarbonyloksy)pirolidyno-2,5-dion |
418-630-3 |
136465-99-1 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
606-077-00-2 |
(3S,4S)-3-heksylo-4-[(R)-2-hydroksytridecylo]oksetan-2-on |
418-650-2 |
104872-06-2 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
606-078-00-8 |
1-oktyloazepin-2-on |
420-040-6 |
59227-88-2 |
Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 |
H314 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H314 H317 H411 |
|
|
|
|
606-079-00-3 |
2-butylobenzo[d]izotiazol-3-on |
420-590-7 |
4299-07-4 |
Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H314 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H314 H317 H410 |
|
|
|
|
606-081-00-4 |
(3β,5α,6β)-3-(acetyloksy)-5-bromo-6-hydroksyandrostan-17-on |
419-790-7 |
4229-69-0 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
606-082-00-X |
masa poreakcyjna: oksymu butan-2-onu; syn-O,O'-di(oksym butan-2-onu)dietoksysilanu |
406-930-7 |
|
STOT RE 1 Skin Sens. 1 Aquatic Chronic 3 |
H372 ** H317 H412 |
GHS08 GHS07 Dgr |
H372 ** H317 H412 |
|
|
|
|
606-083-00-5 |
2-chloro-5-sec-heksadecylohydrochinon |
407-750-1 |
137193-60-3 |
Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 |
H319 H315 H317 H412 |
GHS07 Wng |
H319 H315 H317 H412 |
|
|
|
|
606-084-00-0 |
1-(4-metoksybenzofuran-5-ylo)-3-fenylopropano-1,3-dion |
414-540-3 |
484-33-3 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
606-085-00-6 |
(1R,4S)-2-azabicyklo[2.2.1]hept-5-en-3-on |
418-530-1 |
79200-56-9 |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 |
H302 H318 H317 |
GHS05 GHS07 Dgr |
H302 H318 H317 |
|
|
|
|
606-086-00-1 |
1-(3,3-dimetylocykloheksylo)pent-4-en-1-on |
422-330-8 |
56973-87-6 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
606-087-00-7 |
6-etylo-5-fluoro-4(3H)-pirymidon |
422-460-5 |
137234-87-8 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
606-088-00-2 |
2,4,4,7-tetrametylookt-6-en-3-on |
422-520-0 |
74338-72-0 |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
606-089-00-8 |
masa poreakcyjna: 1,4-diamino-2-chloro-3-fenoksyantrachinonu; 1,4-diamino-2,3-bisfenoksyantrachinonu |
423-220-2 |
12223-77-7 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
606-090-00-3 |
1-[3-[(dimetyloamino)metylo]-4-hydroksyfenylo]etanon |
430-920-1 |
73096-98-7 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H302 H318 H412 |
GHS05 GHS07 Dgr |
H302 H318 H412 |
|
|
|
|
606-091-00-9 |
6-chloro-5-(2-chloroetylo)-1,3-dihydroindol-2-on |
421-320-0 |
118289-55-7 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
606-092-00-4 |
masa poreakcyjna: (E)-oksacykloheksadec-12-en-2-onu; (E)-oksacykloheksadec-13-en-2-onu a) (Z)-oksacykloheksadec-12-en-2-onu i b) (Z)-oksacykloheksadec-13-en-2-onu |
422-320-3 |
|
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
606-093-00-X |
5-etylo-2,4-dihydro-4-(2-fenoksyetylo)-3H-1,2,4-triazol-3-on |
414-470-3 |
95885-13-5 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
606-094-00-5 |
N-[etylo(3-metylobutylo)amino]-3-metylo-1-fenylo-spiro[[1]benzo-pirano[2,3-c]pirazolo-4(1H),1'(3'H)-izobenzofuran]-3'-on |
417-460-7 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
606-095-00-0 |
(R, S)-2-azabicyklo[2.2.1]hept-5-en-3-on |
421-830-3 |
49805-30-3 |
Acute Tox. 4 * Skin Sens. 1 |
H302 H317 |
GHS07 Wng |
H302 H317 |
|
|
|
|
606-096-00-6 |
3-(6-O-(6-dezoksy-α-L-mannopiranozylo-O-(α-D-glukopiranozylo)-(β-D-glukopiranozylo)oksy)-2-(3,4-dihydroksyfenylo)-5,7-dihydroksy-4H-1-benzopiran-4-on |
424-170-4 |
130603-71-3 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
606-097-00-1 |
2,2''-dihydroksy-4,4''-(2-hydroksy-propano-1,3-diylodioksy)dibenzofenon |
424-210-0 |
23911-85-5 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
606-098-00-7 |
1-benzylo-5-(heksadecyloksy)-2,4-imidazolidynodion |
431-220-9 |
158574-65-3 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
606-099-00-2 |
5-metoksy-4'-(trifluorometylo)walerofenon |
425-000-1 |
61718-80-7 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
606-100-00-6 |
2-butyrylo-3-hydroksy-5-tiocykloheksan-3-ylo-cykloheks-2-en-1-on |
425-150-8 |
94723-86-1 |
Repr. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 |
H360F*** H302 H317 H412 |
GHS08 GHS07 Dgr |
H360F*** H302 H317 H412 |
|
|
|
|
606-101-00-1 |
masa poreakcyjna: 1,5-bis[(2-etyloheksylo)amino]-9,10-antracenodionu; 1-[(2-etyloheksylo)amino]-5-[3-[(2-etyloheksylo)oksy]propylo] amino-9,10-antracenodionu; 1,5-bis[3-[(2-etyloheksylo)oksy] propylo]amino-9,10-antracenodionu; 1-[(2-etyloheksylo)amino]-5-[3-metoksypropylo)amino]-9,10-antracenodionu; 1-[3-[(2-etyloheksylo)oksy]propylo]amino-5-[(3-metoksypropylo)amino]-9,10-antracenodionu; 1,5-bis[(3-metylooksypropylo)amino]-9,10-antracenodionu |
426-050-7 |
165038-51-7 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
606-102-00-7 |
4-(3-trietoksysililopropoksy)-2-hydroksybenzofenon |
431-490-8 |
79876-59-8 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
606-103-00-2 |
1-(4-(trans-4-etylocykloheksylo)fenylo)etanon |
426-460-6 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
606-104-00-8 |
1-(4-(trans-4-pentylocykloheksylo)fenylo)etanon |
426-830-7 |
78531-59-6 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
606-105-00-3 |
3,4,3',4'-tetrafenylo-1,1'-etanodiylobispirolo-2,5-dion |
431-500-0 |
226065-73-2 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
606-106-00-9 |
1-(4-(trans-4-butylocykloheksylo)fenylo)etanon |
427-320-7 |
83626-30-6 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
606-107-00-4 |
8-azaspiro[4.5]dekano-7,9-dion |
427-770-4 |
1075-89-4 |
Acute Tox. 3 * Aquatic Chronic 2 |
H301 H411 |
GHS06 GHS09 Dgr |
H301 H411 |
|
|
|
|
606-108-00-X |
1,1,1,2,2,4,5,5,5-nonafluoro-4-(trifluorometylo)-3-pentanon |
436-710-6 |
756-13-8 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
606-109-00-5 |
2-(4-metylo-3-pentenylo)antrachinon |
428-320-1 |
71308-16-2 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 4 |
H302 H317 H413 |
GHS07 Wng |
H302 H317 H413 |
|
|
|
|
606-110-00-0 |
5-etoksy-5H-furan-2-on |
428-330-4 |
2833-30-9 |
Skin Corr. 1B Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 |
H314 H312 H302 H373** H317 |
GHS05 GHS08 GHS07 Dgr |
H314 H312 H302 H373** H317 |
|
|
|
|
606-111-00-6 |
5-amino-6-metylo-1,3-dihydrobenzoimidazol-2-on |
428-410-9 |
67014-36-2 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H317 H411 |
GHS07 GHS09 Wng |
H302 H317 H411 |
|
|
|
|
606-112-00-1 |
(4aR*,8aR*)-4a,5,9,10,11,12-heksahydro-3-metoksy-11-metylo-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-on |
428-690-2 |
1668-86-6 |
Acute Tox. 4 * Eye Irrit. 2 Aquatic Chronic 3 |
H302 H319 H412 |
GHS07 Wng |
H302 H319 H412 |
|
|
|
|
606-113-00-7 |
1-[4-(4-benzoilofenylosulfanylo)fenylo]-2-metylo-2-(4-metylofenylosulfonylo)propan-1-on |
429-040-0 |
272460-97-6 |
Eye Dam. 1 Aquatic Chronic 4 |
H318 H413 |
GHS05 Dgr |
H318 H413 |
|
|
|
|
606-114-00-2 |
4,4',5,5',6,6',7,7'-oktachloro-(2,2')biizoindolilo-1,1',3,3'-tetraon |
429-150-9 |
67887-47-2 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
606-115-00-8 |
profoksydim (ISO); 2-{(EZ)-1-[(2RS)-2-(4-chlorofenoksy)propoksyimino]butylo}-3-hydroksy-5-(tian-3-ylo)cykloheks-2-en-1-on |
— |
139001-49-3 |
Carc. 2 Repr. 2 Skin Sens. 1 |
H351 H361d H317 |
GHS08 GHS07 Wng |
H351 H361d H317 |
|
|
|
|
606-116-00-3 |
tepraloksydim (ISO); (RS)-(EZ)-2-{1-[(2E)-3-chloroalliloksyimino]propylo}-3-hydroksy-5-perhydropiran-4-ylocykloheksa-2-en-1-on |
— |
149979-41-9 |
Carc. 2 Repr. 2 |
H351 H361fd |
GHS08 Wng |
H351 H361fd |
|
|
|
|
606-117-00-9 |
2,6-bis(1,1-dimetyloetylo)-4-(fenylenometyleno)cykloheksa-2,5-dien-1-on |
429-460-4 |
7078-98-0 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
606-118-00-4 |
N-(1,3-dimetylobutylo)-N'-(fenylo)-1,4-benzochinonodiimina |
429-640-2 |
52870-46-9 |
Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H400 H410 |
GHS07 GHS09 Wng |
H319 H410 |
|
|
|
|
606-119-00-X |
(E)-3-metylo-5-cyklopentadeken-1-on |
429-900-5 |
— |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
606-120-00-5 |
2,5-dihydroksy-5-metylo-3-(morfolin-4-ylo)-2-cyklopenten-1-on |
430-170-5 |
114625-74-0 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
606-121-00-0 |
(+)-(1S,2S,3S,5R)-2,6,6-trimetylobicyklo[3.1.1]heptano-3-spiro-1'-(cykloheks-2'-en-4'-on) |
430-460-1 |
133636-82-5 |
Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H314 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H314 H317 H410 |
|
|
|
|
606-122-00-6 |
3-(2-bromopropionoilo)-4,4-dimetylo-1,3-oksazolan-2-on |
430-820-8 |
114341-88-7 |
Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373** H315 H318 H317 H400 H410 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H302 H373** H315 H318 H317 H410 |
|
|
|
|
606-123-00-1 |
4-heksadecylo-1-fenylopirazolidyn-3-on |
430-840-7 |
— |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
606-124-00-7 |
1-cyklopropylo-3-(2-metylotio-4-trifluorometylofenylo)-1,3-propanodion |
421-080-7 |
161462-35-7 |
STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H373** H400 H410 |
GHS08 GHS09 Wng |
H373** H410 |
|
|
|
|
606-125-00-2 |
1-benzyloimidazolidyno-2,4-dion |
421-340-1 |
6777-05-5 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
606-126-00-8 |
1,4-bis(2,3-dihydroksypropyloamino)antrachinon |
421-470-7 |
99788-75-7 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
606-128-00-9 |
2,2'-(1,3-fenyleno)bis[5-chloro-1H-izoindolo]-1,3(2H)-dion |
422-650-8 |
148935-94-8 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
606-129-00-4 |
5-amino-[2S-di(metylofenylo)amino]-1,6-difenylo-4Z-heksen-3-on; (2S,4Z)-5-amino-2-(dibenzyloamino)-1,6-difenyloheks-4-en-3-on |
423-090-7 |
156732-13-7 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
606-130-00-X |
4-(1,4-dioksaspiro[4.5]dec-8-ylo)-cycloheksanon |
423-860-2 |
56309-94-5 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
606-131-00-5 |
cykliczny 3-(1,2-etanodiyloacetalo)-estra-5(10),9(11)-dieno-3,17-dion |
427-230-8 |
5571-36-8 |
Repr. 1B STOT RE 2 * Aquatic Chronic 2 |
H360F*** H373** H411 |
GHS08 GHS09 Dgr |
H360F*** H373** H411 |
|
|
|
|
606-132-00-0 |
(6β)-6,19-epoksyandrost-4-eno-3,17-dion |
433-490-3 |
6563-83-3 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
606-134-00-1 |
androsta-1,4,9(11)-trieno-3,17-dion |
433-560-3 |
15375-21-0 |
Repr. 2 |
H361f*** |
GHS08 Wng |
H361f*** |
|
|
|
|
606-135-00-7 |
cycloheksadekanon |
438-930-8 |
2550-52-9 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
606-136-00-2 |
(3S,6R,9S,12R,15S,18R,21S,24R)-6,18-dibenzylo-3,9,15,21-tetraizobutylo-4,10,12,16,22,24-heksametylo-1,7,13,19-tetraoksa-4,10,16,22-tetraazacyklo-tetrakozano-2,5,8,11,14,17,20,23-oktaon |
444-350-6 |
133413-70-4 |
Eye Irrit. 2 Aquatic Chronic 4 |
H319 H413 |
GHS07 Wng |
H319 H413 |
|
|
|
|
606-137-00-8 |
trans-7,7'-dimetylo-(4H,4H')-(2,2')bi[benzo[1,4]tiazinilideno]-3,3'-dion |
444-750-0 |
211387-26-7 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
606-138-00-3 |
(2-butylo-5-nitrobenzofuran-3-ylo)[4-(3-dibutyloaminopropoksy)fenylo]metanon |
444-800-1 |
141645-23-0 |
Flam. Liq. 3 Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H226 H302 H373** H315 H318 H317 H400 H410 |
GHS02 GHS05 GHS08 GHS07 GHS09 Dgr |
H226 H302 H373** H315 H318 H317 H410 |
|
M=10 |
|
|
606-139-00-9 |
(S)-4-(3,4-dichlorofenylo)-3,4-dihydro-2H-naftalen-1-on |
444-830-5 |
124379-29-9 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
606-140-00-4 |
2-hydroksy-1-(4-(4-(2-hydroksy-2-metylopropionylo)benzylo)fenylo)-2-metylopropan-1-on |
444-860-9 |
474510-57-1 |
STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H373** H400 H410 |
GHS08 GHS09 Wn |
H373** H410 |
|
|
|
|
606-141-00-X |
3-(metoksykarbonylo)-4-okso-3,4,5,6-tetrahydro-2-pirydynolan sodu |
418-410-7 |
— |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
606-142-00-5 |
masa poreakcyjna: (1RS,2SR,7SR,8SR,E) 9 i 10-etylideno-3-oksatricyklo[6.2.1.0(2,7)]undekan-4-onu; (1RS,2SR,7SR,8SR,Z)-10-etylideno-3-oksatricyklo[6.2.1.0(2,7)]undekan-4-on; (1RS,2SR,7SR,8SR,Z)-9-etylideno-3-oksatricyklo[6.2.1.0(2,7)]undekan-4-onu |
434-290-9 |
— |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
606-143-00-0 |
abamektyna (połączenie awermektyny B1a i awermektyny B1b) (ISO) [1] awermektyna B1a (czystość ≥ 80 %); [2] |
_ [1] 265-610-3 [2] |
71751-41-2 [1] 65195-55-3 [2] |
Repr. 2 Acute Tox. 2 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361d H300 H330 H372 (układ nerwowy) H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H361d H300 H330 H372 (układ nerwowy) H410 |
|
STOT RE 1; H372: C ≥ 5 % STOT RE 2; H373: 0,5 % ≤C< 5 % M = 10 000 |
|
|
606-144-00-6 |
acekwinocyl (ISO); octan 3-dodecylo-1,4-diokso-1,4-dihydronaftalen-2-ylu |
— |
57960-19-7 |
Skin Sens. 1 STOT SE 1 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H370 (płuca) (droga wziewna) H373 (układ krążenia) H400 H410 |
GHS07 GHS08 GHS09 Dgr |
H317 H370 (płuca) (droga wziewna) H373 (układ krążenia) H410 |
|
M = 1 000 |
|
|
606-145-00-1 |
sulkotrion (ISO); [2-chloro-4-(metylosulfonylo)benzoilo]cykloheksano-1,3-dion |
|
99105-77-8 |
Repr. 2 STOT RE 2 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 |
H361d H373 (nerki) H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H361d H373 (nerki) H317 H410 |
|
M = 1 M = 10 |
|
|
606-146-00-7 |
tralkoksydym (ISO); 2-(N-etoksypropanoimidoilo)-3-hydroksy-5-mezytylocykloheks-2-en-1-on |
— |
87820-88-0 |
Carc. 2 Acute Tox. 4 Aquatic Chronic 2 |
H351 H302 H411 |
GHS08 GHS07 GHS09 Wng |
H351 H302 H411 |
|
|
|
|
606-147-00-2 |
cykloheksydym (ISO); 2-(N-etoksybutanoimidoilo)-3-hydroksy-5-(tetrahydro-2H-tiopiran-3-ylo)cykloheks-2-en-1-on |
405-230-9 |
101205-02-1 |
Repr. 2 |
H361d |
GHS08 Wng |
H361d |
|
|
|
|
607-001-00-0 |
kwas mrówkowy … % |
200-579-1 |
64-18-6 |
Skin Corr. 1A |
H314 |
GHS05 Dgr |
H314 |
|
Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; H314: 10 % ≤ C < 90 % Skin Irrit. 2; H315: 2 % ≤C < 10 % Eye Irrit. 2; H319: 2 %≤ <10 % |
B |
|
607-002-00-6 |
kwas octowy … % |
200-580-7 |
64-19-7 |
Flam. Liq. 3 Skin Corr. 1A |
H226 H314 |
GHS02 GHS05 Dgr |
H226 H314 |
|
Skin Corr. 1A; H314: C ≥90 % Skin Corr. 1B; H314: 25 %≤ C <90 % Skin Irrit. 2; H315: 10 % ≤C <25 % Eye Irrit. 2; H319: 10 % ≤ C < 25 % |
B |
|
607-003-00-1 |
kwas chlorooctowy |
201-178-4 |
79-11-8 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Aquatic Acute 1 |
H331 H311 H301 H314 H400 |
GHS06 GHS05 GHS09 Dgr |
H331 H311 H301 H314 H400 |
|
STOT SE 3; H335: C≥ 5 % |
|
|
607-004-00-7 |
TCA (ISO); kwas trichlorooctowy |
200-927-2 |
76-03-9 |
Skin Corr. 1A Aquatic Acute 1 Aquatic Chronic 1 |
H314 H400 H410 |
GHS05 GHS09 Dgr |
H314 H410 |
|
STOT SE 3; H335: C ≥ 1 % |
|
|
607-005-00-2 |
TCA sodu (ISO); trichlorooctan sodu |
211-479-2 |
650-51-1 |
STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 |
H335 H400 H410 |
GHS07 GHS09 Wng |
H335 H410 |
|
|
|
|
607-006-00-8 |
kwas szczawiowy |
205-634-3 |
144-62-7 |
Acute Tox. 4 * Acute Tox. 4 * |
H312 H302 |
GHS07 Wng |
H312 H302 |
|
* |
|
|
607-007-00-3 |
sole kwasu szczawiowego (z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku) |
— |
— |
Acute Tox. 4 * Acute Tox. 4 * |
H312 H302 |
GHS07 Wng |
H312 H302 |
|
* |
A |
|
607-008-00-9 |
bezwodnik octowy |
203-564-8 |
108-24-7 |
Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B |
H226 H332 H302 H314 |
GHS02 GHS05 GHS07 Dgr |
H226 H332 H302 H314 |
|
Skin Corr. 1B; H314: C ≥ 2 % Skin Irrit. 2; H315: 5 % ≤C < 25 % Eye Dam. 1; H318: 5 % ≤ C < 25 % Eye Irrit. 2; H319: 1 % ≤C < 5 % STOT SE 3; H335: C ≥ 5 % |
|
|
607-009-00-4 |
bezwodnik ftalowy |
201-607-5 |
85-44-9 |
Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H302 H335 H315 H318 H334 H317 |
GHS08 GHS05 GHS07 Dgr |
H302 H335 H315 H318 H334 H317 |
|
|
|
|
607-010-00-X |
bezwodnik propionowy |
204-638-2 |
123-62-6 |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
|
Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 10 % ≤ C < 25 % Eye Irrit. 2; H319: 10 % ≤ C < 25 % |
|
|
607-011-00-5 |
chlorek acetylu; chlorek kwasu octowego |
200-865-6 |
75-36-5 |
Flam. Liq. 2 Skin Corr. 1B |
H225 H314 |
GHS02 GHS05 Dgr |
H225 H314 |
EUH014 |
|
|
|
607-012-00-0 |
chlorek benzoilu; chlorek kwasu benzoesowego |
202-710-8 |
98-88-4 |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 |
H332 H312 H302 H314 H317 |
GHS05 GHS07 Dgr |
H332 H312 H302 H314 H317 |
|
|
|
|
607-013-00-6 |
węglan dimetylu |
210-478-4 |
616-38-6 |
Flam. Liq. 2 |
H225 |
GHS02 Dgr |
H225 |
|
|
|
|
607-014-00-1 |
mrówczan metylu; ester metylowy kwasu mrówkowego |
203-481-7 |
107-31-3 |
Flam. Liq. 1 Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 |
H224 H332 H302 H319 H335 |
GHS02 GHS07 Dgr |
H224 H332 H302 H319 H335 |
|
|
|
|
607-015-00-7 |
mrówczan etylu; ester etylowy kwasu mrówkowego |
203-721-0 |
109-94-4 |
Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 |
H225 H332 H302 H319 H335 |
GHS02 GHS07 Dgr |
H225 H332 H302 H319 H335 |
|
|
|
|
607-016-00-2 |
mrówczan propylu; [1] mrówczan izopropylu [2] |
203-798-0 [1] 210-901-2 [2] |
110-74-7 [1] 625-55-8 [2] |
Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 STOT SE 3 |
H225 H319 H335 H336 |
GHS02 GHS07 Dgr |
H225 H319 H335 H336 |
|
|
C |
|
607-017-00-8 |
mrówczan butylu; ester butylowy kwasu mrówkowego; [1] mrówczan tert-butylu; ester tert-butylowy kwasu mrówkowego [2] mrówczan izobutylu; ester izobutylowy kwasu mrówkowego [3] |
209-772-5 [1] 212-105-0 [2] 208-818-1 [3] |
592-84-7 [1] 762-75-4 [2] 542-55-2 [3] |
Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 |
H225 H319 H335 |
GHS02 GHS07 Dgr |
H225 H319 H335 |
|
|
C |
|
607-018-00-3 |
mrówczan izopentylu; ester izopentylowy kwasu mrówkowego; [1] mrówczan 2-metylobutylu; ester 2-metylobutylowy kwasu mrówkowego [2] |
203-769-2 [1] 252-343-2 [2] |
110-45-2 [1] 35073-27-9 [2] |
Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 |
H225 H319 H335 |
GHS02 GHS07 Dgr |
H225 H319 H335 |
|
|
C |
|
607-019-00-9 |
chloromrówczan metylu; ester metylowy kwasu chloromrówkowego |
201-187-3 |
79-22-1 |
Flam. Liq. 2 Acute Tox. 2 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B |
H225 H330 H312 H302 H314 |
GHS02 GHS06 GHS05 Dgr |
H225 H330 H312 H302 H314 |
|
|
|
|
607-020-00-4 |
chloromrówczan etylu; ester etylowy kwasu chloromrówkowego |
208-778-5 |
541-41-3 |
Flam. Liq. 2 Acute Tox. 2 * Acute Tox. 4 * Skin Corr. 1B |
H225 H330 H302 H314 |
GHS02 GHS06 GHS05 Dgr |
H225 H330 H302 H314 |
|
|
|
|
607-021-00-X |
octan metylu |
201-185-2 |
79-20-9 |
Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 |
H225 H319 H336 |
GHS02 GHS07 Dgr |
H225 H319 H336 |
EUH066 |
|
|
|
607-022-00-5 |
octan etylu |
205-500-4 |
141-78-6 |
Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 |
H225 H319 H336 |
GHS02 GHS07 Dgr |
H225 H319 H336 |
EUH066 |
|
|
|
607-023-00-0 |
octan winylu; ester winylowy kwasu octowego |
203-545-4 |
108-05-4 |
Flam. Liq. 2 Carc. 2 Acute Tox. 4 STOT SE 3 |
H225 H351 H332 H335 |
GHS02 GHS08 GHS07 Dgr |
H225 H351 H332 H335 |
|
|
D |
|
607-024-00-6 |
octan propylu; [1] octan izopropylu [2] |
203-686-1 [1] 203-561-1 [2] |
109-60-4 [1] 108-21-4 [2] |
Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 |
H225 H319 H336 |
GHS02 GHS07 Dgr |
H225 H319 H336 |
EUH066 |
|
C |
|
607-025-00-1 |
octan butylu |
204-658-1 |
123-86-4 |
Flam. Liq. 3 STOT SE 3 |
H226 H336 |
GHS02 GHS07 Wng |
H226 H336 |
EUH066 |
|
|
|
607-026-00-7 |
octan sec-butylu; ester sec-butylowy kwasu octowego; [1] octan izobutylu; ester izobutylowy kwasu octowego; [2] octan tert-butylu; ester tert-butylowy kwasu octowego [3] |
203-300-1 [1] 203-745-1 [2] 208-760-7 [3] |
105-46-4 [1] 110-19-0 [2] 540-88-5 [3] |
Flam. Liq. 2 |
H225 |
GHS02 Dgr |
H225 |
EUH066 |
|
C |
|
607-027-00-2 |
propionian metylu; ester metylowy kwasu propionowego |
209-060-4 |
554-12-1 |
Flam. Liq. 2 Acute Tox. 4 * |
H225 H332 |
GHS02 GHS07 Dgr |
H225 H332 |
|
|
|
|
607-028-00-8 |
propionian etylu; ester etylowy kwasu propionowego |
203-291-4 |
105-37-3 |
Flam. Liq. 2 |
H225 |
GHS02 Dgr |
H225 |
|
|
|
|
607-029-00-3 |
propionian butylu; ester butylowy kwasu propionowego [1] propionian sec-butylu; ester sec-butylowy kwasu propionowego; [2] propionian izobutylu; ester izobutylowy kwasu propionowego [3] |
209-669-5 [1] -[2] 208-746-0 [3] |
590-01-2 [1] 591-34-4 [2] 540-42-1 [3] |
Flam. Liq. 3 |
H226 |
GHS02 Wng |
H226 |
|
|
C |
|
607-030-00-9 |
propionian propylu; ester propylowy kwasu propionowego |
203-389-7 |
106-36-5 |
Flam. Liq. 3 Acute Tox. 4 * |
H226 H332 |
GHS02 GHS07 Wng |
H226 H332 |
|
|
|
|
607-031-00-4 |
maślan butylu; ester butylowy kwasu masłowego |
203-656-8 |
109-21-7 |
Flam. Liq. 3 |
H226 |
GHS02 Wng |
H226 |
|
|
C |
|
607-032-00-X |
akrylan etylu; ester etylowy kwasu akrylowego |
205-438-8 |
140-88-5 |
Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 |
H225 H332 H312 H302 H319 H335 H315 H317 |
GHS02 GHS07 Dgr |
H225 H332 H312 H302 H319 H335 H315 H317 |
|
Skin Irrit. 2; H315: C ≥ 5 % Eye Irrit. 2; H319: C ≥ 5 % STOT SE 3; H335: C ≥ 5 % |
D |
|
607-033-00-5 |
metakrylan butylu; ester butylowy kwasu metakrylowego |
202-615-1 |
97-88-1 |
Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 |
H226 H319 H335 H315 H317 |
GHS02 GHS07 Wng |
H226 H319 H335 H315 H317 |
|
|
D |
|
607-034-00-0 |
akrylan metylu; ester metylowy kwasu akrylowego |
202-500-6 |
96-33-3 |
Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 |
H225 H332 H312 H302 H319 H335 H315 H317 |
GHS02 GHS07 Dgr |
H225 H332 H312 H302 H319 H335 H315 H317 |
|
|
D |
|
607-035-00-6 |
metakrylan metylu; ester metylowy kwasu metakrylowego |
201-297-1 |
80-62-6 |
Flam. Liq. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 |
H225 H335 H315 H317 |
GHS02 GHS07 Dgr |
H225 H335 H315 H317 |
|
|
D |
|
607-036-00-1 |
octan 2-metoksyetylu; octan metyloglikolu; ester metoksyetylowy kwasu octowego |
203-772-9 |
110-49-6 |
Repr. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H360FD H332 H312 H302 |
GHS08 GHS07 Dgr |
H360FD H332 H312 H302 |
|
|
|
|
607-037-00-7 |
octan 2-etoksyetylu; octan etyloglikolu; ester etoksyetylowy kwasu octowego |
203-839-2 |
111-15-9 |
Flam. Liq. 3 Repr. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H226 H360FD H332 H312 H302 |
GHS02 GHS08 GHS07 Dgr |
H226 H360FD H332 H312 H302 |
|
|
|
|
607-038-00-2 |
octan 2-butoksyetylu; octan butyloglikolu; ester 2-butoksyetylowy kwasu octowego |
203-933-3 |
112-07-2 |
Acute Tox. 4 * Acute Tox. 4 * |
H332 H312 |
GHS07 Wng |
H332 H312 |
|
|
|
|
607-039-00-8 |
2,4-D (ISO); kwas (2,4-dichlorofenoksy)octowy |
202-361-1 |
94-75-7 |
Acute Tox. 4 * STOT SE 3 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H302 H335 H318 H317 H412 |
GHS05 GHS07 Dgr |
H302 H335 H318 H317 H412 |
|
|
|
|
607-040-00-3 |
sole i estry 2,4-D; sole i estry kwasu (2,4-dichlorofenoksy)octowego |
— |
— |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H302 H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H317 H411 |
|
|
A |
|
607-041-00-9 |
2,4,5-T (ISO); kwas (2,4,5-trichlorofenoksy)octowy |
202-273-3 |
93-76-5 |
Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H319 H335 H315 H400 H410 |
GHS07 GHS09 Wng |
H302 H319 H335 H315 H410 |
|
|
|
|
607-042-00-4 |
sole i estry 2,4,5-T; sole i estry kwasu (2,4,5-trichlorofenoksy)octowego |
— |
— |
Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H319 H335 H315 H400 H410 |
GHS07 GHS09 Wng |
H302 H319 H335 H315 H410 |
|
|
A |
|
607-043-00-X |
dikamba (ISO); kwas 2,5-dichloro-6-metoksybenzoesowy; kwas 3,6-dichloro-2-metoksybenzoesowy |
217-635-6 |
1918-00-9 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H302 H318 H412 |
GHS05 GHS07 Dgr |
H302 H318 H412 |
|
|
|
|
607-044-00-5 |
kwas 2,5-dichloro-6-metoksybenzoesowy – zwiazek z dimetyloaminą (1:1); kwas 3,6-dichloro-2-metoksybenzoesowy – związek z dimetyloaminą (1:1); kwas 3,6-dichloro-o-anyżowy – związek z dimetyloaminą (1:1); 2,5-dichloro-6-metoksybenzoesan dimetyloamoniowy; [1]sól potasowa kwasu 3,6-dichloro-o-anyżowego [2] |
218-951-7 [1] 233-002-7 [2] |
2300-66-5 [1] 10007-85-9 [2] |
Eye Irrit. 2 Aquatic Chronic 3 |
H319 H412 |
GHS07 Wng |
H319 H412 |
|
|
|
|
607-045-00-0 |
dichloroprop (ISO); kwas 2-(2,4-dichlorofenoksy)propionowy |
204-390-5 |
120-36-5 |
Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 |
H312 H302 H315 H318 |
GHS05 GHS07 Dgr |
H312 H302 H315 H318 |
|
|
|
|
607-046-00-6 |
sole dichloropropu; sole kwasu 2-(2,4-dichlorofenoksy)propionowego |
— |
— |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H332 H312 H302 |
GHS07 Wng |
H332 H312 H302 |
|
|
A |
|
607-047-00-1 |
fenoprop (ISO); kwas 2-(2,4,5-trichlorofenoksy)propionowy |
202-271-2 |
93-72-1 |
Acute Tox. 4 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H315 H400 H410 |
GHS07 GHS09 Wng |
H302 H315 H410 |
|
|
|
|
607-048-00-7 |
sole fenopropu sole kwasu 2-(2,4,5-trichlorofenoksy)propionowego |
— |
— |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H332 H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H332 H312 H302 H410 |
|
|
A |
|
607-049-00-2 |
mekoprop (ISO); kwas 2-(4-chloro-2-metylofenoksy)propionowy; (RS)-kwas 2-(4-chloro-2-metylofenoksy)propionowy; [1] kwas 2-(4-chloro-2-metylofenoksy)propionowy [2] |
230-386-8 [1] 202-264-4 [2] |
7085-19-0 [1] 708519-0 [2] |
Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H315 H318 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H302 H315 H318 H410 |
|
M=100 |
|
|
607-050-00-8 |
sole mekopropu |
— |
— |
Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H315 H318 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H302 H315 H318 H410 |
|
|
A |
|
607-051-00-3 |
MCPA (ISO); kwas (4-chloro-2-metylofenoksy)octowy |
202-360-6 |
94-74-6 |
Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H315 H318 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H302 H315 H318 H410 |
|
|
|
|
607-052-00-9 |
sole i estry MCPA |
— |
— |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H332 H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H332 H312 H302 H410 |
|
|
A |
|
607-053-00-4 |
MCPB (ISO); kwas 4-(4-chloro-2-metylofenoksy)butanowy |
202-365-3 |
94-81-5 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-054-00-X |
sole i estry MCPB |
— |
— |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
A |
|
607-055-00-5 |
endotal sodowy (ISO); 7-oksabicyklo[2.2.1]heptano-2,3-dikarboksylan disodu |
204-959-8 |
129-67-9 |
Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H301 H312 H319 H335 H315 |
GHS06 Dgr |
H301 H312 H319 H335 H315 |
|
|
|
|
607-057-00-6 |
kumachlor (ISO); 3-[1-(4-chlorofenylo)-3-oksobutylo]-4-hydroksykumaryna; 3-[1-(4-chlorofenylo)-3-oksobutylo]-4-hydroksy-2-okso-2H-chromen |
201-378-1 |
81-82-3 |
STOT RE 2 * Aquatic Chronic 3 |
H373 ** H412 |
GHS08 Wng |
H373 ** H412 |
|
|
|
|
607-058-00-1 |
kumafuryl (ISO); fumaryn; 3-[1-(2-furylo)-3-oksobutylo]-4-hydroksy-2-okso-2H-chromen; 3-[1-(2-furylo)-3-oksobutylo]-4-hydroksykumaryna |
204-195-5 |
117-52-2 |
Acute Tox. 3 * STOT RE 1 Aquatic Chronic 3 |
H301 H372 ** H412 |
GHS06 GHS08 Dgr |
H301 H372 ** H412 |
|
|
|
|
607-060-00-2 |
dikumarol; 4,4'-dihydroksy-3,3'-metylenobis(2H-chromen-2-on); 3,3'-metylenobis(4-hydroksy-2-okso-2H-chromen) |
200-632-9 |
66-76-2 |
STOT RE 1 Acute Tox. 4 * Aquatic Chronic 2 |
H372 ** H302 H411 |
GHS08 GHS07 GHS09 Dgr |
H372 ** H302 H411 |
|
|
|
|
607-061-00-8 |
kwas akrylowy; kwas propenowy; kwas etenokarboksylowy |
201-177-9 |
79-10-7 |
Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A Aquatic Acute 1 |
H226 H332 H312 H302 H314 H400 |
GHS02 GHS05 GHS07 GHS09 Dgr |
H226 H332 H312 H302 H314 H400 |
|
STOT SE 3; H335: C ≥ 1 % |
D |
|
607-062-00-3 |
akrylan butylu; ester butylowy kwasu akrylowego |
205-480-7 |
141-32-2 |
Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 |
H226 H319 H335 H315 H317 |
GHS02 GHS07 Wng |
H226 H319 H335 H315 H317 |
|
|
D |
|
607-063-00-9 |
kwas izomasłowy |
201-195-7 |
79-31-2 |
Acute Tox. 4 * Acute Tox. 4 * |
H312 H302 |
GHS07 Wng |
H312 H302 |
|
|
|
|
607-064-00-4 |
chloromrówczan benzylu; ester benzylowy kwasu chloromrówkowego |
207-925-0 |
501-53-1 |
Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H314 H400 H410 |
GHS05 GHS09 Dgr |
H314 H410 |
|
STOT SE 3; H335: C ≥ 5 % |
|
|
607-065-00-X |
kwas bromooctowy |
201-175-8 |
79-08-3 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1A Skin Sens. 1 Aquatic Acute 1 |
H331 H311 H301 H314 H317 H400 |
GHS06 GHS05 GHS09 Dgr |
H331 H311 H301 H314 H317 H400 |
|
|
|
|
607-066-00-5 |
kwas dichlorooctowy |
201-207-0 |
79-43-6 |
Skin Corr. 1A Aquatic Acute 1 |
H314 H400 |
GHS05 GHS09 Dgr |
H314 H400 |
|
|
|
|
607-067-00-0 |
chlorek dichloroacetylu; chlorek kwasu dichlorooctowego |
201-199-9 |
79-36-7 |
Skin Corr. 1A Aquatic Acute 1 |
H314 H400 |
GHS05 GHS09 Dgr |
H314 H400 |
|
|
|
|
607-068-00-6 |
kwas jodooctowy |
200-590-1 |
64-69-7 |
Acute Tox. 3 * Skin Corr. 1A |
H301 H314 |
GHS06 GHS05 Dgr |
H301 H314 |
|
|
|
|
607-069-00-1 |
bromooctan etylu; ester etylowy kwasu bromooctowego |
203-290-9 |
105-36-2 |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * |
H330 H310 H300 |
GHS06 Dgr |
H330 H310 H300 |
|
|
|
|
607-070-00-7 |
chlorooctan etylu; ester etylowy kwasu chlorooctowego |
203-294-0 |
105-39-5 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 |
H331 H311 H301 H400 |
GHS06 GHS09 Dgr |
H331 H311 H301 H400 |
|
|
|
|
607-071-00-2 |
metakrylan etylu; ester etylowy kwasu metakrylowego |
202-597-5 |
97-63-2 |
Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 |
H225 H319 H335 H315 H317 |
GHS02 GHS07 Dgr |
H225 H319 H335 H315 H317 |
|
|
D |
|
607-072-00-8 |
akrylan 2-hydroksyetylu; ester 2-hydroksyetylowy kwasu akrylowego |
212-454-9 |
818-61-1 |
Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 |
H311 H314 H317 H400 |
GHS06 GHS05 GHS09 Dgr |
H311 H314 H317 H400 |
|
* Skin Sens. 1; H317: C ≥ 0,2 % |
D |
|
607-073-00-3 |
4-CPA (ISO); kwas (4-chlorofenoksy)octowy |
204-581-3 |
122-88-3 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
607-074-00-9 |
chlorofenak (ISO); kwas (2,3,6-trichlorofenylo)octowy |
201-599-3 |
85-34-7 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
607-075-00-4 |
chlorofenprop metylowy (ISO); 2-chloro-3-(4-chlorofenylo)propionian metylu |
238-413-5 |
14437-17-3 |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H312 H302 H410 |
|
|
|
|
607-076-00-X |
dodyna (ISO); octan 1-dodecyloguanidyn-2-ium |
219-459-5 |
2439-10-3 |
Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H319 H315 H400 H410 |
GHS07 GHS09 Wng |
H302 H319 H315 H410 |
|
|
|
|
607-077-00-5 |
erbon (ISO); 2,2-dichloropropionian 2-(2,4,5-trichlorofenoksy)etylu |
— |
136-25-4 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
607-078-00-0 |
fluenetyl (ISO); bifenyl-4-ilooctan 2-fluoroetylu |
— |
4301-50-2 |
Acute Tox. 1 Acute Tox. 2 * |
H310 H300 |
GHS06 Dgr |
H310 H300 |
|
|
|
|
607-079-00-6 |
kelewan (ISO); 5-(1,2,4,5,6,7,8,8,9,10-dekachloro-3-hydroksypentacyklo[5.3.02,6.04,10.05,9]dekan-3-ylo)-4-oksopentanian etylu; 5-(1,2,4,5,6,7,8,8,9,10-dekachloro-3-hydroksypentacyklo[5.3.02,6.04,10.05,9]dekan-3-ylo)-4-oksowalerianian etylu |
— |
4234-79-1 |
Acute Tox. 3 * Acute Tox. 4 * Aquatic Chronic 2 |
H311 H302 H411 |
GHS06 GHS09 Dgr |
H311 H302 H411 |
|
|
|
|
607-080-00-1 |
chlorek chloroacetylu; chlorek kwasu chlorooctowego |
201-171-6 |
79-04-9 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Skin Corr. 1A Aquatic Acute 1 |
H331 H311 H301 H372 ** H314 H400 |
GHS06 GHS08 GHS05 GHS09 Dgr |
H331 H311 H301 H372 ** H314 H400 |
EUH014 EUH029 |
|
|
|
607-081-00-7 |
kwas fluorooctowy |
205-631-7 |
144-49-0 |
Acute Tox. 2 * Aquatic Acute 1 |
H300 H400 |
GHS06 GHS09 Dgr |
H300 H400 |
|
|
|
|
607-082-00-2 |
fluorooctany rozpuszczalne |
— |
— |
Acute Tox. 2 * Aquatic Acute 1 |
H300 H400 |
GHS06 GHS09 Dgr |
H300 H400 |
|
|
A |
|
607-083-00-8 |
2,4-DB (ISO); kwas 4-(2,4-dichlorofenoksy)butanowy |
202-366-9 |
94-82-6 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
607-084-00-3 |
sole 2,4-DB; sole kwasu 4-(2,4-dichlorofenoksy)butanowego |
— |
— |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|
|
A |
|
607-085-00-9 |
benzoesan benzylu |
204-402-9 |
120-51-4 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
607-086-00-4 |
ftalan diallilu; ester diallilowy kwasu ftalowego |
205-016-3 |
131-17-9 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
607-088-00-5 |
kwas metakrylowy; kwas 2-metylopropenowy |
201-204-4 |
79-41-4 |
Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A |
H312 H302 H314 |
GHS05 GHS07 Dgr |
H312 H302 H314 |
|
STOT SE 3; H335: C ≥ 1 % |
D |
|
607-089-00-0 |
kwas propionowy … %; kwas etanokarboksylowy … %; kwas metylooctowy … % |
201-176-3 |
79-09-4 |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
|
Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H319 10 % ≤ C < 25 % Eye Irrit. 2; H319: 10 % ≤ C < 25 % STOT SE 3; H335: C ≥ 10 % |
B |
|
607-090-00-6 |
kwas 2-sulfanylooctowy; kwas tioglikolowy; kwas merkaptooctowy |
200-677-4 |
68-11-1 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B |
H331 H311 H301 H314 |
GHS06 GHS05 Dgr |
H331 H311 H301 H314 |
|
* |
|
|
607-091-00-1 |
kwas trifluoroctowy … % |
200-929-3 |
76-05-1 |
Acute Tox. 4 * Skin Corr. 1A Aquatic Chronic 3 |
H332 H314 H412 |
GHS05 GHS07 Dgr |
H332 H314 H412 |
|
* |
B |
|
607-092-00-7 |
mleczan metylu; ester metylowy kwasu mlekowego; [1] (±)-mleczan metylu; [2] (R)-mleczan metylu; [3] (S)-mleczan metylu; (-)-mleczan metylu [4] |
208-930-0 [1] 218-449-8 [2] 241-420-6 [3] 248-704-9 [4] |
547-64-8 [1] 2155-30-8 [2] 17392-83-5 [3] 27871-49-4 [4] |
Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 |
H226 H319 H335 |
GHS02 GHS07 Wng |
H226 H319 H335 |
|
|
C |
|
607-093-00-2 |
chlorek propionoilu; chlorek kwasu propionowego |
201-170-0 |
79-03-8 |
Flam. Liq. 2 Skin Corr. 1B |
H225 H314 |
GHS02 GHS05 Dgr |
H225 H314 |
EUH014 |
|
B D |
|
607-094-00-8 |
kwas nadoctowy … % |
201-186-8 |
79-21-0 |
Flam. Liq. 3 Org. Perox. D **** Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A Aquatic Acute 1 |
H226 H242 H332 H312 H302 H314 H400 |
GHS02 GHS05 GHS07 GHS09 Dgr |
H226 H242 H332 H312 H302 H314 H400 |
|
* STOT SE 3; H335: C ≥ 1 % |
B D |
|
607-095-00-3 |
kwas maleinowy |
203-742-5 |
110-16-7 |
Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 |
H302 H319 H335 H315 H317 |
GHS07 Wng |
H302 H319 H335 H315 H317 |
|
Skin Sens. 1; H317: C ≥0,1 % |
|
|
607-096-00-9 |
bezwodnik maleinowy |
203-571-6 |
108-31-6 |
Acute Tox. 4 * Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 |
H302 H314 H334 H317 |
GHS08 GHS05 GHS07 Dgr |
H302 H314 H334 H317 |
|
|
|
|
607-097-00-4 |
1,2-bezwodnik kwasu benzeno-1,2,4-trikarboksylowego; bezwodnik trimelitowy |
209-008-0 |
552-30-7 |
STOT SE 3 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H335 H318 H334 H317 |
GHS08 GHS05 GHS07 Dgr |
H335 H318 H334 H317 |
|
|
|
|
607-098-00-X |
dibezwodnik 1,2:4,5-benzenotetrakarboksylowy; dibezwodnik 1,2:4,5-benzenotetrakarboksylowy; dibezwodnik piromelitowy |
201-898-9 |
89-32-7 |
Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H318 H334 H317 |
GHS08 GHS05 Dgr |
H318 H334 H317 |
|
|
|
|
607-099-00-5 |
bezwodnik cykloheks-4-eno-1,2-dikarboksylowy; bezwodnik 1,2,3,6-tetrahydroftalowy; [1] bezwodnik cis-1,2,3,6-tetrahydroftalowy; [2] bezwodnik 3,4,5,6-tetrahydroftalowy; [3] bezwodnik tetrahydroftalowy [4] |
201-605-4 [1] 213-308-7 [2] 219-374-3 [3] 247-570-9 [4] |
85-43-8 [1] 935-79-5 [2] 2426-02-0 [3] 26266-63-7 [4] |
Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H334 H317 H412 |
GHS08 GHS05 Dgr |
H318 H334 H317 H412 |
|
|
C |
|
607-100-00-9 |
dibezwodnik benzofenono-3,3',4,4'-tetrakarboksylowy; dibezwodnik 4,4'-karbonylodiftalowy |
219-348-1 |
2421-28-5 |
Eye Irrit. 2 STOT SE 3 |
H319 H335 |
GHS07 Wng |
H319 H335 |
|
Eye Irrit 2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 % |
|
|
607-101-00-4 |
bezwodnik 1,4,5,6,7,7-heksachlorobicyklo[2.2.1]hept-5-eno-2,3-dikarboksylowy; bezwodnik 1,4,5,6,7,7-heksachloro-5-norborneno-2,3-dikarboksylowy |
204-077-3 |
115-27-5 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H319 H335 H315 |
GHS07 Wng |
H319 H335 H315 |
|
Skin Irrit.2; H315: C ≥ 1 % Eye Irrit. 2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 % |
|
|
607-102-00-X |
bezwodnik cykloheksano-1,2-dikarboksylowy; bezwodnik heksahydroftalowy; [1] bezwodnik cis-cykloheksano-1,2-dikarboksylowy [2] bezwodnik trans-cykloheksano-1,2-dikarboksylowy [3] |
201-604-9 [1] 236-086-3 [2] 238-009-9 [3] |
85-42-7 [1] 13149-00-3 [2] 14166-21-3 [3] |
Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H318 H334 H317 |
GHS08 GHS05 Dgr |
H318 H334 H317 |
|
|
C |
|
607-103-00-5 |
bezwodnik bursztynowy |
203-570-0 |
108-30-5 |
Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 |
H302 H319 H335 |
GHS07 Wng |
H302 H319 H335 |
|
* Eye Irrit. 2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 % |
|
|
607-104-00-0 |
dibezwodnik cyklopentano-1,2,3,4-tetrakarboksylowy |
227-964-7 |
6053-68-5 |
Eye Irrit. 2 STOT SE 3 |
H319 H335 |
GHS07 Wng |
H319 H335 |
|
Eye Irrit. 2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 % |
|
|
607-105-00-6 |
bezwodnik norborn-5-eno-2,3-dikarboksylowy; bezwodnik 8,9,10-trinorborn-5-eno-2,3-dikarboksylowy; [1] bezwodnik 1,2,3,6-tetrahydro-3,6-metanoftalowy; [2] bezwodnik (1α,2α,3β,6β)-1,2,3,6-tetrahydro-3,6-metanoftalowy [3] |
204-957-7 [1] 212-557-9 [2] 220-384-5 [3] |
129-64-6 [1] 826-62-0 [2] 2746-19-2 [3] |
Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H318 H334 H317 |
GHS08 GHS05 Dgr |
H318 H334 H317 |
|
|
C |
|
607-106-00-1 |
bezwodnik 1-metylo-5-norborneno-2,3-dikarboksylowy |
— |
123748-85-6 |
Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Resp. Sens. 1 |
H302 H319 H335 H315 H334 |
GHS08 GHS07 Dgr |
H302 H319 H335 H315 H334 |
|
STOT SE 3; H335: C ≥ 10 % |
C |
|
607-107-00-7 |
akrylan 2-etyloheksylu; ester 2-etyloheksylowy kwasu akrylowego |
203-080-7 |
103-11-7 |
STOT SE 3 Skin Irrit. 2 Skin Sens. 1 |
H335 H315 H317 |
GHS07 Wng |
H335 H315 H317 |
|
|
D |
|
607-108-00-2 |
akrylan 1-hydroksypropan-2-ylu; ester 1-hydroksypropan-2-ylowy kwasu akrylowego; [1] akrylan 2-hydroksypropylu; ester 2-hydroksypropylowy kwasu akrylowego; [2] monoester kwasu akrylowego i propano1,2-diolu [3] |
220-852-9 [1] 213-663-8 [2] 247-118-0 [3] |
2918-23-2 [1] 999-61-1 [2] 25584-83-2 [3] |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 |
H331 H311 H301 H314 H317 |
GHS06 GHS05 Dgr |
H331 H311 H301 H314 H317 |
|
* Skin Sens. 1; H317:C ≥0,2 % |
C D |
|
607-109-00-8 |
diakrylan heksametylenu; diakrylan heksano-1,6-diylu |
235-921-9 |
13048-33-4 |
Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H319 H315 H317 |
GHS07 Wng |
H319 H315 H317 |
|
|
D |
|
607-110-00-3 |
triakrylan pentaerytrytolu; 3-akryloksy-2,2-(akryloksymetylo)propan-1-ol; triakrylan pentaerytrytu |
222-540-8 |
3524-68-3 |
Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H319 H315 H317 |
GHS07 Wng |
H319 H315 H317 |
|
|
D |
|
607-111-00-9 |
akrylan 2,2-bis(akryloksymetylo)butylu; triakrylan trimetylopropanu; ester 2,2-bis(akryloksymetylo)butylowy kwasu akrylowego |
239-701-3 |
15625-89-5 |
Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H319 H315 H317 |
GHS07 Wng |
H319 H315 H317 |
|
|
D |
|
607-112-00-4 |
diakrylan 2,2-dimetylopropano-1,3-diylu; diakrylan glikolu neopentylowego |
218-741-5 |
2223-82-7 |
Acute Tox. 3 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H311 H319 H315 H317 |
GHS06 Dgr |
H311 H319 H315 H317 |
|
* |
D |
|
607-113-00-X |
metakrylan izobutylu; ester izobutylowy kwasu metakrylowego |
202-613-0 |
97-86-9 |
Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 |
H226 H319 H335 H315 H317 H400 |
GHS02 GHS07 GHS09 Wng |
H226 H319 H335 H315 H317 H400 |
|
|
D |
|
607-114-00-5 |
dimetakrylan etylenu; dimetakrylan glikolu etylenowego |
202-617-2 |
97-90-5 |
STOT SE 3 Skin Sens. 1 |
H335 H317 |
GHS07 Wng |
H335 H317 |
|
STOT SE 3; H335: C ≥ 10 % |
D |
|
607-115-00-0 |
akrylan izobutylu; ester izobutylowy kwasu akrylowego |
203-417-8 |
106-63-8 |
Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 |
H226 H332 H312 H315 H317 |
GHS02 GHS07 Wng |
H226 H332 H312 H315 H317 |
|
|
D |
|
607-116-00-6 |
akrylan cykloheksylu; ester cykloheksylowy kwasu akrylowego |
221-319-3 |
3066-71-5 |
STOT SE 3 Skin Irrit. 2 Aquatic Chronic 2 |
H335 H315 H411 |
GHS07 GHS09 Wng |
H335 H315 H411 |
|
STOT SE 3; H335: C ≥ 10 % |
D |
|
607-117-00-1 |
akrylan 2,3-epoksypropylu; ester 2,3-epoksypropylowy kwasu akrylowego |
203-440-3 |
106-90-1 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Corr. 1B Skin Sens. 1 |
H331 H311 H301 H314 H317 |
GHS06 GHS05 Dgr |
H331 H311 H301 H314 H317 |
|
* Skin Sens. 1; H317:C ≥0,2 % |
D |
|
607-118-00-7 |
diakrylan 1-metylopropan-1,3-diylu; diakrylan glikolu 1,3-butylenowego |
243-105-9 |
19485-03-1 |
Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 |
H312 H314 H317 |
GHS05 GHS07 Dgr |
H312 H314 H317 |
|
|
D |
|
607-119-00-2 |
diakrylan tetrametylenu; diakrylan butano-1,4-diylu; diakrylan glikolu 1,4-butylenowego |
213-979-6 |
1070-70-8 |
Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 |
H312 H314 H317 |
GHS05 GHS07 Dgr |
H312 H314 H317 |
|
|
D |
|
607-120-00-8 |
diakrylan 2,2'-oksydietylu; diakrylan glikolu dietylenowego |
223-791-6 |
4074-88-8 |
Acute Tox. 3 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H311 H319 H315 H317 |
GHS06 Dgr |
H311 H319 H315 H317 |
|
* Skin Sens. 1; H317:C≥0,2 % |
D |
|
607-121-00-3 |
akrylan norborn-2-ylu; ester norborn-2-ylowy kwasu akrylowego |
— |
10027-06-2 |
Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 |
H312 H315 H317 |
GHS07 Wng |
H312 H315 H317 |
|
|
D |
|
607-122-00-9 |
tetrakrylan pentaerytrytu; diakrylan 2,2-(diakryloksymetylo)propano-1,3-diylu; tetrakrylan pentaerytrytolu |
225-644-1 |
4986-89-4 |
Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H319 H315 H317 |
GHS07 Wng |
H319 H315 H317 |
|
|
D |
|
607-124-00-X |
metakrylan 2-hydroksyetylu; ester 2-hydroksyetylowy kwasu metakrylowego |
212-782-2 |
868-77-9 |
Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H319 H315 H317 |
GHS07 Wng |
H319 H315 H317 |
|
|
D |
|
607-125-00-5 |
metakrylan 2-hydroksypropylu; ester 2-hydroksypropylowy kwasu metakrylowego; [1] metakrylan 3-hydroksypropylu; ester 3-hydroksypropylowy kwasu metakrylowego [2] |
213-090-3 [1] 220-426-2 [2] |
923-26-2 [1] 2761-09-3 [2] |
Eye Irrit. 2 Skin Sens. 1 |
H319 H317 |
GHS07 Wng |
H319 H317 |
|
|
C D |
|
607-126-00-0 |
diakrylan 2,2'-(etylenodioksy)dietylu; diakrylan trietylenoglikolu |
216-853-9 |
1680-21-3 |
Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H319 H315 H317 |
GHS07 Wng |
H319 H315 H317 |
|
|
D |
|
607-127-00-6 |
metakrylan 2-(dietyloamino)etylu; ester 2-(dietyloamino)etylowy kwasu metakrylowego |
203-275-7 |
105-16-8 |
Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H332 H319 H315 H317 |
GHS07 Wng |
H332 H319 H315 H317 |
|
|
D |
|
607-128-00-1 |
metakrylan 2-(tert-butyloamino)etylu; ester 2-(tert-butyloamino)etylowy kwasu metakrylowego |
223-228-4 |
3775-90-4 |
Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H319 H315 H317 |
GHS07 Wng |
H319 H315 H317 |
|
|
D |
|
607-129-00-7 |
mleczan etylu; DL-mleczan etylu; ester etylowy kwasu mlekowego; [1] (S)-2-hydroksypropanian etylu; L-mleczan etylu; (S)-mleczan etylu [2] |
202-598-0 [1] 211-694-1 [2] |
97-64-3 [1] 687-47-8 [2] |
Flam. Liq. 3 STOT SE 3 Eye Dam. 1 |
H226 H335 H318 |
GHS02 GHS05 GHS07 Dgr |
H226 H335 H318 |
|
|
C |
|
607-130-00-2 |
octan pentylu; [1] octan izopentylu; [2] octan 1-metylobutylu; [3] octan 2-metylobutylu; [4] octan 2(lub 3)-metylobutylu [5] |
211-047-3 [1] 204-662-3 [2] 210-946-8 [3] 210-843-8 [4] 282-263-3 [5] |
628-63-7 [1] 123-92-2 [2] 626-38-0 [3] 624-41-9 [4] 84145-37-9 [5] |
Flam. Liq. 3 |
H226 |
GHS02 Wng |
H226 |
EUH066 |
|
C |
|
607-131-00-8 |
propionian izopentylu; [1] propionian pentylu; [2] propionian 2-metylobutylu [3] |
203-322-1 [1] 210-852-7 [2] 219-449-0 [3] |
105-68-0 [1] 624-54-4 [2] 2438-20-2 [3] |
Flam. Liq. 3 |
H226 |
GHS02 Wng |
H226 |
|
|
C |
|
607-132-00-3 |
metakrylan 2-(dimetyloamino)etylu; ester 2-(dimetyloamino)etylowy kwasu metakrylowego |
220-688-8 |
2867-47-2 |
Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H312 H302 H319 H315 H317 |
GHS07 Wng |
H312 H302 H319 H315 H317 |
|
|
D |
|
607-133-00-9 |
akrylany monoalkilowe lub monoarylowe, lub monoalkiloarylowe, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Chronic 2 |
H319 H335 H315 H411 |
GHS07 GHS09 Wng |
H319 H335 H315 H411 |
|
STOT SE 3; H335: C ≥ 10 % |
A |
|
607-134-00-4 |
metakrylany monoalkilowe lub monoarylowe, lub monoalkiloarylowe, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H319 H335 H315 |
GHS07 Wng |
H319 H335 H315 |
|
STOTSE 3; H335: C ≥ 10 % |
A |
|
607-135-00-X |
kwas masłowy; kwas propano-1-karboksylowy |
203-532-3 |
107-92-6 |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
|
|
|
|
607-136-00-5 |
chlorek butanoilu; chlorek butyrylu; chlorek kwasu masłowego |
205-498-5 |
141-75-3 |
Flam. Liq. 2 Skin Corr. 1B |
H225 H314 |
GHS02 GHS05 Dgr |
H225 H314 |
|
|
|
|
607-137-00-0 |
acetylooctan metylu; ester metylowy kwasu acetylooctowego |
203-299-8 |
105-45-3 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
607-138-00-6 |
chloromrówczan butylu; ester butylowy kwasu chloromrówkowego |
209-750-5 |
592-34-7 |
Flam. Liq. 3 Acute Tox. 3 * Skin Corr. 1B |
H226 H331 H314 |
GHS02 GHS06 GHS05 Dgr |
H226 H331 H314 |
|
|
|
|
607-139-00-1 |
kwas 2-chloropropionowy |
209-952-3 |
598-78-7 |
Acute Tox. 4 * Skin Corr. 1A |
H302 H314 |
GHS05 GHS07 Dgr |
H302 H314 |
|
|
|
|
607-140-00-7 |
chlorek 2-metylopropanoilu; chlorek 2-metylopropionylu; chlorek izobutyrylu |
201-194-1 |
79-30-1 |
Flam. Liq. 2 Skin Corr. 1A |
H225 H314 |
GHS02 GHS05 Dgr |
H225 H314 |
|
|
|
|
607-141-00-2 |
bis(chloromrówczan) 2,2'-oksydietylenu; bis(chloromrówczan) glikolu dietylenowego |
203-430-9 |
106-75-2 |
Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 |
H302 H315 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H315 H318 H411 |
|
|
|
|
607-142-00-8 |
chloromrówczan propylu; ester propylowy kwasu chloromrówkowego |
203-687-7 |
109-61-5 |
Flam. Liq. 2 Acute Tox. 3 * Skin Corr. 1B |
H225 H331 H314 |
GHS02 GHS06 GHS05 Dgr |
H225 H331 H314 |
|
|
|
|
607-143-00-3 |
kwas walerianowy; kwas pentanowy; kwas butanokarboksylowy |
203-677-2 |
109-52-4 |
Skin Corr. 1B Aquatic Chronic 3 |
H314 H412 |
GHS05 Dgr |
H314 H412 |
|
|
|
|
607-144-00-9 |
kwas adypinowy; kwas butano-1,4-dikarboksylowy |
204-673-3 |
124-04-9 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
607-145-00-4 |
kwas metanosulfonowy |
200-898-6 |
75-75-2 |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
|
|
|
|
607-146-00-X |
kwas fumarowy; kwas trans-etyleno-1,2-dikarboksylowy |
203-743-0 |
110-17-8 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
607-147-00-5 |
ester dietylowy kwasu szczawiowego; szczawian dietylu |
202-464-1 |
95-92-1 |
Acute Tox. 4 * Eye Irrit. 2 |
H302 H319 |
GHS07 Wng |
H302 H319 |
|
|
|
|
607-148-00-0 |
chlorek guanidynium; chlorowodorek guanidyny; chlorek guanidyny |
200-002-3 |
50-01-1 |
Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 |
H302 H319 H315 |
GHS07 Wng |
H302 H319 H315 |
|
|
|
|
607-149-00-6 |
uretan (INN); karbaminian etylu; karbamian etylu; uretan etylu |
200-123-1 |
51-79-6 |
Carc. 1B |
H350 |
GHS08 Dgr |
H350 |
|
|
|
|
607-150-00-1 |
endotal (ISO); kwas 7-oksabicyklo[2.2.1]heptano-2,3-dikarboksylowy |
205-660-5 |
145-73-3 |
Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H301 H312 H319 H335 H315 |
GHS06 Dgr |
H301 H312 H319 H335 H315 |
|
|
|
|
607-151-00-7 |
propargit (ISO); siarczan(IV) 2-(4-tert-butylofenoksy)cykloheksylu-prop-2-ynylu |
219-006-1 |
2312-35-8 |
Carc. 2 Acute Tox. 3 * Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H331 H315 H318 H400 H410 |
GHS06 GHS08 GHS05 GHS09 Dgr |
H351 H331 H315 H318 H410 |
|
M = 10 |
|
|
607-152-00-2 |
2,3,6-TBA (ISO); kwas 2,3,6-trichlorobenzoesowy |
200-026-4 |
50-31-7 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
607-153-00-8 |
benazolina (ISO); kwas 4-chloro-2-okso-2,3-dihydrobenzotiazol-3-ilooctowy |
223-297-0 |
3813-05-6 |
Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 3 |
H319 H315 H412 |
GHS07 Wng |
H319 H315 H412 |
|
|
|
|
607-154-00-3 |
2-[(N-benzoilo-N-3,4-dichlorofenylo)amino]propionian etylu; N-benzoilo-N-(3,4-dichlorofenylo)alaninian etylu; benzoiloprop etylowy (ISO) |
244-845-5 |
22212-55-1 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
607-155-00-9 |
kwas 3-[3-amino-5-(1-metyloguanidyno)-1-oksopentyloamino]-6-(4-amino-2-okso-1,2-dihydropirymidyn-1-ylo)-2,3-dihydro-6H-pirano-2-karboksylowy; blastycydyna-S |
— |
2079-00-7 |
Acute Tox. 2 * |
H300 |
GHS06 Dgr |
H300 |
|
|
|
|
607-156-00-4 |
chlorfenson (ISO); 4-chlorobenzenosulfonian 4-chlorofenylu |
201-270-4 |
80-33-1 |
Acute Tox. 4 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H315 H400 H410 |
GHS07 GHS09 Wng |
H302 H315 H410 |
|
|
|
|
607-158-00-5 |
chlorooctan sodu |
223-498-3 |
3926-62-3 |
Acute Tox. 3 * Skin Irrit. 2 Aquatic Acute 1 |
H301 H315 H400 |
GHS06 GHS09 Dgr |
H301 H315 H400 |
|
|
|
|
607-159-00-0 |
chlorobenzylat (ISO); bis(4-chlorofenylo)hydroksyoctan etylu; 4,4'-dichlorobenzilan etylu |
208-110-2 |
510-15-6 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
607-160-00-6 |
2-[4-(4-chlorofenoksy)fenoksy]propanian izobutylowy; chlofop izobutylowy (ISO) |
— |
51337-71-4 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
607-161-00-1 |
sól dietanoloamonowa 4-CPA; (4-chlorofenoksy)octan bis(2-hydroksyetylo)ammonium; (4-chlorofenoksy)octan bis(2-hydroksyetylo)amoniowy |
— |
— |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
607-162-00-7 |
dalapon; kwas 2,2-dichloropropionowy; [1] dalapon sodu; 2,2-dichloropropionian sodu [2] |
200-923-0 [1] 204-828-5 [2] |
75-99-0 [1] 127-20-8 [2] |
Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 |
H315 H318 H412 |
GHS05 Dgr |
H315 H318 H412 |
|
|
|
|
607-163-00-2 |
3-acetylo-6-metylo-2H-pirano-2,4(3H)-dion; kwas dehydrooctowy |
208-293-9 |
520-45-6 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
607-164-00-8 |
3-acetylo-6-metylo-4-okso-4H-piran-2-olan sodu; dehydrooctan sodu |
224-580-1 |
4418-26-2 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
607-165-00-3 |
dichlofop metylowy (ISO); (RS)-2-[4-(2,4-dichlorofenoksy)fenoksy]propanian metylu; (RS)-2-[4-(2,4-dichlorofenoksy)fenoksy]propanian metylu; |
257-141-8 |
51338-27-3 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|
|
|
|
607-166-00-9 |
octan medinoterbu (ISO); octan 3-metylo-2,4-dinitro-6-tert-butylofenolu |
219-634-6 |
2487-01-6 |
Acute Tox. 3 * Acute Tox. 4 * |
H301 H312 |
GHS06 Dgr |
H301 H312 |
|
|
|
|
607-167-00-4 |
3-chloroakrylan sodu |
— |
4312-97-4 |
Acute Tox. 4 * Acute Tox. 4 * |
H312 H302 |
GHS07 Wng |
H312 H302 |
|
|
|
|
607-168-00-X |
6,7-metylenodioksy-3-metylo-1,2,3,4-tetrahydronaftaleno-1,2-dikarboksylan dipropylu; propylizon |
— |
83-59-0 |
Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H311 H302 H400 H410 |
GHS06 GHS09 Dgr |
H311 H302 H410 |
|
|
|
|
607-169-00-5 |
fluorooctan sodu |
200-548-2 |
62-74-8 |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 |
H330 H310 H300 H400 |
GHS06 GHS09 Dgr |
H330 H310 H300 H400 |
|
|
|
|
607-170-00-0 |
szczawian dimetylo(1,2,3-tritian-5-ylo) amoniowy; szczawian tiocyklamu (ISO) |
250-859-2 |
31895-22-4 |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H400 H410 |
GHS07 GHS09 Wng |
H312 H302 H410 |
|
|
|
|
607-173-00-7 |
[3-metylo-4-(5-nitro-3-etoksykarbonylo-2-tienylo)azo]fenylonitrylodipropionian dimetylu |
400-460-6 |
— |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
607-174-00-2 |
masa poreakcyjna: 3-(2,2,4,4-tetrametylo-21-okso-7-oksa-3,20-diazadispiro[5.1.11.2]henejkozan-20-ylo)propanianów dodecylu i tetradecylu o nierozgałęzionych łańcuchach węglowych |
400-580-9 |
— |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
607-175-00-8 |
2-nitrobenzylideno(acetylo)octan metylu |
400-650-9 |
39562-27-1 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-176-00-3 |
masa poreakcyjna: α-3-[3-(2H-benzotriazol-2-ilo)-5-tert-butylo-4-hydroksyfenylo]propionylo-ω-hydroksypoli(oksyetylenu) i α-3-[3-(2H-benzotriazol-2-ilo)-5-tert-butylo-4-hydroksyfenylo]propionylo-ω-3-[3-(2H-benzotriazol-2-ilo)-5-tert-butylo-4-hydroksyfenylo]propionyloksypoli(oksyetylenu) |
400-830-7 |
— |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-177-00-9 |
tribenuron metylu (ISO); 2-{[3-(6-metoksy-4-metylo-1,3,5-triazyn-2-ylo)-3-metyloureido]sulfonylo}-benzoesan metylu |
401-190-1 |
101200-48-0 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
M = 100 |
|
|
607-178-00-4 |
2-{[3-(4,6-dimetoksypirymidyn-2-ylo)ureido]sulfonylo}metylobenzoesan metylu |
401-340-6 |
83055-99-6 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-179-00-X |
kwas (benzo-1,3-tiazol-2-ilosulfanylo)bursztynowy |
401-450-4 |
95154-01-1 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-180-00-5 |
2-hydroksy-9H-karbazolo-1-karboksylan potasu |
401-630-2 |
96566-70-0 |
Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Aquatic Chronic 3 |
H302 H319 H335 H412 |
GHS07 Wng |
H302 H319 H335 H412 |
|
|
|
|
607-181-00-0 |
fluorek 3,5-dichloro-2,4-difluorobenzoilu |
401-800-6 |
101513-70-6 |
Acute Tox. 3 * Skin Corr. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 |
H331 H314 H302 H317 H412 |
GHS06 GHS05 Dgr |
H331 H314 H302 H317 H412 |
EUH029 |
|
|
|
607-182-00-6 |
3-sulfoamoilotiofeno-2-karboksylan metylu |
402-050-2 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-183-00-1 |
bis(2-hydroksy-5-alkilobenzoesan) cynku (alkil – nierozgałęziony łańcuch o 13-18 atomach węgla) |
402-280-3 |
— |
Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 |
H319 H315 H411 |
GHS07 GHS09 Wng |
H319 H315 H411 |
|
|
|
|
607-184-00-7 |
19-izocyjaniano-11-(6-izocyjanianoheksylo)-10,12-diokso-2,9,11,13-tetraazanonadekanotian S-3-(trimetoksysililo)propylu |
402-290-8 |
85702-90-5 |
Flam. Liq. 3 Resp. Sens. 1 Skin Sens. 1 |
H226 H334 H317 |
GHS02 GHS08 Dgr |
H226 H334 H317 |
|
|
|
|
607-185-00-2 |
trans-3-(dimetyloamino)akrylan etylu; (E)-3-(dimetyloamino)akrylan etylu |
402-650-4 |
1117-37-9 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-186-00-8 |
chinoklorak (ISO); kwas 3,7-dichlorochinolino-8-karboksylowy |
402-780-1 |
84087-01-4 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-187-00-3 |
bursztynian bis(2,2,6,6-tetrametylo-4-piperydylu) |
402-940-0 |
62782-03-0 |
Eye Irrit. 2 Aquatic Chronic 3 |
H319 H412 |
GHS07 Wng |
H319 H412 |
|
|
|
|
607-188-00-9 |
wodoro-3-[N-(2-karboksylanoetylo)-N-oktadek-9-enylokarbamoilo]akrylan sodu |
402-970-4 |
— |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-189-00-4 |
kwas trimetylenodiaminotetraoctowy |
400-400-9 |
1939-36-2 |
Acute Tox. 4 * Eye Dam. 1 |
H302 H318 |
GHS05 GHS07 Dgr |
H302 H318 |
|
|
|
|
607-190-00-X |
(akryloamido)metoksyoctan metylu (zawierający ≥ 0,1 % akrylamidu) |
401-890-7 |
77402-03-0 |
Carc. 1B Muta. 1B Acute Tox. 4 * Eye Irrit. 2 |
H350 H340 H302 H319 |
GHS08 GHS07 Dgr |
H350 H340 H302 H319 |
|
|
|
|
607-191-00-5 |
3,4-epoksymaślan izobutylu |
401-920-9 |
100181-71-3 |
Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H317 H400 H410 |
GHS07 GHS09 Wng |
H315 H317 H410 |
|
|
|
|
607-192-00-0 |
N-karboksylanometylo-N-[2-(2-hydroksyetoksy)etylo]glicynian disodu |
402-360-8 |
92511-22-3 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-194-00-1 |
węglan glikolu propylenowego; węglan propano-1,2-diylu; 4-metylo-1,3-dioksolan-2-on |
203-572-1 |
108-32-7 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
607-195-00-7 |
octan 2-metoksy-1-metyloetylu; octan 1-metoksypropan-2-ylu; octan 1-metoksy-2-propylu; ester 2-metoksypropylowy kwasu octowego |
203-603-9 |
108-65-6 |
Flam. Liq. 3 |
H226 |
GHS02 Wng |
H226 |
|
|
|
|
607-196-00-2 |
kwas heptanowy; kwas enantowy; kwas heksanokarboksylowy |
203-838-7 |
111-14-8 |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
|
|
|
|
607-198-00-3 |
3,4,5-trihydroksybenzoesan propylu; ester propylowy kwasu 3,4,5-trihydroksybenzoesowego |
204-498-2 |
121-79-9 |
Acute Tox. 4 * Skin Sens. 1 |
H302 H317 |
GHS07 Wng |
H302 H317 |
|
|
|
|
607-199-00-9 |
3,4,5-trihydroksybenzoesan oktylu; ester oktylowy kwasu 3,4,5-trihydroksybenzoesowego |
213-853-0 |
1034-01-1 |
Acute Tox. 4 * Skin Sens. 1 |
H302 H317 |
GHS07 Wng |
H302 H317 |
|
|
|
|
607-200-00-2 |
3,4,5-trihydroksybenzoesan dodecylu; ester dodecylowy kwasu 3,4,5-trihydroksybenzoesowego |
214-620-6 |
1166-52-5 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-201-00-8 |
dichlorek tiokarbonylu; chlorek tiokarbonylu; tiofosgen |
207-341-6 |
463-71-8 |
Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H331 H302 H319 H335 H315 |
GHS06 Dgr |
H331 H302 H319 H335 H315 |
|
|
|
|
607-203-00-9 |
{[(4-hydroksy-3,5-di-tert-butylofenylo)metylo]sulfanylo}octan 2-etyloheksylu |
279-452-8 |
80387-97-9 |
Repr. 1B Skin Sens. 1 Aquatic Chronic 3 |
H360D *** H317 H412 |
GHS08 GHS07 Dgr |
H360D *** H317 H412 |
|
|
|
|
607-204-00-4 |
(chlorofenylo)[chloro(metylo)fenylo]metan, mieszanina izomerów |
400-140-6 |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-205-00-X |
chlorooctan metylu; ester metylowy kwasu chlorooctowego |
202-501-1 |
96-34-4 |
Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 3 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 |
H226 H331 H301 H335 H315 H318 |
GHS02 GHS06 GHS05 Dgr |
H226 H331 H301 H335 H315 H318 |
|
|
|
|
607-206-00-5 |
chlorooctan izopropylu; ester izopropylowy kwasu chlorooctowego |
203-301-7 |
105-48-6 |
Flam. Liq. 3 Acute Tox. 3 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H226 H301 H319 H335 H315 |
GHS02 GHS06 Dgr |
H226 H301 H319 H335 H315 |
|
|
|
|
607-207-00-0 |
haloksyfop etotylowy (ISO); 2-[4-(3-chloro-5-trifluorometylo-2-pirydyloksy)fenoksy]propionian 2-etoksyetylu; haloksyfop-(2-etoksyetylu) |
402-560-5 |
87237-48-7 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
607-208-00-6 |
kwas 4,8,12-trimetylotrideka-3,7,11-trienowy (mieszanina izomerów: 3,7-trans/trans; 3,7-trans/cis; 3,7-cis/trans; 3,7-cis/cis) |
403-000-2 |
91853-67-7 |
Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H400 H410 |
GHS07 GHS09 Wng |
H315 H410 |
|
|
|
|
607-209-00-1 |
masa poreakcyjna (pentatio)bistiomrówczanu, (tetratio)bistiomrówczanu i (tritio)bistiomrówczanu O, O'-diizopropylu; masa poreakcyjna (pentatio)bistiomrówczanu, (tetratio)bistiomrówczanu i (tritio)bistiomrówczanu O, O'-di(1-metyloetylu) |
403-030-6 |
— |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|
|
|
|
607-210-00-7 |
akrylamidoglikolan metylu (zawierajacy ≥ 0,1 % akrylamidu) |
403-230-3 |
77402-05-2 |
Carc. 1B Muta. 1B Skin Corr. 1B Skin Sens. 1 |
H350 H340 H314 H317 |
GHS08 GHS05 GHS07 Dgr |
H350 H340 H314 H317 |
|
|
|
|
607-211-00-2 |
3-(3-tert-butylo-4-hydroksy-5-metylofenylo)propionian metylu |
403-270-1 |
6386-39-6 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
607-212-00-8 |
poli[oksypropylenokarbonylo-co-oksy(etyloetyleno)karbonyl], zawierajacy 27 % hydroksywalerianianu |
403-300-3 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-213-00-3 |
3,3-bis(tert-pentyloperoksy)maślan etylu; 3,3-bis[(1,1-dimetylopropylo)peroksy]butanian etylu |
403-320-2 |
67567-23-1 |
Org. Perox. D**** Flam. Liq. 3 Aquatic Chronic 2 |
H242 H226 H411 |
GHS02 GHS09 Dgr |
H242 H226 H411 |
|
|
|
|
607-214-00-9 |
kwas N, N-hydrazynodioctowy |
403-510-5 |
19247-05-3 |
Acute Tox. 3 * STOT RE 2 * Skin Sens. 1 Aquatic Chronic 3 |
H301 H373 ** H317 H412 |
GHS06 GHS08 Dgr |
H301 H373 ** H317 H412 |
|
|
|
|
607-215-00-4 |
kwas 3-(3-tert-butylo-4-hydroksyfenylo)propionowy |
403-920-4 |
107551-67-7 |
Acute Tox. 4 * Eye Irrit. 2 |
H302 H319 |
GHS07 Wng |
H302 H319 |
|
|
|
|
607-216-00-X |
produkty reakcji kwasu glutaminowego z N-(C12-14-alkilo)propyleno-1,3-diaminą |
403-950-8 |
— |
Acute Tox. 2 * Acute Tox. 4 * Skin Corr. 1B Aquatic Acute 1 |
H330 H302 H314 H400 |
GHS06 GHS05 GHS09 Dgr |
H330 H302 H314 H400 |
|
|
|
|
607-217-00-5 |
2-[4-(2,6-dihydro-2,6-diokso-7-fenylo-1,5-dioksoindocen-3-ylo)fenoksy]octan 2-etoksyetylu |
403-960-2 |
— |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
607-218-00-0 |
dichloroprop-P (ISO); kwas (+)-R-2-(2,4-dichlorofenoksy)propionowy |
403-980-1 |
15165-67-0 |
Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 |
H302 H315 H318 H317 |
GHS05 GHS07 Dgr |
H302 H315 H318 H317 |
|
|
|
|
607-219-00-6 |
ditiodioctan bis(2-etyloheksylu) |
404-510-8 |
62268-47-7 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H317 H411 |
GHS07 GHS09 Wng |
H302 H317 H411 |
|
|
|
|
607-221-00-7 |
kwas 6-dokozyloksy-1-hydroksy-4-[1-(4-hydroksy-3-metylofenantren-1-ylo)-3-okso-2-oksafenalen-1-ylo]-naftaleno-2-karboksylowy |
404-550-6 |
— |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
607-222-00-2 |
metakrylan 6-(2,3-dimetylomaleimido)-heksylu |
404-870-6 |
63740-41-0 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-223-00-8 |
transflutryna (ISO); trans-2-(2,2-dichlorowinylo)-3,3-dimetylocyklopropanokarboksylan 2,3,5,6-tetrafluorobenzylu |
405-060-5 |
118712-89-3 |
Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H400 H410 |
GHS07 GHS09 Wng |
H315 H410 |
|
|
|
|
607-224-00-3 |
2-(3-nitrobenzylideno)acetooctan metylu |
405-270-7 |
39562-17-9 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
607-225-00-9 |
kwas 3-azydosulfonylobenzoesowy |
405-310-3 |
15980-11-7 |
Self-React. C **** STOT RE 2 * Eye Dam. 1 Skin Sens. 1 |
H241 H373 ** H318 H317 |
GHS02 GHS08 GHS05 GHS07 Dgr |
H241 H373 ** H318 H317 |
|
|
|
|
607-226-00-4 |
masa poreakcyjna: wodorocykloheksano-1,2-dikarboksylanu 2-akryloksyetylu i wodorocykloheksano-1,2-dikarboksylan 2-metakryloksyetylu |
405-360-6 |
— |
Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H315 H318 H317 H412 |
GHS05 GHS07 Dgr |
H315 H318 H317 H412 |
|
|
|
|
607-227-00-X |
2-amino-2-metylopropionian potasu – oktahydrat |
405-560-3 |
120447-91-8 |
Acute Tox. 4 * Skin Corr. 1A |
H302 H314 |
GHS05 GHS07 Dgr |
H302 H314 |
|
|
|
|
607-228-00-5 |
ftalan bis(2-metoksyetylu) |
204-212-6 |
117-82-8 |
Repr. 1B |
H360Df |
GHS08 Dgr |
H360Df |
|
|
|
|
607-229-00-0 |
chlorek dietylokarbamoilu |
201-798-5 |
88-10-8 |
Carc. 2 Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H351 H332 H302 H319 H335 H315 |
GHS08 GHS07 Wng |
H351 H332 H302 H319 H335 H315 |
|
|
|
|
607-230-00-6 |
kwas 2-etyloheksanowy |
205-743-6 |
149-57-5 |
Repr. 2 |
H361d *** |
GHS08 Wng |
H361d *** |
|
|
|
|
607-231-00-1 |
chlopyralid (ISO); kwas 3,6-dichloropirydyno-2-karboksylowy |
216-935-4 |
1702-17-6 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-232-00-7 |
pirydat (ISO); tiowęglan O-(6-chloro-3-fenylopirydazyn-4-ylu) S-oktylu |
259-686-7 |
55512-33-9 |
Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H317 H400 H410 |
GHS07 GHS09 Wng |
H315 H317 H410 |
|
|
|
|
607-233-00-2 |
akrylan heksylu |
219-698-5 |
2499-95-8 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H319 H335 H315 H317 H411 |
GHS07 GHS09 Wng |
H319 H335 H315 H317 H411 |
|
|
|
|
607-234-00-8 |
flurenol (ISO); kwas 9-hydroksy-9H-fluoreno-9-karboksylowy |
207-397-1 |
467-69-6 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-235-00-3 |
mekrylat; 2-cyjanoakrylan metylu |
205-275-2 |
137-05-3 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H319 H335 H315 |
GHS07 Wng |
H319 H335 H315 |
|
STOT SE 3; H335: C ≥ 10 % |
|
|
607-236-00-9 |
2-cyjanoakrylan etylu |
230-391-5 |
7085-85-0 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H319 H335 H315 |
GHS07 Wng |
H319 H335 H315 |
|
STOT SE 3; H335: C ≥ 10 % |
|
|
607-237-00-4 |
2-chloro-4-(trifluorometylo)tiazolo-5-karboksylan benzylu; flurazol |
276-942-3 |
72850-64-7 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-238-00-X |
tau-fluwalinat (ISO); N-[2-chloro-4-(trifluorometylo)fenylo]-D-walinian cyjano(3-fenoksyfenylo)metylu; (R)-2-[2-chloro-4-(trifluorometylo)anilino]-3-metylobutanian (RS)-cyjano(3-fenoksyfenylo)metylu |
— |
102851-06-9 |
Acute Tox. 4 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H315 H400 H410 |
GHS07 GHS09 Wng |
H302 H315 H410 |
|
|
|
|
607-239-00-5 |
fenpropatryna (ISO); 2,2,3,3-tetrametylocyklopropanokarboksylan α-cyjano-3-fenoksybenzylu; 2,2,3,3-tetrametylocyklopropanokarboksylan (RS)-cyjano(3-fenoksyfenylo)metylu |
254-485-0 |
39515-41-8 |
Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H301 H312 H400 H410 |
GHS06 GHS09 Dgr |
H330 H301 H312 H410 |
|
|
|
|
607-240-00-0 |
bezwodnik cis-4-metylo-1,2,3,6-tetrahydroftalowy; [1] bezwodnik 4-metylo-1,2,3,6-tetrahydroftalowy; [2] bezwodnik 3-metylo-1,2,3,6-tetrahydroftalowy; [3] bezwodnik metylotetrahydroftalowy; [4] bezwodnik metylo-1,2,3,6-tetrahydroftalowy; [5] bezwodnik 4-metylotetrahydroftalowy; [6] bezwodnik 2-metylo-2,3,5,6-tetrahydroftalowy [7] |
216-906-6 [1] 222-323-8 [2] 226-247-6 [3] 234-290-7 [4] 247-830-1 [5] 251-823-9 [6] 255-853-3 [7] |
1694-82-2 [1] 3425-89-6 [2] 5333-84-6 [3] 11070-44-3 [4] 26590-20-5 [5] 34090-76-1 [6] 42498-58-8 [7] |
Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H318 H334 H317 |
GHS08 GHS05 Dgr |
H318 H334 H317 |
|
|
C |
|
607-241-00-6 |
bezwodnik 4-metyloheksahydroftalowy; [1] bezwodnik metyloheksahydroftalowy; [2] bezwodnik 1-metyloheksahydroftalowy; [3] bezwodnik 3-metyloheksahydroftalowy [4] |
243-072-0 [1] 247-094-1 [2] 256-356-4 [3] 260-566-1 [4] |
19438-60-9 [1] 25550-51-0 [2] 48122-14-1 [3] 57110-29-9 [4] |
Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 |
H318 H334 H317 |
GHS08 GHS05 Dgr |
H318 H334 H317 |
|
|
C |
|
607-242-00-1 |
bezwodnik tetrachloroftalowy |
204-171-4 |
117-08-8 |
Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H334 H317 H400 H410 |
GHS08 GHS05 GHS09 Dgr |
H318 H334 H317 H410 |
|
|
|
|
607-243-00-7 |
3,6-dichloro-2-metoksybenzoesan sodu; [1] kwas 3,6-dichloro-o-anyżowy, związek z 2,2'-iminodietanolem (1:1); [2] kwas 3,6-dichloro-o-anyżowy, związek z 2-aminoetanolem (1:1) [3] |
217-846-3 [1] 246-590-5 [2] 258-527-9 [3] |
1982-69-0 [1] 25059-78-3 [2] 53404-28-7 [3] |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-244-00-2 |
akrylan izooktylu |
249-707-8 |
29590-42-9 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H335 H315 H400 H410 |
GHS07 GHS09 Wng |
H319 H335 H315 H410 |
|
STOT SE 3; H335: C ≥ 10 % |
|
|
607-245-00-8 |
akrylan tert-butylu |
216-768-7 |
1663-39-4 |
Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H225 H332 H312 H302 H335 H315 H317 H411 |
GHS02 GHS07 GHS09 Dgr |
H225 H332 H312 H302 H335 H315 H317 H411 |
|
|
D |
|
607-246-00-3 |
metakrylan allilu; ester prop-2-en-1-ylowy kwasu 2-metyloprop-2-enowego |
202-473-0 |
96-05-9 |
Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 |
H226 H331 H312 H302 H400 |
GHS02 GHS06 GHS09 Dgr |
H226 H331 H312 H302 H400 |
|
|
|
|
607-247-00-9 |
metakrylan dodecylu |
205-570-6 |
142-90-5 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H335 H315 H400 H410 |
GHS07 GHS09 Wng |
H319 H335 H315 H410 |
|
STOT SE 3; H335: C ≥ 10 % |
|
|
607-248-00-4 |
naptalam sodowy (ISO); N-1-naftyloftalamian sodu |
205-073-4 |
132-67-2 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
607-249-00-X |
diakrylan (1-metyloetano-1,2-diylo)bis[oksy(metyloetano-2,1-diylu)]; diakrylan glikolu tripropylenowego; TPGDA |
256-032-2 |
42978-66-5 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H319 H335 H315 H317 H411 |
GHS07 GHS09 Wng |
H319 H335 H315 H317 H411 |
|
STOT SE 3; H335: C ≥ 10 % |
|
|
607-250-00-5 |
4H-3,1-benzoksazyno-2,4(1H)-dion |
204-255-0 |
118-48-9 |
Eye Irrit. 2 Skin Sens. 1 |
H319 H317 |
GHS07 Wng |
H319 H317 |
|
|
|
|
607-251-00-0 |
octan 2-metoksypropylu |
274-724-2 |
70657-70-4 |
Flam. Liq. 3 Repr. 1B STOT SE 3 |
H226 H360D *** H335 |
GHS02 GHS08 GHS07 Dgr |
H226 H360D *** H335 |
|
|
|
|
607-252-00-6 |
lambda-cyhalotryna (ISO); masa poreakcyjna: (Z)-(1R)-cis-3-(2-chloro-3,3,3-trifluoropropenylo)-2,2-dimetylocyklopropanokarboksylanu (S)-α-cyjano-3-fenoksybenzylu i (Z)-(1S)-cis-3-(2-chloro-3,3,3-trifluoropropenylo)-2,2-dimetylocyklopropanokarboksylanu (R)-α-cyjano-3-fenoksybenzylu (1:1) |
415-130-7 |
91465-08-6 |
Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H301 H312 H400 H410 |
GHS06 GHS09 Dgr |
H330 H301 H312 H410 |
|
M=10000 |
|
|
607-253-00-1 |
cyflutryna (ISO); 3-(2,2-dichlorowinylo)-2,2-dimetylocyklopropanokarboksylan α-cyjano-3-fenoksy-4-fluorobenzylu; 3-(2,2-dichlorowinylo)-2,2-dimetylocyklopropanokarboksylan cyjano(3-fenoksy-4-fluorofenylo)metylu |
269-855-7 |
68359-37-5 |
Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H300 H331 H400 H410 |
GHS06 GHS09 Dgr |
H300 H331 H410 |
|
M=1000 |
|
|
607-254-00-7 |
ester (SR)-α-cyjano-(3-fenoksy-4-fluorofenylo)metylowy kwasu (1RS, 3RS; 1RS; 3SR)-3-(2,2-dichlorowinylo)-2,2-dimetylocyklopropanokarboksylowego; beta-cyflutryna |
269-855-7 |
68359-37-5 |
Acute Tox. 2 * Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H300 H400 H410 |
GHS06 GHS09 Dgr |
H330 H300 H410 |
|
|
|
|
607-255-00-2 |
fluroksypyr (ISO); kwas 4-amino-3,5-dichloro-6-fluoro-2-pirydyloksyoctowy |
— |
69377-81-7 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-256-00-8 |
azoksystrobina (ISO); (E)-2-{2-[6-(2-cyjanofenoksy)pirymidyn-4-yloksy]fenylo}-3-metoksyakrylan metylu |
— |
131860-33-8 |
Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H400 H410 |
GHS06 GHS09 Dgr |
H331 H410 |
|
|
|
|
607-257-00-3 |
propionian izopropylu |
211-300-8 |
637-78-5 |
Flam. Liq. 2 |
H225 |
GHS02 Dgr |
H225 |
|
|
|
|
607-258-00-9 |
3-[2-(3-benzylo-4-etoksy-2,5-dioksoimidazolidyn-1-ylo)-3-(4-metoksybenzoilo)acetamido]-4-chlorobenzoesan dodecylu |
403-990-6 |
70950-45-7 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-259-00-4 |
(2R,3S)-(-)-3-(4-metoksyfenylo)oksiranokarboksylan metylu |
404-130-2 |
105560-93-8 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|
|
|
|
607-260-00-X |
2-(3-nitrobenzylideno)acetylooctan etylu; 2-(3-nitrofenylometylideno)acetylooctan etylu |
404-490-0 |
39562-16-8 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|
|
|
|
607-261-00-5 |
(3,5-di-tert-butylo-4-hydroksyfenylo)metylosulfanylooctan izo(C10-14)alkilu |
404-800-4 |
118832-72-7 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-262-00-0 |
kwas 7-chloro-1-cyklopropylo-6-fluoro-4-okso-1,4-dihydrochinolino-3-karboksylowy |
405-050-0 |
86393-33-1 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
607-263-00-6 |
1,3-propanodiamino-N, N,N',N'-tetraoctan potasu żelaza(III) – 1/2 hydrat (półwodzian) |
405-680-6 |
— |
Self-heat. 2 **** Aquatic Chronic 2 |
H252 H411 |
GHS02 GHS09 Wng |
H252 H411 |
|
|
|
|
607-264-00-1 |
kwas 2-chloro-4-(metylosulfonylo)benzoesowy |
406-520-8 |
53250-83-2 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-265-00-7 |
2-chloro-2,2-difenylooctan etylu |
406-580-5 |
52460-86-3 |
Skin Irrit. 2 Aquatic Chronic 3 |
H315 H412 |
GHS07 Wng |
H315 H412 |
|
|
|
|
607-266-00-2 |
masa poreakcyjna: bis[2-hydroksy-3,5-di-tert-butylobenzoesanu] wodorotlenku glinu; kwasu 3,5-di-tert-butylo-2-hydroksybenzoesowego |
406-890-0 |
130296-87-6 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
607-267-00-8 |
(5S,6R,7R)-3-bromometylo-5,8-diokso-7-(2-fenyloacetamido)-5-tia-1-azabicyklo[4.2.0]okt-2-eno-2-karboksylan tert-butylu |
407-620-4 |
33610-13-8 |
Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 3 |
H334 H317 H412 |
GHS08 Dgr |
H334 H317 H412 |
|
|
|
|
607-268-00-3 |
(R)-2-hydroksypropanian 2-metylopropylu; (R)-2-hydroksypropionian izobutylu |
407-770-0 |
61597-96-4 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
607-269-00-9 |
kwas (R)-2-(4-hydroksyfenoksy)propanowy |
407-960-3 |
94050-90-5 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-270-00-4 |
3,9-bis{2-[3-(3-tert-butylo-4-hydroksy-5-metylofenylo)propionyloksy]-1,1-dimetyloetylo}-2,4,8,10-tetraoksaspiro[5.5]undekan |
410-730-5 |
90498-90-1 |
Acute Tox. 4 * |
H312 |
GHS07 Wng |
H312 |
|
|
|
|
607-271-00-X |
1-[(2-izopropylo-5-metylocykloheksyloksy)karbonyloksy]-2-hydroksypropan; węglan 2-hydroksypropylu-(2-izopropylo-5-metylocykloheksylu) |
417-420-9 |
156324-82-2 |
Eye Irrit. 2 Aquatic Chronic 2 |
H319 H411 |
GHS07 GHS09 Wng |
H319 H411 |
|
|
|
|
607-272-00-5 |
fluroksypyr meptylowy (ISO); 4-amino-3,5-dichloro-6-fluoro-2-pirydyloksy)octan metyloheptylu; [1] fluroksypyr butometylowy (ISO); 4-amino-3,5-dichloro-6-fluoro-2-pirydyloksy)octan 2-butoksy-1-metyloetylu [2] |
279-752-9 [1] -[2] |
81406-37-3 [1] 154486-27-8 [2] |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-273-00-0 |
7-[2,6-dimetylo-8-(2,2-dimetylobutyryloksy)-1,2,6,7,8,8a-heksahydro-1-naftylo]-3,5-dihydroksyheptanian amonu |
404-520-2 |
— |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-274-00-6 |
3-aminobut-2-enian 2-(N-benzylo-N-metyloamino)etylu |
405-350-1 |
54527-73-0 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-275-00-1 |
benzoiloksybenzeno-4-sulfonian sodu |
405-450-5 |
66531-87-1 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-276-00-7 |
bis[(1-metyloimidazolo)(2-etyloheksaniano)]cynk |
405-635-0 |
— |
Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H400 H410 |
GHS05 GHS09 Dgr |
H315 H318 H410 |
|
|
|
|
607-277-00-2 |
masa poreakcyjna: chlorowodorku 2(heksylotio)etyloaminy; propionianu sodu |
405-720-2 |
— |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H302 H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H317 H411 |
|
|
|
|
607-278-00-8 |
masa poreakcyjna izomerów: fenetylonaftalenosulfonianu sodu; naftyloetylobenzenosulfonianu sodu |
405-760-0 |
— |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|
|
|
|
607-279-00-3 |
masa poreakcyjna bis(wodoromaleinianu) oktadecyloaminodietylu; wodoromaleinianu wodoroftalanu oktadecyloaminodietylu |
405-960-8 |
— |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-280-00-9 |
4-chloro-1-hydroksybutano-1-sulfonian sodu |
406-190-5 |
54322-20-2 |
Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 |
H302 H319 H317 |
GHS07 Wng |
H302 H319 H317 |
|
|
|
|
607-281-00-4 |
masa poreakcyjna 3-[3-(2H-benzotriazol-2-ilo)-5-(1,1-dimetyloetylo)-4-hydroksyfenylo]propanianów (C7-9)alkili (rozgałęzionych i nierozgałęzionych) |
407-000-3 |
127519-17-9 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-282-00-X |
octan 2-acetoksymetylo-4-benzyloksybutylu |
407-140-5 |
131266-10-9 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-283-00-5 |
(E)-4-okso-4-fenylobut-2-enian etylu; 4-okso-4-fenylokrotonian etylu |
408-040-4 |
15121-89-8 |
Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H315 H318 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H312 H302 H315 H318 H317 H410 |
|
|
|
|
607-284-00-0 |
masa poreakcyjna: 3,3'-[1,4-fenylenobis(karbonyloiminopropano-3,1-diyloimino)]bis(10-amino-6,13-dichloro)trifenodioksazyno-4,11-disulfonianu) sodu i litu (9:1) |
410-040-4 |
136213-76-8 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-285-00-6 |
masa poreakcyjna: kwasu 7-[(3-aminofenylo)sulfonyloamino]naftaleno-1,3-disulfonowego; 7-[(3-aminofenylo)sulfonyloamino]naftaleno-1,3-disulfonianu sodu; 7-[(3-aminofenylo)sulfonyloamino]naftaleno-1,3-disulfonianu potasu |
410-065-0 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
|
|
|
|
|
607-286-00-1 |
masa poreakcyjna: 7-{3-[4-(2-hydroksynaftyloazo)fenyloazo]fenylosulfonyloamino}naftaleno-1,3-disulfonianów sodu/potasu; |
410-070-8 |
141880-36-6 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
607-287-00-7 |
1,2,3,6-tetrahydroftalan (1-metylo-2-metakryloksyetylu)-metylu |
410-140-8 |
— |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-288-00-2 |
{c-[3-(1-{3-[e,6-dichloro-5-cyjano-pirymidyn-f-ylo(metylo)amino]propylo}-2-hydroksy-4-metylo-6-okso-1,6-dihydro-3-pirydylazo)-4-sulfonianofenylosulfa-moilo]ftalocyjanino-a, b,d-trisulfoniano(6-)}niklan(II) tetrasodu, gdzie: a = 1, 2, 3 lub 4; b = 8, 9, 10 lub 11; c = 15, 16, 17 lub 18; d = 22, 23, 24 lub 25; e i f są odpowiednio 2 i 4 lub 4 i 2 |
410-160-7 |
148732-74-5 |
Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 |
H319 H317 H412 |
GHS07 Wng |
H319 H317 H412 |
|
|
|
|
607-289-00-8 |
kwas 3-(3-{4-[2,4-bis(1,1-dimetylopropylo)fenoksy]butyloaminokarbonylo-4-hydroksynaftalen-1-ylo}tio)propanowy |
410-370-9 |
105488-33-3 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-290-00-3 |
masa poreakcyjna (proporcja nieznana): 2-(C14-18)alkiloksykarbonylo-1-(3-alliloksy-2-hydroksypropoksykarbonylo)etano-1-sulfonianu amonu; 2-(C14-18)alkiloksykarbonylo-1-(3-alliloksy-2-hydroksypropoksykarbonylo)etano-1-sulfonianu amonu |
410-540-2 |
— |
Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H317 H400 H410 |
GHS07 GHS09 Wng |
H315 H317 H410 |
|
|
|
|
607-291-00-9 |
ω-(C5/C6-cykloalkilo)alkanokarboksylan dodecylu |
410-630-1 |
104051-92-5 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-292-00-4 |
masa poreakcyjna: kwasu [1-(metoksymetylo)-2-(C12-alkoksy)etoksy]octowego; kwasu [1-(metoksymetylo)-2-(C14-alkoksy)etoksy]octowego |
410-640-6 |
— |
Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H400 H410 |
GHS05 GHS09 Dgr |
H315 H318 H410 |
|
|
|
|
607-293-00-X |
masa poreakcyjna: disulfonianu eteru mono-2,4,6-trimetylononylodifenylowego N-aminoetylopiperazonium; disulfonianu eteru di-2,4,6-trimetylononylodifenylowego N-aminoetylopiperazonium |
410-650-0 |
— |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H318 H317 H411 |
|
|
|
|
607-294-00-5 |
2-benzoiloksy-1-hydroksyetanosulfonian sodu |
410-680-4 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-295-00-0 |
masa poreakcyjna: fosfonoetano-1,2-dikarboksylanu tetrasodu; fosfonobutano-1,2,3,4-tetrakarboksylanu heksasodu |
410-800-5 |
— |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-296-00-6 |
masa poreakcyjna: tetraestrów pentaerytrytolu z kwasem heptanowym i kwasem 2-etyloheksanowym |
410-830-9 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-297-00-1 |
(E, E)-3,3'-(1,4-fenylenodimetylideno)bis(kwas 2-oksobornano-10-sulfonowy); |
410-960-6 |
92761-26-7 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-298-00-7 |
2-(trimetyloamonium)etoksykarboksybenzeno-4-sulfonian |
411-010-3 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-299-00-2 |
3-(acetylosulfanylo)-2-metylopropanian metylu; 3-(acetylotio)-2-metylopropanian metylu |
411-040-7 |
97101-46-7 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|
|
|
|
607-300-00-6 |
[2-(5-chloro-2,6-difluoropirymidyn-4-yloamino)-5-(b-sulfamoilo-c, d-sulfonianoftalocyjanin-a-ylo-K4,N29,N30,N31,N32-sulfonyloamino)benzoesano(5-)]miedzian(II) trisodu, gdzie a = 1,2,3,4; b = 8,9,10,11; c = 15,16,17,18; d = 22,23,24,25 |
411-430-7 |
— |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
607-301-00-1 |
masa poreakcyjna: kwasu dodekanowego; poli(1-7)mleczanowych estrów kwasu dodekanowego |
411-860-5 |
— |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-302-00-7 |
masa poreakcyjna: kwasu tetradekanowego poli(1-7)mleczanowych estrów kwasu tetradekanowego |
411-910-6 |
— |
Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H315 H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H315 H318 H317 H411 |
|
|
|
|
607-303-00-2 |
kwas 1-cyklopropylo-6,7-difluoro-4-okso-1,4-dihydrochinolino-3-karboksylowy |
413-760-7 |
93107-30-3 |
Repr. 2 Aquatic Chronic 3 |
H361f *** H412 |
GHS08 Wng |
H361f *** H412 |
|
|
|
|
607-304-00-8 |
fluazyfop butylowy (ISO); (RS)-2-[4-(5-trifluorometylo-2-pirydyloksy)fenoksy]propanian butylu |
274-125-6 |
69806-50-4 |
Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H360D *** H400 H410 |
GHS08 GHS09 Dgr |
H360D *** H410 |
|
|
|
|
607-305-00-3 |
fluazyfop-P butylowy (ISO); (R)-2-[4-(5-trifluorometylo-2-pirydyloksy)fenoksy]propanian butylu |
— |
79241-46-6 |
Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H361d *** H400 H410 |
GHS08 GHS09 Wng |
H361d *** H410 |
|
|
|
|
607-306-00-9 |
chlozolinat (ISO); (RS)-3-(3,5-dichlorofenylo)-5-metylo-2,4-diokso-1,3-oksazolidyno-5-karboksylan etylu |
282-714-4 |
84332-86-5 |
Carc. 2 Aquatic Chronic 2 |
H351 H411 |
GHS08 GHS09 Wng |
H351 H411 |
|
|
|
|
607-307-00-4 |
winchlozolina (ISO); (RS)-3-(3,5-dichlorofenylo)-5-metylo-5-winylo-1,3-oksazolidyno-2,4-dion |
256-599-6 |
50471-44-8 |
Carc. 2 Repr. 1B Skin Sens. 1 Aquatic Chronic 2 |
H351 H360FD H317 H411 |
GHS08 GHS07 GHS09 Dgr |
H351 H360FD H317 H411 |
|
|
|
|
607-308-00-X |
estry 2,4-D (ISO); estry kwasu (2,4-dichlorofenoksy)octowego |
— |
— |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|
|
A |
|
607-309-00-5 |
karfentrazon etylowy (ISO); (RS)-2-chloro-3-[2-chloro-5-(4-difluorometylo-3-metylo-5-okso-4,5-dihydro-1H-1,2,4-triazol-1-ilo)-4-fluorofenylo]propanian etylu |
— |
128639-02-1 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-310-00-0 |
krezoksym metylu (ISO); (E)-2-metoksyimino[2-(o-toliloksymetylo)fenylo]octan metylu |
— |
143390-89-0 |
Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H400 H410 |
GHS08 GHS09 Wng |
H351 H410 |
|
|
|
|
607-311-00-6 |
benazolina etylowa (ISO); 4-chloro-2-okso-2,3-dihydrobenzotiazol-3-ilooctan etylu |
246-591-0 |
25059-80-7 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-312-00-1 |
kwas metoksyoctowy |
210-894-6 |
625-45-6 |
Repr. 1B Acute Tox. 4 * Skin Corr. 1B |
H360FD H302 H314 |
GHS08 GHS05 GHS07 Dgr |
H360FD H302 H314 |
|
STOT SE 3; H335: C ≥ 5 % |
|
|
607-313-00-7 |
chlorek neodekanoilu |
254-875-0 |
40292-82-8 |
Acute Tox. 2 * Acute Tox. 4 * Skin Corr. 1B |
H330 H302 H314 |
GHS06 GHS06 Dgr |
H330 H302 H314 |
|
STOT SE 3; H335: C ≥ 5 % |
|
|
607-314-00-2 |
etofumesat (ISO); metanosulfonian (±)-2-etoksy-3,3-dimetylo-2,3-dihydrobenzofuran-5-ylu |
247-525-3 |
26225-79-6 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-315-00-8 |
glifosat (ISO); N-(fosfonometylo)glicyna |
213-997-4 |
1071-83-6 |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|
|
|
|
607-316-00-3 |
glifosat-trimesium; glifosat trimetylosulfonium |
— |
81591-81-3 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
607-317-00-9 |
ftalan bis(2-etyloheksylu); ftalan di(2-etyloheksylu); DEHP |
204-211-0 |
117-81-7 |
Repr. 1B |
H360FD |
GHS08 Dgr |
H360FD |
|
|
|
|
607-318-00-4 |
ftalan dibutylu; DBP |
201-557-4 |
84-74-2 |
Repr. 1B Aquatic Acute 1 |
H360Df H400 |
GHS08 GHS09 Dgr |
H360Df H400 |
|
|
|
|
607-319-00-X |
deltametryna (ISO); (1R,3R)-3-(2,2-dibromowinylo)-2,2-dimetylocyklopropanokarboksylan (S)-α-cyjano-3-fenoksybenzylu |
258-256-6 |
52918-63-5 |
Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H301 H400 H410 |
GHS06 GHS09 Dgr |
H331 H301 H410 |
|
M=1000000 |
|
|
607-320-00-5 |
benzeno-1,3-dikarboksylan bis[4-(winyloksy)butylu]; benzeno-1,3-dikarboksylan bis[4-(etenyloksy)butylu] |
413-930-0 |
130066-57-8 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
607-321-00-0 |
(S)-2-chloropropanian metylu |
412-470-8 |
73246-45-4 |
Flam. Liq. 3 STOT RE 2 * Eye Irrit. 2 |
H226 H373 ** H319 |
GHS02 GHS08 Wng |
H226 H373 ** H319 |
|
|
|
|
607-322-00-6 |
kwas 4-(4,4-dimetylo-3-oksopirazolidyn-1-ylo)benzoesowy |
413-120-7 |
107144-30-9 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
607-323-00-1 |
akrylan 2-[1-(2-hydroksy-3,5-di-tert-pentylofenylo)etylo]-4,6-di-tert-pentylofenylu |
413-850-6 |
123968-25-2 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-324-00-7 |
masa poreakcyjna: kwasu N, N-di(C14-C18 alkilo)ftalamowego; di(C14-C18 alkilo)aminy |
413-800-3 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-325-00-2 |
kwas (S)-2-chloropropanowy |
411-150-5 |
29617-66-1 |
Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A |
H312 H302 H314 |
GHS05 GHS07 Dgr |
H312 H302 H314 |
|
|
|
|
607-326-00-8 |
masa poreakcyjna: 2-(α-2,4,6-trimetylonon-2-en-1-ylo)wodorobursztynianu izobutylu; 2-(ß-2,4,6-trimetylonon-2-en-1-ylo)wodorobursztynianu izobutylu |
410-720-0 |
141847-13-4 |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|
|
|
|
607-327-00-3 |
dioctan 2-(2-jodoetylo)propano-1,3-diylu |
411-780-0 |
127047-77-2 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
607-328-00-9 |
4-bromometylo-3-metoksybenzoesan metylu |
410-310-1 |
70264-94-7 |
Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H315 H318 H317 H410 |
|
|
|
|
607-329-00-4 |
masa poreakcyjna: 2-(C12-18-n-alkilo)aminobutanodianu sodu; 2-oktadecenyloaminobutanodianu sodu, gdzie n-alkil oznacza alkil o nierozgałęzionym łańcuchu węglowym |
411-250-9 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-330-00-X |
kwas (S)-2,3-dihydro-1H-indolo-2-karboksylowy |
410-860-2 |
79815-20-6 |
Repr. 2 STOT RE 2 * Skin Sens. 1 |
H361f *** H373 ** H317 |
GHS08 GHS07 Wng |
H361f *** H373 ** H317 |
|
|
|
|
607-331-00-5 |
masa poreakcyjna: dekanodianu bis(2,2,6,6-tetrametylo-1-oktyloksypiperydyn-4-ylu); 1,8-bis({2,2,6,6-tetrametylo-4-[(2,2,6,6-tetrametylo-1-oktyloksypiperydyn-4-ylo)dekano-1,10-dioilo]piperydyn-1-ylo}oksy)oktanu |
406-750-9 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-332-00-0 |
chloromrówczan cyklopentylu |
411-460-0 |
50715-28-1 |
Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 |
H226 H331 H302 H373 ** H318 H317 |
GHS02 GHS06 GHS08 GHS05 Dgr |
H226 H331 H302 H373 ** H318 H317 |
|
|
|
|
607-333-00-6 |
masa poreakcyjna: N-(2,2,6,6-tetrametylopiperydyn-4-ylo)-β-alaninianu dodecylu; N-(2,2,6,6-tetrametylopiperydyn-4-ylo)-β-alaninianu tetradecylu |
405-670-1 |
— |
Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373 ** H314 H400 H410 |
GHS08 GHS05 GHS07 GHS09 Dgr |
H302 H373 ** H314 H410 |
|
|
|
|
607-334-00-1 |
1-etylo-6,7,8-trifluoro-4-okso-1,4-dihydrochinolino-3-karboksylan etylu |
405-880-3 |
100501-62-0 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
607-335-00-7 |
(R)-2-[4-(3-chloro-5-trifluorometylo-2-pirydyloksy)fenoksy]propanian metylu |
406-250-0 |
72619-32-0 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
607-336-00-2 |
octan 4-metylo-8-metylenotricyklo[3.3.1.13,7]dekan-2-ylu |
406-560-6 |
122760-85-4 |
Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H315 H317 H411 |
GHS07 GHS09 Wng |
H315 H317 H411 |
|
|
|
|
607-337-00-8 |
2-benzotiazolilotiobursztynian di-tert-(C12-14)-alkiloamoniowy |
406-052-4 |
125078-60-6 |
Flam. Liq. 3 Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 |
H226 H302 H315 H318 H411 |
GHS02 GHS05 GHS07 GHS09 Dgr |
H226 H302 H315 H318 H411 |
|
|
|
|
607-338-00-3 |
2-hydroksy-2-metylobut-3-enian 2-metylopropylu |
406-235-9 |
72531-53-4 |
Eye Irrit. 2 Skin Irrit. 2 |
H319 H315 |
GHS07 Wng |
H319 H315 |
|
|
|
|
607-339-00-9 |
chlorek 2,3,4,5-tetrachlorobenzoilu |
406-760-3 |
42221-52-3 |
Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 |
H302 H314 H317 |
GHS05 GHS07 Dgr |
H302 H314 H317 |
|
|
|
|
607-340-00-4 |
octan 1,3-bis(4-benzoilo-3-hydroksyfenoksy)propan-2-ylu |
406-990-4 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-341-00-X |
(9S)-9-amino-9-deoksyerytromycyna |
406-790-7 |
26116-56-3 |
Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H400 H410 |
GHS05 GHS09 Dgr |
H318 H410 |
|
|
|
|
607-342-00-5 |
3,4-dimetoksybenzoesan 4-chlorobutylu |
410-950-1 |
69788-75-6 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-343-00-0 |
bis(2-karboksybenzoesan) 4,7-metanooktahydro-1H-indenodiylu dimetylu |
407-410-2 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-344-00-6 |
masa poreakcyjna: kwasu 3-[N-(3-dimetyloaminopropylo)(C4-8)perfluoroalkilosulfonoamido]propanowy; propionianu N-[dimetylo-3-(C4-8)perfluoroalkilosulfonoamido]propyloamoniowego; propionianu kwasu 3-[N-(3-dimetylopropyloamonio)(C4-8)perfluoroalkilosulfonoamido]propanowego |
407-810-7 |
— |
STOT RE 2 * |
H373 ** |
GHS08 Wng |
H373 ** |
|
|
|
|
607-345-00-1 |
(R)-2-(2,4-dichlorofenoksy)propanian potasu |
413-580-9 |
113963-87-4 |
Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 |
H302 H315 H318 H317 |
GHS05 GHS07 Dgr |
H302 H315 H318 H317 |
|
|
|
|
607-346-00-7 |
3-ikozylo-4-henikozylidenooksetan-2-on |
401-210-9 |
83708-14-9 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-347-00-2 |
(R)-2-(2,4-dichlorofenoksy)propanian sodu |
413-340-3 |
119299-10-4 |
Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 |
H302 H315 H318 H317 |
GHS05 GHS07 Dgr |
H302 H315 H318 H317 |
|
|
|
|
607-348-00-8 |
bis[(R)-2-(2,4-dichlorofenoksy)propanian] magnezu |
413-360-2 |
— |
Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 |
H302 H315 H318 H317 |
GHS05 GHS07 Dgr |
H302 H315 H318 H317 |
|
|
|
|
607-349-00-3 |
wodoro-2,2'-ditiobisbenzoesan mono(tetrapropyloamoniowy) |
411-270-8 |
— |
Aquatic Chronic 3 |
H412 |
|
H412 |
|
|
|
|
607-350-00-9 |
bis{4-[1,2-bis(etoksykarbonylo)etyloamino]-3-metylocykloheksylo}metan |
412-060-9 |
136210-32-7 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
607-351-00-4 |
O-(4-amino-3,5-dichloro-6-fluoropirydyn-2-yloksy)octan metylu |
407-550-4 |
69184-17-4 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-352-00-X |
bezwodnik 4,4'-oksydiftalowy |
412-830-4 |
1823-59-2 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-353-00-5 |
masa poreakcyjna: egzo-tricyklo[5.2.1.02,6]dekano-endo-2-karboksylanu etylu; endo-tricyklo[5.2.1.02,6]dekano-egzo-2-karboksylanu etylu |
407-520-0 |
80657-64-3 |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
607-354-00-0 |
2-cykloheksylopropanian etylu |
412-280-5 |
2511-00-4 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-355-00-6 |
4-chlorobenzoesan p-tolilu |
411-530-0 |
15024-10-9 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
607-356-00-1 |
trans-2,2,6-trimetylocykloheksanokarboksylan etylu |
412-540-8 |
— |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
607-357-00-7 |
masa poreakcyjna: trans-4-acetoksy-4-metylo-2-propylotetrahydro-2H-piranu; cis-4-acetoksy-4-metylo-2-propylotetrahydro-2H-piranu |
412-450-9 |
131766-73-9 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-358-00-2 |
(1S,3S,5R,6R)-6-fenylo-1-dioksoacetamidopenamo-3-karboksylan 4-nitrofenylometylu |
412-670-5 |
54275-93-3 |
Resp. Sens. 1 |
H334 |
GHS08 Dgr |
H334 |
|
|
|
|
607-359-00-8 |
(1S,4R,6R,7R)-7-fenylo-3-metyleno-1-oksoacetamidocefamo-4-karboksylan 4-nitrofenylometylu |
412-800-0 |
76109-32-5 |
Resp. Sens. 1 |
H334 |
GHS08 Dgr |
H334 |
|
|
|
|
607-360-00-3 |
3-acetoacetyloamino-4-metoksytolueno-6-sulfonian sodu |
411-680-7 |
133167-77-8 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-361-00-9 |
(R)-2-(4-hydroksyfenoksy)propanian metylu |
411-950-4 |
96562-58-2 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
607-362-00-4 |
masa poreakcyjna: 2-{2-[bis(2-hydroksyetylo)amino]etoksykarbonylometylo}heksadec-4-enianu 3-metoksypropyloamoniowego/[tris(2-hydroksyetylo)]amoniowego; 2-{2-[bis(2-hydroksyetylo)amino]etoksykarbonylometylo)tetradec-4-enianu 3-metoksypropyloamoniowego/[tris(2-hydroksyetylo)]amoniowego; 2-(3-metoksypropylokarbamoilometylo)heksadec-4-enianu 3-metoksypropyloamoniowego/[tris(2-hydroksyetylo)]amoniowego; 2-(3-metoksypropylokarbamoilometylo)tetradec-4-enianu 3-metoksypropyloamoniowego/[tris-(2-hydroksyetylo)]amoniowego |
413-500-2 |
— |
Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 |
H315 H318 H411 |
GHS05 GHS09 Dgr |
H315 H318 H411 |
|
|
|
|
607-363-00-X |
3-metoksyakrylan metylu |
412-900-4 |
5788-17-0 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-364-00-5 |
3-fenylo-7-[4-(tetrahydrofurfuryloksy)fenylo]-1,5-dioksa-s-indaceno-2,6-dion |
413-330-9 |
134724-55-3 |
Aquatic Chronic 4 |
H413 |
|
H413 |
|
|
|
|
607-365-00-0 |
chlorowodorek chlorku 2-(2-amino-1,3-tiazol-4-ilo)-(Z)-2-metoksyiminoacetylu |
410-620-7 |
119154-86-8 |
Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 |
H302 H314 H317 |
GHS05 GHS07 Dgr |
H302 H314 H317 |
|
|
|
|
607-366-00-6 |
chlorek 3,5-dimetylobenzoilu |
413-010-9 |
6613-44-1 |
Skin Corr. 1B Skin Sens. 1 |
H314 H317 |
GHS05 GHS07 Dgr |
H314 H317 |
|
|
|
|
607-367-00-1 |
bis(N-karboksymetylo)-N-metyloglicyniano(2-)-N, O,O, N-żelazian(1-) potasu – monohydrat |
411-640-9 |
153352-59-1 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
607-368-00-7 |
1-(N,N-dimetylokarbamoilo)-3-tert-butylo-5-karbetoksymetylosulfanylo-1H-1,2,4-triazol |
411-650-3 |
110895-43-7 |
Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H301 H400 H410 |
GHS06 GHS09 Dgr |
H331 H301 H410 |
|
|
|
|
607-369-00-2 |
masa poreakcyjna: kwasu trans-(2R)-5-acetoksy-1,3-oksatiolano-2-karboksylowego; kwasu cis-(2R)-5-acetoksy-1,3-oksatiolano-2-karboksylowego |
411-660-8 |
147027-04-1 |
Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 |
H302 H315 H318 H317 |
GHS05 GHS07 Dgr |
H302 H315 H318 H317 |
|
|
|
|
607-370-00-8 |
2-{[2-acetoksy-3-(1,1-dimetyloetylo)-5-metylofenylo]metylo}-6-(1,1-dimetyloetylo)-4-metylofenol |
412-210-3 |
41620-33-1 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-371-00-3 |
4-(2-chlorofenylo)-2-{2-[1,3-diokso-1,3-dihydro-(2)izoindol-2-ilo]etoksymetylo}-6-metylo-1,4-dihydropirydyno-3,5-dikarboksylan 3-etylu 5-metylu |
413-410-3 |
88150-62-3 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-372-00-9 |
oksyetylenowany di(norbornenokarboksylan) bisfenolu A |
412-410-0 |
— |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-373-00-4 |
(R)-2-[4-(6-chlorochinoksalin-2-yloksy)fenoksy]propanian (±)tetrahydrofurfurylu |
414-200-4 |
119738-06-6 |
Muta. 2 Repr. 1B Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H341 H360Df H302 H373 ** H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H341 H360Df H302 H373 ** H410 |
|
|
|
|
607-374-00-X |
dichlorek 5-amino-2,4,6-trijodobenzeno-1,3-dikarbonylu |
417-220-1 |
37441-29-5 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-376-00-0 |
2,4-dibromobutanian benzylu |
420-710-8 |
23085-60-1 |
Repr. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361f *** H315 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H361f *** H315 H317 H410 |
|
|
|
|
607-377-00-6 |
monochlorowodorek trans-4-cykloheksylo-L-proliny |
419-160-1 |
90657-55-9 |
Repr. 2 Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 |
H361f *** H302 H315 H318 H317 |
GHS08 GHS05 GHS07 Dgr |
H361f *** H302 H315 H318 H317 |
|
|
|
|
607-378-00-1 |
(Z)-α-metoksyimino-2-furylooctan amonu |
405-990-1 |
97148-39-5 |
Flam. Sol. 2 |
H228 |
GHS02 Dgr |
H228 |
|
|
T |
|
607-379-00-7 |
masa poreakcyjna: stearynianu 2-[N-(2-hydroksyetylo)stearamido]etylu; {bis[2-(stearoiloksy)etylo]amino}metylosulfonianu sodu; [bis(2-hydroksyetylo)amino]metylosulfonianu sodu; N, N-bis(2-hydroksyetylo)stearamidu |
401-230-8 |
|
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-380-00-2 |
masa poreakcyjna: 1,2-bis(heksyloksykarbonylo)etanosulfonianu amonu; 1-heksyloksykarbonylo-2-oktyloksykarbonyloetanosulfonianu amonu; 2-heksyloksykarbonylo-1-oktyloksykarbonyloetanosulfonianu amonu |
407-320-3 |
— |
Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 |
H315 H318 H412 |
GHS05 Dgr |
H315 H318 H412 |
|
|
|
|
607-381-00-8 |
masa poreakcyjna: triestrów 2,2-bis(hydroksymetylo)butanolu z kwasami C7-alkanowymi i kwasem 2-etyloheksanowym |
413-710-4 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-382-00-3 |
kwas 2-[(4-amino-2-nitrofenylo)amino]benzoesowy |
411-260-3 |
117907-43-4 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|
|
|
|
607-383-00-9 |
masa poreakcyjna: heksadekanianu 2,2,6,6-tetrametylopiperydyn-4-ylu; oktadekanianu 2,2,6,6-tetrametylopiperydyn-4-ylu |
415-430-8 |
86403-32-9 |
Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H318 H317 H410 |
|
|
|
|
607-384-00-4 |
masa poreakcyjna: estry rozgałęzionych alkoholi C14-C15 z kwasem 3,5-di-tert-butylo-4-hydroksyfenylopropanowym; 3,5-bis(1,1-dimetyloetylo)-4-hydroksybenzenopropaniany rozgałęzionych i linowych alkili C15; 3,5-bis(1,1-dimetyloetylo)-4-hydroksybenzenopropaniany rozgałęzionych i linowych alkili C13; |
413-750-2 |
171090-93-0 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-385-00-X |
kopolimer alkoholu winylowego i octanu winylu częściowo acetylowany metylosulfonianem 4-[2-(4-formylofenylo)etenylo]-1-metylopirydyniowy |
414-590-6 |
125229-74-5 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-386-00-5 |
masa poreakcyjna: kwasu tetradekanowego (42,5-47,5 %); estrów poli(1-7)mleczanowych kwasu tetradekanowego (52,5-57,5 %) |
412-580-6 |
174591-51-6 |
Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H315 H318 H317 H410 |
|
|
|
|
607-387-00-0 |
masa poreakcyjna: kwasu dodekanowego (35-40 %); estrów poli(1-7)mleczanowych kwasu dodekanowego (60-65 %) |
412-590-0 |
58856-63-6 |
Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H315 H318 H317 H410 |
|
|
|
|
607-388-00-6 |
kwas 4-etyloamino-3-nitrobenzoesowy |
412-090-2 |
2788-74-1 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 |
H302 H317 H412 |
GHS07 Wng |
H302 H317 H412 |
|
|
|
|
607-389-00-1 |
N, N-bis(karboksymetylo)-3-amino-2-hydroksypropanian trisodu |
414-130-4 |
119710-96-2 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
607-390-00-7 |
1,2,3,4-tetrahydro-6-nitrochinoksalina |
414-270-6 |
41959-35-7 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
607-391-00-2 |
cyklopropano-1,1-dikarboksylan dimetylu |
414-240-2 |
6914-71-2 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-392-00-8 |
4-[(5-cyjano-1,6-dihydro-2-hydroksy-1,4-dimetylo-6-oksopirydyn-3-ylo)azo]benzoesan 2-fenoksyetylu |
414-260-1 |
88938-37-8 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-393-00-3 |
kwas 3-(cis-prop-1-enylo)-7-amino-8-okso-5-tia-1-azabicyklo[4.2.0]-okt-2-eno-2-karboksylowy |
415-750-8 |
106447-44-3 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-394-00-9 |
kwas 5-metylopirazyno-2-karboksylowy |
413-260-9 |
5521-55-1 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-395-00-4 |
masa poreakcyjna: 1-dodecylo-4-allilo-(2 lub 3)-sulfobutanodianu sodu; 1-dodecylo-4-allilo-(2 lub 3)-sulfobutanodianu sodu |
410-230-7 |
— |
Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 |
H314 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H314 H317 H411 |
|
|
|
|
607-396-00-X |
2-(4-metoksybenzylideno)malonian bis(1,2,2,6,6-pentametylopiperydyn-4-ylu) |
414-840-4 |
147783-69-5 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-397-00-5 |
masa poreakcyjna: salicylanów wapnia (alkilowanych rozgałęzionymi C10-14 i C18-30); fenolanów wapnia (alkilowanych rozgałęzionymi C10-14 i C18-30); siarkowanych fenolanów wapnia (alkilowanych rozgałęzionymi C10-14 i C18-30) |
415-930-6 |
— |
Repr. 2 Skin Sens. 1 |
H361f*** H317 |
GHS08 GHS07 Wng |
H361f*** H317 |
|
|
|
|
607-398-00-0 |
N-{5-chloro-3-[4-(dietyloamino)-2-metylofenyloimino]-4-metylo-6-oksocykloheksa-1,4-dienylo}karbaminian etylu |
414-820-5 |
125630-94-6 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-399-00-6 |
2,2-dimetylopropanian 3-metylobut-3-enylu |
415-610-6 |
104468-21-5 |
Skin Irrit. 2 Aquatic Chronic 3 |
H315 H412 |
GHS07 Wng |
H315 H412 |
|
|
|
|
607-400-00-X |
3-{[(dibutyloamino)tioksometylo]tio}propanian metylu |
414-400-1 |
32750-89-3 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-401-00-5 |
3-hydroksy-5-oksocykloheks-3-eno-1-karboksylan etylu |
414-450-4 |
88805-65-6 |
Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 |
H315 H318 H317 |
GHS05 GHS07 Dgr |
H315 H318 H317 |
|
|
|
|
607-402-00-0 |
ester metylowy N-(fenoksykarbonylo)-L-waliny |
414-500-5 |
153441-77-1 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-403-00-6 |
masa poreakcyjna: bursztynianu bis(1S,2S,4S)-(1-benzylo-4-tert-butoksykarboksyamido-2-hydroksy-5-fenylo)pentyloamoniowego; alkoholu izopropylowego |
414-810-0 |
— |
STOT RE 2 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H373 ** H318 H400 H410 |
GHS08 GHS05 GHS09 Dgr |
H373 ** H318 H410 |
|
|
|
|
607-404-00-1 |
masa poreakcyjna: kwasu ((Z)-3,7-dimetylookta-2,6-dienylo)oksykarbonylopropanowego; butanodianu di((E)-3,7-dimetylookta-2,6-dienylu); butanodianu di((Z)-3,7-dimetylookta-2,6-dienylu); butanodianu (Z)-3,7-dimetylookta-2,6-dienylu; kwasu ((E)-3,7-dimetylookta-2,6-dienylo)oksykarbonylopropanowego |
415-190-4 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-405-00-7 |
p-hydroksybenzoesan 2-heksylodecylu |
415-380-7 |
148348-12-3 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-406-00-2 |
2,5-dichlorobenzoesan potasu |
415-700-5 |
184637-62-5 |
Acute Tox. 4 * Eye Dam. 1 |
H302 H318 |
GHS05 GHS07 Dgr |
H302 H318 |
|
|
|
|
607-407-00-8 |
2-karboksy-3-(2-tienylo)propanian etylu; 2-karboksy-3-(2-tienylo)propionian etylu |
415-680-8 |
143468-96-6 |
Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 |
H315 H318 H317 |
GHS05 GHS07 Dgr |
H315 H318 H317 |
|
|
|
|
607-408-00-3 |
N-(4-fluorofenylo)glicynian potasu |
415-710-1 |
184637-63-6 |
STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H373 ** H318 H317 H412 |
GHS08 GHS05 GHS07 Dgr |
H373 ** H318 H317 H412 |
|
|
|
|
607-409-00-9 |
masa poreakcyjna: kwasu (3R)-{1S-[1α,2α,6β-((2S)-2-metylo-1-oksobutoksy)-8aγ]-heksahydro-2,6-dimetylo-1-naftaleno}-3,5-dihydroksyheptanowego; obojętnej biomasy z Aspergillus terreus |
415-840-7 |
— |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
607-410-00-4 |
monowodoro-2-(heksadec-2-enylo)butanodian mono[2-(dimetyloamino)-etylu] i/ lub monowodoro-3-(heksadec-2-enylo)butanodian mono[2-(dimetyloamino)etylu] |
415-880-5 |
779343-34-9 |
Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H315 H318 H317 H410 |
|
|
|
|
607-411-00-X |
4-metylobenzenosulfonian (S)-oksiranylometanolu |
417-210-7 |
70987-78-9 |
Carc. 1B Muta. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H350 H341 H318 H317 H411 |
GHS08 GHS05 GHS07 GHS09 Dgr |
H350 H341 H318 H317 H411 |
|
|
|
|
607-412-00-5 |
2-(1-cyjanocykloheksylo)octan etylu |
415-970-4 |
133481-10-4 |
Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 3 |
H302 H373 ** H412 |
GHS08 GHS07 Wng |
H302 H373 ** H412 |
|
|
|
|
607-413-00-0 |
trans-4-fenylo-L-prolina |
416-020-1 |
96314-26-0 |
Repr. 2 Skin Sens. 1 |
H361f *** H317 |
GHS08 GHS07 Wng |
H361f *** H317 |
|
|
|
|
607-414-00-6 |
4,4',4''-(1,3,5-triazyno-2,4,6-triylotriimino)tribenzoesan tris(2-etyloheksylu) |
402-070-1 |
88122-99-0 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-415-00-1 |
poli(metakrylan metylu)-co-(metakrylan butylu)-co-(karbaminian 4-akryloksybutyloizopropenylo-α, α-dimetylobenzylu)-co-(bezwodnik maleinowy) |
419-590-1 |
— |
Flam. Sol. 1 Skin Sens. 1 |
H228 H317 |
GHS02 GHS07 Dgr |
H228 H317 |
|
|
T |
|
607-416-00-7 |
4-(2-karboksymetylotio)etoksy-1-hydroksy-5-izobutyloksykarbonyloamino-N-(3-dodecyloksypropylo)-2-naftamid |
420-730-7 |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-417-00-2 |
chloroformian 3-chloropropylu |
425-770-9 |
628-11-5 |
Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 |
H331 H302 H373** H315 H318 H317 |
GHS06 GHS05 GHS08 Dgr |
H331 H302 H373** H315 H318 H317 |
|
|
|
|
607-418-00-8 |
4-aminobenzoesan 2-etyloheksylu |
420-170-3 |
26218-04-2 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-419-00-3 |
kwas {3'-karboksymetylo-5-[2-(3-etylo-3H-benzotiazol-2-ylideno)-1-metyloetylideno]-4,4'-diokso-2'-tiokso-(2,5')-bitiazolidynyliden-3-ylo}octowy; |
422-240-9 |
166596-68-5 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
607-420-00-9 |
kwas 2,2-bis(hydroksymetylo)butanowy |
424-090-1 |
10097-02-6 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
607-421-00-4 |
cypermetryna (ISO) cis/trans +/- 40/60; (1RS,3RS;1RS,3SR)-3-(2,2-dichlorowinylo)-2,2-dimetylocyklopropanokarboksylan (RS)-α-cyjano-3-fenoksybenzylu |
257-842-9 |
52315-07-8 |
Acute Tox. 4 * Acute Tox. 4 * STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 |
H332 H302 H335 H400 H410 |
GHS07 GHS09 Wng |
H332 H302 H335 H410 |
|
|
|
|
607-422-00-X |
alfa-cypermetryna (ISO); (racemat zawierający (1S,3S)-3-(2,2-dichlorowinylo)-2,2-dimetylocyklopropanokarboksylan (R)-α-cyjano-3-fenoksybenzylu; (1R,3R)-3-(2,2-dichlorowinylo)-2,2-dimetylocyklopropanokarboksylan (S)-α-cyjano-3-fenoksybenzylu); (1RS,3RS)-3-(2,2-dichlorowinylo)-2,2-dimetylocyklopropano-karboksylan (RS)- a-cyjano-3-fenoksybenzylu) |
257-842-9 |
67375-30-8 |
Acute Tox. 3 * STOT RE 2 * STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H373** H335 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H301 H373** H335 H410 |
|
M=1000 |
|
|
607-423-00-5 |
estry mekopropu (ISO) i estry mekopropu-P (ISO) |
— |
— |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|
|
A |
|
607-424-00-0 |
trifloksystrobina (ISO); ester metylowy kwasu (E, E)-α-metoksyimino-{2-[({1-[3-(trifluorometylo)fenylo]etylideno}amino)oksy]metylo}benzenooctowego; (E)-metoksyimino-{(E)-α-[1-(α, α,α-trifluoro-m-tolilo)etylidenoaminooksy]-o-tolilo}octan metylu |
— |
141517-21-7 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
607-425-00-6 |
metalaksyl (ISO); N-(2,6-dimetylofenylo)-N-(metoksyacetylo)-DL-alaninian metylu |
260-979-7 |
57837-19-1 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 |
H302 H317 H412 |
GHS07 Wng |
H302 H317 H412 |
|
|
|
|
607-426-00-1 |
ester dipentylowy kwasu benzeno-1,2-dikarboksylowego o rozgałęzionym i nie-rozgałęzionym łańcuchu węglowym; [1] ftalan izopentylu n-pentylu; [2] ftalan di-n-pentylu; [3] ftalan diizopentylu [4] |
284-032-2 [1] -[2] 205-017-9 [3] 210-088-4 [4] |
84777-06-0 [1] -[2] 131-18-0 [3] 605-50-5 [4] |
Repr. 1B Aquatic Acute 1 |
H360FD H400 |
GHS08 GHS09 Dgr |
H360FD H400 |
|
|
|
|
607-427-00-7 |
heptanian bromoksynilu (ISO); heptanian 2,6-dibromo-4-cyjanofenylu |
260-300-4 |
56634-95-8 |
Repr. 2 Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361d *** H332 H302 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H361d *** H332 H302 H317 H410 |
|
|
|
|
607-428-00-2 |
wersenian czterosodowy |
200-573-9 |
64-02-8 |
Acute Tox. 4 * Eye Dam. 1 |
H302 H318 |
GHS05 GHS07 Dgr |
H302 H318 |
|
|
|
|
607-429-00-8 |
kwas wersenowy; (EDTA) |
200-449-4 |
60-00-4 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
607-430-00-3 |
BBP; ftalan benzylu butylu |
201-622-7 |
85-68-7 |
Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H360Df H400 H410 |
GHS08 GHS09 Dgr |
H360Df H410 |
|
|
|
|
607-431-00-9 |
praletryna (ISO); ETOC; 2,2-dimetylo-3-(2-metyloprop-1-enylo)cyklopropanokarboksylan 2-metylo-4-okso-3-(prop-2-ynylo)cyklopent-2-en-1-ylu |
245-387-9 |
23031-36-9 |
Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H302 H400 H410 |
GHS06 GHS09 Dgr |
H331 H302 H410 |
|
|
|
|
607-432-00-4 |
S-metolachlor; masa poreakcyjna (S)-2-chloro-N-(2-etylo-6-metylofenylo)-N-(2-metoksy-1-metyloetylo)acetamidu (80-100 %); [1] (R)-2-chloro-N-(2-etylo-6-metylofenylo)-N-(2-metoksy-1-metyloetylo)acetamidu (0-20 %) [2] |
-[1] -[2] |
87392-12-9 [1] 178961-20-1 [2] |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
607-433-00-X |
cypermetryna cis/trans +/- 80/20; (1RS,3RS;1RS,3SR)-3-(2,2-dichlorowinylo)-2,2-dimetylocyklopropanokarboksylan (RS)-α-cyjano-3-fenoksybenzylu |
257-842-9 |
52315-07-8 |
Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H335 H315 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H335 H315 H317 H410 |
|
|
|
|
607-434-00-5 |
mekoprop-P (ISO) [1] i jego sole; kwas (R)-2-(4-chloro-2-metylofenoksy)propanowy i jego sole |
240-539-0 |
16484-77-8 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|
|
|
|
607-435-00-0 |
2,2-dihydroksyoctan (1R,2S,5R)-2-izopropylo-5-metylocykloheksylu |
416-810-6 |
111969-64-3 |
STOT RE 2 * Eye Dam. 1 Aquatic Chronic 2 |
H373 ** H318 H411 |
GHS08 GHS05 GHS09 Dgr |
H373 ** H318 H411 |
|
|
|
|
607-436-00-6 |
neodekanian 2-hydroksy-3-(2-etylo-4-metyloimidazoilo)propylu |
417-350-9 |
— |
Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H400 H410 |
GHS05 GHS09 Dgr |
H315 H318 H410 |
|
|
|
|
607-437-00-1 |
kwas 3-(4-aminofenylo)-2-cyjanoprop-2-enowy |
417-480-6 |
252977-62-1 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-438-00-7 |
2-[(aminosulfonylo)metylo]benzoesan metylu |
419-010-5 |
112941-26-1 |
Acute Tox. 4 * Eye Irrit. 2 |
H302 H319 |
GHS07 Wng |
H302 H319 |
|
|
|
|
607-439-00-2 |
tetrahydrofurano-2-karboksylan metylu |
420-670-1 |
37443-42-8 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-440-00-8 |
2-aminosulfonylo-6-(trifluorometylo)pirydyno-3-karboksylan metylu |
421-220-7 |
144740-59-0 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-441-00-3 |
kwas 3-[3-(2-dodecyloksy-5-metylofenylokarbamoilo)-4-hydroksy-1-naftylotio]propanowy |
421-490-6 |
167684-63-1 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-442-00-9 |
[hydroksy-(4-fenylobutylo)fosfinylo]octan benzylu |
416-050-5 |
87460-09-1 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-444-00-X |
masa poreakcyjna: dibenzoesanu cis-1,4-dimetylocykloheksylu; dibenzoesanu trans-1,4-dimetylocykloheksylu |
416-230-3 |
35541-81-2 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-445-00-5 |
tris(4-metylobenzenosulfonian) żelaza(III) |
420-960-8 |
77214-82-5 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-446-00-0 |
2-[4-(2-chloro-4-nitrofenyloazo)-3-(1-oksopropylo)amino]fenyloaminopropanian metylu |
416-240-8 |
155522-12-6 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
607-447-00-6 |
4-[4-(4-hydroksyfenyloazo)fenyloamino]-3-nitrobenzenosulfonian sodu |
416-370-5 |
156738-27-1 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
607-448-00-1 |
kwas 2,3,5,6-tetrafluorobenzoesowy |
416-800-1 |
652-18-6 |
Skin Irrit. 2 Eye Dam. 1 |
H315 H318 |
GHS05 Dgr |
H315 H318 |
|
|
|
|
607-449-00-7 |
masa poreakcyjna: tri[bis(2-metylopropylo)naftalenosulfonianu] 4,4',4''-{(2,4,6-triokso-1,3,5(2H,4H,6H)-triazyno-1,3,5-triylo)-tris[metyleno(3,5,5-trimetylocykloheksano-3,1-diylo)iminokarbonyloksy-2,1-etanodiylo(etylo)amino]}trisbenzenodiazoniowego; tetra[bis(2-metylopropylo)naftalenosulfonianu] 4,4',4'',4'''-[(5,5'-{karbonylobis[imino(1,5,5-trimetylocykloheksano-3,1-diylo)metyleno]}-2,4,6-triokso-1,3,5(2H,4H,6H)-triazyno-1,1',3,3'-tetraylo)tetrakis[metyleno-(3,5,5-trimetylocykloheksano-3,1-diylo)iminokarbonyloksyetano-2,1-diylo(etylo)amino]]tetrakisbenzenodiazoniowego; |
417-080-1 |
— |
Self-react. D **** Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H242 H317 H400 H410 |
GHS02 GHS07 GHS09 Dgr |
H242 H317 H410 |
|
|
|
|
607-450-00-2 |
(Z)-2-({[1-(2-aminotiazol-4-ilo)-2-(benzotiazol-2-ilotio)-2-oksoetylideno]amino}oksy)-2-metylopropanian tert-butylu |
419-040-9 |
89604-92-2 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-451-00-8 |
4-{4-amino-5-hydroksy-3-[4-(2-sulfoksyetylosulfonylo)fenyloazo]-2,7-disulfonaftalen-6-yloazo}-6-(3-{4-amino-5-hydroksy-3-[4-(2-sulfoksyetylosulfonylo)fenyloazo]-2,7-disulfonaftaleno-6-yloazo}fenylokarbonyloamino)benzenosulfonian sodu |
417-640-5 |
161935-19-9 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
607-453-00-9 |
bis(2,2-dimetyloktanian) 4-benzylo-2,6-dihydroksy-4-azaheptylenu |
418-100-1 |
172964-15-7 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
607-454-00-4 |
masa poreakcyjna: kwasu trans-2-(1-metyloetylo)-1,3-dioksano-5-karboksylowego; kwasu cis-2-(1-metyloetylo)-1,3-dioksano-5-karboksylowego |
418-170-3 |
116193-72-7 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
607-455-00-X |
sole Na/Li kwasu 1-amino-4-{3-[4-chloro-6-(2,5-disulfofenyloamino)-1,3,5-triazyn-2-yloamino]-2,2-dimetylopropyloamino}antrachinono-2-sulfonowego |
419-520-8 |
172890-93-6 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-456-00-5 |
3-amino-4-chlorobenzoesan heksadecylu |
419-700-6 |
143269-74-3 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-457-00-0 |
diwodoro-1,1''-dihydroksy-8,8''-[p-fenylenobis(imino-{6-[4-(2-aminoetylo)piperazyn-1-ylo]}-1,3,5-triazyno-4,2-diyloimino)]-bis(2,2'-azonaftaleno-1',3,6-trisulfonian) tetrasodu |
420-350-1 |
172277-97-3 |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|
|
|
|
607-458-00-6 |
masa poreakcyjna: propenianu 2-(2,6-dibromo-4-{1-[3,5-dibromo-4-(2-hydroksyetoksy)fenylo]-1-metyloetylo}fenoksy)etylu; dipropenianu 2,2'-dietylo-[4,4'-bis(2,6-dibromofenoksy)-1-metyloetylidenu]; 2,2'-[(1-metyloetylideno)bis{[(2,6-dibromo-4,1-fenyleno)oksy]etanolu}] |
420-850-1 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-459-00-1 |
4-{2-[5-cyjano-1,2,3,6-tetrahydro-1-(2-izopropoksyetoksykarbonylometylo)-4-metylo-2,6-diokso-3-pirydylideno]hydrazyno}benzoesan izopentylu; |
418-930-4 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-460-00-7 |
oktadek-9-enian 3-tridecyloksypropyloamoniowy |
418-990-1 |
778577-53-0 |
STOT RE 2 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H373 ** H319 H315 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H373 ** H319 H315 H410 |
|
|
|
|
607-461-00-2 |
masa poreakcyjna: 2-(4-{3-metylo-4-[6-sulfoniano-4-(2-sulfonianofenyloazo)naftalen-1-yloazo]fenyloamino}-6-[3-(2-siarczanoetano-sulfonylo)fenyloamino]-1,3,5-triazyn-2-yloamino)benzeno-1,4-disulfonianu pentasodu; 2-(4-{3-metylo-4-[7-sulfoniano-4-(2-sulfonianofenyloazo)naftalen-1-yloazo]fenyloamino}-6-[3-(2-siarczanoetano-sulfonylo)fenyloamino]-1,3,5-triazyn-2-yloamino)benzeno-1,4-disulfonianu pentasodu |
421-160-1 |
— |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-462-00-8 |
masa poreakcyjna: octanu 1-heksylu; octanu 2-metylopentylu; octanu 3-metylopentylu; octanu 4-metylopentylu; innych mieszanych octanów C6-alkilowych o łańcuchu węglowym prostym lub rozgałęzionym |
421-230-1 |
88230-35-7 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-463-00-3 |
kwas 3-(fenotiazyn-10-ylo)propanowy |
421-260-5 |
362-03-8 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-464-00-9 |
masa poreakcyjna: kwasu 7-chloro-1-etylo-6-fluoro-1,4-dihydro-4-oksochinolino-3-karboksylowego; kwasu 5-chloro-1-etylo-6-fluoro-1,4-dihydro-4-oksochinolino-3-karboksylowego |
421-280-4 |
|
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-465-00-4 |
7-{4-[4-(2-cyjanoamino-4-hydroksy-6-oksydopirymidyn-5-yloazo)-benzamido]-2-etoksyfenyloazo}-naftaleno-1,3-disulfonian tris(2-hydroksyetylo)amoniowy |
421-440-3 |
778583-04-3 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-466-00-X |
masa poreakcyjna: 1-{1-[2-chloro-5-(heksadecyloksykarbonylo)fenylokarbamoilo]-3,3-dimetylo-2-oksobutylo}-1H-2,3,3a,7a-tetrahydrobenzotriazolo-5-karboksylanu fenylu; 2-{1-[2-chloro-5-(heksadecyloksykarbonylo)fenylokarbamoilo]-3,3-dimetylo-2-oksobutylo}-1H-2,3,3a,7a-tetrahydrobenzotriazolo-5-karboksylanu fenylu; 3-{1-[2-chloro-5-(heksadecyloksykarbonylo)fenylokarbamoilo]-3,3-dimetylo-2-oksobutylo}-1H-2,3,3a,7a-tetrahydrobenzotriazolo-5-karboksylanu fenylu |
421-480-1 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-467-00-5 |
dikaprylan 1,1,3,3-tetrabutylodistannoksano-1,3-diylu; dioktanian 1,1,3,3-tetrabutylodistannoksano-1,3-diylu |
419-430-9 |
56533-00-7 |
Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H373 ** H314 H400 H410 |
GHS08 GHS05 GHS07 GHS09 Dgr |
H312 H302 H373 ** H314 H410 |
|
|
|
|
607-468-00-0 |
masa poreakcyjna: 4-{[4-(5-sulfoniano-2-metoksyfenyloamino)-6-chloro-1,3,5-triazyn-2-ylo]amino}-2-[(1,4-dimetylo-6-oksydo-2-okso-5-sulfonianometylo-1,2-dihydropirydyn-3-ylo)azo]benzenosulfonianu monosodu; 4-{[4-(5-sulfoniano-2-metoksyfenyloamino)-6-chloro-1,3,5-triazyn-2-ylo]amino}-2-[(1,4-dimetylo-6-oksydo-2-okso-5-sulfonianometylo-1,2-dihydropirydyn-3-ylo)azo]benzenosulfonianu disodu; 4-{[4-(5-sulfoniano-2-metoksyfenyloamino)-6-chloro-1,3,5-triazyn-2-ylo]amino}-2-[(1,4-dimetylo-6-oksydo-2-okso-5-sulfonianometylo-1,2-dihydropirydyn-3-ylo)azo]benzenosulfonianu trisodu; 4-{[4-(5-sulfoniano-2-metoksyfenyloamino)-6-chloro-1,3,5-triazyn-2-ylo]amino}-2-[(1,4-dimetylo-6-oksydo-2-okso-5-sulfonianometylo-1,2-dihydropirydyn-3-ylo)azo]benzenosulfonianu tetrasodu |
419-450-8 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-469-00-6 |
7-{[4,6-bis(3-dietyloaminopropyloamino)-1,3,5-triazyn-2-ylo]amino}-4-hydroksy-3-[4-(4-sulfonianofenyloazo)fenyloazo]naftaleno-2-sulfonian disodu; |
419-460-2 |
120029-06-3 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-470-00-1 |
6,13-dichloro-3,10-bis-(2-{4-[3-(2-hydroksysulfonyloksyetanosulfonylo)fenyloamino]-6-(2,5-disulfonianofenyloamino)-1,3,5-triazyn-2-yloamino}etyloamino)benzo[5,6][1,4]-oksazyno[2,3-b]fenoksazyno-4,11-disulfonian potasu sodu |
414-100-0 |
154336-20-6 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
607-471-00-7 |
1,6-bis((dibenzylotiokarbamoilo)disulfanylo)heksan |
429-280-6 |
151900-44-6 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-473-00-8 |
pentaerytrytol, dipentaerytrytol, kwasy tłuszczowe, C6-10, estry zmieszane z kwasem adypinowym, heptanowym i izostearynowym |
426-590-3 |
187412-41-5 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-474-00-3 |
kwas 4-[4-(4-dimetyloaminobenzyliden-1-ylo)-3-metylo-5-okso-2-pirazolin-1-ylo]benzoesowy |
410-430-4 |
117573-89-4 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-475-00-9 |
masa poreakcyjna: 7-(4-{4-chloro-6-[metylo(3-sulfonianofenylo)amino]-1,3,5-triazyn-2-yloamino}-2-ureidofenyloazo)naftaleno-1,3,6-trisulfonianu tetrasodu; 7-(4-{4-chloro-6-[metylo(4-sulfonianofenylo)amino]-1,3,5-triazyn-2-yloamino}-2-ureidofenyloazo)naftaleno-1,3,6-trisulfonianu tetrasodu (1:1) |
412-940-2 |
148878-18-6 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-476-00-4 |
N, N-bis(karboksymetylo)-β-alaninian trisodu |
414-070-9 |
129050-62-0 |
Skin Corr. 1B Aquatic Chronic 3 |
H314 H412 |
GHS05 Dgr |
H314 H412 |
|
|
|
|
607-477-00-X |
metanosulfonian (1α5α6α)-6-nitro-3-benzylo-3-azabicyklo[3,1,0]heksanu sól |
426-740-8 |
— |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|
|
|
|
607-478-00-5 |
wodoroftalan tetrametyloamoniowy |
416-900-5 |
79723-02-7 |
Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 |
H301 H373 ** H400 |
GHS06 GHS08 GHS09 Dgr |
H301 H373 ** H400 |
|
|
|
|
607-479-00-0 |
4-chloro-3-[2-(5,5-dimetylo-2,4-diokso-1,3-oksazolidyn-3-ylo)-4,4-dimetylo-3-oksopentanoamido]benzoesan heksadecylu |
418-550-9 |
168689-49-4 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-480-00-6 |
kwas 1,2-benzenodikarboksylowy; estry di-C7-11-alkilowe o łańcuchach prostych lub rozgałęzionych |
271-084-6 |
68515-42-4 |
Repr. 1B |
H360Df |
GHS08 Dgr |
H360Df |
|
|
|
|
607-481-00-1 |
masa poreakcyjna: cytrynianu triheksylowego; cytrynianu diheksylooktylowego; cytrynianu dioktyloheksylowego; cytrynianu diheksylodecylowego |
430-290-8 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-482-00-7 |
N-[1-(S)-etoksykarbonylo-3-fenylopropylo]-L-alanilo-N-karboksybezwodnik |
430-360-8 |
84793-24-8 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
607-483-00-2 |
kwas 1,2-benzenodikarboksylowy; estry di-C6-8 alkilowe o łańcuchach rozgałęzionych, bogate w C7 |
276-158-1 |
71888-89-6 |
Repr. 1B |
H360D*** |
GHS08 Dgr |
H360D*** |
|
|
|
|
607-484-00-8 |
2-{[3-acetyloamino-4-(6-bromo-2-metylo-1,3-diokso-2,3-dihydro-1H-izoindol-5-yloazo)fenylo]etyloamino}propionian etylu |
430-480-0 |
221452-67-1 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-485-00-3 |
1-piperydynokarboksylan (3S-trans)-fenylo-3-[(1,3-benzo-dioksol-5-yloksy)metylo]-4-(4-fluorofenylu) |
430-510-2 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-486-00-9 |
5'-(6-chloro-4-(2-(2-winylosulfonyloetoksy)etyloamino)-1,3,5-triazyn-2-yloamino)-4'-hydroksy-2,3'-azodinaftaleno-1,2',5,7'-disulfonian potasu i sodu; |
402-110-8 |
110081-40-8 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-487-00-4 |
masa poreakcyjna: 4-(3-etoksykarbonylo-4-{5-[3-etoksykarbonylo-5-hydroksy-1-(4-sulfonianofenylo)pirazol-4-ilo]penta-2,4-dienylideno}-4,5-dihydro-5-oksopirazol-1-ilo)benzenosulfonianu disodu; 4-(3-etoksykarbonylo-4-{5-[3-etoksykarbonylo-5-oksydo-1-(4-sulfonianofenylo)pirazol-4-ilo]penta-2,4-dienylideno}-4,5-dihydro-5-oksopirazol-1-ilo)benzenosulfonianu trisodu |
402-660-9 |
— |
Repr. 1B Aquatic Chronic 3 |
H360D *** H412 |
GHS08 Dgr |
H360D *** H412 |
|
|
|
|
607-488-00-X |
(2-acetyloamino-5-fluoro-4-izotiocyjanianofenoksy)octan etylu |
414-210-9 |
147379-38-2 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-489-00-5 |
masa poreakcyjna: linolenianu 2-etyloheksylu, linolanu 2-etyloheksylu i oleinianu 2-etyloheksylu; epoksyoleinianu 2-etyloheksylu; diepoksylinolanu 2-etyloheksylu; triepoksylinolenianu 2-etyloheksylu |
414-890-7 |
71302-79-9 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-490-00-0 |
N-[2-hydroksy-3-(C12-16-alkiloksy)propylo]-N-metyloglicyna |
415-060-7 |
— |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
607-491-00-6 |
masa poreakcyjna: diestru 4,4'-metylenobis[2-(2-hydroksy-5-metylobenzylo)-3,6-dimetylofenolu] oraz kwasu 6-diazo-5,6-dihydro-5-oksonaftaleno-1-sulfonowego (1:2); triestru 4,4'-metylenobis[2-(2-hydroksy-5-metylobenzylo)-3,6-dimetylofenolu] oraz kwasu 6-diazo-5,6-dihydro-5-oksonaftaleno-1-sulfonowego (1:3) |
427-140-9 |
— |
Carc. 2 |
H351 |
GHS08 Wng |
H351 |
|
|
|
|
607-492-00-1 |
propanian 2-[1-(3',3'-dimetylo-1'-cykloheksylo)etoksy]-2-metylopropylu |
415-490-5 |
141773-73-1 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-493-00-7 |
(3aR,4R,7aR)-2-metylo-4-(1S,2R,3-triacetoksypropylo)-3a,7a-dihydro-4H-pirano[3,4-d]oksazolo-6-karboksylan metylu |
415-670-3 |
78850-37-0 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-494-00-2 |
oktylofosfonian bis(2-etyloheksylu) |
417-170-0 |
52894-02-7 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-495-00-8 |
4-sulfofenylo-6-[(1-oksononylo)amino]heksanian sodu; |
417-550-6 |
168151-92-6 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-496-00-3 |
fosforan(III) 2,2'-metylenobis(4,6-di-tert-butylofenylo)-2-etyloheksylu; fosforyn 2,2'-metylenobis(4,6-di-tert-butylofenylo)-2-etyloheksylu |
418-310-3 |
126050-54-2 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-497-00-9 |
izostearynian tlenek ceru |
419-760-3 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-498-00-4 |
heksadekanian (E)-3,7-dimetylookta-2,6-dienylu |
421-370-3 |
3681-73-0 |
Skin Irrit. 2 Aquatic Chronic 4 |
H315 H413 |
GHS07 Wng |
H315 H413 |
|
|
|
|
607-499-00-X |
etano-1,2-diylobis(heksadec-2-enylobursztynian) bis[dimetylo(2-hydroksyetylo)amoniowy] |
421-660-1 |
— |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H318 H317 H411 |
|
|
|
|
607-500-00-3 |
2,2-bis[(5-tetrapropyleno-2-hydroksy)fenylo]etanian wapnia; |
421-670-4 |
— |
Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H400 H410 |
GHS07 GHS09 Wng |
H315 H410 |
|
|
|
|
607-501-00-9 |
masa poreakcyjna: tiofosforanu(V) trifenylu i pochodnych tert-butylofenylowych |
421-820-9 |
192268-65-8 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-502-00-4 |
4-dodecylobenzenosulfonian (N-benzylo-N, N,N-tributylo)amoniowy |
422-200-0 |
178277-55-9 |
Skin Corr. 1B Acute Tox. 4 * Aquatic Chronic 2 |
H314 H302 H411 |
GHS05 GHS07 GHS09 Dgr |
H314 H302 H411 |
|
|
|
|
607-503-00-X |
2,4,6-tripropylo-2,4,6-triokso-1,3,5,2,4,6-trioksatrifosforinan |
422-210-5 |
68957-94-8 |
Skin Corr. 1B |
H314 |
GHS05 Dgr |
H314 |
|
|
|
|
607-504-00-5 |
1-hydroksy-2-(4-(4-karboksyfenyloazo)-2,5-dimetoksyfenyloazo)-7-amino-3-naftalenosulfonian diamonu |
422-670-7 |
— |
Repr. 2 Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H361f H301 H373** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H361f H301 H373** H410 |
|
|
|
|
607-505-00-0 |
7-{4-[4-(5-amino-4-sulfoniano-2-{4-[(2-sulfonianoetoksy)sulfonylo]-fenyloazo}fenyloamino)-6-chloro-1,3,5-triazyn-2-ylo]amino-2-ureidofenyloazo}naftaleno-1,3,6-trisulfonian pentasodu |
422-930-1 |
|
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-506-00-6 |
masa poreakcyjna: (4-chloro-2-{[4,5-dihydro-3-metylo-5-okso-1-(3-sulfonianofenylo)-1H-pirazol-4-ilo]azo}-5-metylo)-benzenosulfonianu strontu; (4-chloro-2-{[4,5-dihydro-3-metylo-5-okso-1-(3-sulfonianofenylo)-1H-pirazol-4-ilo]azo}-5-metylo)-benzenosulfonianu disodu |
422-970-8 |
|
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-507-00-1 |
2,4-diamino-3-[4-(2-sulfonianoetoksysulfonylo)fenyloazo]-5-[4-(2-sulfonianoetoksysulfonylo)-2-sulfonianofenyloazo]benzenosulfonian potasu sodu |
422-980-2 |
187026-95-5 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-508-00-7 |
3,3'-{iminobis[sulfonylo-4,1-fenyleno-(5-hydroksy-3-metylopirazolo-1,4-diylo)-azo-4,1-fenylenosulfonyloimino-(4-amino-6-hydroksypirymidyno-2,5-diylo)azo-4,1-fenylenosulfonyloimino-(4-amino-6-hydroksypirymidyno-2,5-diylo)azo]bis(benzenosulfonian)} disodu |
423-110-4 |
— |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-509-00-2 |
2-fenoksyetylo 4-aminobenzoesan |
430-880-5 |
88938-23-2 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-510-00-8 |
4,4-ditlenek kwasu (2S,5R)-6,6-dibromo-3,3-dimetylo-7-okso-4-tia-1-azabicyklo[3.2.0]heptano-2-karboksylowego |
427-200-4 |
76646-91-8 |
Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 |
H302 H315 H318 H317 |
GHS05 GHS07 Dgr |
H302 H315 H318 H317 |
|
|
|
|
607-511-00-3 |
masa poreakcyjna: kwasu 4-[(3-izobutoksy-1-izobutoksykarbonylo-3-oksopropylo) (3-oktyloksypropylo)amino]-4-oksomasłowego; kwasu 4-[(3-izobutoksy-1-izobutoksykarbonylo-3-oksopropylo) (3-oktyloksypropylo)amino]-4-oksomasłowego |
423-750-4 |
— |
Eye Irrit. 2 Aquatic Chronic 2 |
H319 H411 |
GHS07 GHS09 Wng |
H319 H411 |
|
|
|
|
607-512-00-9 |
2,4-diamino-3,5-bis[4-(2-sulfonianoetoksy)sulfonylofenyloazo]benzenosulfonian trisodu |
423-970-0 |
182926-43-8 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-513-00-4 |
masa poreakcyjna: 4-benzoiloamino-6-(6-etenosulfonylo-1-sulfonianonaftalen-2-yloazo)-5-hydroksynaftaleno-2,7-disulfonianu trisodu; soli sodowej kwasu 5-(benzoiloamino)-4-hydroksy-3-[(1-sulfo-6-{[2-(sulfoksy)etylo]sulfonylo}-2-naftylo)azo]naftaleno-2,7-disulfonowego; kwasu 5-(benzoiloamino)-4-hydroksy-3-[(1-sulfo-6-{[2-(sulfoksy)etylo]sulfonylo}-2-naftylo)azo]naftaleno-2,7-disulfonowego |
423-200-3 |
— |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|
|
|
|
607-514-00-X |
N-(1-metoksy-1-oksobut-2-en-3-ylo)walinian potasu |
427-240-2 |
134841-35-3 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-515-00-5 |
masa poreakcyjna: disulfonianu eteru heksylodifenylowego disodu; disulfonianu eteru diheksylodifenylowego disodu |
429-650-7 |
147732-60-3 |
Eye Irrit. 2 Aquatic Chronic 2 |
H319 H411 |
GHS07 GHS09 Wng |
H319 H411 |
|
|
|
|
607-516-00-0 |
N, N'-bis(trifluoroacetylo)-S, S'-bis-L-homocysteina |
429-670-6 |
105996-54-1 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
607-517-00-6 |
kwas (S)-α-(acetylotio)benzenopropanowy; kwas (S)-α-(acetylosulfanylo)benzenopropanowy |
430-300-0 |
76932-17-7 |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 |
H302 H318 H317 |
GHS05 GHS07 Dgr |
H302 H318 H317 |
|
|
|
|
607-518-00-1 |
kwas 3-oksoandrost-4-eno-17-β-karboksylowy |
414-990-0 |
302-97-6 |
Repr. 2 Aquatic Chronic 4 |
H361f H413 |
GHS08 Wng |
H361f H413 |
|
|
|
|
607-519-00-7 |
polioctan [((4-((4-(etylo-etyleno)amino)fenylo)-(4-(etylo-(2-oksyetyleno)amino)fenylo)metynylo)cykloheksa-2,5-dienylideno)-N-etylo-N-(2-hydroksyetylo)amoniowy] |
427-280-0 |
176429-27-9 |
STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H335 H315 H318 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H335 H315 H318 H410 |
|
|
|
|
607-520-00-2 |
masa poreakcyjna: 4,5-dihydro-2-[(dipropioniano)(C6-18)alkilo]-3H-imidazolo-N-etylofosforanu sodu; 4,5-dihydro-2-[(dipropioniano)(C6-18)alkilo]-3H-imidazolo-N-etylofosforanu disodu |
427-740-0 |
— |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
607-521-00-8 |
tetraetylo N, N'-(metylenodicykloheksano-4,1-diylo)bis-DL-asparaginian |
429-270-1 |
136210-30-5 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
607-522-00-3 |
sól sodowa polimeru: 2-metylo-buta-1,3-dieno-1-sulfonian sodu z kwasem akrylowym i 2-hydroksyetylo-2-metyloakrylanem |
429-720-7 |
184246-86-4 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-523-00-9 |
masa poreakcyjna związków: 3-amino-10-[4-(4-amino-3-sulfonianoanilino)-6-[metylo-(2-sulfonianoetylo)amino]-1,3,5-triazyn-2-yloamino]-6-13-dichlorobenzo[1,2-B:4,5-B']di[1,4]benzoksazyno-4,11-disulfonian od mono do tetra(litu i/lub sodu); 3-amino-10-[4,6-bis(4-amino-3-sulfonianoanilino)-1,3,5-triazyn-2-yloamino]-6-13-dichlorobenzo[1,2-B:4,5-B']di[1,4]benzoksazyno-4,11-disulfonian od mono do tetra(litu i/lub sodu); 10,10'-diamino-6,6',13,13'-tetrachloro-3,3'-[6-[metylo-(2-sulfonianoetylo)amino]-1,3,5-triazyn-2,4-diylodiimino]bis[benzo[1,2-B:4,5-B']di[1,4]benzoksazyno-4,11-disulfonian od mono do penta(litu i/lub sodu); 10-amino-6,6',13,13'-tetrachloro-10'[4-(4-amino-3-sulfonianoanilino)-[6-metylo-(2-sulfonianoetylo)amino]-1,3,5-triazyn-2,4-diimino]bis[benzo[1,2-B:4,5-B']di[1,4]benzoksazyno-4,11-disulfonian od mono do hepta(litu i/lub sodu); 10,10'-diamino-6,6',3,3'[(2-sulfoniano)-1,4-fenylenodiiminobis[6-metylo-(2-sulfonianoetylo)amino]-1,3,5-triazyn-2,4-diylodiimino]bis[benzo[1,2-B:4,5-B']di[1,4]benzoksazyno-4,11-disulfonian od mono do hepta(litu i/lub sodu) |
430-200-7 |
— |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
607-524-00-4 |
oleju talowego estry 2-[(tetrahydro-2H-piran-2-ylo)tio]etylowe |
430-310-5 |
— |
Aquatic Chronic 4 |
H413 |
|
H413 |
|
|
|
|
607-525-00-X |
kwas (Z)-2-metoksymino-2-[2-(trityloamino)tiazolo-4-yl]octowy |
431-520-1 |
64485-90-1 |
Flam. Sol. 1**** Carc. 2 Aquatic Chronic 3 |
H228 H351 H412 |
GHS02 GHS08 Dgr |
H228 H351 H412 |
|
|
|
|
607-526-00-5 |
kartap (ISO); 1,3-bis(karbamoilotio)-2-(dimetyloamino)propan |
— |
15263-53-3 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-527-00-0 |
masa poreakcyjna: dodekanodianu 1-(1'H,1'H,2'H,2'H-tridekafluorooktylu)-12-(1''H,1''H,2''H,2''H-tridekafluorooktylu); dodekanodianu 1-(1'H,1'H,2'H,2'H-tridekafluorooktylu)-12-(1''H,1''H,2''H,2''H-heptadekafluorodecylu); dodekanodianu 1-(1'H,1'H,2'H,2'H-tridekafluorooktylu)-12-(1''H,1''H,2''H,2''H-henikozafluorododecylu); dodekanodianu 1-(1'H,1'H,2'H,2'H-tridekafluorooktylu)-12-(1''H,1''H,2''H,2''H-pentakozafluorotetradecylu); dodekanodianu 1-(1'H,1'H,2'H,2'H-heptadekafluorodecylu)-12-(1''H,1''H,2''H,2''H-heptadekafluorodecylu); dodekanodianu 1-(1'H,1'H,2'H,2'H-heptadekafluoro-decylu)-12-(1''H,1''H,2''H,2''H-henikozafluorododecylu) |
423-180-6 |
— |
STOT RE 2 * |
H373 ** |
GHS08 Wng |
H373 ** |
|
|
|
|
607-528-00-6 |
kwas (S)-3-metylo-2-(2-oksotetrahydropirymidyno-1-ylo)masłowy |
430-900-2 |
192725-50-1 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-529-00-1 |
4-toluenosulfonian cis-4-amonio-1-cykloheksanokarboksylan benzylu |
426-070-6 |
67299-45-0 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-530-00-7 |
masa poreakcyjna izomerów: 3-(3,5-di-trans-butylo-4-hydroksyfenylo)propionianu C7-9-alkilowego |
406-040-9 |
125643-61-0 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-531-00-2 |
3-amino-4,6-dibromo-2-metylo-benzoesan metylu |
425-190-6 |
119916-05-1 |
STOT RE 2 * Aquatic Chronic 2 |
H373** H411 |
GHS08 GHS09 Wng |
H373** H411 |
|
|
|
|
607-532-00-8 |
kwas (S)-l-[2-trans-butoksykarbonylo-3-(2-metoksyetoksy) propylo]-l-cyklopentanokarboksylowy, sól cykloheksyloaminy |
425-510-4 |
167944-94-7 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-533-00-3 |
monowodoro 6-chloro-3,10-bis[2-[4-chloro-6-(2,4-disulfofenyloamino)-1,3,5-triazyno-2-yl-amino]etyloamino]-13-etylobenzo[5,6][1,4]oksazyno[2,3-b]fenoksazyno-4,11-disulfonian pentasodu |
414-910-4 |
— |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
607-534-00-9 |
2-(3-benzoilofenylo)propanian etylu |
414-920-9 |
60658-04-0 |
Acute Tox. 3 * STOT RE 1 Skin Sens. 1 Aquatic Chronic 2 |
H301 H372** H317 H411 |
GHS06 GHS08 GHS09 Dgr |
H301 H372** H317 H411 |
|
|
|
|
607-535-00-4 |
kwas 4-jodo-2-sulfoniano-benzoesowy, sól potasu |
426-620-5 |
— |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
607-536-00-X |
kwas (2,6-ksyliloksy) octowy |
430-910-7 |
13335-71-2 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H302 H318 H412 |
GHS05 GHS07 Dgr |
H302 H318 H412 |
|
|
|
|
607-537-00-5 |
2-(3-benzoilofenylo)propionian izopropyloamoniowy |
417-970-1 |
— |
Acute Tox. 3 * Acute Tox. 4 * STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H312 H372** H318 H400 H410 |
GHS06 GHS05 GHS08 GHS09 Dgr |
H301 H312 H372** H318 H410 |
|
|
|
|
607-539-00-6 |
((4-(5-okso-3-propylizoksazolidyn-4-ylidenometyno) fenylo)propoksykarbonylometylenoamino)octan propylu |
431-000-2 |
198705-81-6 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-540-00-1 |
kwas 1-(merkaptometylo)cyklopropylooctowy |
420-240-3 |
162515-68-6 |
Skin Corr. 1B Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H314 H312 H302 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H314 H312 H302 H317 H411 |
|
|
|
|
607-541-00-7 |
kwas [(1-metylo-1,2-etanodiylo)bis [nitrylobis(metyleno)]]tetrakisfosfonowy |
421-940-1 |
28698-31-9 |
Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H400 H410 |
GHS05 GHS09 Dgr |
H318 H410 |
|
|
|
|
607-542-00-2 |
2-(4-butanosulfonoamidofenoksy)tetradekanian metylu |
422-110-1 |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-543-00-8 |
polioctan [((4-((4-(etylo-etyleno) amino)fenylo)-(4-(etylo-(2-oksye-tyleno)amino)fenylo)metynylo)-3-metylocykloheksa-2,5-dienylideno)-N-etylo-N-(2-hydroksyetylo)amoniowy] |
427-480-8 |
176429-22-4 |
STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H335 H315 H318 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H335 H315 H318 H410 |
|
|
|
|
607-544-00-3 |
6,8-difluoro-1-(formylometyloamino)-1,4-dihydro-7-(4-metylo)piperazyno-1-yl)-4-oksochinolino-3-karboksylan etylu |
427-490-2 |
158585-86-5 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-545-00-9 |
octan 1,2-dimetylo-3-(1-metyloetenylo) cyklopentylu |
424-070-0 |
94346-09-5 |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
607-546-00-4 |
masa poreakcyjna: {[5-acetyloamino-4-(2-chloro-4-nitrofenyloazo)fenylo]metoksy-karbonylometyloamino}octanu metylu; {[5-acetyloamino-4-(2-chloro-4-nitrofenyloazo)fenylo] etoksykarbonylometyloamino}octanu metylu |
424-290-7 |
188070-47-5 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-547-00-X |
2,2-dimetylopropanian 18-metylononadecylu |
424-370-1 |
125496-22-2 |
Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 |
H315 H317 H413 |
GHS07 Wng |
H315 H317 H413 |
|
|
|
|
607-548-00-5 |
metanosulfonian 1-(2,4-dichlorofenylo)-2-(1H-imidazol-1-ylo)etanonu; |
431-010-7 |
154486-26-7 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|
|
|
|
607-549-00-0 |
(E)-2((3-(1,3-benzodioksol-5-ylo)-2-metylo-1-propenylo) amino)benzoesan metylu |
424-430-7 |
125778-19-0 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-550-00-6 |
kwas 2-amino-4-bromo-5-chlorobenzoesowy |
424-700-4 |
— |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
607-551-00-1 |
2-amino-6-jodopurynian tetrabutyloamoniowy |
424-710-9 |
156126-48-6 |
Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H312 H302 H373** H315 H318 H317 H411 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H312 H302 H373** H315 H318 H317 H411 |
|
|
|
|
607-552-00-7 |
3-amino-4-izopropoksybenzoesan heksadecylu |
424-830-1 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-553-00-2 |
kwas 7-amino-4-hydroksy-2-naftalenosulfonowy, połączony z kwasem 5 (lub 8)-amino-8 (lub 5)-[[4-[[4-[[4-amino-6(lub 7)-sulfo-1-naftylo]azo]fenylo] amino]-3-sulfofenylo]azo]-2-naftalenosulfonowym oraz kwasem 4-hydroksy-7-(fenyloamino)-2-naftalenosulfonowym, sól sodowa; |
424-850-0 |
— |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-554-00-8 |
kwas 2,4-diamino-5-[4-[(2-sulfoksylo etylo)sulfonylo]fenyloazo]benzenosulfonowy |
424-870-1 |
27624-67-5 |
Expl. 1.1 Eye Dam. 1 Aquatic Chronic 3 |
H201 H318 H412 |
GHS01 GHS05 Dgr |
H201 H318 H412 |
|
|
|
|
607-555-00-3 |
1,1,3,3-tetrametylobutyloperoksypiwalan |
424-980-8 |
22288-41-1 |
Flam. Liq. 2 Org. Perox. D Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H225 H242 H315 H317 H411 |
GHS02 GHS07 GHS09 Dgr |
H225 H242 H315 H317 H411 |
|
|
|
|
607-556-00-9 |
2-acetoksymetyleno-4-acetylofenylooctan |
425-160-2 |
24085-06-1 |
Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373** H318 H317 H400 H410 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H302 H373** H318 H317 H410 |
|
|
|
|
607-557-00-4 |
sól: (1S-cis)-1-amino-2,3-dihydro-1H-indeno-2-olu oraz kwasu [R-[R*R*]]-2,3-dihydroksybutanodiowego |
425-210-3 |
169939-84-8 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-558-00-X |
(2R,5S)-5-(4-amino-2-okso-2H-pirymidyn-1-ylo)-[1.3]-oksatiolano-2-karboksylan 2S-izopropylo-5R-metylo-1R-cykloheksylu |
425-250-1 |
147027-10-9 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-559-00-5 |
olej kokosowy, produkty reakcji z estrami gliceryny kwasu 3,5-bis (1,1-dimetyloetylo)-4-hydroksy-benzenopropanowego |
425-400-6 |
179986-09-5 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-560-00-0 |
kwas (R, S)-2-butylooktanodiowy |
431-210-4 |
50905-10-7 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-561-00-6 |
4-hydroksy-3-(N'-(2-(2-hydroksyetylenosulfonylo)etyleno)ureido)-5-nitrobenzenosulfonian sodu |
425-460-3 |
— |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
607-562-00-1 |
masa poreakcyjna: metanosulfonianu (2R,3R)-3-(2-etoksyfenoksy)-2-hydroksy-3-fenylopropyloamoniowego; metanosulfonianu (2S,3S)-3-(2-etoksyfenoksy)-2-hydroksy-3-fenylopropyloamoniowego |
425-530-3 |
98769-75-6 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|
|
|
|
607-563-00-7 |
kwas 5,7-dichloro-4-hydroksychinolino-3-karboksylowy |
431-250-2 |
171850-30-9 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-564-00-2 |
5-sulfoniano-1,3-benzenodikarboksylan 1,6-heksanodiamoniowy sodu |
425-730-0 |
51178-75-7 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-565-00-8 |
2-(2-aminoetoksymetylo)-4-(2-chlorofenylo)-1,4-dihydro-6-metylo-3,5-pirydynodikarboksylan 3-etylu 5-metylu |
425-820-1 |
88150-42-9 |
Acute Tox. 3 * STOT RE 2 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H373** H318 H400 H410 |
GHS06 GHS05 GHS08 GHS09 Dgr |
H301 H373** H318 H410 |
|
|
|
|
607-566-00-3 |
masa poreakcyjna: dodecylohydroksybenzenokarboksylanu dodecylofenylu; hydroksybenzenodikarboksylanu bis(dodecylofenylo)dodecylu |
426-140-6 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-567-00-9 |
3-jodo-6-metylobenzenosulfonian potasu |
426-300-5 |
— |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-568-00-4 |
2-chloro-3-(benzyloksy)propionian potasu |
426-350-8 |
138666-92-9 |
Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 |
H302 H373** H318 H317 |
GHS05 GHS08 GHS07 Dgr |
H302 H373** H318 H317 |
|
|
|
|
607-569-00-X |
masa poreakcyjna: 2-amino-4-(2,6-difluoropirymidyno-4-yloamino)benzenosulfonianu sodu; 2-amino-4-(4,6-difluoropirymidyno-4-yloamino)benzenosulfonianu sodu |
426-470-0 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-570-00-5 |
monohydrat (6R-trans)-7-amino-8-okso-3-[[[1-(sulfometylo)-1H-tetrazolo-5-ylo]tio]metylo]-5-tia-1-azabicyklo[4.2.0]okt-2-eno-2-karboksylan sodu |
426-520-1 |
71420-85-4 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-571-00-0 |
(3-hydroksy-2-pentylo-2-cyklopenten-1-ylo)octan metylu |
431-400-7 |
57374-49-9 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-572-00-6 |
(Z)-(2-trifenylometylo-aminotiazol-4-ilo)metoksyiminooctan dietylotiofosforylu |
426-790-0 |
162208-27-7 |
Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H373** H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H312 H302 H373** H317 H410 |
|
|
|
|
607-573-00-1 |
masa poreakcyjna: 7-(2,4-difluoropirymidyn-2-yloamino)-4-hydroksy-3-(4-metoksy-2-sulfonianofenyloazo)naftaleno-2-sulfonianu disodu; 7-(4,6-difluoropirymidyn-2-yloamino)-4-hydroksy-3-(4-metoksy-2-sulfonianofenyloazo)naftaleno-2-sulfonianu disodu |
426-840-1 |
— |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-574-00-7 |
butanodionian mono[1R-(1-α,2β,5α)]-mono[5-metylo-2-(1-metyloetylo)cykloheksylu] |
426-890-4 |
77341-67-4 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-575-00-2 |
kwas 4-(5-(5-[1-(4-karboksyfenylo)heksahydro-2,4,6-trioksopirymidyno-5-ylideno]penta-1,3-dienylo)-1,2,3,4-tetrahydro-6-hydroksy-2,4-dioksopirymidyn-1-ylo)benzoesowy, sól trietyloaminowa |
426-900-7 |
— |
STOT SE 3 Aquatic Chronic 3 |
H335 H412 |
GHS07 Wng |
H335 H412 |
|
|
|
|
607-576-00-8 |
rozgałęziony 3-[3,5-di(trans-butylo)-4-hydroksyfenylo] propanian oktylu |
427-030-0 |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-577-00-3 |
(1R)-10-kamforosulfonian (2R*,3S*)-2-(2,4-difluorofenylo)-3-(5-fluoro-4-pirymidynylo)-1-(1H-1,2,4-triazol-1-ylo)butan-2-ylu |
427-100-0 |
— |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H302 H318 H317 H412 |
GHS05 GHS07 Dgr |
H302 H318 H317 H412 |
|
|
|
|
607-578-00-9 |
4-((4-dietyloamino-2-metylofenylo)imino)-4,5-dihydro-1-izopropylo-5-okso-1H-pirazolo-3-karboksylan etylu |
427-110-5 |
— |
Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 4 |
H302 H373** H413 |
GHS08 GHS07 Wng |
H302 H373** H413 |
|
|
|
|
607-579-00-4 |
[(p-etoksyanilino)metyleno]malonian dietylu |
431-430-0 |
103976-28-9 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
607-580-00-X |
7-chloro-l-(2,4-difluorofenylo)-6-fluoro-1,4-dihydro-4-okso-1,8-naftyrydyno-3-karboksylan etylu |
422-360-1 |
100491-29-0 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-581-00-5 |
2-etoksy-4-karboksymetylobenzoesan etylu |
427-630-2 |
99469-99-5 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-582-00-0 |
masa poreakcyjna: 7-(4-(4-fluoro-6-(4-(2-sulfonianoetylosulfonylo)fenyloamino)-1,3,5-triazyn-2-yloamino)-2-ureidofenyloazo)naftaleno-1,3,6-trisulfonianu tetrasodu; 7-(4-(4-hydroksy-6-(4-(2-sulfonianoetylosulfonylo)fenyloamino)-1,3,5-triazyn-2-ylamino)-2-ureidofenyloazo)naftaleno-1,3,6-trisulfonianu tetrasodu |
427-650-1 |
— |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-583-00-6 |
kwas 4-amino-3-[[4-[[2-(sulfooksy)etylo]sulfonylo]fenylo] azo]-1-naftaleno sulfonowy |
427-680-5 |
188907-52-0 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|
|
|
|
607-584-00-1 |
3-[2-acetyloamino-4-[4-chloro-6-[4-(2-sulfonoetoksyianokyetylosulfonylo)fenyloamino]-1, 3,5-triazyn-2-yloamino]fenyloazo]naftaleno-1,5-disulfonian trisodu |
427-710-7 |
215612-56-9 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|
|
|
|
607-585-00-7 |
2-[(2-hydroksy-6-sulfoniano-1-naftylo)azo]naftaleno-1-sulfonian strontu |
427-930-3 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-586-00-2 |
3-amino-4-chlorobenzoesan dodecylu |
428-020-9 |
6195-20-6 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
607-587-00-8 |
cis-4-[4-[[2-(2,4-dichlorofenylo)-2-(1H-imidazol-1-ylometylo)-1,3-dioksolan-4-ylo] metoksy]fenylo]piperazyno-1-karboksylan etylu |
428-030-3 |
67914-69-6 |
Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373** H400 H410 |
GHS08 GHS07 GHS09 Wng |
H302 H373** H410 |
|
|
|
|
607-588-00-3 |
masa poreakcyjna: 2,3,4,5-tetrabromobenzoesanu 2-etyloheksylu; 3,4,5,6-tetrabromo ftalanu bis(2-etyloheksylu) |
428-050-2 |
— |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
607-589-00-9 |
tetrakis(1,2,2,6,6-pentametylo-4-piperydylo)-1,2,3,4-butanotetrakarboksylan |
428-070-1 |
91788-83-9 |
STOT RE 1 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H372** H302 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H372** H302 H410 |
|
|
|
|
607-590-00-4 |
3-[2-(5,5-dimetylo-2,4-diokso-1,3-oksazolidyn-3-ylo)-4,4-dimetylo-3-oksowaleramido]-4-izopropoksybenzoesan heksadecylu |
428-140-1 |
210706-50-6 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-591-00-X |
masa poreakcyjna: 5-(4-fluoro-6-morfolin-4-ylo-1,3,5-triazyn-2-yloamino)-4-hydroksy-3-(4-(2-sulfooksyetanosulfonylo)fenyloazo)naftaleno-2,7-disulfonianu trisodu; 3-(4-etenosulfonylofenyloazo)-5-(4-fluoro-6-morfolin-4-ylo-1,3,5-triazyn-2-yloamino)-4-hydroksynaftaleno-2,7-disulfonianu disodu |
428-400-4 |
— |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-592-00-5 |
cykloheksano-1,4-dikarboksylan di(C9-11-alkilu) |
428-870-0 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-593-00-0 |
4-aliloksybenzoesan 4-(2-metyloakryloyloksy)fenylu |
429-000-2 |
159235-16-2 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
607-594-00-6 |
(1S,5R,6S)-5-(1-etylopropoksy)-7-oksabicyklo[4.1.0]hept-3-eno-3-karboksylan etylu |
429-020-1 |
204254-96-6 |
STOT RE 2 * Skin Sens. 1 |
H373** H317 |
GHS08 GHS07 Wng |
H373** H317 |
|
|
|
|
607-595-00-1 |
2-oksopropionian N-amidyno-N-metyloglicyny |
429-120-5 |
208535-04-0 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-596-00-7 |
2-(4-fenoksyfenylo)mleczan etylu |
429-220-9 |
132584-17-9 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
607-597-00-2 |
4,4'-bis{4-[4-(2-hydroksyetyloamino)-6-(4-sulfonianoanilino)-1,3,5-triazyn-2-yloamino]fenyloazo}stylbeno-2,2'-disulfonian tetrasodu |
429-230-3 |
— |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-598-00-8 |
3-amino-4-[4-[4-(2-(2-etenylosulfonyloetoksy)etyloamino)-6-fluoro-1,3,5-triazyn-2-yloamino]-2-sulfofenyloazo]-5-hydroksynaftaleno-2,7-disulfonian trisodu |
429-240-8 |
212652-59-0 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-599-00-3 |
3,5,5-trimetyloperoksyheksanian 1,1-dimetylopropylu |
431-610-9 |
68860-54-8 |
Org. Perox. D Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H242 H317 H400 H410 |
GHS02 GHS07 GHS09 Dgr |
H242 H317 H410 |
|
|
|
|
607-600-00-7 |
propanian (1S,1'R)-[1-(3',3'-dimetylo-1'-cykloheksylo)etoksykarbonylo]metylu |
431-700-8 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-601-00-2 |
2-hydroksy-1,2,3-propanotrikarboksylan 1,4-dihydroksy-2,2,6,6-tetrametylopiperydyniowy |
429-370-5 |
220410-74-2 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
607-602-00-8 |
(3-cyjanometylo-3,4-dihydro-4-oksoftalazyn-1-ylo)octan etylu |
429-680-0 |
122665-86-5 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
607-603-00-3 |
4,4',4''-(nitrylootris(etano-2,1-diylimino(6-chloro-1,3,5-triazyno-4,2-diyl)imino))tris(5-hydroksy-6-(1-sulfonaftalen-2-yloazo)-2,7-naftaleno)disulfonian litu sodu |
429-730-1 |
193562-37-7 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
607-604-00-9 |
benzoesan guanidyny |
429-820-0 |
26739-54-8 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
607-605-00-4 |
4-jodo-2-(3-(4-metoksy-6-metylo-1,3,5-triazyn-2-ylo)ureidosulfonylo)benzoesan metylu |
429-890-2 |
144550-06-1 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-606-00-X |
kwas (Z)-2-(2-t-butoksykarbonyloamino-4-tiazolilo)pent-2-enowy |
430-100-3 |
86978-24-7 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
607-607-00-5 |
masa poreakcyjna: bis(C10-14 o rozgałęzionym łańcuchu alkilosalicylanu) wapnia; bis(C18-30 alkilosalicylanu) wapnia; (C18-30 alkilosalicylano-C10-14 o łańcuchu rozgałęzionym alkilosalicylanu) wapnia; bis(C10-14 o łańcuchu rozgałęzionym alkilofenolanu) wapnia; bis(C18-30-alkilofenolanu) wapnia; (C18-30 alkilofenolano-C10-14 o łańcuchu rozgałęzionym fenolanu) wapnia; C10-14 o łańcuchu rozgałęzionym alkilofenolu; C18-30-alkilofenolu |
430-180-1 |
— |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
607-608-00-0 |
2-(4-{5-[1-(2,5-disulfofenylo)-4,5-dihydro-3-metylokarbamoilo-5-oksopirazol-4-ylideno]-3-(2-pirolidynon-1-ylo)-1,3-pentadienylo}-3-metylokarbamoilo-5-oksopirazol-1-ylo)benzeno-1,4-disulfonian pentapotasu |
430-210-1 |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-609-00-6 |
(3R)-4-cyjano-3-hydroksybutanian etylu |
430-220-6 |
141942-85-0 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
607-610-00-1 |
4-hydroksy-6-(sulfonianometyloamino)-5-(2-(2-siarczanoetylosulfonylo)fenyloazo)naftaleno-2-sulfonian trisodu |
430-280-3 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-611-00-7 |
3-amino-2,2,3-trimetylomaślan metylu |
431-720-7 |
90886-53-6 |
Skin Corr. 1B Acute Tox. 4 * Aquatic Chronic 3 |
H314 H302 H412 |
GHS05 GHS07 Dgr |
H314 H302 H412 |
|
|
|
|
607-612-00-2 |
masa poreakcyjna: kwasu 3,3,4,4,5,5,6,6,7,7,8,8,8-tridekafluoro-1-oktanosulfonowego; 3,3,4,4,5,5,6,6,7,7,8,8,8-tridekafluoro-1-oktanosulfonianu amonu |
432-190-1 |
182176-52-9 |
Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 |
H302 H373** H318 |
GHS05 GHS08 GHS07 Dgr |
H302 H373** H318 |
|
|
|
|
607-613-00-8 |
masa poreakcyjna: kwasu bursztynowego; kwasu monoperoksobursztynowego; bursztynianu monometylu; monoperoksobursztynianu monometylu; bursztynianu dimetylu; kwas glutarowego; kwasu monoperoksoglutarowego; kwasu diperoksoglutarowego; glutaranu monometylu; peroksoglutaranu monometylu; glutaranu dimetylu; kwasu adypinowego; kwasu monoperoksyadypinowego; kwasu diperoksyadypinowego; adypinianu monometylu; peroksoadypinianu monometylu; adypinianu dimetylu; nadtlenku wodoru; roztworu metanolu w wodzie |
432-790-1 |
|
Acute Tox. 4* Acute Tox. 4* Acute Tox. 4* Skin Corr. 1B STOT SE 2 |
H332 H312 H302 H314 H371 (oczy) |
GHS07 GHS05 GHS08 Dgr |
H332 H312 H302 H314 H371 (oczy) |
|
|
|
|
607-614-00-3 |
kwas 2-(10-okso-10H-9-oksa-10-fosfafenantren-10-ylometylo)bursztynowy |
426-480-5 |
63562-33-4 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
607-615-00-9 |
produkt reakcji tioglicerolu i kwasu merkaptooctowego, złożony głównie z 3-merkapto-1,2-bismerkaptoacetoksypropanu i oligomerów tej substancji |
431-120-5 |
— |
Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 |
H331 H302 H319 H317 |
GHS06 Dgr |
H331 H302 H319 H317 |
|
|
|
|
607-616-00-4 |
chlorek 2,4-dichloro-5-fluorobenzoilu |
428-390-1 |
86393-34-2 |
STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H335 H315 H318 H317 H412 |
GHS05 GHS07 Dgr |
H335 H315 H318 H317 H412 |
|
|
|
|
607-617-00-X |
4,5-epoksycykloheksano-1,2-dikarboksylan bis(2-etyloheksylu) |
430-700-5 |
10138-36-0 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-618-00-5 |
disiarczan(IV) sodowy menadionu; sól sodowa kwasu 1,2,3,4-tetrahydro-2-metylo-1,4-diokso-2-naftalenosulfonowego |
204-987-0 |
130-37-0 |
Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H315 H400 H410 |
GHS07 GHS09 Wng |
H319 H315 H410 |
|
|
|
|
607-619-00-0 |
disiarczan(IV) nikotynoamido-menadionu; związek kwasu 1,2,3,4-tetrahydro-2-metylo-1,4-dioksonaftaleno-2-sulfonowego z nikotyno-3-amidem (1:1) |
277-543-7 |
73581-79-0 |
Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H315 H400 H410 |
GHS07 GHS09 Wng |
H319 H315 H410 |
|
|
|
|
607-620-00-6 |
nitrylotrioctan trisodu |
225-768-6 |
5064-31-3 |
Carc. 2 Acute Tox. 4 * Eye Irrit. 2 |
H351 H302 H319 |
GHS08 GHS07 Wng |
H351 H302 H319 |
|
Carc. 2; H351: C ≥ 5 % |
|
|
607-621-00-1 |
milbemektyna (ISO); [masa poreakcyjna milbemycyny A3 (Nr CAS 51596-10-2) i milbemycyny A4 (Nr CAS 51596-11-3) (30:70)] |
— |
— |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H332 H302 H400 H410 |
GHS07 GHS09 Wng |
H332 H302 H410 |
|
M=100 |
|
|
607-622-00-7 |
2-etyloheksanian 2-etyloheksylu |
231-057-1 |
7425-14-1 |
Repr. 2 |
H361d*** |
GHS08 Wng |
H361d*** |
|
|
|
|
607-624-00-8 |
kwas perfluorooktanosulfonowy; kwas heptadekafluorooktano-1-sulfonowy; [1] perfluorooktanosulfonian potasu; heptadekafluorooktano-1-sulfononian potasu; [2] perfluorooktanosulfonian dietanoloaminy; [3] heptadekafluorooktanosulfononian amonu; heptadekafluorooktanosulfononian amonu; [4] perfluorooktanosulfonian litu; heptadekafluorooktanosulfononian litu [5] |
217-179-8 [1] 220-527-1 [2] 274-460-8 [3] 249-415-0 [4] 249-644-6 [5] |
1763-23-1 [1] 2795-39-3 [2] 70225-14-8 [3] 29081-56-9 [4] 29457-72-5 [5] |
Carc. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Lact. Aquatic Chronic 2 |
H351 H360D*** H372** H332 H302 H362 H411 |
GHS08 GHS07 GHS09 Dgr |
H351 H360D*** H372** H332 H302 H362 H411 |
|
|
|
|
607-625-00-3 |
chlodinafop propargilowy (ISO) |
— |
105512-06-9 |
Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373** H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H302 H373** H317 H410 |
|
Skin Sens. 1; H317: C ≥ 0,001 % M=1 |
|
|
607-626-00-9 |
1-(2,4-dichlorofenylo)-5-(trichlorometylo)-1H-l,2,4-triazolo-3-karboksylan etylu |
401-290-5 |
103112-35-2 |
Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H350 H400 H410 |
GHS08 GHS09 Dgr |
H350 H410 |
|
|
|
|
607-627-00-4 |
4-nitrobenzenosulfonian [(4S,5S)-4-benzylo-2-okso-5-oksazolidynylo]metylu |
416-360-0 |
162221-28-5 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-628-00-X |
addukt kwasu 4-okso-4-(p-tolylo)butanowego z 4-etylomorfoliną |
419-240-6 |
171054-89-0 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-629-00-5 |
kwas [[2-metylo-l-(l-oksopropoksy)propoksy] (4-fenylobutylo)fosfinylo]octowy |
419-270-1 |
123599-82-6 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
607-630-00-0 |
3-(trimetoksysilylo)akrylan propylu |
419-560-6 |
4369-14-6 |
Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 3 |
H332 H314 H317 H412 |
GHS05 GHS07 Dgr |
H332 H314 H317 H412 |
|
|
|
|
607-631-00-6 |
masa poreakcyjna: okso(fenylo)octanu 2-(2-((okso(fenylo)acetylo)oksy)etoksy)etylu; okso(fenylo)octanu (2-(2-hydroksyetoksy)etylu) |
442-300-8 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-632-00-1 |
N-[3-(2,4-di-(1,1-dimetylo-propylo)fenoksy)-propylo]-1-hydroksy-5-(2-metylopropylo-oksykarbonyloamino)-naftamid |
420-210-1 |
111244-14-5 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-633-00-7 |
5-{[4-chloro-6-(1-naftyloamino)-1,3,5-triazin-2-ylo]amino}-4-hydroksy-3-[(E)-(4-metoksy-2-sulfonianofenylo)diazenylo]-2,7-naftalenodisulfonian trisodu |
440-480-2 |
341026-59-3 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
607-634-00-2 |
chlorek (S)-(–)-2-acetoksypropionylu; octan (1S)-2-chloro-1-metylo-2-oksoetylu |
420-610-4 |
36394-75-9 |
Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 |
H302 H314 H317 |
GHS05 GHS07 Dgr |
H302 H314 H317 |
|
|
|
|
607-635-00-8 |
N-(3-propioniano)-L-aspartanian trisodu |
422-090-4 |
172737-80-3 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-636-00-3 |
propionian 1-bromo-2-metylopropylu |
422-900-6 |
158894-67-8 |
Flam. Liq. 3 Carc. 2 Skin Corr. 1B Skin Sens. 1 |
H226 H351 H314 H317 |
GHS02 GHS05 GHS08 GHS07 Dgr |
H226 H351 H314 H317 |
|
|
|
|
607-637-00-9 |
8-amino-5-{4-[2-(sulfonoetoksy)sulfonylo]fenyloazo}naftaleno-2-sulfonian disodu |
423-730-5 |
250688-43-8 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-638-00-4 |
ester 2-butylooktylowy kwasu 2-hydroksybenzoesowego; 2-hydroksybenzoesan 2-bytylooktylu |
431-090-3 |
190085-41-7 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-639-00-X |
octan 2-(2-okso-5-(1,1,3,3-tetrametylobutylo)-2,3-dihydro-1-benzofuran-3-ylo)-4-(1,1,3,3-tetrametylobutylo)fenylu |
431-770-1 |
216698-07-6 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-641-00-0 |
kwas 2-(formyloamino)-3-tiofenokarboksylowy; kwas 2-formamido-3-tiofenokarboksylowy |
431-930-9 |
43028-69-9 |
Acute Tox. 4 * Skin Sens. 1 |
H302 H317 |
GHS07 Wng |
H302 H317 |
|
|
|
|
607-642-00-6 |
3,6,9-tritiaundekametyleno-1,11-dimetakrylan |
432-210-7 |
141631-22-3 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
607-643-00-1 |
(2S)-2-hydroksybursztynian dimetylu |
432-310-0 |
617-55-0 |
Flam. Liq. 3 Eye Dam. 1 Skin Sens. 1 |
H226 H318 H317 |
GHS02 GHS05 GHS07 Dgr |
H226 H318 H317 |
|
|
|
|
607-644-00-7 |
2,2-dimetylo-6-metylenocykloheksanokarboksylan metylu |
432-350-9 |
81752-87-6 |
Skin Irrit. 2 |
H315 |
GHS07 Wng |
H315 |
|
|
|
|
607-645-00-2 |
2-(4-fluoro-6-(metylo-(2-(sulfatoetylosulfonylo)etylo)amino)-1,3,5-triazin-2-yloamino)-5-hydroksy-6-(4-metylo-2-sulfonianofenyloazo)naftaleno-1,7-disulfonian tetrasodu |
432-550-6 |
243858-01-7 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-646-00-8 |
2,4-dideoksy-3,5-O-(1-metyloetylideno)-1,1-dimetyloetylowy D-erytro-heksanian 2-[(4R,6S)-6-(hydroksymetylo)-2,2-dimetylo-1,3-dioksan-4-ylo]octan tert-butylu |
432-960-5 |
124655-09-0 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
607-647-00-3 |
5-acetoksy-2-(R, S)butyrylooksymetylo-1,3-oksatiolan |
433-530-1 |
143446-73-5 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 |
H302 H317 H400 |
GHS07 GHS09 Wng |
H302 H317 H400 |
|
|
|
|
607-649-00-4 |
octan [3-(chlorokarbonylo)-2-metylofenylu] |
433-690-0 |
167678-46-8 |
Skin Corr. 1A Skin Sens. 1 |
H314 H317 |
GHS05 GHS07 Dgr |
H314 H317 |
|
|
|
|
607-650-00-X |
1,3-benzenodikarboksylan 2-metylo-l,5-pentanodiaminy; izoftalan 2-metylo-l,5-pentanodiaminy |
433-910-5 |
145153-52-2 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-651-00-5 |
2-(nonanoyloksy)benzenosulfonian sodu |
434-360-9 |
91125-43-8 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
607-652-00-0 |
chlorowodorek etylo N2-dodekanoylo-L-argininianu |
434-630-6 |
60372-77-2 |
Eye Dam. 1 Aquatic Acute 1 |
H318 H400 |
GHS05 GHS09 Dgr |
H318 H400 |
|
|
|
|
607-653-00-6 |
3-(4-(7-acetyloamino-1-hydroksy-3-sulfonianonaftalen-2-yloazo)-5-metoksy-2-sulfonianofenyloazo)-7-(4-amino-3-sulfonianofenyloamino)-4-hydroksynaftaleno-2-sulfonian tetrakis(bis(2-hydroksyetylo)metyloamoniowy) |
434-840-8 |
225786-91-4 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-654-00-1 |
(S)-3-hydroksy-γ-butyrolakton |
434-990-4 |
7331-52-4 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-655-00-7 |
6,8-dichlorooktanian etylu |
435-080-1 |
1070-64-0 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-656-00-2 |
sól sodowa kwasu 4-amino-3,6-bis[[5-[[4-chloro-6-[(2-metylo-4-sulfofenylo)amino]-1,3,5-triazin-2-ylo]amino]-2-sulfofenylo]azo]-5-hydroksy-2,7-naftalenodisulfonowego |
435-350-7 |
141250-43-3 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
607-657-00-8 |
7-(4-(4-(3-(2-sulfatoetanosulfonylo)fenyloamino)-6-(4-(2-sulfatoetanosulfonylo)fenyloamino)-1,3,5-triazin-2-yloamino)-2-ureidofenyloazo)naftaleno-1,3,6-trisulfonian pentasodu |
436-920-8 |
172399-10-9 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-658-00-3 |
sól litowa, potasowa, sodowa kwasu 3,10-diamino-6,13-dichloro-2-((6-(((4-(1,1-dimetyloetylo)fenylo)sulfonylo)amino)-2-naftalenylo)sulfonylo)-4,11-trifenodioksazynodisulfonowego |
440-770-9 |
371921-63-0 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
607-659-00-9 |
sól pentasodowa kwasu N-[5-[[4-[[3-[(aminokarbonylo)amino]-4-[(3,6,8-trisulfonianonaftalen-2-ylo)azo]fenylo]amino]-6-chloro-1,3,5-triazin-2-ylo]amino]-2-sulfoniano-4-[[4-[[-2-(oksysulfoniano)etylo] sulfonylo]fenylo]azo]fenylo]-3-aminopropanowego |
442-030-0 |
321912-47-4 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-660-00-4 |
sól trisodowa 2-{4-[4-[4-fluoro-6-(2-(2-winylosulfonyloetoksy)etyloamino)-1,3,5-triazin-2-yloamino]fenyloazo]fenyloazo}naftaleno-4,6,8-trisulfonianu |
442-230-8 |
321679-52-1 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
607-661-00-X |
4'-(bromometylo)bifenylo-2-karboksylan 1,1-dimetyloetylu |
442-850-9 |
114772-40-6 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
607-662-00-5 |
2-(acetyloamino)-3-chloropropionian metylu |
442-860-3 |
87333-22-0 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
607-663-00-0 |
naftaleno-2,6-dikarboksylan bis(2-etyloheksylu) |
442-980-6 |
127474-91-3 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-664-00-6 |
2-chlorosulfonylo-4-(metanosulfonyloaminometylo) benzoesan metylu |
443-120-2 |
393509-79-0 |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|
|
|
|
607-665-00-1 |
trans-metylo-2-etylo-but-2-enian |
443-150-6 |
101226-85-1 |
Flam. Liq. 3 |
H226 |
GHS02 Wng |
H226 |
|
|
|
|
607-666-00-7 |
kwas (2S)-5-(benzylooksy)-2-(1,3-diokso-1,3-dihydro-2H-izoindol-2-ylo)-5-oksopentanowy |
443-560-5 |
88784-33-2 |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
607-667-00-2 |
węglan chloro-1-etylocykloheksylu |
444-950-8 |
99464-83-2 |
Muta. 2 Skin Sens. 1 |
H341 H317 |
GHS08 GHS07 Wng |
H341 H317 |
|
|
|
|
607-668-00-8 |
trans-2-izopropylo-5-karboksy-1,3-dioksan |
445-770-2 |
42031-28-7 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
607-669-00-3 |
(9-acetoksy-3,8,10-trietylo-7,8,10-trimetylo-1,5-dioksa-9-aza-spiro[5.5]undec-3-ylo)oktadekanian metylu |
445-990-9 |
376588-17-9 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
607-670-00-9 |
szczawian dibutylo-3-(4-(5-amonio-2-buty-lo)benzofuran-3-ylo)karbonylo)fenoksy)propylamoniowy; diszczawian (5-amino-2-butylobenzofuran-3-ylo) [4-(3-dibutyloaminopropoksy)fenylo]metanonu |
448-700-9 |
500791-70-8 |
STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H373** H318 H317 H400 H410 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H373** H318 H317 H410 |
|
M=10 |
|
|
607-671-00-4 |
1,4-cykloheksanodikarboksylan dietylu |
417-310-0 |
72903-27-6 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
607-672-00-X |
masa poreakcyjna: (2-benzoylo)benzoesanu 2-hydroksy-3-(metakryloyloksy)propylu; (2-benzoylo)benzoesanu 1-hydroksymetylo-2-(metakryloyloksy)etylu; (2-benzoylo)benzoesanu x-hydroksy-y-(metakryloyloksy)propylu (lub -etylu) |
419-000-0 |
— |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-673-00-5 |
tosylan 1-etylo-5,6,7,8-tetrahydrochinoliny |
419-570-0 |
— |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
607-675-00-6 |
masa poreakcyjna: kwasu cis-9-oktadekanodiowego; kwasu cis-9-cis-12-oktadekadienodiowego; kwasu heksadekanodiowego; kwasu oktadekanodiowego |
422-260-8 |
— |
Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H400 H410 |
GHS05 GHS09 Dgr |
H318 H410 |
|
|
|
|
607-676-00-1 |
masa poreakcyjna: kwasu 2-metylononanodiowego; kwasu 2,4-dimetylo-4-metoksykarbonyloundekanodiowego; kwasu 2,4,6-trimetylo-4,6-dimetoksykarbonylotridekanodiowego; kwasu 8,9-dimetylo-8,9-dimetoksykarbonyloheksadekanodiowego |
423-670-1 |
— |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
607-677-00-7 |
N-{[metylo[[2-(1-metyloetylo)-4-tiazolylo]metylo]amino]karbonylo}-L-walinian 2,5-dioksopirolidyn-1-ylu |
424-660-8 |
— |
STOT RE 2 * Eye Dam. 1 Skin Sens. 1 |
H373** H318 H317 |
GHS05 GHS08 GHS07 Dgr |
H373** H318 H317 |
|
|
|
|
607-678-00-2 |
masa poreakcyjna: (2R,3R)-3-izopropylobicyclo[2.2.1]hept-5-eno-2-karboksylanu etylu; (2S,3S)-3-izopropylobicyclo[2.2.1]hept-5-eno-2-karboksylanu etylu |
427-090-8 |
— |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-679-00-8 |
masa poreakcyjna: dioctanu 3-{5-[3-(4-{1,6-dihydro-2-hydroksy-4-metylo-1-[3-(metyloamonio)propylo]-6-okso-3-pirydylazo}benzamido)-fenyloazo]-1,2-dihydro-6-hydroksy-4-metylo-2-okso-1-pirydylo}propylo(metylo)amoniowego; dioctanu 3-{5-[4-(3-{1,6-dihydro-2-hydroksy-4-metylo-1-[3-(metyloamonio)propylo]-6-okso-3-pirydylazo}benzamido)-fenyloazo]-1,2-dihydro-6-hydroksy-4-metylo-2-okso-1-pirydylo}propylo(dimetylo)amoniowego; dioctanu 3-{5-[3-(4-{1-[3-(dimetyloamonio)propylo]-1,6-dihydro-2-hydroksy-4-metylo-6-okso-3-pirydylazo}benzamido)-fenyloazo]-1,2-dihydro-6-hydroksy-4-metylo-2-okso-1-pirydylo}propylo(dimetylo)amoniowego |
431-440-5 |
— |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|
|
|
|
607-680-00-3 |
octan tert-butylo(6-{2-[4-(4-fluorofenylo)-6-isopropylo-2-[metylo(-metylosulfonyl)amino]pirymidyn-5-ylo]winylo}(4S,6S)-2,2-dimetylo[l,3]dioksan-4-ylowy) |
432-810-9 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-681-00-9 |
masa poreakcyjna: kwasu 9-nonylo-10-oktylo-19-karbonylooksyheksadecylononadekanowego; kwasu 9-nonylo-10-oktylo-19-karbonylooksyoktadecylononadekanowego; 9-nonylo-10-oktylononadekanodioanu diheksadecylu; 9-nonylo-10-oktylononadekanodioanu 1-oktadecylu, 19-heksadecylu; 9-nonylo-10-oktylononadecanodioanu dioktadecylu |
432-910-2 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-682-00-4 |
masa poreakcyjna chińskiej kalafonii z kwasem akrylowym |
434-230-1 |
144413-22-9 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-683-00-X |
masa poreakcyjna: 3-((1E)-2-metyloprop-1-enylo)-2,2-dimetylocyklopropanokarboksylanu metylu 3-((1Z)-2-metyloprop-1-enylo)-2,2-dimetylocyklopropanokarboksylanu metylu (20:80) |
435-450-0 |
— |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
607-684-00-5 |
alkany, produkty hydroformylacji C12-14, pozostałości po destylacji, C-(wodoro sulfobutanodianu), disodowe sole |
435-660-2 |
243662-67-1 |
Skin Irrit. 2 Skin Sens. 1 |
H315 H317 |
GHS07 Wng |
H315 H317 |
|
|
|
|
607-685-00-0 |
2-kokoilooksyetanosulfonian amonu |
441-050-7 |
— |
Skin Irrit. 2 Eye Dam. 1 |
H315 H318 |
GHS05 Dgr |
H315 H318 |
|
|
|
|
607-686-00-6 |
6,6'-bis(diazo-5,5',6,6'-tetrahydro-5,5'-diokso)[metyleno-bis(5-(6-diazo-5,6-dihydro-5-okso-1-naftylosulfonylooksy)-6-metylo-2-fenyleno]di(naftaleno-1-sulfonian) |
441-550-5 |
— |
Self-react. C **** Carc. 2 |
H242 H351 |
GHS02 GHS08 Dgr |
H242 H351 |
|
|
|
|
607-687-00-1 |
masa poreakcyjna: benzenosulfonianu 2-{3,6-bis-[(2-etylofenylo)-metyloamino]-ksantylium-9-ylu} (2-10 %); benzenosulfonianu 2-{3,6-bis-[(2,3-dimetylofenylo)-metyloamino]-ksantylium-9-ylu}-(2-10 %); benzenosulfonianu 2-{3,6-bis-[(2,4-dimetylofenylo)-metyloamino]-ksantylium-9-ylu}-(2-10 %); benzenosulfonianu 2-{3,6-bis-[(2,5-dimetylofenylo)-metyloamino]-ksantylium-9-ylu}-(2-10 %); 2-{3-[(2,3-dimetylofenylo)-metyloamino]-6-[(2-etylofenylo)-metyloamino]-ksantylium-9-ylo}-benzenosulfonianu (7-20 %); 2-{3-[(2,4-dimetylofenylo)-metyloamino]-6-[(2-etylofenylo)-metyloamino]-ksantylium-9-ylo}-benzenosulfonianu (7-20 %); 2-{3-[(2,5-dimetylofenylo)-metyloamino]-6-[(2-etylofenylo)-metyloamino]-ksantylium-9-ylo}-benzenosulfonianu (7-20 %); 2-{3-[(2,3-dimetylofenylo)-metyloamino]-6-[(2,4-dimetylofenylo)-metyloamino]-ksantylium-9-ylo}-benzenosulfonianu (7-20 %); 2-{3-[(2,3-dimetylofenylo)-metyloamino]-6-[(2,5-dimetylofenylo)-metyloamino]-ksantylium-9-ylo}-benzenosulfonianu (7-20 %); 2-{3-[(2,4-dimetylofenylo)-metyloamino]-6-[(2,5-dimetylofenylo)-metyloamino]-ksantylium-9-ylo}-benzenosulfonianu (7-20 %); |
442-800-6 |
— |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
607-688-00-7 |
chlorek (R)-1-cycloheksa-1,4-dienylo-1-metoksykarbonylo-metyloamoniowy |
444-320-2 |
— |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
607-689-00-2 |
masa poreakcyjna: 1,4-dimetylocykloheksanokarboksylanu („isomer para-” zawierający izomery cis-i trans-); 1,3-dimetylocykloheksanokarboksylanu („meta-isomer” zawierający izomery cis-i trans-) |
444-920-4 |
— |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
607-690-00-8 |
[2S,2S']-6,6,6'6'-tetra-metoksy-2,2'-[N, N'-bis(trifluoroacetylo)-S, S'-bi(L-homocysteinylo)diimino]diheksanian dimetylu |
432-860-1 |
255387-46-3 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
607-691-00-3 |
sole magnezowe kwasów tłuszczowych, C16-18 i C18 nienasyconych, rozgałęzionych i liniowych |
448-690-6 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-692-00-9 |
sole cynkowe kwasów tłuszczowych, C16-18 i C18 nienasyconych, rozgałęzionych i liniowych |
446-470-4 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-693-00-4 |
2-(1-(dietyloaminohydroksyfenylo)metanoilo)benzoesan heksylu |
443-860-6 |
302776-68-7 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
607-694-00-X |
5,5-difenylo-2-izooksazolino-3-karboksylan etylu |
443-870-0 |
163520-33-0 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|
|
|
|
607-696-00-0 |
amylu mrówczan |
211-340-6 |
638-49-3 |
Flam. Liq. 3 Eye Irrit. 2 STOT SE 3 |
H226 H319 H335 |
GHS02 GHS07 Dgr |
H226 H319 H335 |
|
|
C |
|
607-697-00-6 |
tert-butylu propionian |
— |
20487-40-5 |
Flam. Liq. 2 |
H225 |
GHS02 Dgr |
H225 |
|
|
C |
|
607-698-00-1 |
kwas 4-tert-butylobenzoesowy |
202-696-3 |
98-73-7 |
Repr. 1B STOT RE 1 Acute Tox. 4 |
H360F H372 H302 |
GHS07 GHS08 Dgr |
H360F H372 H302 |
|
|
|
|
607-699-00-7 |
bifentryna (ISO); rel-(1R,3R)-3-[(1Z)-2-chloro-3,3,3-trifluoroprop-1-en-1-ylo]-2,2-dimetylocyklopropanokarboksylan (2-metylobifenyl-3-ylo)metylu |
|
82657-04-3 |
Carc. 2 Acute Tox. 3 Acute Tox. 2 STOT RE 1 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H351 H331 H300 H372 (układ nerwowy) H317 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H351 H331 H300 H372 (układ nerwowy) H317 H410 |
|
M = 10 000 M = 100 000 |
|
|
607-700-00-0 |
indoksakarb (ISO); (4aS)-7-chloro-2-{(metoksykarbonylo)[4-(trifluorometoksy)fenylo]karbamoilo}-2,5-dihydroindeno[1,2-e][1,3,4]oksadiazino-4a(3H)-karboksylan metylu [1] masa poreakcyjna (S)-indoksakarbu i (R)-indoksakarbu 75:25; 7-chloro-2-{(metoksykarbonylo)[4-(trifluorometoksy)fenylo]karbamoilo}-2,5-dihydroindeno[1,2-e][1,3,4]oksadiazyno-4a(3H)-karboksylanu metylu [2] |
|
173584-44-6 [1] 144171-61-9 [2] |
Acute Tox. 3 Acute Tox. 4 STOT RE 1 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H301 H332 H372 (krew, układ nerwowy, serce) H317 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H301 H332 H372 (krew, układ nerwowy, serce) H317 H410 |
|
M = 1 M = 1 |
|
|
607-702-00-1 |
ftalan diheksylu |
201-559-5 |
84-75-3 |
Repr. 1B |
H360FD |
GHS08 Dgr |
H360FD |
|
|
|
|
607-703-00-7 |
pentadekafluorooktanian amonu |
223-320-4 |
3825-26-1 |
Carc. 2 Repr. 1B Lact. Acute Tox. 4 Acute Tox. 4 STOT RE 1 Eye Dam.1 |
H351 H360D H362 H332 H302 H372 (wątroba) H318 |
GHS08 GHS07 GHS05 Dgr |
H351 H360D H362 H332 H302 H372 (wątroba) H318 |
|
|
|
|
607-704-00-2 |
kwas perfluorooktanowy |
206-397-9 |
335-67-1 |
Carc. 2 Repr. 1B Lact. Acute Tox. 4 Acute Tox. 4 STOT RE 1 Eye Dam. 1 |
H351 H360D H362 H332 H302 H372 (liver) H318 |
GHS08 GHS07 GHS05 Dgr |
H351 H360D H362 H332 H302 H372 (liver) H318 |
|
|
|
|
607-705-00-8 |
kwas benzoesowy |
200-618-2 |
65-85-0 |
STOT RE 1 Skin Irrit. 2 Eye Dam. 1 |
H372 (płuca) (droga wziewna) H315 H318 |
GHS08 GHS05 Dgr |
H372 (płuca) (droga wziewna) H315 H318 |
|
|
|
|
607-706-00-3 |
2,5-dichlorobenzoesan metylu |
220-815-7 |
2905-69-3 |
Acute Tox. 4 STOT SE 3 Aquatic Chronic 2 |
H302 H336 H411 |
GHS07 GHS09 Wng |
H302 H336 H411 |
|
|
|
|
608-001-00-3 |
acetonitryl; cyjanek metylu; nitryl kwasu octowego |
200-835-2 |
75-05-8 |
Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 |
H225 H332 H312 H302 H319 |
GHS02 GHS07 Dgr |
H225 H332 H312 H302 H319 |
|
|
|
|
608-002-00-9 |
trichloroacetonitryl; nitryl kwasu trichlorooctowego |
208-885-7 |
545-06-2 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Chronic 2 |
H331 H311 H301 H411 |
GHS06 GHS09 Dgr |
H331 H311 H301 H411 |
|
|
|
|
608-003-00-4 |
akrylonitryl; cyjanek winylu; nitryl kwasu akrylowego |
203-466-5 |
107-13-1 |
Flam. Liq. 2 Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H225 H350 H331 H311 H301 H335 H315 H318 H317 H411 |
GHS02 GHS06 GHS08 GHS05 GHS09 Dgr |
H225 H350 H331 H311 H301 H335 H315 H318 H317 H411 |
|
* |
D |
|
608-004-00-X |
2-hydroksy-2-metylopropionitryl; 2-cyjanopropan-2-ol; cyjanohydryna acetonu; acetocyjanohydryna |
200-909-4 |
75-86-5 |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H330 H310 H300 H410 |
|
|
|
|
608-005-00-5 |
butanonitryl; cyjanek propylu; butyronitryl |
203-700-6 |
109-74-0 |
Flam. Liq. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * |
H225 H331 H311 H301 |
GHS02 GHS06 Dgr |
H225 H331 H311 H301 |
|
|
|
|
608-006-00-0 |
bromoksynil (ISO); 3,5-dibromo-4-hydroksybenzonitryl; fenol bromoksynilu |
216-882-7 |
1689-84-5 |
Repr. 2 Acute Tox. 2 * Acute Tox. 3 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361d *** H330 H301 H317 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H361d *** H330 H301 H317 H410 |
|
M = 10 |
|
|
608-007-00-6 |
joksynyl (ISO); 4-hydroksy-3,5-dijodobenzonitryl |
216-881-1 |
1689-83-4 |
Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H361d *** H331 H301 H312 H373 ** H319 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H361d *** H331 H301 H312 H373 ** H319 H410 |
|
M = 10 |
|
|
608-008-00-1 |
chloroacetonitryl; cyjanek chlorometylu; nitryl kwasu chlorooctowego |
203-467-0 |
107-14-2 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Chronic 2 |
H331 H311 H301 H411 |
GHS06 GHS09 Dgr |
H331 H311 H301 H411 |
|
|
|
|
608-009-00-7 |
malononitryl; dicyjanek metylu; dinitryl kwasu malonowego |
203-703-2 |
109-77-3 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H331 H311 H301 H410 |
|
|
|
|
608-010-00-2 |
metakrylonitryl; 2-metylprop-2-enonitryl; nitryl kwasu metakrylowego; cyjanek 1-metylowinylu |
204-817-5 |
126-98-7 |
Flam. Liq. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Skin Sens. 1 |
H225 H331 H311 H301 H317 |
GHS02 GHS06 Dgr |
H225 H331 H311 H301 H317 |
|
* Skin Sens. 1; H317: C ≥0,2 % |
D |
|
608-011-00-8 |
etanodinitryl; cyjanogen; dicyjan; dinitryl kwasu szczawiowego |
207-306-5 |
460-19-5 |
Press. Gas Flam. Gas 1 Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H220 H331 H400 H410 |
GHS02 GHS04 GHS06 GHS09 Dgr |
H220 H331 H410 |
|
|
U |
|
608-012-00-3 |
benzonitryl; cyjanek fenylu |
202-855-7 |
100-47-0 |
Acute Tox. 4 * Acute Tox. 4 * |
H312 H302 |
GHS07 Wng |
H312 H302 |
|
|
|
|
608-013-00-9 |
2-chlorobenzonitryl |
212-836-5 |
873-32-5 |
Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 |
H312 H302 H319 |
GHS07 Wng |
H312 H302 H319 |
|
|
|
|
608-014-00-4 |
chlorotalonil (ISO); tetrachloroizoftalonitryl |
217-588-1 |
1897-45-6 |
Carc. 2 Acute Tox. 2 * STOT SE 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H330 H335 H318 H317 H400 H410 |
GHS06 GHS05 GHS08 GHS09 Dgr |
H351 H330 H335 H318 H317 H410 |
|
M=10 |
|
|
608-015-00-X |
dichlobenyl (ISO); 2,6-dichlorobenzonitryl |
214-787-5 |
1194-65-6 |
Acute Tox. 4 * Aquatic Chronic 2 |
H312 H411 |
GHS07 GHS09 Wng |
H312 H411 |
|
|
|
|
608-016-00-5 |
1,4-dicyjano-2,3,5,6-tetrachlorobenzen; nitryl kwasu tetrachlorotereftalowego; tetrachlorotereftalonitryl |
401-550-8 |
1897-41-2 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
608-017-00-0 |
oktanian bromoksynilu (ISO); oktanian 2,6-dibromo-4-cyjanofenylu |
216-885-3 |
1689-99-2 |
Repr. 2 Acute Tox. 3 * Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361d *** H331 H302 H317 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H361d *** H331 H302 H317 H410 |
|
M = 10 |
|
|
608-018-00-6 |
oktanian joksynylu (ISO); oktanian 2,6-dijodo-4-cyjanofenylu |
223-375-4 |
3861-47-0 |
Repr. 2 Acute Tox. 3 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361d *** H301 H319 H317 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H361d *** H301 H319 H317 H410 |
|
M = 10 |
|
|
608-019-00-1 |
2,2'-dimetylo-2,2'-azodipropiononitryl; 2,2'-dimetylo-2,2'-diazenylodipropanonitryl ADZN |
201-132-3 |
78-67-1 |
Self-react. C Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 3 |
H242 H332 H302 H412 |
GHS02 GHS07 Dgr |
H242 H332 H302 H412 |
|
|
T |
|
608-020-00-7 |
difenoksymetylenocyjanoamid |
427-300-8 |
79463-77-7 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
608-021-00-2 |
3-[2-(diaminometylenoamino)tiazol-4-ilometylotio]propanonitryl |
403-710-2 |
76823-93-3 |
Acute Tox. 4 * Skin Sens. 1 |
H302 H317 |
GHS07 Wng |
H302 H317 |
|
|
|
|
608-022-00-8 |
3,7-dimetylooktanonitryl |
403-620-3 |
40188-41-8 |
Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H315 H317 H411 |
GHS07 GHS09 Wng |
H315 H317 H411 |
|
|
|
|
608-023-00-3 |
fenbukonazol (ISO); 4-(4-chlorofenylo)-2-fenylo-2-[(1H-1,2,4-triazol-1-ilo)metylo]butanonitryl |
406-140-2 |
114369-43-6 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
608-024-00-9 |
2-[4-(N-butylo-N-fenetyloamino)fenylo]etyleno-1,1,2-trikarbonitryl |
407-650-8 |
97460-76-9 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
608-025-00-4 |
2-nitro-4,5-bis(benzyloksy)fenyloacetonitryl |
410-970-0 |
117568-27-1 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
608-026-00-X |
3-cyjano-3,5,5-trimetylocykloheksanon |
411-490-4 |
7027-11-4 |
Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Chronic 3 |
H302 H373 ** H317 H412 |
GHS08 GHS07 Wng |
H302 H373 ** H317 H412 |
|
|
|
|
608-027-00-5 |
masa poreakcyjna: 3-(4-etylofenylo)-2,2-dimetylopropanonitrylu; 3-(2-etylofenylo)-2,2-dimetylopropanonitryl; 3-(3-etylofenylo)-2,2-dimetylopropanonitrylu |
412-660-0 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
608-028-00-0 |
2-cyjano-3-fenyloaminoakrylan 4-(2-cyjano-3-fenyloamino)akryloiloksymetylocykloheksylometylu |
413-510-7 |
147374-67-2 |
STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 |
H373 ** H317 H411 |
GHS08 GHS09 Wng |
H373 ** H317 H411 |
|
|
|
|
608-029-00-6 |
6-hydroksy-4-metylo-1-[3-(1-metyloetoksy)propylo]-2-okso-1,2-dihydropirydyno-3-karbonitryl |
411-990-2 |
68612-94-2 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
608-030-00-1 |
N-acetylo-N-[5-cyjano-3-(2-dibutyloamino-4-fenylotiazol-5-ilometyleno)-4-metylo-2,6-diokso-1,2,3,6-tetrahydropirydyn-1-ylo]benzamid |
412-340-0 |
147741-93-3 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
608-031-00-7 |
2-benzylo-2-metylobut-3-enonitryl |
407-870-4 |
97384-48-0 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
608-032-00-2 |
acetamiprid (ISO); (E)-N1-[(6-chloro-3-pirydylo)metylo]-N2-cyjano-N1-metyloacetamidyna |
— |
135410-20-7 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
608-033-00-8 |
N-butylo-3-(2-chloro-4-nitrofenylohydrazono)-1-cyjano-2-metyloprop-1-eno-1,3-dikarboksyimid |
407-970-8 |
75511-91-0 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
608-034-00-3 |
chlorofenapir (ISO); 4-bromo-2-(4-chlorofenylo)-1-etoksymetylo-5-trifluorometylopirolo-3-karbonitryl |
— |
122453-73-0 |
Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H302 H400 H410 |
GHS06 GHS09 Dgr |
H331 H302 H410 |
|
M=100 |
|
|
608-035-00-9 |
(±)-α-[(2-acetylo-5-metylofenylo)amino]-2,6-dichlorobenzenoacetonitryl |
419-290-9 |
— |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|
|
|
|
608-036-00-4 |
3-(2-{4-[2-(4-cyjanofenylo)winylo]fenylo}-winylo)benzonitryl |
419-060-8 |
79026-02-1 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
608-037-00-X |
masa poreakcyjna: (E)-trideka-2,12-dienonitrylu; (E)-trideka-3,12-dienonitrylu; (Z)-trideka-3,12-dienonitrylu |
422-190-8 |
|
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
608-038-00-5 |
2,2,4-trimetylo-4-fenylobutanonitryl |
422-580-8 |
75490-39-0 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
608-039-00-0 |
2-fenyloheksanonitryl |
423-460-8 |
3508-98-3 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
608-040-00-6 |
4,4'-ditiobis{5-amino-1-[2,6-dichloro-4-(trifluorometylo)fenylo]-1H-pirazolo-3-karbonitryl} |
423-490-1 |
130755-46-3 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
608-041-00-1 |
4'-[(2-butylo-4-okso-1,3-diazaspiro[4.4]non-1-eno-3-ylo)metylo]-(1,1'-bifenylo)-2-karbonitryl |
423-500-4 |
138401-24-8 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
608-042-00-7 |
bromowodorek (S)-2,2-difenylo-2-(3-pirolidynylo)acetonitrylu |
421-810-4 |
194602-27-2 |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H302 H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H317 H411 |
|
|
|
|
608-043-00-2 |
3-(cis-heks-3-enyloksy)propanonitryl |
415-220-6 |
142653-61-0 |
Acute Tox. 3 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H302 H400 H410 |
GHS06 GHS09 Dgr |
H331 H302 H410 |
|
|
|
|
608-044-00-8 |
2-cykloheksylideno-2-fenyloacetonitryl |
423-740-1 |
10461-98-0 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
608-046-00-9 |
5-(4-chloro-2-nitro-fenyloazo)-1,2-dihydro-6-hydroksy-1,4-dimetylo-2-okso-pirydyno-3-karbonitryl |
425-310-7 |
77889-90-8 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
608-047-00-4 |
2-piperydyn-1-ylo-benzonitryl |
427-330-1 |
72752-52-4 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
608-048-00-X |
1-(3-cyklopentyloksy-4-metoksyfenylo)-4-okso-cykloheksanokarbonitryl |
427-450-4 |
152630-47-2 |
Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H373** H317 H411 |
GHS08 GHS07 GHS09 Wng |
H302 H373** H317 H411 |
|
|
|
|
608-049-00-5 |
2-(4-(4-(butylo-(1-metyloheksylo)amino)fenylo)-3-cyjano-5-okso-1,5-dihydropirol-2-ilideno)propanodinitryl |
429-180-2 |
157362-53-3 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
608-050-00-0 |
masa poreakcyjna: 5-(2-cyjano-4-nitrofenyloazo)-2-(2-(2-hydroksyetoksy)etyloamino)-4-metylo-6-fenyloaminonikotynonitrylu; 5-(2-cyjano-4-nitrofenyloazo)-6-(2-(2-hydroksyetoksy)etyloamino)-4-metylo-2-fenyloaminonikotynonitrylu |
429-760-5 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
608-051-00-6 |
(R)-4-(4-dimetyloamino-1-(4-fluorofenylo)-1-hydroksybutylo)-3-(hydroksymetylo)benzonitryl |
430-760-2 |
219861-18-4 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H317 H411 |
GHS07 GHS09 Wng |
H302 H317 H411 |
|
|
|
|
608-052-00-1 |
(S)-4-(4-dimetyloamino-1-(4-fluorofenylo)-1-hydroksybutylo)-3-(hydroksymetylo)benzonitryl |
430-770-7 |
128173-52-4 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H317 H411 |
GHS07 GHS09 Wng |
H302 H317 H411 |
|
|
|
|
608-053-00-7 |
(R,S)-4-(4-dimetyloamino-1-(4-fluorofenylo)-1-hydroksybutylo)-3-(hydroksymetylo)benzonitryl |
430-780-1 |
103146-25-4 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H317 H411 |
GHS07 GHS09 Wng |
H302 H317 H411 |
|
|
|
|
608-054-00-2 |
hemisiarczan (R,S)-4-(4-dimetyloamino-1-(4-fluorofenylo)-1-hydroksybutylo)-3-(hydroksymetylo)benzonitrylu |
430-790-6 |
— |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H302 H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H317 H411 |
|
|
|
|
608-056-00-3 |
metylosiarczan N-metylo-N-cyjanometylomorfoliniowy |
429-340-1 |
— |
Acute Tox. 4 * Eye Dam. 1 |
H302 H318 |
GHS05 GHS07 Dgr |
H302 H318 |
|
|
|
|
608-057-00-9 |
wodorosiarczan 4-cyjanometylo-4-metylomorfolin-4-oniowy |
431-200-1 |
208538-34-5 |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 |
H302 H318 H317 |
GHS05 GHS07 Dgr |
H302 H318 H317 |
|
|
|
|
608-058-00-4 |
esfenwalerat (ISO); (S)-α-cyjano-3-fenoksybenzylo-(S)-2-(4-chlorofenylo)-3-metylomaślan; (S)-2-(4-chlorofenylo)-3-metylomaślan (S)-α cyjanofenoksybenzylu |
— |
66230-04-4 |
Acute Tox. 3 * Acute Tox. 3 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H331 H301 H317 H400 H410 |
GHS06 GHS09 Dgr |
H331 H301 H317 H410 |
|
M = 10000 |
|
|
608-059-00-X |
5-amino-1-(2,6-dichloro-4-(trifluorometylo)fenylo)-1H-pirazolo-3-karbonitryl |
421-240-6 |
120068-79-3 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
608-060-00-5 |
5-metylo-2-[(2-nitrofenylo)amino]-3-tiofenokarbonitryl |
421-300-1 |
138564-59-7 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
608-062-00-6 |
2-fluoro-4-hydroksybenzonitryl |
422-810-7 |
82380-18-5 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|
|
|
|
608-063-00-1 |
(S)-α-hydroksy-3-fenoksy-benzenoacetonitryl |
441-070-6 |
61826-76-4 |
Acute Tox. 3 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H318 H317 H400 H410 |
GHS06 GHS05 GHS09 Dgr |
H301 H318 H317 H410 |
|
|
|
|
608-064-00-7 |
metylosiarczan cyjanometylotrimetyloamoniowy |
433-720-2 |
— |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
608-065-00-2 |
sole bromoksynilu, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Repr. 2 Acute Tox. 2 * Acute Tox. 3 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361d *** H330 H301 H317 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H361d *** H330 H301 H317 H410 |
|
M = 10 |
A |
|
608-066-00-8 |
sole joksynylu, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H361d *** H331 H301 H312 H373 ** H319 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H361d *** H331 H301 H312 H373 ** H319 H410 |
|
M = 10 |
A |
|
609-001-00-6 |
1-nitropropan |
203-544-9 |
108-03-2 |
Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H226 H332 H312 H302 |
GHS02 GHS07 Wng |
H 226 H332 H312 H302 |
|
* |
|
|
609-002-00-1 |
2-nitropropan |
201-209-1 |
79-46-9 |
Flam. Liq. 3 Carc. 1B Acute Tox. 4 * Acute Tox. 4 * |
H226 H350 H332 H302 |
GHS02 GHS08 GHS07 Dgr |
H226 H350 H332 H302 |
|
|
|
|
609-003-00-7 |
nitrobenzen |
202-716-0 |
98-95-3 |
Carc. 2. Repr. 1B Acute Tox. 3 Acute Tox. 3 Acute Tox. 3 STOT RE 1 Aquatic Chronic 3 |
H351 H360F H301 H331 H311 H372 (krew) H412 |
GHS06 GHS08 Dgr |
H351 H360F H301 H331 H311 H372 (krew) H412 |
|
|
|
|
609-004-00-2 |
dinitrobenzen; [1] 1,4-dinitrobenzen; [2] 1,3-dinitrobenzen; [3] 1,2-dinitrobenzen [4] |
246-673-6 [1] 202-833-7 [2] 202-776-8 [3] 208-431-8 [4] |
25154-54-5 [1] 100-25-4 [2] 99-65-0 [3] 528-29-0 [4] |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H300 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H330 H310 H300 H373 ** H410 |
|
|
|
|
609-005-00-8 |
1,3,5-trinitrobenzen |
202-752-7 |
99-35-4 |
Expl. 1.1 Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H201 H330 H310 H300 H373** H400 H410 |
GHS01 GHS06 GHS08 GHS09 Dgr |
H201 H330 H310 H300 H373** H410 |
|
|
|
|
609-006-00-3 |
4-nitrotoluen |
202-808-0 |
99-99-0 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 2 |
H331 H311 H301 H373 ** H411 |
GHS06 GHS08 GHS09 Dgr |
H331 H311 H301 H373 ** H411 |
|
|
|
|
609-007-00-9 |
2,4-dinitrotoluen; [1] dinitrotoluen; [2] |
204-450-0 [1] 246-836-1 [2] |
121-14-2 [1] 25321-14-6 [2] |
Carc. 1B Muta. 2 Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H350 H341 H361f*** H331 H311 H301 H373** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H350 H341 H361f*** H331 H311 H301 H373** H410 |
|
|
|
|
609-008-00-4 |
2,4,6-trinitrotoluen; TNT; trotyl |
204-289-6 |
118-96-7 |
Expl. 1.1 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 2 |
H201 H331 H311 H301 H373 ** H411 |
GHS01 GHS06 GHS08 GHS09 Dgr |
H201 H331 H311 H301 H373 ** H411 |
|
|
|
|
609-009-00-X |
2,4,6-trinitrofenol; kwas pikrynowy |
201-865-9 |
88-89-1 |
Expl. 1.1 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * |
H201 H331 H311 H301 |
GHS01 GHS06 Dgr |
H201 H331 H311 H301 |
|
|
|
|
609-010-00-5 |
sole kwasu pikrynowego; pikryniany |
— |
— |
Unst. Expl Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * |
H201 H331 H311 H301 |
GHS01 GHS06 Dgr |
H201 H331 H311 H301 |
|
|
T |
|
609-011-00-0 |
2,4,6-trinitroanizol |
— |
606-35-9 |
Expl. 1.1 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 2 |
H201 H332 H312 H302 H411 |
GHS01 GHS07 GHS09 Wng |
H201 H332 H312 H302 H411 |
|
|
|
|
609-012-00-6 |
2,4,6-trinitro-m-krezol; 2,4,6-trinitro-3-metylofenol |
210-027-1 |
602-99-3 |
Expl. 1.1 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H201 H332 H312 H302 |
GHS01 GHS07 Wng |
H201 H332 H312 H302 |
|
|
|
|
609-013-00-1 |
2,4,6-trinitro-m-ksylen |
211-187-5 |
632-92-8 |
Expl. 1.1 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * |
H201 H332 H312 H302 H373 ** |
GHS01 GHS08 GHS07 Wng |
H201 H332 H312 H302 H373 ** |
|
|
|
|
609-015-00-2 |
4-nitrofenol; p-nitrofenol |
202-811-7 |
100-02-7 |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * |
H332 H312 H302 H373 ** |
GHS08 GHS07 Wng |
H332 H312 H302 H373 ** |
|
|
|
|
609-016-00-8 |
dinitrofenol (masa poreakcyjna izomerów); [1] 2,4(lub 2,6)-dinitrofenolu [2] |
247-096-2 [1] 275-732-9 [2] |
25550-58-7 [1] 71629-74-8 [2] |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H311 H301 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H331 H311 H301 H373 ** H410 |
|
|
|
|
609-018-00-9 |
2,4,6-trinitrorezorcynol; 2,4,6-trinitrorezorcyna; kwas styfninowy |
201-436-6 |
82-71-3 |
Expl. 1.1 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H201 H332 H312 H302 |
GHS01 GHS07 Dgr |
H201 H332 H312 H302 |
|
|
|
|
609-019-00-4 |
2,4,6-trinitrorezorcynolan ołowiu(II); styfninian ołowiu(II) |
239-290-0 |
15245-44-0 |
Unst. Expl Repr. 1A Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H200 H360Df H332 H302 H373 ** H400 H410 |
GHS01 GHS08 GHS07 GHS09 Dgr |
H200 H360Df H332 H302 H373 ** H410 |
|
|
1 |
|
609-019-01-1 |
2,4,6-trinitrorezorcynolan ołowiu(II); styfninian ołowiu(II) (≥ 20 % flegmatyzatora) |
239-290-0 |
15245-44-0 |
Expl. 1.1 Repr. 1A Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H201 H360Df H332 H302 H373 ** H400 H410 |
GHS01 GHS08 GHS07 GHS09 Dgr |
H201 H360Df H332 H302 H373 ** H410 |
|
|
1 |
|
609-020-00-X |
DNOK (ISO); 4,6-dinitro-o-krezol; 2-metylo-4,6-dinitrofenol |
208-601-1 |
534-52-1 |
Muta. 2 Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H341 H330 H310 H300 H315 H318 H317 H400 H410 |
GHS06 GHS08 GHS05 GHS07 GHS09 Dgr |
H341 H330 H310 H300 H315 H318 H317 H410 |
EUH044 |
|
|
|
609-021-00-5 |
DNOK – sól sodowa; 2-metylo-4,6-dinitrofenolan sodu; [1] DNOK – sól potasowa; 2-metylo-4,6-dinitrofenolan potasu [2] |
219-007-7 [1] -[2] |
2312-76-7 [1] 5787-96-2 [2] |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H311 H301 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H331 H311 H301 H373 ** H410 |
|
|
|
|
609-022-00-0 |
DNOK – sól amonowa; 2-metylo-4,6-dinitrofenolan amonu |
221-037-0 |
2980-64-5 |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H300 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H330 H310 H300 H373 ** H410 |
|
|
|
|
609-023-00-6 |
dinokap (ISO); izomeryczna masa poreakcyjna trans-but-2-enianu (krotonianu) 2,6-dinitro-4-oktan-x-ylofenylu i trans-but-2-enianu 2,4-dinitro-6-oktan-x-ylofenylu, gdzie x = 2, 3 lub 4 |
254-408-0 |
39300-45-3 |
Repr. 1B Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H360D*** H332 H302 H373** H315 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H360D*** H332 H302 H373** H315 H317 H410 |
|
M=100 |
|
|
609-024-00-1 |
binapakryl (ISO); 3-metylobut-2-enian 2-sec-butylo-4,6-dinitrofenylu; |
207-612-9 |
485-31-4 |
Repr. 1B Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H360D *** H312 H302 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H360D *** H312 H302 H410 |
|
|
|
|
609-025-00-7 |
dinoseb (ISO); 2-sec-butylo-4,6-dinitrofenol |
201-861-7 |
88-85-7 |
Repr. 1B Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H360Df H311 H301 H319 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H360Df H311 H301 H319 H410 |
EUH044 |
|
|
|
609-026-00-2 |
sole i estry 2-sec-butylo-4,6-dinitrofenolu, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Repr. 1B Acute Tox. 3 * Acute Tox. 3 * Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H360Df H311 H301 H319 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H360Df H311 H301 H319 H410 |
EUH044 |
|
A |
|
609-027-00-8 |
dinokton (ISO); masa poreakcyjna izomerów: węglanu metylu-4,6-dinitro-2-oktanylofenylu i węglanu metylu-2,6-dinitro-4-oktanylofenylu |
— |
63919-26-6 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
609-028-00-3 |
dineks (ISO); 2-cykloheksylo-4,6-dinitrofenol |
205-042-5 |
131-89-5 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H331 H311 H301 H410 |
|
|
|
|
609-029-00-9 |
sole i estry dineksu (ISO); sole i estry 2-cykloheksylo-4,6-dinitrofenolu |
— |
— |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H331 H311 H301 H410 |
|
|
A |
|
609-030-00-4 |
dinoterb (ISO); 2-tert-butylo-4,6-dinitrofenol |
215-813-8 |
1420-07-1 |
Repr. 1B Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H360D *** H300 H311 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H360D *** H300 H311 H410 |
EUH044 |
|
|
|
609-031-00-X |
sole i estry dinoterbu (ISO); sole i estry 2-tert-butylo-4,6-dinitrofenolu |
— |
— |
Repr. 1B Acute Tox. 2 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H360D *** H300 H311 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H360D *** H300 H311 H410 |
|
|
A |
|
609-032-00-5 |
bromofenoksym (ISO); O-2,4-dinitrofenylooksym 3,5-dibromo-4-hydroksybenzaldehydu |
236-129-6 |
13181-17-4 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
609-033-00-0 |
dinosam (ISO); 2-(1-metylobutylo)-4,6-dinitrofenol |
— |
4097-36-3 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H331 H311 H301 H410 |
|
|
|
|
609-034-00-6 |
sole i estry dinosamu (ISO); sole i estry 2-(1-metylobutylo)-4,6-dinitrofenolu |
— |
— |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H311 H301 H400 H410 |
GHS06 GHS09 Dgr |
H331 H311 H301 H410 |
|
|
A |
|
609-035-00-1 |
nitroetan |
201-188-9 |
79-24-3 |
Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * |
H226 H332 H302 |
GHS02 GHS07 Wng |
H226 H332 H302 |
|
* |
|
|
609-036-00-7 |
nitrometan |
200-876-6 |
75-52-5 |
Flam. Liq. 3 Acute Tox. 4 * |
H226 H302 |
GHS02 GHS07 Wng |
H226 H302 |
|
* |
|
|
609-037-00-2 |
5-nitro-1,2-dihydroacenaftylen |
210-025-0 |
602-87-9 |
Carc. 1B |
H350 |
GHS08 Dgr |
H350 |
|
|
|
|
609-038-00-8 |
2-nitronaftalen |
209-474-5 |
581-89-5 |
Carc. 1B Aquatic Chronic 2 |
H350 H411 |
GHS08 GHS09 Dgr |
H350 H411 |
|
|
|
|
609-039-00-3 |
4-nitrobifenyl |
202-204-7 |
92-93-3 |
Carc. 1B Aquatic Chronic 2 |
H350 H411 |
GHS08 GHS09 Dgr |
H350 H411 |
|
|
|
|
609-040-00-9 |
nitrofen (ISO); eter 2,4-dichlorofenylowo-4-nitrofenylowy |
217-406-0 |
1836-75-5 |
Carc. 1B Repr. 1B Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H350 H360D *** H302 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350 H360D *** H302 H410 |
|
|
|
|
609-041-00-4 |
2,4-dinitrofenol |
200-087-7 |
51-28-5 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 |
H331 H311 H301 H373 ** H400 |
GHS06 GHS08 GHS09 Dgr |
H331 H311 H301 H373 ** H400 |
|
|
|
|
609-042-00-X |
pendimetalina (ISO); N-(1-etylopropylo)-3,4-dimetylo-2,6-dinitroanilina |
254-938-2 |
40487-42-1 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
609-043-00-5 |
kwintocen (ISO); pentachloronitrobenzen |
201-435-0 |
82-68-8 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
609-044-00-0 |
technazen (ISO); 1,2,4,5-tetrachloro-3-nitrobenzen |
204-178-2 |
117-18-0 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|
|
|
|
609-045-00-6 |
masa poreakcyjna: węglanu metylu-4,6-dinitro-2-oktan-3-ylofenylu i węglanu metylu-4,6-dinitro-2-oktan-4-ylofenylu; dinokton-6 |
— |
8069-76-9 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
|
|
|
609-046-00-1 |
trifluralina (ISO); (zawierająca < 0,5 ppm NPDA); α, α,α-trifluoro-2,6-dinitro-N, N-dipropylo-p-toluidyna (zawierająca < 0,5 ppm NPDA); 2,6-dinitro-N, N-dipropylo-4-(trifluorometylo)anilina (zawierająca < 0,5 ppm NPDA); N, N-dipropylo-2,6-dinitro-4-trifluorometyloanilina (zawierająca < 0,5 ppm NPDA) |
216-428-8 |
1582-09-8 |
Carc. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H317 H410 |
|
M=10 |
|
|
609-047-00-7 |
2-nitroanizol |
202-052-1 |
91-23-6 |
Carc. 1B Acute Tox. 4 * |
H350 H302 |
GHS08 GHS07 Dgr |
H350 H302 |
|
|
|
|
609-048-00-2 |
3-nitrobenzenosulfonian sodu |
204-857-3 |
127-68-4 |
Eye Irrit. 2 Skin Sens. 1 |
H319 H317 |
GHS07 Wng |
H319 H317 |
|
|
|
|
609-049-00-8 |
2,6-dinitrotoluen |
210-106-0 |
606-20-2 |
Carc. 1B Muta. 2 Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 |
H350 H341 H361f *** H331 H311 H301 H373 ** H412 |
GHS06 GHS08 Dgr |
H350 H341 H361f *** H331 H311 H301 H373 ** H412 |
|
|
|
|
609-050-00-3 |
2,3-dinitrotoluen |
210-013-5 |
602-01-7 |
Carc. 1B Muta. 2 Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H350 H341 H361f *** H331 H311 H301 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H350 H341 H361f *** H331 H311 H301 H373 ** H410 |
|
|
|
|
609-051-00-9 |
3,4-dinitrotoluen |
210-222-1 |
610-39-9 |
Carc. 1B Muta. 2 Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 2 |
H350 H341 H361f *** H331 H311 H301 H373 ** H411 |
GHS06 GHS08 GHS09 Dgr |
H350 H341 H361f *** H331 H311 H301 H373 ** H411 |
|
|
|
|
609-052-00-4 |
3,5-dinitrotoluen |
210-566-2 |
618-85-9 |
Carc. 1B Muta. 2 Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 |
H350 H341 H361f *** H331 H311 H301 H373 ** H412 |
GHS06 GHS08 Dgr |
H350 H341 H361f *** H331 H311 H301 H373 ** H412 |
|
|
|
|
609-053-00-X |
hydrazynotrinitrometan |
414-850-9 |
— |
Expl. 1.1 **** Self-react. A Carc. 1B Acute Tox. 3 * Acute Tox. 3 * Skin Sens. 1 |
H201 H240 H350 H331 H301 H317 |
GHS01 GHS06 GHS08 Dgr |
H201 H240 H350 H331 H301 H317 |
|
|
|
|
609-054-00-5 |
2,3-dinitrofenol; [1] 2,5-dinitrofenol; [2] 2,6-dinitrofenol; [3] 3,4-dinitrofenol; [4] sole dinitrofenolu [5] |
200-628-7 [1] 206-348-1 [2] 209-357-9 [3] 209-415-3 [4]-[5] |
66-56-8 [1] 329-71-5 [2] 573-56-8 [3] 577-71-9 [4]-[5] |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 2 |
H331 H311 H301 H373 ** H411 |
GHS06 GHS08 GHS09 Dgr |
H331 H311 H301 H373 ** H411 |
|
|
|
|
609-055-00-0 |
2,5-dinitrotoluen |
210-581-4 |
619-15-8 |
Carc. 1B Muta. 2 Repr. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 2 |
H350 H341 H361f *** H331 H311 H301 H373 ** H411 |
GHS06 GHS08 GHS09 Dgr |
H350 H341 H361f *** H331 H311 H301 H373 ** H411 |
|
|
|
|
609-056-00-6 |
2,2-dibromo-2-nitroetanol |
412-380-9 |
69094-18-4 |
Expl. 1.1 Carc. 2 Acute Tox. 4 * STOT RE 2 * Skin Corr. 1A Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H201 H351 H302 H373 ** H314 H317 H400 H410 |
GHS01 GHS08 GHS05 GHS07 GHS09 Dgr |
H201 H351 H302 H373 ** H314 H317 H410 |
|
* STOT SE 3; H335: C ≥ 1 % |
T |
|
609-057-00-1 |
3-chloro-2,4-difluoro-1-nitrobenzen |
411-980-8 |
3847-58-3 |
Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H314 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H302 H314 H317 H410 |
|
|
|
|
609-058-00-7 |
2-nitro-2-fenylopropano-1,3-diol |
410-360-4 |
5428-02-4 |
STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H372 ** H312 H302 H317 H411 |
GHS08 GHS07 GHS09 Dgr |
H372 ** H312 H302 H317 H411 |
EUH070 |
|
|
|
609-059-00-2 |
2-chloro-6-etyloamino-4-nitrofenol |
411-440-1 |
131657-78-8 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H317 H411 |
GHS07 GHS09 Wng |
H302 H317 H411 |
|
|
|
|
609-060-00-8 |
4-[(3-hydroksypropylo)amino]-3-nitrofenol |
406-305-9 |
92952-81-3 |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|
|
|
|
609-061-00-3 |
O-(4-nitrofenylometylo)oksym ketonu (E, Z)-4-chlorofenylowo-cyklopropylowego |
406-100-4 |
94097-88-8 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
609-062-00-9 |
2-bromo-2-nitropropanol |
407-030-7 |
24403-04-1 |
Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H311 H302 H373 ** H314 H317 H400 H410 |
GHS06 GHS08 GHS05 GHS09 Dgr |
H311 H302 H373 ** H314 H317 H410 |
|
|
|
|
609-063-00-4 |
2-[(4-chloro-2-nitrofenylo)amino]etanol |
413-280-8 |
59320-13-7 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
609-064-00-X |
mezotrion (ISO); 2-[4-(metylosulfonylo)-2-nitrobenzoilo]-cykloheksano-1,3-dion |
— |
104206-82-8 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
609-065-00-5 |
2-nitrotoluen |
201-853-3 |
88-72-2 |
Carc. 1B Muta. 1B Repr. 2 Acute Tox. 4 * Aquatic Chronic 2 |
H350 H340 H361f *** H302 H411 |
GHS08 GHS07 GHS09 Dgr |
H350 H340 H361f *** H302 H411 |
|
|
|
|
609-066-00-0 |
3-amino-10-{4-(10-amino-6,13-dichloro-4,11-disulfonianobenzo[5,6][1,4]-oksazyno[2,3-b]fenoksazyn-3-yloamino)-6-[metylo(2-sulfonianoetylo)amino]-1,3,5-triazyn-2-yloamino}-6,13-dichlorobenzo[5,6][1,4]oksazyno[2,3-b]-fenoksazyno-4,11-disulfonian litu sodu |
418-870-9 |
154212-58-5 |
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT SE 2 ** |
H332 H312 H302 H371 ** |
GHS08 GHS07 Dgr |
H332 H312 H302 H371 ** |
|
|
|
|
609-067-00-6 |
sól sodowo-potasowa 4-(3-aminopropyloamino)-2,6-bis[3-(4-metoksy-2-sulfofenyloazo)4-hydroksy-2-sulfo-7-naftyloamino]-1,3,5-triazyny |
416-280-6 |
156769-97-0 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
609-068-00-1 |
piżmo ksylenowe; 5-tert-butylo-2,4,6-trinitro-m-ksylen |
201-329-4 |
81-15-2 |
Expl. 1.1 Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H201 H351 H400 H410 |
GHS01 GHS08 GHS09 Wng |
H201 H351 H410 |
|
|
T |
|
609-069-00-7 |
piżmo ketonowe; 3,5-dinitro-2,6-dimetylo-4-tert-butyloacetofenon; 4'-tert-butylo-2',6'-dimetylo-3',5'-dinitroacetofenon |
201-328-9 |
81-14-1 |
Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H400 H410 |
GHS08 GHS09 Wng |
H351 H410 |
|
|
|
|
609-070-00-2 |
1,4-dichloro-2-(1,1,2,3,3,3-heksafluoropropoksy)-5-nitrobenzen |
415-580-4 |
130841-23-5 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|
|
|
|
609-071-00-8 |
masa poreakcyjna: 2-metylosulfanylo-4,6-bis(2-hydroksy-4-metoksyfenylo)-1,3,5-triazyny; 2-(4,6-bismetylosulfanylo-1,3,5-triazyn-2-ylo)-5-metoksyfenolu |
423-520-3 |
156137-33-6 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
609-072-00-3 |
4-mezylo-2-nitrotoluen |
430-550-0 |
1671-49-4 |
Repr. 2 Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 |
H361f*** H302 H317 H412 |
GHS08 GHS07 Wng |
H361f*** H302 H317 H412 |
|
|
|
|
609-073-00-9 |
litu, potasu i sodu N,N''-bis(6-(7-(4-(4-chloro-1,3,5-triazyn-2-ylo)amino-4-(2-ureidofenyloazo)naftaleno-1,3,6-trisulfoniano)-N'-(2-aminoetylo)piperazyna |
427-850-9 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
610-001-00-3 |
trichloronitrometan; chloropikryna; nitrochloroform |
200-930-9 |
76-06-2 |
Acute Tox. 2 * Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 |
H330 H302 H319 H335 H315 |
GHS06 Dgr |
H330 H302 H319 H335 H315 |
|
|
|
|
610-002-00-9 |
1,1-dichloro-1-nitroetan |
209-854-0 |
594-72-9 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * |
H331 H311 H301 |
GHS06 Dgr |
H331 H311 H301 |
|
|
|
|
610-003-00-4 |
chlorodinitrobenzen |
— |
— |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H331 H311 H301 H373 ** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H331 H311 H301 H373 ** H410 |
|
|
C |
|
610-004-00-X |
2-chloro-1,3,5-trinitrobenzen |
201-864-3 |
88-88-0 |
Expl. 1.1 Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H201 H330 H310 H300 H400 H410 |
GHS01 GHS06 GHS09 Dgr |
H201 H330 H310 H300 H410 |
|
|
|
|
610-005-00-5 |
1-chloro-4-nitrobenzen; p-chloronitrobenzen |
202-809-6 |
100-00-5 |
Carc. 2 Muta. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 2 |
H351 H341 H331 H311 H301 H373 ** H411 |
GHS06 GHS08 GHS09 Dgr |
H351 H341 H331 H311 H301 H373 ** H411 |
|
|
|
|
610-006-00-0 |
chloronitroaniliny, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Acute Tox. 2 * Acute Tox. 1 Acute Tox. 2 * STOT RE 2 * Aquatic Chronic 2 |
H330 H310 H300 H373 ** H411 |
GHS06 GHS08 GHS09 Dgr |
H330 H310 H300 H373 ** H411 |
|
|
A C |
|
610-007-00-6 |
1-chloro-1-nitropropan |
209-990-0 |
600-25-9 |
Acute Tox. 4 * Acute Tox. 4 * |
H332 H302 |
GHS07 Wng |
H332 H302 |
|
* |
|
|
610-008-00-1 |
2,6-dichloro-4-nitroanizol |
403-350-6 |
17742-69-7 |
Acute Tox. 3 * Aquatic Chronic 2 |
H301 H411 |
GHS06 GHS09 Dgr |
H301 H411 |
|
|
|
|
610-009-00-7 |
2-chloro-4-nitroanilina |
204-502-2 |
121-87-9 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|
|
|
|
610-010-00-2 |
2-bromo-1-(2-furylo)-2-nitroeten; 2-bromo-1-(2-furylo)-2-nitroetylen |
406-110-9 |
35950-52-8 |
Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373 ** H314 H317 H400 H410 |
GHS08 GHS05 GHS07 GHS09 Dgr |
H302 H373 ** H314 H317 H410 |
|
|
|
|
611-001-00-6 |
azobenzen; difenylodiazen |
203-102-5 |
103-33-3 |
Carc. 1B Muta. 2 Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H350 H341 H332 H302 H373 ** H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350 H341 H332 H302 H373 ** H410 |
|
|
|
|
611-002-00-1 |
azoksybenzen; tlenek difenylodiazenu |
207-802-1 |
495-48-7 |
Acute Tox. 4 * Acute Tox. 4 * |
H332 H302 |
GHS07 Wng |
H332 H302 |
|
|
|
|
611-003-00-7 |
fenaminosulf (ISO); 4-(dimetyloamino)fenylodiazosulfonian sodu |
205-419-4 |
140-56-7 |
Acute Tox. 3 * Acute Tox. 4 * Aquatic Chronic 3 |
H301 H312 H412 |
GHS06 Dgr |
H301 H312 H412 |
|
|
|
|
611-004-00-2 |
octan 2-metylo-ONN-azoksymetylu |
209-765-7 |
592-62-1 |
Carc. 1B Repr. 1B |
H350 H360D *** |
GHS08 Dgr |
H350 H360D *** |
|
|
|
|
611-005-00-8 |
(2-hydroksy-5-{4'-[6-hydroksy-2-oksydo-3-(2-hydroksy-5-sulfonianofenyloazo)fenyloazo]bifenyl-4-yloazo}-1-karboksylanofenylo)miedzian(II) disodu; C.I. Direct Brown 95; brąz bezpośredni 95 |
240-221-1 |
16071-86-6 |
Carc. 1B |
H350 |
GHS08 Dgr |
H350 |
|
|
|
|
611-006-00-3 |
(4-amino-3-metylofenylo)(2-tolilo)diazen; 4-amino-2',3-dimetyloazobenzen; AAT; o-aminoazotoluen |
202-591-2 |
97-56-3 |
Carc. 1B Skin Sens. 1 |
H350 H317 |
GHS08 Dgr |
H350 H317 |
|
|
|
|
611-007-00-9 |
tricyklazol (ISO); 5-metylo-1,2,4-triazolo[3,4-b]benzo-1,3-tiazol; |
255-559-5 |
41814-78-2 |
Acute Tox. 4 * |
H302 |
GHS07 Wng |
H302 |
|
|
|
|
611-008-00-4 |
4-aminoazobenzen; (4-aminofenylo)fenylodiazen; 4-fenyloazoanilina |
200-453-6 |
60-09-3 |
Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H350 H400 H410 |
GHS08 GHS09 Dgr |
H350 H410 |
|
|
|
|
611-009-00-X |
(1-{5-[4-(4-anilino-3-sulfofenyloazo)-2-metylo-5-metylosulfonoamidofenyloazo]4-hydroksy-2-oksydo-3-(fenyloazo)fenyloazo}-5-nitro-4-sulfoniano-2-naftolano)żelazian(II) sodu |
401-220-3 |
— |
Acute Tox. 4 * Aquatic Chronic 3 |
H332 H412 |
GHS07 Wng |
H332 H412 |
|
|
|
|
611-010-00-5 |
2'-(2-cyjano-4,6-dinitrofenyloazo)-5'-(N, N-dipropyloamino)propanoanilid |
403-010-7 |
106359-94-8 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
611-011-00-0 |
dimleczan N, N,N',N'-tetrametylo-3,3'-propylenobis[iminokarbonylo-4,1-fenylenoazo(1,6-dihydro-2-hydroksy-4-metylo-6-oksypirydyn-3,1-diylo)]-di(propyloamoniowy) |
403-340-1 |
— |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dg |
H318 H411 |
|
|
|
|
611-012-00-6 |
masa poreakcyjna 6-metylo-2-[4-(2,4,6-triaminopirymidyn-5-yloazo)fenylo]benzotiazolo-7-sulfonianów: 2,2-iminodietanolu, N, N-dietylopropylo-1,3-diaminy i 2-metyloaminoetanolu |
403-410-1 |
114565-65-0 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
611-013-00-1 |
1-hydroksy-7-(3-sulfonianoanilino)-2-{3-metylo-4-[2-metoksy-4-(3-sulfonianofenyloazo)fenyloazo]fenyloazo}naftaleno-3-sulfonian trilitu |
403-650-7 |
117409-78-6 |
Expl. 1.3 **** Aquatic Chronic 2 |
H203 H411 |
GHS01 GHS09 Dgr |
H203 H411 |
|
|
|
|
611-014-00-7 |
wodorotlenek 1-{4-[3-acetamido-4-(4'-nitro-2,2'disulfonianostilben-4-yloazo)anilino]-6-(2,5-disulfonianoanilino)-1,3,5-triazyno-2-ylo}-3-karboksypirydynium tetrasodu |
404-250-5 |
115099-55-3 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
611-015-00-2 |
4-amino-5-hydroksy-6-(4-{2-[2-(sulfonianooksy)etylosulfonylo]etylokarbamoilo}fenyloazo)-3-{4-[2-(sulfonianooksy)etylosulfonylo]fenyloazo}naftaleno-2,7-disulfonian tetrasodu |
404-320-5 |
116889-78-2 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
611-016-00-8 |
masa poreakcyjna: dichlorku dichlorowodorku 1,1'-[(dihydroksyfenyleno)bis{azo-3,1-fenylenoazo[1-(3-dimetyloamino-propylo)-6-hydroksy-4-metylo-2-okso-1,2-dihydropirydyno-5,3-diylo]}dipirydyniowego (mieszanina izomerów) i dichlorku 1-[1-(3-dimetyloaminopropylo)-5-(3-{[4-(1-{3-dimetyloaminopropylo}-2-hydroksy-4-metylo-6-okso-5-pirydynio-1,6-dihydro-3-pirydyloazo)-fenyloazo]-2,4(lub 2,6 lub 3,5)-dihydroksyfenyloazo}fenyloazo)-6-hydroksy-4-metylo-2-okso-1,2-dihydro-3-pirydylo]-pirydyniowego |
404-540-1 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
611-017-00-3 |
2-[4-(dietyloaminopropylokarbamoilo)fenyloazo]-3-okso-N-(2,3-dihydro-2-oksobenzoimidazol-5-ilo)butanoamid |
404-910-2 |
— |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
611-018-00-9 |
5-[4-(7-amino-1-hydroksy-3-sulfoniano-2-naftyloazo)-6-sulfoniano-1-naftyloazo]izoftalan tetraamonu |
405-130-5 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
611-019-00-4 |
6-amino-4-hydroksy-3-[7-sulfoniano-4-(4-sulfonianofenyloazo)-1-naftyloazo]naftaleno-2,7-disulfonian tetralitu |
405-150-4 |
106028-58-4 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
611-020-00-X |
6-amino-4-hydroksy-3-[7-sulfoniano-4-(4-sulfonianofenyloazo)-1-naftyloazo]naftaleno-2,7-disulfonian tetrakis(tetrametyloamoniowy) |
405-170-3 |
116340-05-7 |
Acute Tox. 3 * Skin Sens. 1 Aquatic Chronic 3 |
H301 H317 H412 |
GHS06 Dgr |
H301 H317 H412 |
|
|
|
|
611-021-00-5 |
octan 2-[4-(4-cyjano-3-metyloizotiazol-5-iloazo)-N-etylo-3-metyloanilino]etylu |
405-480-9 |
— |
Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Aquatic Chronic 4 |
H302 H373 ** H315 H413 |
GHS08 GHS07 Wng |
H302 H373 ** H315 H413 |
|
|
|
|
611-022-00-0 |
3-karboksy-4-hydroksybenzenosulfonian 4-dimetyloaminobenzenodiazoniowy |
404-980-4 |
— |
Self-react. C Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H242 H331 H301 H312 H373 ** H318 H317 H400 H410 |
GHS02 GHS06 GHS08 GHS05 GHS09 Dgr |
H242 H331 H301 H312 H373 ** H318 H317 H410 |
|
|
T |
|
611-023-00-6 |
7-(4,6-dichloro-1,3,5-triazyn-2-yloamino)-4-hydroksy-3-{4-[2-(sulfonianoksy)etylosulfonylo]fenyloazo}naftaleno-2-sulfonian disodu |
404-600-7 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
611-024-00-1 |
barwniki azowe na bazie benzydyny; barwniki 4,4'-diaryloazobifenylowe, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Carc. 1B |
H350 |
GHS08 Dgr |
H350 |
|
|
A |
|
611-025-00-7 |
4-amino-3-[4'-(2,4-diaminofenyloazo)-(1,1'-bifenyl-4-yloazo)]-5-hydroksy-6-fenyloazonaftaleno-2,7-disulfonian disodu; C.I. Direct Black 38; czerń bezpośrednia 38 |
217-710-3 |
1937-37-7 |
Carc. 1B Repr. 2 |
H350 H361d *** |
GHS08 Dgr |
H350 H361d *** |
|
|
|
|
611-026-00-2 |
3,3'-(1,1'-bifenylo-4,4'-diylobisazo)bis-(5-amino-4-hydroksynaftaleno-2,7-disulfonian) tetrasodu; C.I. Direct Blue 6; błękit bezpośredni 6 |
220-012-1 |
2602-46-2 |
Carc. 1B Repr. 2 |
H350 H361d *** |
GHS08 Dgr |
H350 H361d *** |
|
|
|
|
611-027-00-8 |
3,3'-(1,1'-bifenylo-4,4'-diylobisazo)bis-(4-aminonaftaleno-1-sulfonian) disodu; C.I. Direct Red 28; czerwień bezpośrednia 28 |
209-358-4 |
573-58-0 |
Carc. 1B Repr. 2 |
H350 H361d *** |
GHS08 Dgr |
H350 H361d *** |
|
|
|
|
611-028-00-3 |
C,C'-azodi(formamid); C,C'-azoformamid; dikarbamoilodiazen |
204-650-8 |
123-77-3 |
Resp. Sens. 1 |
H334 |
GHS08 Dgr |
H334 |
|
|
G |
|
611-029-00-9 |
barwniki azowe pochodne o-dianizydyny; barwniki 4,4'-diaryloazo-3,3'-dimetoksybifenylowe, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Carc. 1B |
H350 |
GHS08 Dgr |
H350 |
|
|
A |
|
611-030-00-4 |
barwniki pochodne o-tolidyny; barwniki 4,4'-diaryloazo-3,3'-dimetylobifenylowe, z wyjątkiem tych wymienionych gdzie indziej w niniejszym załączniku |
— |
— |
Carc. 1B |
H350 |
GHS08 Dgr |
H350 |
|
|
A |
|
611-031-00-X |
chlorowodorek 4,4'-(4-iminocykloheksa-2,5-dienylidenometyleno)dianiliny; C.I. Basic Red 9; czerwień zasadowa 9 |
209-321-2 |
569-61-9 |
Carc. 1B |
H350 |
GHS08 Dgr |
H350 |
|
|
|
|
611-032-00-5 |
1,4,5,8-tetraaminoantrachinon; C.I. Disperse Blue 1; błękit zawiesinowy 1 |
219-603-7 |
2475-45-8 |
Carc. 1B Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 |
H350 H315 H318 H317 |
GHS08 GHS05 GHS07 Dgr |
H350 H315 H318 H317 |
|
|
|
|
611-033-00-0 |
[4,4''-azoksybis(2,2'-disulfonianostilbeno-4,4'-diyloazo)]bis[(5'-sulfonianobenzeno-2,2'-diolano-O(2),O(2),N(1)]miedzian(II) heksasodu |
400-020-3 |
82027-60-9 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
611-034-00-6 |
N-{5-[bis(2-metoksyetylo)amino]-2-[(5-nitro-2,1-benzoizotiazol-3-ilo)azo]fenylo}acetamid |
402-430-8 |
105076-77-5 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
611-035-00-1 |
6-amino-4-hydroksy-3-[7-sulfoniano-4-(5-sulfoniano-2-naftyloazo)-1-naftyloazo]naftaleno-2,7-disulfonian tetralitu |
403-660-1 |
107246-80-0 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
611-036-00-7 |
octan 2-[4-(5,6(lub 6,7)-dichloro-1,3-benzotiazol-2-iloazo)-N-metylo-m-toluidyno]etylu; octan 2-[4-(5,6(lub 6,7)-dichloro-1,3-benzotiazol-2-iloazo)-3,N-dimetyloanilino]etylu |
405-440-0 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
611-037-00-2 |
metylosiarczan 3(lub 5)-[4-(N-benzylo-N-etyloamino)-2-metylofenyloazo]1,4-dimetylo-1,2,4-triazolium |
406-055-0 |
124584-00-5 |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H302 H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H317 H411 |
|
|
|
|
611-038-00-8 |
1-hydroksynaftaleno-2-azo-4'-(5',5''-dimetylobifenylo)-4''-azo(4''-fenylosulfonyloksybenzeno)-2',2'',4-trisulfonian trisodu |
406-820-9 |
— |
Eye Irrit. 2 |
H319 |
GHS07 Wng |
H319 |
|
|
|
|
611-039-00-3 |
kwas 7-[(4,6-dichloro-1,3,5-triazyn-2-ylo)-amino]-4-hydroksy-3-[4-(2-sulfoksyetylo)-sulfonylofenyloazo]naftaleno-2-sulfonowy |
407-050-6 |
117715-57-8 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
611-040-00-9 |
kwas 3-[5-acetyloamino-4-{4-[4,6-bis-(3-dietyloaminopropyloamino)-1,3,5-triazyn-2-yloamino]fenyloazo}-2-(2-metoksyetoksy)fenyloazo]-6-amino-4-hydroksynaftaleno-2-sulfonowy |
407-670-7 |
115099-58-6 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
611-041-00-4 |
2-({4-[(4,6-bis{[3-(dietyloamino)propylo]-amino}-1,3,5-triazyn-2-ylo)amino]fenylo}-azo)-N-(2-okso-2,3-dihydro-1H-benzimidazol-5-ilo)-3-oksobutanoamid |
407-680-1 |
98809-11-1 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H318 H317 H411 |
|
|
|
|
611-042-00-X |
5-amino-3-[5-(2-bromoakryloiloamino)-2-sulfonianofenyloazo]-4-hydroksy-6-(4-winylosulfonylofenyloazo)naftaleno-2,7-disulfonian trisodu |
411-770-6 |
136213-71-3 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
611-043-00-5 |
masa poreakcyjna: N(1')-N(2):N(1''')-N(2'')-η-6-[2-amino-4-(lub 6)-hydroksy(lub 4-amino-2-hydroksy)fenyloazo]-6''-(1-karboniloilo-2-hydroksyprop-1-enyloazo)-5',5'''-disulfamoilo-3,3''-disulfonianobis(naftaleno-2,1'-azobenzeno-1,2'-diolano-O(1),O(2')-chromianu trisodu; N(1')-N(2):N(1''')-N(2'')-η-6,6''-bis(1-karboniloilo-2-hydroksyprop-1-enyloazo)-5',5'''-disulfamoilo-3,3''-disulfonianobis(naftaleno-2,1'-azobenzeno-1,2'-diolano-O(1),O(2')-chromianu trisodu; N(1')-N(2):N(1''')-N(2'')-η-6,6''-bis-[2-amino-4-(lub 6)-hydroksy-(lub 4-amino-2-hydroksy)fenyloazo]-5',5'''-disulfamoilo-3,3''-disulfonianobis(naftaleno-2,1'-azobenzeno-1,2'-diolano-O(1),O(2')-chromianu trisodu (2:1:1) |
402-850-1 |
— |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
611-044-00-0 |
masa poreakcyjna: bis{1-[(2-hydroksy-5-nitrofenylo)azo]-2-naftalenolano(2-)]-chromianu(1-) tert-alkilo(C12-14)-amoniowego; bis{1-[(2-hydroksy-4-nitrofenylo)azo]-2-naftalenolano(2-)]-chromianu(1-) tert-alkilo(C12-14)-amoniowego; bis[1-{[5-(1,1-dimetylopropylo)2-hydroksy-3-nitrofenylo]azo}-2-naftalenolano(2-)]-chromianu(1-) tert-alkilo(C12-14)-amoniowego; ({1-[(2-hydroksy-3-nitrofenylo)azo]-2-naftalenolano(2-)}-{1-[(2-hydroksy-5-nitrofenylo)azo]-2-naftalenolano(2-)]}-chromianu(1-); tert-alkilo(C12-14)-amoniowego [1-{[5-(1,1-dimetylopropylo)-2-hydroksy-3-nitrofenylo]azo}-2-naftalenolano(2-)]-[1-[(2-hydroksy-5-nitrofenylo)azo]-2-naftalenolano(2-)]]-chromianu(1-) tert-alkilo(C12-14)-amoniowego; {1-[4(lub 5)-nitro-2-oksydofenyloazo]-2-naftolano}[1-(3-nitro-2-oksydo-5-pentylofenyloazo)-2-naftolano]-chromianu(1-) tert-alkilo(C12-14)-amoniowego |
403-720-7 |
117527-94-3 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
611-045-00-6 |
2-{4-[N-(4-acetoksybutylo)-N-etylo]amino-2-metylofenyloazo}-3-acetylo-5-nitrotiofen |
404-830-8 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
611-046-00-1 |
4,4'-diamino-2-metyloazobenzen; 4,4'-diamino-2-metylodifenylodiazen |
407-590-2 |
43151-99-1 |
Acute Tox. 3 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H373 ** H317 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H301 H373 ** H317 H410 |
|
|
|
|
611-047-00-7 |
masa poreakcyjna: 2-({4-[N-etylo-N-(2-acetoksyetylo)-amino]fenylo}azo)-5,6-dichlorobenzotiazolu; 2-({4-[N-etylo-N-(2-acetoksyetylo)-amino]fenylo}azo)-6,7-dichlorobenzotiazolu (1:1) |
407-890-3 |
111381-11-4 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
611-048-00-2 |
masa poreakcyjna: 2-({4-[bis(2-acetoksyetylo)amino]fenylo}azo)-5,6-dichlorobenzotiazolu; 2-({4-[bis(2-acetoksyetylo)amino]fenylo}azo)-6,7-dichlorobenzotiazolu (1:1) |
407-900-6 |
111381-12-5 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
611-049-00-8 |
masa poreakcyjna: 7-[4-(3-dietyloaminopropyloamino)-6-(3-dietyloamoniopropyloamino)-1,3,5-triazyn-2-yloamino]-4-hydroksy-3-(4-fenyloazofenyloazo)-naftaleno-2-sulfonianu, kwasu octowego i kwasu mlekowego (2:1:1) |
408-000-6 |
118658-98-3 |
STOT RE 2 * Skin Sens. 1 Aquatic Chronic 3 |
H373 ** H317 H412 |
GHS08 Wng |
H373 ** H317 H412 |
|
|
|
|
611-050-00-3 |
masa poreakcyjna: 7-amino-3-[[4-[[4-[[4-[[4-[(6-amino-1-hydroksy-3-sulfoniano-2-naftylo)azo]7-sulfoniano-1-naftylo]azo]fenylo]amino]-3-sulfonianofenylo]azo]6-sulfoniano-1-naftylo]azo]-4-hydroksynaftaleno-2-sulfonianu pentasodu; 7-amino-8-[4-[4-[4-[4-(2-amino-5-hydroksy-7-sulfoniano-naftalen-1-yloazo)-7-sulfonianonaftalen-1-yloazo]-fenyloamino]-3-sulfoniano-fenyloazo]-6-sulfoniano-naftalen-1-yloazo]-4-hydroksynaftaleno-2-sulfonianu pentasodu; 7-amino-8-[4-[4-[4-[4-(6-amino-1-hydroksy-3-sulfoniano-naftalen-1-yloazo)-7-sulfonianonaftalen-1-yloazo]-fenyloamino]-3-sulfoniano-fenyloazo]-6-sulfoniano-naftalen-1-yloazo]-4-hydroksynaftaleno-2-sulfonianu pentasodu; 7-amino-4-hydroksy-3-[4-[4-[4-(4-hydroksy-7-sulfoniano-naftalen-1-yloazo)-2-sulfoniano-fenyloamino]fenyloazo]-6-sulfoniano-naftalen-1-yloazo]naftaleno-2-sulfonianu tetrasodu; 7-amino-4-hydroksy-3-[4-[4-[4-(4-amino-7-sulfoniano-naftalen-1-yloazo)-2-sulfoniano-fenyloamino]fenyloazo]-6-sulfoniano-naftalen-1-yloazo]naftaleno-2-sulfonianu tetrasodu |
415-350-3 |
— |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|
|
|
|
611-051-00-9 |
chlorek 2-{4-[N-etylo-N-(2-hydroksyetylo)amino]-2-metylofenylo}azo-6-metoksy-3-metylobenzotiazolium |
411-110-7 |
136213-74-6 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
611-052-00-4 |
akwa-[5-({2,4-dihydroksy-5-[(2-hydroksy-3,5-dinitrofenylo)azo]fenylo}azo)-naftaleno-2-sulfonian] monosodu, kompleks z żelazem |
400-720-9 |
— |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
611-053-00-X |
dichlorowodorek 2,2'-diazenylobis(2-metylopropionoamidyny); dichlorowodorek 2,2'-azobis-(2-metylopropionoamidyny) |
221-070-0 |
2997-92-4 |
Acute Tox. 4 * Skin Sens. 1 |
H302 H317 |
GHS07 Wng |
H302 H317 |
|
|
|
|
611-055-00-0 |
C.I. Disperse Yellow 3; żółcień zawiesinowa 3; N-{4-[(2-hydroksy-5-metylofenylo)azo]-fenylo}acetamid |
220-600-8 |
2832-40-8 |
Carc. 2 Skin Sens. 1 |
H351 H317 |
GHS08 GHS07 Wng |
H351 H317 |
|
|
|
|
611-056-00-6 |
C.I. Solvent Yellow 14; żółcień rozpuszczalnikowa 14; 1-fenyloazo-2-naftol |
212-668-2 |
842-07-9 |
Carc. 2 Muta. 2 Skin Sens. 1 Aquatic Chronic 4 |
H351 H341 H317 H413 |
GHS08 GHS07 Wng |
H351 H341 H317 H413 |
|
|
|
|
611-057-00-1 |
6-hydroksy-1-(3-izopropoksypropylo)-4-metylo-2-okso-5-[4-(fenyloazo)-fenyloazo]-1,2-dihydropirydyno-3-karbonitryl |
400-340-3 |
85136-74-9 |
Carc. 1B Aquatic Chronic 4 |
H350 H413 |
GHS08 Wng |
H350 H413 |
|
|
|
|
611-058-00-7 |
mrówczan {6-[4-hydroksy-3-(2-metoksyfenyloazo)-2-sulfoniano-7-naftyloamino]-1,3,5-triazyno-2,4-diylo}bis-[(amino-1-metyloetylo)amoniowy] |
402-060-7 |
108225-03-2 |
Carc. 1B Eye Dam. 1 Aquatic Chronic 2 |
H350 H318 H411 |
GHS08 GHS05 GHS09 Dgr |
H350 H318 H411 |
|
|
|
|
611-059-00-2 |
2-{6-[4-chloro-6-(3-{N-metylo-N-[4-chloro-6-(3,5-disulfoniano-2-naftyloazo)-1-hydroksy-6-naftyloamino]1,3,5-triazyn-2-ylo}aminometylo)fenyloamino]-1,3,5-triazyn-2-yloamino}-3,5-disulfoniano-1-hydroksy-2-naftyloazonaftaleno-1,5-disulfonian oktasodu |
412-960-1 |
148878-21-1 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|
|
|
|
611-060-00-8 |
masa poreakcyjna: 5-{8-[4-(4-{4-[7-(3,5-dikarboksylanofenyloazo)-8-hydroksy-3,6-disulfonianonaftalen-1-yloamino]-6-hydroksy-1,3,5-triazyn-2-ylo}-2,5-dimetylopiperazyn-1-ylo)-6-hydroksy-1,3,5-triazyn-2-yloamino]-1-hydroksy-3,6-disulfonianonaftalen-2-yloazo}-izoftalanu sodu; 5-{8-[4-(4-{4-[7-(3,5-dikarboksylanofenyloazo)-8-hydroksy-3,6-disulfonianonaftalen-1-yloamino]-6-hydroksy-1,3,5-triazyn-2-ylo}-2,5-dimetylopiperazyn-1-ylo)-6-hydroksy-1,3,5-triazyn-2-yloamino]-1-hydroksy-3,6-disulfonianonaftalen-2-yloazo}-izoftalanu ammonium; kwasu 5-{8-[4-(4-{4-[7-(3,5-dikarboksylanofenyloazo)-8-hydroksy-3,6-disulfonianonaftalen-1-yloamino]-6-hydroksy-1,3,5-triazyn-2-ylo}-2,5-dimetylopiperazyn-1-ylo)-6-hydroksy-1,3,5-triazyn-2-yloamino]-1-hydroksy-3,6-disulfonaftalen-2-yloazo]izoftalowego |
413-180-4 |
187285-15-0 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
611-061-00-3 |
5-{5-[4-(5-chloro-2,6-difluoropirymidyn-4-yloamino)benzamido]-2-sulfonianofenyloazo}-1-etylo-6-hydroksy-4-metylo-2-okso-3-pirydylometanosulfonian disodu |
412-530-3 |
— |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|
|
|
|
611-062-00-9 |
2-(8-{4-chloro-6-[3-({4-chloro-6-[3,6-disulfoniano-2-(1,5-disulfonianonaftalen-2-yloazo)-1-hydroksynaftalen-8-yloamino]-1,3,5-triazyn-2-ylo}aminometylo)fenyloamino]-1,3,5-triazyn-2-yloamino}-3,6-disulfoniano-1-hydroksynaftalen-2-yloazo)-naftaleno-1,5-disulfonian oktasodu |
413-550-5 |
— |
Skin Irrit. 2 Eye Dam. 1 |
H315 H318 |
GHS05 Dgr |
H315 H318 |
|
|
|
|
611-063-00-4 |
[4'-(8-acetyloamino-3,6-disulfoniano-2-naftyloazo)4''-(6-benzoiloamino-3-sulfoniano-2-naftyloazo)bifenylo-1,3',3'',1'''-tetraolano-O,O',O'',O''']-miedzian(II) trisodu |
413-590-3 |
164058-22-4 |
Carc. 1B |
H350 |
GHS08 Dgr |
H350 |
|
|
|
|
611-064-00-X |
4-(3,4-dichlorofenylodiazenylo)-2,6-di-sec-butylofenol |
410-600-8 |
124719-26-2 |
STOT RE 2 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H373 ** H315 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H373 ** H315 H410 |
|
|
|
|
611-065-00-5 |
4-(4-nitrofenylodiazenylo)-2,6-di-sec-butylofenol |
410-610-2 |
111850-24-9 |
STOT RE 2 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H373 ** H319 H315 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H373 ** H319 H315 H317 H410 |
|
|
|
|
611-066-00-0 |
5-[4-chloro-6-(N-etyloanilino)-1,3,5-triazyn-2-yloamino]-4-hydroksy-3-(1,5-disulfonianonaftalen-2-yloazo)-naftaleno-2,7-disulfonian tetrasodu |
411-540-5 |
130201-57-9 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H318 H317 H411 |
|
|
|
|
611-067-00-6 |
masa poreakcyjna: 7-anilino-4-hydroksy-3-[2-metoksy-5-metylo-4-(4-sulfonianofenyloazo)-fenylazo]naftaleno-2-sulfonianu bis{tris[2-(1-hydroksy-2-metyloetoksy)-etylo]amoniowego}; 7-anilino-4-hydroksy-3-[2-metoksy-5-metylo-4-(4-sulfonianofenyloazo)-fenylazo]naftaleno-2-sulfonianu bis{tris[2-(2-hydroksy-2-metyloetoksy)-etylo]amoniowego} |
406-910-8 |
— |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|
|
|
|
611-068-00-1 |
4-amino-3,6-bis{5-[4-chloro-6-(2-hydroksyetyloamino)-1,3,5-triazyn-2-yloamino]-2-sulfonianofenyloazo}5-hydroksynaftaleno-2,7-disulfonian tetrasodu; |
400-690-7 |
85665-98-1 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
611-069-00-7 |
N,N-di[poli(oksyetyleno)-co-poli(oksypropyleno)]-4-[(3,5-dicyjano-4-metylo-2-tienyloazo)]-3-metyloanilina |
413-380-1 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
611-070-00-2 |
masa poreakcyjna: [6-(4-anizydyno)-3-sulfoniano-2-(3,5-dinitro-2-oksydofenyloazo)-1-naftolano][1-(5-chloro-2-oksydofenyloazo)-2-naftolano]-chromianu(1-) disodu; bis[5-(4-anizydyno)-3-sulfoniano-2-(3,5-dinitro-2-oksydofenyloazo)-1-naftolano]chromianu(1-) trisodu |
405-665-4 |
— |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|
|
|
|
611-071-00-8 |
5-hydroksy-1-(4-sulfonianofenylo)-4-(4-sulfonianofenyloazo)pirazolo-3-karboksylan tris(tetrametyloamoniowy) |
406-073-9 |
131013-81-5 |
Acute Tox. 3 * Aquatic Chronic 3 |
H301 H412 |
GHS06 Dgr |
H301 H412 |
|
|
|
|
611-072-00-3 |
dichlorowodorek 2,4-bis{2,2'-[2-(N, N-dimetyloamino)-etoksykarbonylo]fenyloazo}-1,3-dihydroksybenzenu |
407-010-8 |
118208-02-9 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|
|
|
|
611-073-00-9 |
3,3'-{N-[4-(4-bromo-2,6-dicyjanofenyloazo)-3-hydroksyfenylo]imino}-dipropanian dimetylu |
407-310-9 |
122630-55-1 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
611-074-00-4 |
masa poreakcyjna: (3-{4-[5-(5-chloro-2,6-difluoropirymidyn-2-yloamino)-2-metoksy-3-sulfonianofenyloazo]2-oksydofenyloazo}-2,5,7-trisulfoniano-4-naftolano)miedzianu(II) sodu/potasu; (3-{4-[5-(5-chloro-4,6-difluoropirymidyn-2-yloamino)-2-metoksy-3-sulfonianofenyloazo]-2-oksydofenyloazo}-2,5,7-trisulfoniano-4-naftolano)miedzianu(II) sodu/potasu |
407-100-7 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
611-075-00-X |
masa poreakcyjna: 4-amino-3-{4-[4-(2-amino-2-hydroksyfenyloazo)anilino]-3-sulfonianofenyloazo}-6-fenylohydrazono-5-okso-5,6-dihydronaftaleno-2,7-disulfonianu tris(3,5,5-trimetyloheksyloamoniowego); 4-amino-3-{4-[4-(4-amino-2-hydroksyfenyloazo)anilino]-3-sulfonianofenyloazo}-6-fenylohydrazono-5-okso-5,6-dihydronaftaleno-2,7-disulfonianu tris(3,5,5-trimetyloheksyloamoniowego) (2:1) |
406-000-0 |
— |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|
|
|
|
611-076-00-5 |
3-(2,6-dichloro-4-nitrofenylodiazenylo)-1-metylo-2-fenyloindol; 3-(2,6-dichloro-4-nitrofenyloazo)-1-metylo-2-fenyloindol |
406-280-4 |
117584-16-4 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
|
|
|
611-077-00-0 |
(5,5'-diamino-{μ-4,4'-dihydroksy-1:2-κ-2,O4,O4',-3,3'-[3,3'-dihydroksy-1:2-κ-2-O3,O3'-bifenyl-4,4'-ylenobisazo-1:2-(N3,N4-η:N3',N4'-η)]dinaftaleno-2,7-disulfoniano(8)})dimiedzian(2-) dilitu disodu |
407-230-4 |
126637-70-5 |
Acute Tox. 4 * Skin Sens. 1 |
H302 H317 |
GHS07 Wng |
H302 H317 |
|
|
|
|
611-078-00-6 |
mleczan octan [2,2'-(3,3'-dioksydobifenylo-4,4'-diylodiazo)bis(6-{4-[3-(dietyloamino)propyloamino]-6-[3-(dietyloamonio)propyloamino]1,3,5-triazyn-2-yloamino}-3-sulfoniano-1-naftolano)]dimiedzi(II) |
407-240-9 |
159604-94-1 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
611-079-00-1 |
7-[4-chloro-6-(N-etylo-o-toluidyno)-1,3,5-triazyn-2-yloamino]-4-hydroksy-3-(4-metoksy-2-sulfonianofenyloazo)naftaleno-2-sulfonian disodu |
410-390-8 |
147703-64-8 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
611-080-00-7 |
3-{2-acetamido-4-[4-(2-hydroksybutoksy)fenyloazo]fenyloazo}benzenosulfonian sodu |
410-150-2 |
147703-65-9 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
611-081-00-2 |
[7-{2,5-dihydroksy-КO2-7-sulfoniano-6-[4-(2,5,6-trichloropirymidyn-4-yloamino)fenyloazo]-(N1,N7-N)1-naftyloazo}-8-hydroksy-КO8-naftaleno-1,3,5-trisulfoniano(6-)]miedzian(II) tetrasodu |
411-470-5 |
141048-13-7 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|
|
|
|
611-082-00-8 |
masa poreakcyjna: bis(1-(3-(lub 5-)(4-anilino-3-sulfonianofenyloazo)-4-hydroksy-2-oksydofenyloazo)-6-nitro-4-sulfoniano-2-naftolano)żelazianu(1-) pentasodu; ({1-[3-(4-anilino-3-sulfonianofenyloazo)-4-hydroksy-2-oksydofenyloazo]-6-nitro-4-sulfoniano-2-naftolano}-[5-(-3-anilino-3-sulfonianofenyloazo)-4-hydroksy-2-oksydofenyloazo]-6-nitro-4-sulfoniano-2-naftolano}-żelazianu(1-) pentasodu |
407-570-3 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
611-083-00-3 |
masa poreakcyjna: octanu 2-{N-etylo-4-[(5,6-dichlorobenzotiazol-2-ilo)azo]-m-toluidyno]etylu; octanu 2-{N-etylo-4-[(6,7-dichlorobenzotiazol-2-ilo)azo]-m-toluidyno]etylu (1:1) |
411-560-4 |
— |
STOT RE 1 Skin Sens. 1 Aquatic Chronic 2 |
H372 ** H317 H411 |
GHS08 GHS07 GHS09 Dgr |
H372 ** H317 H411 |
|
|
|
|
611-085-00-4 |
masa poreakcyjna: 3-cyjano-5-(2-cyjano-4-nitrofenyloazo)-2-(2-hydroksyetyloamino)-4-metylo-2-[3-(2-fenoksyetoksy)propyloamino]pirydyny; 3-cyjano-5-(2-cyjano-4-nitrofenyloazo)-6-(2-hydroksyetyloamino)-4-metylo-2-[3-(2-fenoksyetoksy)propyloamino]pirydyna; 3-cyjano-5-(2-cyjano-4-nitrofenyloazo)-2-amino-4-metylo-6-[3-(3-hydroksypropoksy)propyloamino]pirydyny; 3-cyjano-5-(2-cyjano-4-nitrofenyloazo)-6-amino-4-metylo-2-[3-(3-metoksypropoksy)propyloamino]pirydyny |
411-880-4 |
— |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
611-086-00-X |
5-({2,4-dihydroksy-5-[(2-hydroksy-3,5-dinitrofenylo)azo]fenylo}azo)naftaleno-2-sulfonian litu, kompleks z żelazem – monohydrat |
411-360-7 |
— |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
611-087-00-5 |
masa poreakcyjna: 3-[(5-cyjano-2-hydroksy-1,4-dimetylo-6-okso-1,6-dihydropirydyn-3-ylo)azo]benzoiloksy-2-fenoksyetanu 3-[(5-cyjano-2-hydroksy-1,4-dimetylo-6-okso-1,6-dihydropirydyn-3-ylo)azo]benzoiloksy-2-etoksy-2-(etylofenolu) |
411-710-9 |
— |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
611-088-00-0 |
masa poreakcyjna: 4-amino-3-{[4-({4-[(2-amino-2-hydroksyfenylo)azo]fenylo}amino)-3-sulfofenylo]azo}5-hydroksy-6-(fenyloazo)naftaleno-2,7-disulfonianu trilitu; 4-amino-3-{[4-({4-[(4-amino-2-hydroksyfenylo)azo]fenylo}amino)-3-sulfofenylo]azo}-5-hydroksy-6-(fenyloazo)naftaleno-2,7-disulfonianu trilitu |
411-890-9 |
— |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H302 H318 H412 |
GHS05 GHS07 Dgr |
H302 H318 H412 |
|
|
|
|
611-089-00-6 |
metylosiarczan(VI) 2-({4-[etylo(2-hydroksyetylo)amino]-2-metylofenylo}azo)-6-metoksy-3-metylobenzotiazolium |
411-100-2 |
136213-73-5 |
STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H373 ** H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H373 ** H317 H410 |
|
|
|
|
611-090-00-1 |
4-metylobenzenosulfonian 2,5-dibutoksy-4-(morfolin-4-ylo)-benzenodiazoniowy |
413-290-2 |
93672-52-7 |
Self-react. C Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H242 H302 H318 H317 H412 |
GHS02 GHS05 GHS07 Dgr |
H242 H302 H318 H317 H412 |
|
|
T |
|
611-091-00-7 |
5-({5-[(5-chloro-6-fluoro-pirymidyn-4-ylo)amino]-2-sulfonianofenylo}azo)-6-hydroksy-1,4-dimetylo-2-okso-1,2-dihydropirydyn-3-ylometylosulfonian sodu (1,0-1,95) / litu (0,051) |
413-470-0 |
134595-59-8 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
611-092-00-2 |
bis(3-{4-[5-(1,1-dimetylopropylo)-2-hydroksy-3-nitrofenyloazo]-3-metylo-5-hydroksy-(1H)pirazol-1-ylo}benzenosulfonamidano)chromian tert-(dodecyl/tetradecyl)amoniowy |
413-210-6 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
611-093-00-8 |
2-{4-[4-fluoro-6-(2-sulfoetyloamino)-1,3,5-triazyn-2-yloamino]-2-ureidofenyloazo}5-(4-sulfofenyloazo)benzeno-1-sulfonian sodu |
410-770-3 |
146177-84-6 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
611-094-00-3 |
masa poreakcyjna: 2-{2-acetyloamino-4-[N, N-bis(2-etoksykarbonyloksyetylo)amino]fenyloazo}-5,6-dichloro-1,3-benzotiazolu; 2-{2-acetyloamino-4-[N, N-bis(2-etoksykarbonyloksyetylo)amino]fenyloazo}6,7-dichloro-1,3-benzotiazolu (1:1) |
411-600-0 |
143145-93-1 |
Aquatic Chronic 4 |
H413 |
— |
H413 |
|
|
|
|
611-095-00-9 |
1,1'-{(1-amino-8-hydroksy-3,6-disulfonianonaftaleno-2,7-diylo)bis[azo(4-sulfoniano-1,3-fenylo)imino-{6-[(4-chloro-3-sulfonianofenylo)amino]-1,3,5-triazyno-2,4-diylo}]}bis(3-karboksypirydynium) diwodorotlenek heksasodu |
412-240-7 |
89797-03-5 |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
611-096-00-4 |
N-[3-acetyloamino-4-(2-cyjano-4-nitrofenyloazo)fenylo]-N-[(1-metoksy)acetylo]glicynian metylu |
413-040-2 |
149850-30-6 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
611-097-00-X |
masa poreakcyjna (1:2) izomerów związków kompleksowych żelaza i mieszaniny izomerów 1,3-dihydroksy-4-[5-(fenyloaminosulfonylo)-2-hydroksyfenyloazo]-n-(5-aminosulfonylo-2-hydroksyfenyloazo)benzenu (n=2,5,6) oraz izomerów 1,3-dihydroksy-4-[(5-fenyloaminosulfonylo)-2-hydroksyfenyloazo]-n-[4-(4-nitro-2-sulfofenyloamino)fenyloazo]benzenu (n=2,5,6) |
414-150-3 |
— |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
611-098-00-5 |
3,3'-[6-(2-hydroksyetyloamino)-1,3,5-triazyno-2,4-diylobisimino(2-metylo-4,1-fenylenoazo)]bisnaftaleno-1,5-disulfonian tetrakis(tetrametyloamoniowy) |
405-950-3 |
131013-83-7 |
Acute Tox. 3 * Aquatic Chronic 3 |
H301 H412 |
GHS06 Dgr |
H301 H412 |
|
|
|
|
611-099-00-0 |
dichlorowodorek dichlorku [metylenobis-(4,1-fenylenoazo{1-[3-(dimetyloamino)-propylo]-1,2-dihydro-6-hydroksy-4-metylo-2-oksopirydyno-5,3-diylo})]-1,1'-dipirydyniowy |
401-500-5 |
118658-99-4 |
Carc. 1B Aquatic Chronic 2 |
H350 H411 |
GHS08 GHS09 Dgr |
H350 H411 |
|
|
|
|
611-100-00-4 |
3,3'-{3(lub 4)-metylo-1,2-fenylenobis[imino(6-chloro)-1,3,5-triazyno-4,2-diyloimino(2-acetamido-5-metoksy)-4,1-fenylenoazo]dinaftaleno-1,5-disulfonian potasu sodu |
403-810-6 |
140876-13-7 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
611-101-00-X |
2'-(4-chloro-3-cyjano-5-formylo-2-tienylo)-azo-5'-dietyloaminoacetanilid |
405-200-5 |
104366-25-8 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
611-102-00-5 |
produkt reakcji: C.I. Sulfur Black 1 i masy poreakcyjnej związków: chlorek 4-{4-[8-amino-1-hydroksy-7-(4-sulfamoilofenyloazo)-3,6-disulfoniano-2-naftylazo]fenylosulfamoiloamino}benzenodiazoniowy disodu; chlorek 4-{4-[2,6-dihydroksy-3-(8-hydroksy-3,6-disulfoniano-1-naftylazo)fenyloazo]fenylosulfonyloamino}benzenodiazoniowy disodu |
424-500-7 |
— |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
611-103-00-0 |
(1-(3-karboksylano-2-oksydo-5-sulfonianofenyloazo)-5-hydroksy-7-sulfonianonaftaleno-2-amido)-niklan(II) trisodu |
407-110-1 |
— |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H318 H317 H411 |
|
|
|
|
611-104-00-6 |
masa poreakcyjna: [2,4(lub 2,6 lub 4,6)-bis(3,5-dinitro-2-oksydofenyloazo)-5-hydroksyfenolano]{2(lub 4 lub 6)-(3,5-dinitro-2-oksydofenyloazo)5-hydroksy-4(lub 2 lub 6)-[4-(4-nitro-2-sulfonianoanilino)fenyloazo]fenolano}żelazianu(1-) trisodu; bis[2,4(lub 2,6 lub 4,6)-bis(3,5-dinitro-2-oksydofenyloazo)-5-hydroksyfenolano]żelazianu(1-) trisodu; [2,4(lub 2,6 lub 4,6)-bis(3,5-dinitro-2-oksydofenyloazo)-5-hydroksyfenolano][2(lub 4 lub 6)-(3,5-dinitro-2-oksydofenyloazo]-5-hydroksy-4(lub 2 lub 6)-(4-nitro-2-sulfonianofenyloazo)fenolano]żelazianu(1-) trisodu; [2,4(lub 2,6 lub 4,6)-bis(3,5-dinitro-2-oksydofenyloazo)-5-hydroksyfenolano][2(lub 4 lub 6)-(3,5-dinitro-2-oksydofenyloazo)-5-hydroksy-4(lub 2 lub 6)-(3-sulfonianofenyloazo)-fenolano]żelazianu(1-) trisodu; 3,3'-(2,4-dihydroksy-1,3(lub 1,5 lub 3,5)-fenylenodiazo)dibenzenosulfonianu disodu |
406-870-1 |
— |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
611-105-00-1 |
4-[4-chloro-6-(N-etyloanilino)-1,3,5-triazyn-2-yloamino]2-[1-(2-chlorofenylo)-5-hydroksy-3-metylo-1H-pirazol-4-iloazo]-benzenosulfonian sodu |
407-800-2 |
136213-75-7 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|
|
|
|
611-106-00-7 |
4,4'-dihydroksy-3,3'-bis[2-sulfoniano-4-(4-sulfonianofenyloazo)fenyloazo]-7,7'-{p-fenylenobis[imino(6-chloro-1,3,5-triazyno-4,2-diylo)imino]}-dinaftaleno-2-sulfonian heksasodu |
410-180-6 |
157627-99-1 |
Eye Dam. 1 |
H318 |
GHS05 Dgr |
H318 |
|
|
|
|
611-107-00-2 |
4-{4-chloro-6-[3,6-disulfoniano-7-(5,8-disulfonianonaftalen-2-yloazo)-8-hydroksynaftalen-1-yloamino]-1,3,5-triazyn-2-yloamino}-5-hydroksy-6-[4-(2-sulfonianoetanosulfonylo)-fenyloazo]naftaleno-1,7-disulfonian potasu sodu |
412-490-7 |
— |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
611-108-00-8 |
5-({4-[(4-chloro-3-sulfonianofenylo)azo]-1-naftylo}azo)-8-(fenyloamino)-1-naftalenosulfonian disodu |
413-600-6 |
6527-62-4 |
Aquatic Chronic 3 |
H412 |
— |
H412 |
|
|
|
|
611-109-00-3 |
produkty reakcji: siarczanu(VI) miedzi(II) i soli tetrasodowej 2,4-bis[6-(2-metoksy-5-sulfonianofenyloazo)-5-hydroksy-7-sulfoniano-2-naftyloamino]-6-(2-hydroksyetyloamino)-1,3,5-triazyny (2:1) |
407-710-3 |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|